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A. Abstract 
Introduction: 
The development and application of next generation sequencing (NGS) technology 
has led to an exponential rise in the number of genes and genetic variants 
associated with epilepsy. The detection of highly penetrant and damaging variants 
in some patients can be sufficient to provide an adequate explanation for the 
entire disease process. Particularly high yields from such diagnostic genetic testing 
are observed in cohorts of children who present with early onset seizures. 
Obtaining a genetic diagnosis can be helpful to families in terms of informing 
further reproductive decisions, providing answers, and preventing further costly 
investigations. Evidence is emerging that certain anti-epileptic therapies may be 
more effective than others in specific genetic epilepsies. 
Aim: 
The aim of this thesis is to explore the potential for genetically-guided therapy for 
children with epilepsy. This will be primarily achieved through describing the 
epidemiology of the genetic epilepsies of childhood, and through researching the 
evidence-base for gene-specific therapy. 
Methods: 
This is a mixed methods study. In chapter 5 The epidemiology of early childhood 
genetic epilepsy is described using a prospective whole Scotland population based 
national cohort. This includes all children presenting under three years of age 
presenting with new onset epilepsy over a defined time period (May 2014 to May 
2017, n =315). These children were tested on a panel of 104 epilepsy-associated 
genes. In chapter 6 the potential for Whole Genome Sequencing (WGS) to identify 
further genetic diagnoses in deeply-phenotyped families is then explored in a 
separate cohort of children presenting in the West of Scotland with severe or drug-
resistant epilepsy (n = 79). In chapter 4, a systematic review approach is used to 
xiii 
 
identify any epilepsy-associated genes for which evidence exists to support a 
specific therapeutic approach. The results from this review considered in both 
cohorts. Chapter 7 describes a new genetic epilepsy due to SMC1A truncation and 
explores the potential for specific therapy in this condition. Chapter 8 evaluates 
whether sub-analysis of genetic data within a randomised controlled trial can be 
harnessed to identify patients most likely to respond to therapy.  
Key results: 
Epilepsy affects 1 per 383 children before their third birthday. In 22% of these 
children a single-gene cause can be identified. For 80% per cent of single-gene 
diagnoses in this group of patients there is some evidence to support a specific 
therapeutic approach. Evidence is variable in quality and nature. Between 1 in 
2,000 and 1 in 2,300 of all children born are likely to have a genetically 
determined epilepsy for which there is currently available some evidence for a 
specific treatment choice. The majority of currently achievable genetic diagnoses 
are concentrated in a small number of genes, with genetic diagnoses beyond the 
20 most common being extremely individually rare. Evidence to support specific 
therapeutic approaches is generally lacking in these rarer genetic epilepsies, 
particularly in those not associated with ion channel dysfunction. A stronger 
evidence base is required, and to generate this this will demand wide 
collaboration, and rigorous study design, and open access to pharmacogenomic 
data. 
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1. Introduction 
The objective of this thesis is to explore the potential for treating epilepsies based 
on information about precise genetic cause, focussing primarily on childhood-onset 
epilepsies. The term precision medicine has been chosen, though the terms 
stratified medicine, and personalised medicine have been used to describe similar 
concepts (Smith R, 2012). The term stratified medicine is typically used to 
describe the identification of subgroups of patients who are likely to benefit, or 
suffer an adverse outcome, from a particular intervention. An example of this is 
the now routine testing of the TPMT enzyme prior to starting treatment with the 
immunosuppressant medication Azathioprine. TPMT testing allows a small subgroup 
of patients (up to 1 in 170) who are deficient in the enzyme, which is critical to 
the metabolism of the drug to be identified since these patients are at increased 
risk of bone marrow toxicity (Drug and Therapeutics Bulletin 2009). Stratification 
does not always have to be on the basis of a blood test. Phenotypic features, for 
example as seizure type in epilepsy, may be effective methods of stratification 
(Marson et al., 2007a, Marson et al., 2007b). The concept of personalised medicine 
can be conceived as the ultimate extension of stratified medicine. Here we have 
moved beyond subgroups to and individual level, taking into account multiple 
variables – perhaps some genetic, some phenotypic, some environmental – when 
deciding on the optimum treatment approach. The difficulty with the concept of 
personalised medicine is that clinicians practice this type of medicine every day, 
albeit without an evidence base. True personalised medicine may not in fact be 
consistent with evidence-based medicine, since no individual patient has 
presented in the same set of circumstances ever before.  
The term precision medicine is likely to mean different things to different people, 
but certainly overlaps with the concepts of stratified and personalised medicine. 
To many in the epilepsy community precision medicine implies a treatment 
targeted at the underlying disease mechanism (Kearney et al., 2019). The mainstay 
of epilepsy treatment is anti-epileptic medications, which are used in an attempt 
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to stop and/or prevent seizures. However, as we begin to better understand the 
biology of these conditions, seizures are likely to be considered an end point of a 
disease process rather than the disease in itself. A precision therapy approach may 
be one that targets underlying biological mechanisms, the clearest example of 
which would be gene-corrective therapy. Nonetheless at times certain established 
anti-epileptic treatments do get close to addressing the primary biological 
mechanisms of the disease: examples include the use of the Ketogenic Diet in 
Glut1-deficiecy syndrome, and sodium channel modifying anti-epileptic 
medications in genetic sodium channel epilepsies. Kӧnig et al. argue that precision 
medicine “should not be viewed as an end point of a novel stratification process 
with clinical utility, but rather as a highly sophisticated and more complex 
process” (Kӧnig et al., 2017). This concept of precision medicine is well suited to 
this thesis, in which multiple channels of investigation are applied to explore 
whether having a better genetic understanding of the epilepsies of early 
childhood, at varying levels of precision, has the potential to deliver better 
treatment. 
This exploration takes place on backdrop of major recent advances in the 
understanding of the genetic causes of epilepsies. These advances have taken 
place largely thanks to the application of Next Generation Sequencing (NGS) 
technology. The dissertation involves two literature review studies and four 
primary investigations. Evidence from these studies has been used to understand in 
what proportion of children presenting with epilepsy a precise genetic diagnosis 
can be made, and then, of those with a precise genetic diagnosis, what proportion 
may be amenable to a precision-therapy approach. In the process of this 
exploration a number of key conceptual issues must be considered. These include 
what the key therapeutic goals in treating epilepsy are, including addressing co-
morbidity; how we think about classifying epilepsies with aetiology in mind; and 
what is meant by drug-resistance. Since these themes keep recurring, and since 
they frame much of the ensuing discussion, the introduction to this thesis will 
provide a general background to them, starting with a review of the epidemiology 
of childhood-onset epilepsy.   
3 
 
1.1 Epilepsy Epidemiology 
1.1.1 Incidence and prevalence of epilepsy 
Epilepsy has been defined as a disorder of the brain characterized by an enduring 
predisposition to generate epileptic seizures. An epileptic seizure is a transient 
occurrence of signs and/or symptoms due to abnormal excessive or synchronous 
neuronal activity in the brain (Fisher et al., 2005). Conceptually this definition 
positions epilepsy somewhere in a hinterland between a symptom and a disease. As 
will be discussed in this thesis, our increasing ability to resolve the causes of 
epilepsy challenges this definition. Nonetheless it is a definition that has proved to 
be operationally practical. In the majority of epidemiological studies any individual 
who has had more than one unprovoked epileptic seizure has been classified as 
having epilepsy. 
A meta-analysis of international epidemiological studies has estimated the point 
prevalence of epilepsy to be 6.38 per 1,000 persons (Fiest et al., 2017). The world 
population is currently 7.6 billion, so it can be expected that there are 
approximately 48 million people globally with epilepsy. 
The incidence of epilepsy is age-dependent, with the highest incidences found in 
the young and the elderly. Age specific-incidence is most accurately represented in 
the data from the long-term population-based cohort of Rochester Minnesota 
(Hauser, Annegers & Kurland, 1993), though this reflects the epidemiology only in 
an advanced post-industrial economy. 
Figure 1.1a is based on the data from the Rochester cohort, demonstrating that 
only in age groups over 70 years does the incidence of epilepsy surpass the levels 
observed in the under five years age groups. 
Epidemiological studies of epilepsy in childhood have been relatively few, and 
these are summarised in table 1.1a.  A consistent finding is that the incidence of 
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epilepsy in the first year of life is higher than in later childhood. Comparison 
between studies is difficult since case definitions may vary slightly. All the studies 
in table 1.1a have excluded children with acute symptomatic seizures, febrile 
seizures, and single seizures. Only the North London study (Eltze et al., 2013) took 
a prospective approach to case identification so all the other studies are 
dependent on accurate case recording in registries and notes. In the studies from 
Helsinki and Nova Scotia cases were identified from single centres, with the 
assumption that patients with epilepsy would all be reviewed in these centres. 
1.1.2 Global and economic burden of epilepsy 
According to the World Health Organisation (WHO) Global Burden of Disease Study, 
Neurological disorders are ranked as the world’s leading cause of disability-
adjusted life years (DALYs) lost, comprising 10.2% of the total. Epilepsy is ranked 
as the fifth leading cause of neurological-related DALYs lost, behind stroke, 
migraine, dementias and meningitis (Feigin et al., 2015). Epilepsy-related 
morbidity has been calculated to cost 12,418,000 DALYs per year and cause 
125,000 deaths (Feigin et al., 2015). Epilepsy was estimated to cost the European 
economy 15.5 Billion Euros in 2004, with direct costs relating to health and social 
care provision, and indirect costs relating to loss of productivity (Maura et al., 
2007).
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Figure 1.1a: Epilepsy age-specific incidence, adapted from Hauser et al. 1993 
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Table 1.1a: Epidemiological studies of epilepsy in childhood. 
Region, Country Age group Methodology Denominator 
population 
(children at 
risk) 
Incident cases 
of epilepsy 
Incidence Reference 
Rochester, MN, USA < 1 year 1935-1984 whole population cohort 
(n = 1,102,882). Patients with 
epilepsy identified from review of 
medical records. 
41,717 36 86 per 100,000 person years (Hauser, 
Annegers & 
Kurland, 1993) 
Rochester, MN, USA < 5 years 193,645 130 67 per 100,000 person years (Hauser, 
Annegers & 
Kurland, 1993) 
Rochester, USA < 10 years 173,464 217 59 per 100,000 person years (Hauser, 
Annegers & 
Kurland, 1993) 
Norway < 1 year 1999-2009 birth cohort. Patients 
with epilepsy identified from data 
linkage to the Norwegian Patient 
Registry 
Data not given Data not given 144 per 100,000 person years (Aaberg et al., 
2017) 
Norway 1-10 years Data not given Data not given 58 per 100,000 person years (Aaberg et al., 
2017) 
Nova Scotia, Canada < 13 months Children < 16 years presenting with 
a second unprovoked seizure 
between 1977 and 1985. Identified 
through EEG referrals 
94,800 112 118 per 100,000 person years (Camfield et al., 
1996) 
Nova Scotia, Canada < 16 years 1,676,000 693 41 per 100,000 person years (Camfield et al., 
1996) 
Helsinki, Sweden < 1 year 1997-2006 birth cohort. Children 
with epilepsy identified from a 
single hospital centre. 
127,730 158 124 per 100,000 person years (Gaily et al., 
2016) 
North London, UK < 2 years Prospective recruitment of new 
incident cases of epilepsy < 24 
months in North London.  
98,090 57 54 per 100,000 person years (Eltze et al., 
2013) 
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1.2 Comorbidity in Epilepsy 
1.2.1 Overall comorbidity 
Patients with epilepsy experience a significantly higher burden of additional 
physical and mental health problems than age-matched controls (Weatherburn et 
al., 2017). Absolute prevalence rates of comorbidity vary markedly between 
studies, depending on the population included and the diagnostic criteria applied 
(Athanasios, Sisodiya & Sander, 2012; Gaitatzis, Trimble & Sander, 2004). In a 
survey of 713 adults with active epilepsy in Northern Sweden, 28.1% had a 
comorbid cognitive disorder, 14.4% had a motor disorder, and 5.9% had a 
psychiatric disorder (Lars, 2005). Children with epilepsy are more than three times 
as likely to be diagnosed with a psychiatric disorder than children with other 
chronic health conditions such as diabetes (Davies, Hayman & Goodman, 2007). 
1.2.2 Comorbidity in childhood-onset epilepsy 
The most commonly encountered comorbidities that are seen in association with 
childhood-onset epilepsy are neurodevelopmental and psychiatric. Overall 30% of 
children with epilepsy onset before the age of 15 years have developmental delay 
(Baca et al., 2011). A systematic review and meta-analysis of 19 studies found that 
6.3% of people with childhood-onset epilepsy have comorbid Autism Spectrum 
Disorder (ASD), compared with the general population prevalence of 0.75 to 1.1% 
(Strasser et al., 2017). Significantly higher rates are observed in those with focal 
seizures (19.9%), infantile spasms (41.9%), and Dravet Syndrome (47.4%) (Strasser 
et al., 2017). The prevalence of comorbid Attention Deficit Hyperactivity Disorder 
(ADHD) was found to be 19.9% in one study (Baca et al., 2011) and 23.7% in 
another (Kwong et al., 2016a), though estimates of the prevalence of ADHD in the 
childhood population range from 1% to 20% (Polanczyk et al., 2007). Anxiety and 
Depression were diagnosed in 32.8% and 22.1% respectively of adolescents with 
epilepsy in a cross-sectional study of 140 patients in Hong Kong, compared with 
equivalent rates of 20.4% and 14.3% in controls with asthma (Kwong et al., 2016b). 
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1.2.3 Comorbidity and age of onset 
Additional morbidity in childhood-onset epilepsy appears to be more prevalent in 
those who receive an epilepsy diagnosis at a young age. Baca et al. followed up a 
community-based cohort of 613 children with a mean age of epilepsy onset of 4.4 
years. Nine years after diagnosis 277 of this cohort underwent re-assessment, 
including medical chart review, parent interview, and completion of a self-
administered generic Health-Related Quality of Life Questionnaire (HRQoL). In this 
group 39% had a Neurodevelopmental Spectrum Disorder (NDSD) such as 
developmental delay, dyslexia or autism; 25.6% had a psychiatric disorder, 14.8% 
had migraine, and 23.8% had another chronic medical condition. The presence of a 
psychiatric comorbidity was significantly associated with lower quality of life, 
using validated measurements (Baca et al., 2011). 
Mortality is significantly higher in children who are diagnosed with epilepsy at a 
young age. Jennum et al. interrogated the Danish National Patient Registry (NPR) 
for patients diagnosed with epilepsy before the age of 20 years between 1998 and 
2002. They identified 3123 children who were diagnosed before their sixth 
birthday, and 5018 who were diagnosed between the ages of six and 20 years. 
Follow-up was reported after 10 years, and outcomes were compared to 10,036 
randomly-chosen controls without epilepsy who were matched for age and gender. 
In the younger-at diagnosis group the hazard ratio for mortality compared with 
controls was 14.46 (95% confidence intervals [CI] 11.8-17.7) and in the older-at-
diagnosis group it was 5.58 (95% CI 4.9-6.4). These data indicate that being 
diagnosed with epilepsy before your sixth birthday is associated with a more than 
10 fold increased risk of mortality over 10 years compared with the general 
population, and a more than two fold risk of mortality compared with those 
diagnosed with epilepsy between the ages of six and 20 years (Jennum et al., 
2017). 
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1.2.4 Drug-resistant epilepsy and comorbidity 
The data presented above suggest that children with early-onset epilepsy are a 
particularly vulnerable group. Within this group there are some who are more 
vulnerable than others.  
A population-based cohort of children with early drug-resistant epilepsy were 
studied by Wirrell et al. (Wirrell et al., 2012). They reviewed the medical records 
of 127 children who had been diagnosed with epilepsy before their third birthday 
and had developed drug-resistance. 85% were followed-up for more than 24 
months. Here drug-resistance was defined as either failure, in relation to seizure 
frequency (more than one seizure in the six months prior to most recent follow-up) 
of two or more antiepileptic drugs; or having undergone resective epilepsy surgery 
or callosotomy after failure of two or more antiepileptic drugs. By these criteria 44 
(35%) children had drug-resistant epilepsy by the time of latest follow-up. 
Mortality in the drug-resistant group was 9/44 (20.5%) compared with 0/83 in the 
non-drug-resistant group (P<0.001). In the drug-resistant group 95% of children had 
developmental delay compared with 36% of the non-drug-resistant group 
(p<0.001). The strongest predictor of drug-resistance in this study was the 
presence of developmental delay at the time of epilepsy diagnosis (odds ratio = 
37.1, 95% confidence intervals 8.38-164.21), suggesting that uncontrolled seizures, 
rather than being a cause of developmental delay, may be a proxy measure of an 
underlying disorder which predisposes to both drug-resistant seizures and 
developmental delay. 
1.2.5 Mortality and Sudden Unexpected Death in Epilepsy 
As detailed above, people with epilepsy have a higher mortality rate than the 
general population. There are positive associations between age of onset (Jennum 
et al., 2017) the development of drug-resistance, and mortality (Wirrell et al., 
2012). Salinpåå and Shinnar conducted 40-year follow-up of a Finish cohort of 245 
children diagnosed with epilepsy in 1964 (median age of onset was three years). 60 
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subjects died (24%) over the follow-up period and this mortality rate was 
estimated to be three times that of a control population. The most common cause 
of death was Sudden Unexplained Death in Epilepsy (SUDEP), which caused 18 
deaths (Sillanpåå & Shinnar, 2010). 
Sudden Unexpected Death in Epilepsy (SUDEP) is defined as a “sudden, 
unexpected, witnessed or unwitnessed, non-traumatic, and non-drowning death 
that occurs in benign circumstances in an individual with epilepsy, with or without 
evidence for a seizure, and excludes documented status epilepticus (Nashef et al., 
2011).” The exact mechanisms involved in SUDEP are unclear, but are likely to be 
complex and multifactorial (Devinsky et al., 2016 Massey et al., 2014). Significant 
risk factors associated with SUDEP are male sex, high frequency of generalised 
tonic-clonic seizures (GTCS), young age of onset, and use of Anti Epileptic Drug 
(AED) polytherapy (Hesdorffer et al., 2011).  
SUDEP may be influenced by genetics. In the severe childhood-onset epilepsy 
Dravet Syndrome, which is caused by mutations in the neuronal sodium channel 
gene SCN1A, mortality has been estimated at 15.84 per 1,000 person-years (Cooper 
et al., 2016) and SUDEP is thought to account for half of deaths (Cooper et al., 
2016; Shmuely et al., 2016). SCN1A has been proposed as a candidate SUDEP gene 
(Bagnall et al., 2016). Other candidate SUDEP genes identified involve regulation 
of cardiac rhythm (Bagnall et al., 2016). Overall, any genetic contribution to 
SUDEP risk is likely to involve a complex polygenic picture. Leu et al. analysed 
Whole Exome Sequencing data from 18 individuals who had succumbed to SUDEP 
and compared this to 87 living people with epilepsy. They found that the SUDEP 
group had a significantly greater polygenic burden of rare genetic variations 
compared to the non-SUDEP group (Leu et al., 2015).  
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1.3 Epilepsy and Quality of Life 
1.3.1 Goals of treatment 
The general aims of treating any medical condition can be summarised as to either 
prolong life, to improve quality of life (QoL), or both. In epilepsy, direct mortality 
is rare. Epilepsy-related mortality remains poorly understood, and no significant 
modifiable risk factors have been identified (Massey et al., 2014) so the primary 
goal of treatment is essentially to improve QoL. 
QoL is multi-dimensional, complex, and difficult to measure. In patients with 
frequent epileptic seizures the aim of therapeutic management is often to stop 
seizures, or at least reduce their frequency, with the expectation that a reduced 
seizure-burden will contribute to an enhanced QoL for the individual. For a patient 
who becomes seizure-free on treatment this difference can lead to substantial 
differences in lifestyle opportunities, such as the ability to drive. Absolute seizure-
freedom in epilepsy consistently associates with improved QoL (Sillanpåå & 
Shinnar, 2005; Jacoby et al., 2007). For patients with severe drug-resistant 
epilepsy, seizure-freedom is, by definition, not achieved. Despite this, therapeutic 
approaches largely focus on reducing seizure frequency, though a balance between 
therapeutic efficacy, and side effects of treatment must be struck. 
Though QoL is what matters most for people with epilepsy, it is rarely used as a 
primary outcome measure in epilepsy therapeutic trials (Noble & Marson, 2016). 
QoL, as well as being difficult to measure objectively, it is dependent on multiple 
variables, and is highly vulnerable to placebo effect (Flik et al., 2017). All major 
therapeutic trials in epilepsy have used seizure frequency as a primary outcome 
measure. It is therefore important to understand how seizure frequency relates to 
QoL. 
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1.3.2 Seizure frequency and quality of life 
Baker et al. obtained questionnaire-based QoL data from >5000 adults with 
epilepsy from 15 European countries. In this sample, at the time of questionnaire 
completion, 38% had had no seizures for 12 months, 24% were experiencing a 
maximum of one seizure per month, and 38% were experiencing more than one 
seizure per month. They identified a significant association between seizure 
frequency and every single aspect of QoL that they measured. These associations 
persisted even when those who were seizure-free were removed from the analysis 
(Baker, Gagnon & McNulty, 1998). This finding has been reproduced in subsequent 
studies (Baker, Gagnon & McNulty, 1998; Leidy et al., 1999; Bautista, Tannahill 
Glen, 2009). It is difficult to determine with certainty whether the observed 
association between seizure frequency and QoL is causal. On the other hand in a 
study of 87 adult patients with temporal lobe epilepsy, psychiatric comorbidity was 
shown to have a significantly stronger association with QoL than seizure frequency, 
though seizure frequency did continue to show an independent association 
(Johnson et al., 2004).  
For younger patients the relative importance of seizure-related factors as an 
influence on QoL may be less. The QUALITÉ study group in Canada obtained 
questionnaire data from 480 children aged eight to 14 years with epilepsy. They 
found a strong relationship between mental health and QoL but not between 
seizure frequency and QoL (Fayed et al., 2015), a finding that was reproduced in 
Taylor et al.’s questionnaire study of 248 UK children (Taylor et al., 2011). Other 
studies have used qualitative methodology to explore younger patients’ ideas 
about how their epilepsy relates to their QoL. These studies also find that seizure-
related factors do not emerge as strong themes, and that participants place more 
emphasis on peer acceptance, and the extent of support from family and friends, 
as determinants of their QoL (Bishop & Allen, 2003, McEwan et al., 2004).  
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1.3.3 Parent/carer-reported QoL 
Where the very young are concerned we depend on proxy assessments of QoL from 
parents or carers. Several validated measures of parent/carer reported QoL have 
been developed including generic questionnaires such as the PedsQL (Varni, Seid & 
Kurtin, 2001), and epilepsy-specific ones such as the QOLCE (Connolly et al., 
2005). Interestingly when both children with epilepsy and their parents complete 
QoL questionnaires there is only a modest correlation between the two, with 
parents broadly underestimating QoL in comparison with their children (Taylor et 
al., 2011, Ronen. et al., 2003, Baca et al., 2010, Verhey et al., 2009). For parents 
and carers seizure-related factors appear to be more important in their assessment 
of QoL than they are for people with epilepsy themselves (Cianchetti et al., 2015, 
Conway et al., 2016, Lagae et al., 2017).  
1.3.4 Caregiver burden 
In any medical condition for which there is expected to be a significant caregiver 
burden, including most chronic neurological conditions and most paediatric 
conditions, it is important to consider the potential impact of any intervention on 
carer QoL. The caregiver burden of drug-resistant childhood epilepsy is substantial 
and has a significant impact on carer QoL. Again, non-seizure-related factors such 
as support systems, and cognitive and behavioural comorbidity appear to be 
stronger determinants of carer QoL than seizure-related factors (Williams et al., 
2003, Lv et al., 2009). 
1.3.5 Therapeutics beyond seizures 
This thesis interrogates the role that genetics may contribute towards the 
development of personalised treatment approaches for people with epilepsy. A 
case that could be made for the promotion of personalised medicine is that 
because these approaches target the underlying cause of a disease they may have 
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broader therapeutic benefits than traditional approaches, which focus purely on 
seizure control.  
A complete assessment of any potential benefits that disease-focussed 
therapeutics in epilepsy may have over symptom-focussed therapeutics must 
clearly look beyond narrow outcome measures such as seizure frequency. Broader 
outcome assessments must take into account the impact of any treatment on 
cognitive, behavioural, social, and QoL measures.  
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1.4 Drug resistance 
1.4.1 Definition and epidemiology of drug-resistance in epilepsy 
Kwan and Brodie followed up a single centre cohort of 525 patients aged nine to 93 
years who were started on antiepileptic drug (AED) treatment following a new 
diagnosis of epilepsy. They defined seizure freedom as no seizures for at least 12 
months and reported that at last follow-up 333 patients (63%) were seizure-free. 
They showed that 47% of patients became seizure-free on the first AED they were 
prescribed, and a further 13% became seizure-free on the second AED prescribed, 
either as replacement for or in addition to the first. Of all the patients who were 
prescribed a third AED only 4% became seizure-free. They therefore concluded 
that failure of two AEDs was predictive of lack of long-term remission, with a 
sensitivity of 96% (Kwan & Brodie, 2000). 
Reflecting the findings from the Kwan and Brodie study, in 2010 the International 
League Against Epilepsy (ILAE) published a proposed definition of drug-resistant 
epilepsy. The proposed definition was as follows: failure of adequate trials of two 
tolerated, appropriately chosen and used AED schedules (whether as monotherapy 
or in combination) to achieve sustained seizure-freedom (Kwan et al., 2009). 
Precise definitions as to what constitutes an “adequate trial” and “sustained 
seizure-freedom” have not been refined, making direct comparisons between 
cohorts difficult. Nonetheless this is a definition that has been widely applied to 
both clinical and research settings. 
1.4.2 Drug resistance in childhood-onset epilepsies 
Ramos-Lizana et al. prospectively followed up a single centre cohort of 508 
paediatric patients with new onset epilepsy, 459 whom received AED-treatment 
(Ramos-Lizana et al., 2012). The mean age at epilepsy diagnosis was 4.9 years and 
follow-up was for a minimum of 24 months. Seizure freedom was defined as having 
no seizures for either 12 months, or for at least three times the longest previous 
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seizure-free interval, whichever was longer. 87 patients satisfied the ILAE 
definition of drug-resistant epilepsy, which represented 17% of the total cohort 
and 19% of the AED-treated group. Ramos-Lizana et al. reported that 73% of AED-
treated cases achieved seizure-freedom on either their first or second AED 
regimen. When compared to the equivalent figure of 65% in the Kwan and Brodie 
study this suggests that paediatric-onset epilepsies are more pharmacosensitive 
than adult-onset epilepsies. The authors also noted that an additional 7% of 
patients became seizure-free on a third or subsequent AED regimen. This 
proportion is also significantly greater than what was observed in the Kwan and 
Brodie study. In a retrospective study of 468 children aged 1-17 years, with median 
age at diagnosis of 5.4 years, Wirrell et al. found that of 25 patients who had 
failure of two AEDs eight (32%) achieved a favourable outcome, defined as seizure-
free for a minimum of 12 months (Wirrell, Wong-Kisiel & Nickels, 2014). 
A consistent finding between the Ramos-Lizana and Wirrell studies is that, in these 
paediatric populations, a failure of two AEDs appears to be less indicative of a 
long-term remission than in the largely adult population study by Kwan and Brodie. 
This may indicate that certain childhood-onset epilepsies are more likely to have a 
therapy-specific response. Alternatively it may reflect the ultimately self-limited 
nature of a proportion of childhood-onset epilepsies, including some that are 
initially resistant to treatment (Ramos-Lizana et al., 2012). However, inconsistency 
of follow-up may also explain these apparent differences between paediatric and 
adult groups.  Short-term seizure-remission outcomes may not reflect long-term 
seizure freedom. Berg et al. found that of 128 patients with childhood-onset 
epilepsy who had failed two AEDs, 73 (57%) had a 12-month remission in seizures, 
but only 28 (22%) achieved three-year seizure freedom (Berg et al., 2009). 
1.4.3 Factors associated with drug-resistant epilepsy in childhood 
Looking specifically at a population who were under three years of age at diagnosis 
of epilepsy, Wirrell et al. found a significantly higher rate of drug-resistance than 
is reported in other studies. They retrospectively reviewed the cases of 127 
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children from the Rochester cohort who were consecutively diagnosed with 
epilepsy before the age of 36 months. They found that 44 (36%) became drug-
resistant. Here drug resistance was defined as a seizure frequency of greater than 
one every six months at final follow-up and failure of two AEDs, or having 
undergone epilepsy surgery after failure to respond to two or more AEDs (Wirrell et 
al., 2012). In an Italian single-centre cohort of 266 children diagnosed with 
epilepsy before the age of 36 months, 173 (65%) satisfied the ILAE definition of 
drug-resistance (Vignoli et al., 2016). 
Infantile onset of epilepsy is consistently associated with drug-resistance (Ramos-
Lizana et al., 2012; Wirrell, Wong-Kisiel & Nickels, 2014; Vignoli et al., 2016). In 
the Wirrell et al. study of children <36 months, the odds ratio for drug-resistance 
for the group who were diagnosed at ≤12 months of age was 6.76 (95% confidence 
interval [CI] 2.00-22.84) (Wirrell et al., 2012). In the Ramos-Lizana study 94 
children were diagnosed before 12 months of age, of whom 29 (30%) developed 
drug-resistance, compared to 59/414 (14%) of those diagnosed after 12 months of 
age (odds ratio 2.68, 95% CI 1.60-4.50) (Ramos-Lizana et al., 2012). 
Other factors that were found to be significantly associated with drug-resistance in 
the Wirrell et al. study were the presence of developmental delay at onset, 
abnormal neurologic examination, abnormal neuroimaging, abnormal initial EEG, 
and the identification of an aetiology (all P<0.005) (Wirrell et al., 2012). Other 
studies also show that drug-resistance is more common in those children who have 
comorbid developmental delay, and in those for whom a genetic, metabolic, or 
structural cause for the seizures is identified (Ramos-Lizana et al., 2012, Vignoli et 
al., 2016). 
1.4.4 Aetiology and drug-resistance 
Children with early onset epilepsy and comorbid developmental delay are more 
likely to develop drug-resistance and they are also more likely to have an 
identifiable genetic, structural or metabolic cause for their seizures. However, an 
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aetiology can only be diagnosed insofar as it is looked for. The studies cited in this 
section have been limited in the extent to which they have investigated cases for 
genetic aetiology, so our understanding of the relationship between aetiology, 
seizure-outcome, and comorbidity is incomplete. By enabling aetiology to be 
identified in a greater proportion of patients, the emergence of high throughput 
genetic testing offers the opportunity to more fully understand these relationships.   
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1.5 The role of genetics in epilepsy 
1.5.1 Introduction 
Until recently the aetiology of most epilepsies was not well understood. However, 
over the past 20 years the application of genetic technologies has enabled 
researchers to gain enormous insights into the genetic basis of many of the 
epilepsies. Some individually rare epilepsies have revealed themselves as 
monogenic conditions. These monogenic epilepsies often present in early 
childhood, are frequently drug-resistant, and are associated with significant co-
morbidities. Collectively these epilepsies have a significant impact on clinical 
resources. More common however are epilepsy syndromes which appear to have 
complex patterns of inheritance. Hundreds of genes have been implicated in the 
pathogenesis of the epilepsies, and every year more epilepsy-associated genes 
continue to be identified. 
1.5.2 Heritability of epilepsy 
Heritability refers to the proportion of phenotypic variance that is attributable to 
genetic variance (Manolio et al., 2009). Heritability had been understood as a 
concept long before the discovery of DNA, through the observation of heredity, 
which is the passing on of traits from one generation to the next. Heredity in 
epilepsy was noted by Hippocrates (460-370 BC) (Turnbull et al., 2005). In 1861 
John Russell Reynolds recorded that one third of epilepsy patients had a positive 
family history (Reynolds, 1861). Epilepsy heritability was first demonstrated 
experimentally by William G Lennox, who between 1947 and 1960 published many 
studies of twins with epilepsy. These studies demonstrated a significantly higher 
concordance for epilepsy in monozygotic compared with dizygotic twins 
(Vadlamudi et al., 2004). The largest epilepsy twin study to date reported 47,626 
twin pairs from USA, Norway, and Denmark in 2005. Concordance rates for epilepsy 
diagnosis were 28% in monozygotic twins compared with 7% in dizygotic twins 
(Kjeldsen et al., 2005). 
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1.5.3 Epilepsy as a feature of genetic syndromes 
Historically, another pointer to the important role of genetics in epilepsy has been 
the prominence of epilepsy as a feature in a number of inherited or genetic 
syndromes. Tuberous Sclerosis, a condition in which 80-90% of patients develop 
epilepsy (Webb, Fryer & Osborne, 1991), was recognised to demonstrate an 
autosomal dominant pattern of inheritance in 1913 (Berg, 1913). The TSC2 and 
TSC1 genes were identified respectively in 1993 (European Chromosome 16 
Tuberous Sclerosis Consortium, 1993) and 1997 (van Slegtenhorst et al., 1997).  
Even before the discovery of the Tuberous Sclerosis genes, the molecular genetic 
mechanism for another developmental disorder became apparent when it was 
found by fluorescence in situ hybridization (FISH) that male patients with 
developmental delay and distinctive dysmorphism, had an unstable regions of DNA 
on the X chromosome. The term Fragile X syndrome was coined (Yu et al., 1991). 
The unstable region was subsequently found to be based on trinucleotide repeats 
in the promoter of the FMR1 gene (Verkek, et al., 1991). 10-40% of patients with 
Fragile X syndrome are reported to have epilepsy (Berry-Kravis et al., 2010). 
Epilepsy is a prominent feature of a number of other well-characterised genetic 
syndromes, and in many cases there is a clinically recognisable epilepsy 
phenotype. These include single gene disorders such as Rett syndrome (Dolce et 
al., 2013); a number of chromosomal microdeletion syndromes (Mullen et al., 
2013, Olson et al., 2014); chromosomal aberrations such as ring chromosome 20 
(Daber et al., 2012); and imprinting disorders, for example Angelman syndrome 
(Thibert et al., 2013). The high prevalence of epilepsy in a wide variety of genetic 
conditions highlights both the importance of genetic determinants in epilepsy and 
the complex nature of epilepsy heritability. 
21 
 
1.5.4 Epilepsies recognised as single gene disorders 
The first epilepsy to be recognised as a single gene disorder was autosomal 
dominant nocturnal frontal lobe epilepsy (ADNFLE). This condition, with a 
relatively consistent phenotype and an autosomal dominant pattern of inheritance, 
was described in five unrelated families in 1995 (Scheffer et al., 1995). A variant in 
the CHRNA4 gene which segregated with affected individuals in a large ADNFLE 
family was described later the same year (Steinlein et al., 1995). CHRNA4 encodes 
the alpha 4 subunit of the neuronal nicotinic acetylcholine receptor, which allows 
sodium (Na+) and calcium (Ca2+) ions to enter nerve cells when acetylcholine binds 
to it. The discovery of CHRNA4 mutations in ADNFLE families paved the way for 
further single gene epilepsy discoveries. Families in which there was an apparent 
dominant inheritance pattern of epilepsy became prime subjects for genetic 
investigation, with the molecular focus being on genes encoding neuronal ion 
channels.  
Genetic epilepsy with febrile seizures Plus (GEFS+), a familial condition in which 
some members have febrile seizures only and others have febrile and afebrile 
seizures, was the second monogenic epilepsy breakthrough (Scheffer & Berkovic, 
1997). In families affected by GEFS+, the epilepsy appeared to demonstrate an 
autosomal dominant pattern of inheritance, yet within families there was a wide 
variation in epilepsy phenotype. Mild cases demonstrated febrile seizures only, and 
the most severe cases had epileptic encephalopathy. Despite this phenotypic 
variation, GEFS+ was verified as a genuine monogenic disorder when mutations in 
the SCN1A gene, encoding a subunit of the neuronal sodium channel, were 
identified in two GEFS+ families (Escayg et al., 2000). 
At the most severe end of the spectrum, some GEFS+ family members were 
diagnosed as severe myoclonic epilepsy of infancy (SMEI) (Singh et al., 2001). SMEI, 
first described in 1978, is typified by a developmental and epileptic 
encephalopathy – a condition in which developmental slowing or regression is seen 
concomitantly with seizure presentation, and in which it is hypothesised that 
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seizure activity directly contributes to cognitive morbidity (Scheffer et al., 2017). 
In most cases SMEI occurs sporadically without any familial inheritance pattern 
(Dravet, 2012). It was subsequently found that de novo SCN1A variants were 
common in SMEI (Claes et al., 2001). Thus SMEI became the first known non-
familial genetic epilepsy. Atypical cases of SMEI (initially termed SME 
“Borderland,” SMEB) were also found to harbour de novo SCN1A mutations 
(Fukuma et al., 2004; Kanai et al., 2004; Harkin et al., 2007). This broadening of 
the phenotype, coupled with the strong association with SCN1A variants, has led to 
the adoption of the term Dravet Syndrome instead of SMEI/SMEB. 60-80% of 
patients with Dravet Syndrome have a de novo SCN1A variant (Dravet, 2012; 
Depienne et al., 2009; Brunklaus et al., 2013). 
Dravet Syndrome is often considered a “model” single gene epilepsy for three main 
reasons: i) to date it is by far the best studied and may be the commonest; ii) the 
phenotype is clearly defined; and iii) a causal variant in a single gene (SCN1A) is 
identified in the majority of cases. The picture is less clear for other epilepsy 
syndromes, in which variants in many different genes appear to associate with 
same phenotype. For example, epilepsy of infancy with migrating focal seizures 
(EIMFS) has been associated with variants in at least 10 different genes (McTague 
et al., 2016). 
1.5.5 Genetic and phenotypic heterogeneity 
As demonstrated by EIMFS, a single epilepsy syndrome can be associated with 
variants in many different genes. Conversely, there are examples of single genes 
that have been associated with more than one distinct epilepsy syndrome – 
phenotypic heterogeneity. Variants in the KCNT1 gene have been associated with 
both ADNFLE (Heron et al., 2012) and EIMFS (Barcia et al., 2012; Ishii et al., 2013). 
KCNQ2 variants are associated with both benign familial neonatal seizures (Singh et 
al., 1998), and early infantile epileptic encephalopathy (Kato et al., 2013). 
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Factors believed to have a significant impact on the genotype-phenotype 
relationship in single gene epilepsies include the specific location and functional 
consequence of the genetic variant, which have been extensively investigated in 
SCN1A-related epilepsy (Harkin et al., 2007; Zuberi et al., 2011; Mulley et al., 
2005), the influence of other modifier genes (Zara & Bianchi, 2009; Dibbens, Heron 
& Mulley, 2007), and environmental influences of gene expression, known as 
epigenetic factors (Roopra, Dingledine & Hsieh, 2012). 
Besides implying the existence of other modifiers, phenotypic heterogeneity raises 
two key points. Firstly, it highlights the importance of carefully defining clinical 
phenotypes independently of aetiology, as advocated by the ILAE multi-axial 
approach (Zara & Bianchi, 2009; Berg et al., 2010; Wilmshurst et al., 2014). 
Secondly, it supports the approach, when looking for a genetic cause for an 
epilepsy, of screening panels of genes rather than single genes. There exists a risk 
of ascertainment bias if clinicians restrict their requesting of genetic investigations 
to single gene sequencing in cases that conform to the established classical 
phenotypes (Cattani et al., 2016; O’Donnell-Luria & Miller, 2016).  
1.5.6 Copy number variation and epilepsy 
Deletions and duplications of large sections of DNA are present in all humans. The 
average human has 2,100-2,500 copy number variants (CNVs) displacing 20 million 
bases of DNA as a consequence (Sebat et al., 2004). This dwarfs the extent of 
human variation due to single nucleotide polymorphisms (SNPs) (Sachidanandam, 
2001). A de novo CNV is expected to occur in one in 20 individuals (Itsara et al., 
2010). 
The pathogenicity of a CNV depends on the genes contained within the deleted or 
duplicated element, and on whether copy loss or copy gain of those genes has any 
functional consequence. 
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A number of well characterised pathogenic CNV-related neurodevelopmental 
syndromes have epilepsy as a prominent feature. These include 22q11 deletion (Di 
George syndrome), 2q22.3 deletion (Mowat-Wilson syndrome), 4p16.3 deletion 
(Wolf-Hirschhorn syndrome), and 22q13.3 deletion (Phelan-McDermid syndrome) 
(Olson et al., 2014). In other situations a rare CNV may disrupt an established 
epilepsy gene such as SCN1A (Lim et al., 2015) or KCNQ2 (Pascual, Wierenga & Ng, 
2013), resulting in an epilepsy phenotype similar to that associated with 
pathogenic single nucleotide variations (SNV) in that gene. 
The most complex interplay between CNVs and epilepsy relates to susceptibility 
loci. These are regions of the genomic that if subject to CNV result in an increased 
predisposition to neurodevelopmental disorders, but with incomplete penetrance. 
Susceptibility variants by definition must, at least in theory, act in combination or 
interaction with other genetic or environmental factors to result in a clinical 
effect. Susceptibility loci for epilepsy have been identified at 1q21.1 (Mefford et 
al., 2008; Mefford et al., 2010; Basel-Vanagaite et al., 2011), 15q11.2 (Mullen et 
al., 2013; Mefford et al., 2010, Helbig et al., 2009), 15q13.3 (Mullen et al., 2013, 
Mefford et al., 2010) and 16p13.11 (Mullen et al., 2013; Mefford et al., 2010; 
Heinzen et al., 2010). All these are also susceptibility loci for other 
neurodevelopmetnal disorders such as learning disability, autism spectrum 
disorder, and schizophrenia. People with epilepsy related to these susceptibility 
loci appear to be more likely to have generalised epilepsies (as opposed to focal 
epilepsies) and associated learning disability (Mullen et al., 2013). 
1.5.7 Complex genetic inheritance 
Single genes appear to be the exception rather than the rule in epilepsy 
(Hildebrand et al., 2016). The most common electro-clinical epilepsy syndromes of 
childhood, including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy 
(JME), and benign childhood epilepsy with centro-temporal spikes (BCECTS) have 
been subject to significant genetic investigation, yet rarely are monogenic causes 
of these epilepsies identified (Heinzen et al., 2012, Klassen et al., 2011). What has 
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emerged is that a large number of susceptibility genes exist for these epilepsies. 
Genetic variants considered to confer susceptibility to epilepsy have been 
associated with susceptibility to other neurodevelopmental disorders such as 
autism, learning disability and attention deficit hyperactivity disorder (Sherr et al., 
2013; de Ligt J et al., 2012). 
Genome wide association studies (GWAS) aim to identify SNPs that are common in 
the population and contribute to disease susceptibility. Because the genome is six 
billion base pairs in size, stringent p values are required to prevent 
overinterpretation of SNP signals. Consequently, very large sample sizes are 
required to demonstrate genome wide significance. A metanalysis of all epilepsy 
GWAS studies, totalling 8,696 cases and 26,157 controls, identified just two loci 
with significance (Hibar et al., 2014). GWAS has been more successful for other 
neurodevelopmental disorders, particularly autism (Anney et al., 2017) and 
schizophrenia (Ripke & O’Donovan, 2017). Hundreds of susceptibility loci have 
been identified in both these conditions, though they collectively explain only a 
tiny proportion of the variance (Manolio et al., 2009). The relative success of 
GWAS in autism and schizophrenia compared with epilepsy is most likely due to the 
significantly larger sample sizes. It may or may not mean that that these 
conditions are less genetically heterogeneous than epilepsy.  
The role of polygenic inheritance in the causation of apparently sporadic severe 
neurodevelopmental disease has been investigated in autism, using a method of 
analysis called polygenic transmission disequilibrium. In a landmark study by 
Weiner et al. participants were recruited from the Simons Simplex Collection 
(SSC), a resource of more than 2,500 families in which a single child was diagnosed 
with autism spectrum disorder (ASD) and no other family member to the level of 
first cousins had ASD. Genotype data from cases, parents, and any unaffected 
siblings, were interrogated for the presence of common SNPs that, through 
published genome GWAS, had previously been associated with i) ASD, ii) 
schizophrenia, and iii) high educational attainment. Remarkably, the genomes of 
the ASD cases were significantly enriched for SNPs in all three groups compared 
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with parents and unaffected siblings. This phenomenon was still observed when 
those cases with relevant de novo variants were analysed as a separate group, 
suggesting that polygenic factors act additively to de novo variants (Weiner et al., 
2017). 
1.5.8 Types of genetic transmission in severe neurodevelopmental 
disorders – from de novo single gene variants to polygenic 
transmission 
Genome wide screening of large numbers of patients with severe 
neurodevelopmental disorders (NDD), including severe early onset epilepsies of 
childhood, reveals a significant enrichment of de novo mutations (DNM), 
particularly involving genes for which loss of function variants are not observed in 
the healthy population. Importantly, not all of the excess DNM observed is 
explained by mutations in known neurodevelopmental disease-associated genes, 
implying that many novel NDD-associated genes are yet to be discovered (McRae et 
al., 2017; Hamdan et al., 2017). 
The Deciphering Developmental Disorders study, which recruited 14,000 children 
and their parents from the UK with wide-ranging developmental disorders, 
identified an excess of 1,796 DNMs among the first 4,293 cases published, 
compared with healthy population controls. If every single one of these DNMs were 
responsible for disease causation in an individual case, that would still leave 2,497 
(58%) cases genetically unexplained. Some at least of these remaining cases will be 
explained by Mendelian mechanisms such as homozygous or compound 
heterozygous inheritance (Martin et al., 2018), dominantly inherited variants from 
affected parents (perhaps with incomplete penetrance or imprinting effects), or X-
linked inheritance. 
Non-Mendelian factors will also play a role, such as polygenic inheritance; non-
germline genetic events such as somatic mutations; epigenetic changes; and 
environmental causes (Figure 1.5a).  
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Figure 3.5a: Causes of severe neurodevelopmental disorders: Blue – Mendelian; 
Green Non-Mendelian genetic; Orange – Non-genetic 
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1.5.9 Conclusion 
Recent advances in our genetic understanding of epilepsy have so far revealed that 
a proportion of cases are associated with variations in single genes or in genomic 
copy number. It is likely that many more genetic associations will come to light. 
More complex genetic patterns are likely to explain much of the remaining 
heritability of epilepsy, though so far conclusions from GWAS studies have been 
limited by sample size. Even in cases of epilepsy where a single gene cause is 
identified, additional genetic modifiers are likely to influence the phenotype. 
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1.6 Epilepsy Aetiology – old and new concepts 
1.6.1 Introduction 
The challenge of describing and classifying the epilepsies has occupied the   
League Against Epilepsy (ILAE) Commission on Terminology, in its various guises, 
since 1970 (Merlis, 1970). From the very inception of this task, it became clear 
that any classification of the epilepsies must necessarily take a multi-axial 
approach, since a number of non-mutually exclusive characteristics can be 
described in relation to any individual’s epilepsy. These include ictal phenomena, 
seizure types, epilepsy syndrome (see table 1.6a); comorbidity; and aetiology 
(Scheffer et al., 2017). It can be argued that there are in fact only two axes - 
aetiology and phenotype – since ictal phenomena, seizure types, epilepsy type, and 
comorbidity can all be considered as components of phenotype.  
Table 2.6a: Definitions of epilepsy phenotype characteristics 
Term Definition Reference 
Ictal phenomena Non-categorical description of clinical 
symptoms and signs associated with an 
epileptic seizure.  
(Blume et al., 2001) 
Seizure type Categorisation of epileptic seizures based on 
ictal phenomena +/- EEG features (e.g. focal, 
myoclonic, tonic etc.) 
(Fisher et al., 2017) 
Epilepsy syndrome Categorisation of epilepsy syndrome based on 
seizure type(s) and evolution, EEG findings, 
and comorbidity 
(Scheffer et al., 
2017) 
1.6.2 Diagnostic resolution 
Phenotype and aetiology of epilepsy can both be diagnosed at varying degrees of 
resolution. The degree of resolution achievable depends on the characteristics of 
the individual case, the availability and limitations of diagnostic resources, as well 
as the limitations of scientific understanding itself. Taking phenotype first: at low 
resolution, an individual could be described as having a “focal epilepsy” if their 
observed seizures have a clinically focal onset. If EEG is not available (or if 
seizures are never captured on EEG), and if the clinical picture and family history 
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do not support the diagnosis of any specific epilepsy syndrome, then the epilepsy 
diagnosis for this individual is likely to remain “unclassified focal epilepsy”. 
Alternatively, if the clinical picture or EEG indicate temporal lobe seizures and 
there is a family history compatible with dominant inheritance, then a much higher 
resolution diagnosis could be made: autosomal dominant familial temporal lobe 
epilepsy. Figure 1.6a gives an example of the spectrum of phenotypic resolution. 
The same spectrum of diagnostic resolution exists for aetiology. At low resolution, 
an aetiological diagnosis of “genetic” may be applied in a case where there is a 
supportive family history, or where what is known about the epilepsy syndrome 
itself (e.g. juvenile myoclonic epilepsy) is suggestive of genetic aetiology. 
Conversely, a high resolution genetic diagnosis may be made if a precise genetic 
change (single nucleotide variation, copy number variation, or chromosomal 
rearrangement) is attributed as the cause of the epilepsy. Figure 1.6b gives an 
example of the spectrum of aetiological resolution. 
The recent NGS revolution has occurred on a backdrop of the epilepsy community 
having made sustained efforts to build a framework for high resolution phenotypic 
diagnosis. An intricate catalogue of epilepsy syndromes has evolved, many of 
which were in fact described long before the ILAE’s efforts at classification began. 
The most recent ILAE position paper on classification of seizures and the epilepsies 
does not provide a list of ILAE designated epilepsy syndromes, though the current 
nosology commission are defining the syndromes. However, in previous ILAE 
proposals (not formally adopted), lists have been provided, with up to 38 different 
epilepsy syndromes catalogued (Engel, 2016; Berg et al., 2010). In the pre-NGS 
era, where aetiological diagnosis was relatively rare, an epilepsy syndrome 
diagnosis inevitably became both description and explanation for clinicians and 
families alike. In the NGS era, the role of the epilepsy syndrome as an explanatory 
diagnosis has lost some traction, but this does not mean it has lost any value as a 
phenotypic descriptor.             .
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Figure 4.6a: An example of increasing phenotypic resolution 
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Figure 1.6b: An example of increasing aetiological resolution
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1.6.3 Aetiological classification – old concepts 
In parallel with efforts to refine phenotypic characterisation of the epilepsies, 
numerous international consensus attempts to classify epilepsy by aetiology have 
been made. The ILAE approved classification of aetiology which remained in place 
from 1989 until the latest revision in 2017, described epilepsy aetiology as being 
idiopathic, cryptogenic, or symptomatic (Commision on Classification and 
Terminology of the International League Against Epilepsy, 1989). In this 
classification epilepsy was considered symptomatic if it was secondary to an 
identified brain lesion – such as dysplasia, neoplasia, vascular, or hypoxic-
ischaemic damage - or to a metabolic disease process; cryptogenic if it behaved 
phenotypically like a symptomatic epilepsy but no underlying cause could be 
identified; and idiopathic if it could be characterised as a recognised seizure 
disorder for which typically no underlying cause could be found. Such an 
aetiological classification, summarised in Figure 1.6c, does not entirely separate 
aetiology from phenotype since the distinction between idiopathic and cryptogenic 
is essentially a phenotypic one.  
Between 1989 and 2017 various unratified ILAE proposals introduced new concepts. 
Among those fundamental to the aetiological concepts being discussed were the 
exchange of the term cryptogenic for probable symptomatic in the 2001 proposal 
(Engel, 2001), and the suggestion that idiopathic epilepsies be better categorised 
as genetic epilepsies in 2010 (Berg et al., 2010) (see figure 1.6d). This latter 
proposal reflected the findings of family studies which clearly demonstrated a 
hereditary predisposition to idiopathic epilepsy. Despite this, precise genetic 
causes of these epilepsies can rarely be identified. 
1.6.4 Aetiological classification – new concepts 
The recent advance of genomic medicine has prompted further revision of epilepsy 
classification. The wide genotypic and phenotypic heterogeneity exposed by the 
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monogenic forms of epilepsy have emphasised the conceptual necessity to keep 
phenotype and aetiology separated in classification (Scheffer et al., 2017). 
We now understand the genetic basis of most inherited metabolic diseases, and an 
increasing proportion of diseases of cortical malformation. In addition, genetic 
diagnosis can be made in a significant minority of severe early onset epilepsies. 
Moreover, in some cases with phenotypes that would have previously been 
considered “idiopathic”, such as childhood absence epilepsy (CAE) (Striano et al., 
2012), juvenile myoclonic epilepsy (JME) (Bailey et al., 2018), and benign 
childhood epilepsy with centrotemporal spikes (BCECTS) (Lemke et al., 2013) a 
precise genetic aetiology can be identified. The latest ILAE classification (see 
Figure 1.6e) therefore recognises that the majority of epilepsies are likely to have 
a genetic basis, though the capability to precisely define this depends on resources 
available, and on current limits of knowledge. Effectively the concept of 
symptomatic epilepsy has become obsolete, since it is now recognised that “all 
epilepsies are symptomatic of something” (Berg et al., 2010). The new 
classification also recognises that the aetiological groups (genetic, structural, 
metabolic, immune) are not mutually exclusive. 
 
Figure 1.6c: ILAE 1989 Classification 
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Figure 1.6d: ILAE 2010 concepts 
 
Figure 1.6e: ILAE 2017 Classification 
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1.6.5 Retro-phenotyping 
In the pre-NGS era, genetic investigation of epilepsies would begin with the 
phenotype and use chromosome linkage approaches and single gene analysis 
(Sanger sequencing, Multiplex Ligation Probe Amplification) to identify and 
investigate genes harbouring mutations associated with these phenotypes. This 
approach inevitably led to a degree of conformational bias since patients with 
conforming phenotypes would be preferentially recruited to such studies, and 
consequently the full phenotypic spectrum associated with each gene was rarely 
represented. In the current NGS era the reverse approach is occurring. Typical NGS 
studies involve large cohorts of patients with a broad range of phenotypes. 
Following identification of a genetic association, phenotypes are investigated and 
described retrospectively. The major consequence of this retro-phenotyping 
approach is that a more complete phenotypic spectrum associated with many 
genes has been unveiled. For example, variants in the gene GABRA1 have been 
associated with a range of phenotypes, including drug-responsive JME, CAE, West 
syndrome, Dravet syndrome, and Ohtahara syndrome (Johannesen et al., 2016, 
Kodera et al., 2016).  
Chapter 7 of this thesis describes a new genetic condition in which epilepsy is 
perhaps the most prominent symptom, but the comorbidities help define it and 
make it recognisable. 
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1.7 Conclusion 
In this introduction I have shown that epilepsy is a common condition that has a 
significant impact on the lives of those affected, the lives of their families, and on 
the health service and economy. Early childhood is associated with a specifically 
high incidence of new-onset epilepsy. Those patients who present in early 
childhood are more likely to develop drug-resistance and have a particularly high 
rate of comorbidity. Those with both early onset and drug-resistance are not only 
more likely to have comorbidity, but are also more likely to have an identifiable 
underlying cause. For children with drug-resistant epilepsy and significant 
cognitive and behavioural comorbidity quality of life is likely to depend on many 
factors beyond seizure control alone.  
Modern genetic testing allows a precise diagnosis to be made in increasing 
proportions of patients with childhood-onset epilepsy. Achieving a genetic 
diagnosis may be useful for many reasons, including prognostication, counselling 
(Brunklaus et al., 2013, Hammond et al., 2010, Shostak, Zarhin & Ottman, 2011, 
Lingen et al., 2016, Might & Wilsey, 2014), advising parents on recurrence risk, and 
preventing further costly investigations (Brunklaus et al., 2013, Tan et al., 2017), 
but any benefits of genetic in terms of guiding treatment have yet to be 
established. If precision approaches to epilepsy treatment are to be evaluated 
meaningfully, outcomes beyond the seizure control, including impact on 
comorbidity and quality of life, must be assessed in a structured and systematic 
way. 
In order to understand what potential impact genetics will have on treatment in 
childhood-onset epilepsy we first need to know how common monogenic forms of 
epilepsy are. This will be addressed in chapters 3 (literature review), 5 (using gene 
panel testing), and 6 (using Whole Genome Sequencing).  
Chapter 4 reviews the current status of the evidence for precision therapy in 
epilepsy. Most of the limited evidence for precision therapy relates to epilepsies in 
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which the genetic cause relates to an ion channel. Chapter 7 looks at whether 
precision approaches can be extended to non-ion channel epilepsies, using SMC1A 
as an example. 
In order to make progress with precision therapy, we are likely to need to move 
beyond the rather reductive idea that treatment decisions can be guided by 
knowledge of the gene alone. Chapter 8 investigates whether the precise nature 
and location of an SCN1A variant is associated with treatment response to 
Cannabidiol, using RCT methodology. 
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2. General Methods 
2.1 Introduction 
In order to assess the potential impact of genotype-driven precision therapy for 
children with epilepsy, two questions need to be answered: 
i) How common are single gene causes of epilepsy?  
ii) What is the current status of, and future scope for, precision therapy in 
these epilepsies? 
A mixed methods approach will be used to answer these questions. In each chapter 
detailed methods will be described separately. Chapters 3 and 4 are literature-
based studies, aiming to answer questions i) and ii) above respectively. Chapters 5 
to 8 are primary research, involving a variety of patient cohorts detailed in table 
2.2a.
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2.2 Summary of cohorts 
Table 2.2a: Summary of patient cohorts in this thesis 
Chapter and cohort Selection Phenotyping Genotyping 
Chapter 5, cohort 1 Prospectively recruited patients presenting 
with epilepsy and/or complex febrile seizures 
before the age of 36 months from the whole of 
Scotland, over a three-year period, without 
determined aetiology (2014-2017). 
Clinician-completed structured 
proforma at recruitment and again 
12 months after genetic results 
communicated. Parent-completed 
developmental, behavioural and 
quality of life questionnaires. 
104 gene epilepsy panel (Glasgow). 
Chapter 5, cohort 2 Retrospectively ascertained patients 
presenting with epilepsy before the age of 36 
months from the West of Scotland, over a 
three-year period (2014-2017).  
Electronic medical record review. Various methods, as arranged by 
clinical team, including single gene 
sequencing, gene panel testing, 
chromosomal microarray, and whole 
genome sequencing. 
Chapter 6 Childhood-onset complex epilepsies managed 
within the West of Scotland. No restriction on 
time of presentation. 
Face-to-face interview with parents 
and patient. Examination of 
patient. Medical record review, 
including EEGs and neuroimaging. 
Trio Whole Genome Sequencing 
(Oxford). 
Chapter 7 Patients recruited to the Deciphering 
Developmental Disorders (DDD) study who had 
de novo truncating variants in the SMC1A gene 
identified. 
Clinician-completed structured 
proforma. 
Trio Whole Exome Sequencing 
already completed as part of the 
Deciphering Developmental 
Disorders (DDD) study prior to 
patient selection. SMC1A variant 
information provided. 
Chapter 8 Patients recruited to the GWPCARE3 and 
GWPCARE4 trials of Cannabidiol versus Placebo 
(multicentre multinational randomised 
controlled trial)s. 
Seizure frequency over 14-week 
treatment period compared with 4-
week baseline. 
SCN1A variant information provided 
by recruiting clinicians 
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2.3 Publicly available tools used for variant interpretation 
Testing methodologies have varied between cohorts and are described in detail 
separately. However, the tools used to interpret the significance genetic variants 
have been consistent between cohorts. Limitations of these tools will be discussed 
in section 6.4. 
2.3.1 Population frequency and variant tolerance data 
The largest publicly available datasets providing population frequency data of 
genetic variants are the Exome Aggregation Consortium (ExAC) and the Genome 
Aggregation Database (gnomAD), both managed by the Broad Institute at Harvard 
University, Massachusetts (Lek et al., 2016). ExAC provides whole exome 
sequencing (WES) data (all protein-encoding DNA) on 60,706 unrelated individuals. 
gnomAD provides whole genome sequencing (WGS) data (all DNA, coding and non-
coding) on 123,136 unrelated individuals. To allow users to account for population-
specific variation, participants were recruited from all major ethnic backgrounds, 
and variants are reported according to broad ethnic groups. Both databases 
exclude individuals with severe paediatric disease, so it is expected that these 
datasets are depleted of variants associated with severe early-onset epilepsies. 
The gnomAD dataset is more complete and accurate because of larger numbers 
and because WGS is intrinsically more accurate than WES. In this thesis variants 
have therefore been checked for population frequency against gnomAD data. For 
example, in chapter 6 candidate variants have only been considered when 
observed in fewer than 0.01% of alleles in gnomAD (equivalent to 1 heterozygote 
per 5,000 individuals for autosomal genes).  
The ExAC dataset provides additional data on variant tolerance that has been used 
when considering candidate genes. For each gene covered by ExAC the number of 
missense variants per gene has been calculated and compared with the number of 
expected variants based on the length of the gene (coding regions only), the 
observed number of synonymous variants observed in the gene, and on missense 
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variation across the exome as a whole. This is expressed as a z-score (standard 
deviations in the number of observed variants from the expected number, using 
chi-squared). The z-score is positive when the observed number is fewer than 
expected and negative with the observed number is greater than expected. Hence, 
genes with high z-scores do not tolerate missense variation. A separate scoring 
system, using a complex “expectation-maximisation algorithm” described in the 
supplementary section 4.4 of Lek et al. (Lek et al., 2016) is used to create a 
measure of the probability that a gene is intolerant of loss-of-function, the 
“Probability of Loss-of-Function Intolerance” (pLI) score. pLI scores of >0.9 are 
considered to indicate significant intolerance of a gene for loss of function. The 
authors state that extreme constraint does not necessarily reflect a lethal 
disease or status as a disease gene, but probably points to genes in which 
heterozygous loss of function confers some non-trivial survival or reproductive 
disadvantage. The pLI score is especially useful in the interpretation of de novo 
protein truncating variants (PTVs) in patients with severe phenotypes.  
2.3.2 Computational tools for predicating the pathogenicity of 
missense variants 
A wide range of tools are available, all with similar functions. These use complex 
machine learning algorithms driven by multiple inputs which include nucleotide 
and amino acid conservation between species, polarity and pH shifts associated 
with amino acid changes, and sequence and structure descriptors relating to the 
region affected. These have been comprehensively reviewed and appraised 
elsewhere (Janita, Ayodeji & Mauno, 2011, Ohanian, Otway & Fatkin, 2012). For 
largely practical reasons – because their use was already established within the 
Glasgow clinical genetics laboratory – the two tools which I selected were 
Polyphen-2® (Adzhubei et al., 2010) and SIFT® (Sorting Intolerant From Tolerant) 
(Kumar, Henikoff & Ng, 2009). 
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Polyphen-2 expresses outputs as an overall probability. This is a composite of a 
sensitivity p-score and a specificity p-score. In chapter 6 to identify candidate 
variants I filtered out those with a Polyphen-2 scores ≤0.8. 
SIFT expresses outputs in terms of scaled probability that a variant is benign. A 
score of 1 represents a predicted benign variant and a score of 0 represents a 
predicted damaging variant. When tested for sensitivity and specificity against 
established pathogenic and benign variants both Polyphen-2 and SIFT demonstrate 
reasonable sensitivity (68% and 69% respectively in one analysis) but poor 
specificity (13% and 16%) for predicting pathogenicity (Flanagan, Patch & Ellard, 
2010). In other words, these tools are much more useful for filtering out benign 
variants than they are for selecting pathogenic ones. 
2.3.3 Computational tools for predicting splicing effects 
In the majority of genes, introns are flanked by the two base sequence GT.. …AG. 
These sequences act as specific signals for the spliceosome to remove transcribed 
intronic RNA from precursor messenger RNA to form mature RNA. Variants 
affecting these flanking regions of intronic sequence typically result in truncation 
(Scotti & Swanson, 2015). The splicing process is complex, and more deeply 
intronic variants can also have an impact on the splicing process. Furthermore, 
variants within coding sequence can result in the creation of aberrant splice sites, 
which can also lead to truncation. Various machine learning tools have been 
developed to predict the impact of variants on splicing. The ones used in this 
thesis are Spice-Site-Finder-Like®, MaxEntScan®, NNSPLICE®, GeneSplicer®, and 
Human Splicing Finder® (Jian, Boerwinkle & Liu, 2013).  
2.3.4 Brain expression data 
Genes that have relatively high expression in brain tissue are more likely to be 
implicated in neurological disease (Negi & Guda, 2017). Various publicly available 
datasets of relative RNA expression in tissues are available. The largest of these is 
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the GTEx consortium dataset, which catalogues quantitative RNA sequencing data 
from 7,051 samples obtained from 449 donors (Aguet et al., 2017). These are 
mostly immediate post-mortem samples taken from otherwise healthy young adults 
who have died from trauma. Data on relative expression of genes in brain are 
available from GTEx. In chapter 6 I have shown that genes associated with severe 
forms of childhood-onset epilepsy have significantly higher brain GTEx ratios. I 
have used these data the prioritise candidate epilepsy genes. 
2.3.5 Missense variant localisation 
The location of a variant within a gene is a major factor which determines its 
pathogenicity. Indirectly this is included in prediction algorithms such as Polyphen-
2 and SIFT. However, these operate on general principles rather than specific 
knowledge about genetically determined functional domains of proteins. For some 
genes, particularly ion channel genes, precise knowledge of the corresponding 
region of protein affected by a missense variant provides important information. 
For example, in severe epilepsies associated SCN1A variants, epilepsy associated 
variants cluster in regions which correspond with transmembrane regions of the 
protein (Zuberi et al., 2011). To obtain information of variant localisation I used 
the Uniprot portal, a database of 60 million sequences manually curated by 
experts who critically review experimental and predicted data for each protein 
(UniProt Consortium, 2017). 
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2.3.6 Gene matching 
One of factors that limits variant interpretation is the current state of knowledge. 
A gene for which there is little known one day may turn out to be of pathological 
significance the next. When a very rare variant in a novel gene is identified in a 
patient its significance will be uncertain, even if the variant appears to be 
damaging and the gene appears to be a good candidate based on factors such as 
known mechanism, ExAC constraint scores and GTEx ratio. If more patients with 
similar phenotypes and similar/identical variants in the same gene are identified, 
then significance dramatically increases. To facilitate, this various “gene 
matching” systems have been developed which clinical researchers can use to 
deposit anonymous phenotype and genotype details of patients, with appropriate 
consent. Programs that will be used in this project are: Decipher (Firth et al., 
2009), Gene Matcher (Sobreira et al., 2015), and Phenome Central (Buske et al., 
2015).  
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3. Meta-analysis of next generation sequencing studies in 
epilepsy 
3.1 Introduction 
The Sanger method of DNA sequencing, developed in 1977 (Sanger, Nicklen & 
Coulson, 1977) remained the mainstay for identifying DNA sequence variants in 
both clinical and research settings until 2005. Though highly accurate, the Sanger 
method is low throughput. As a result, research-based testing using this method 
was largely hypothesis-driven, favouring the sequencing of genes whose function 
was believed to relate to the disease being investigated. From 2005 onwards the 
development of Next Generation Sequencing (NGS) has dramatically increased 
genetic sequencing throughput (Mardis, 2011).  
Currently applied NGS approaches include gene panels in which selected known 
disease-associated genes only are sequenced, clinical exome sequencing 
(sometimes referred to as the Mendeliome) in which all known disease-associated 
genes are sequenced (currently approximately 4,800 genes), a whole exome in 
which all coding DNA is sequenced, and a whole genome in which all DNA, coding 
and non-coding, is sequenced. 
The application of NGS has permitted much larger cohorts of patients to be 
investigated for multiple genetic variants in a more hypothesis-limited manner 
than was the case previously. This has facilitated a revolution in the genetic 
understanding of many diseases, including epilepsy. Prior to the advent of NGS, 
the epilepsy literature emphasised a narrative that heritable disorders of neuronal 
ion channels were the major genetic factor in epilepsy (Helbig et al., 2008). As a 
direct result of NGS, the number of genes associated with epilepsy has risen 
substantially since 2005. Disorders of the ion channel may no longer be the 
dominant theme.  
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NGS has become a mainstream diagnostic test for many clinicians looking after 
patients with epilepsy. A number of research groups have reported their diagnostic 
yield from NGS testing. However, due to biases and inconsistencies in case 
selection, testing procedures and publication, is not clear from any individual 
study which are the most commonly implicated genes in epilepsy.  
The aims of this chapter are: i) to systematically analyse the genes that have been 
associated with epilepsy, and to categorise them into groups based on broad 
function; ii) to perform a meta-analysis of studies reporting the application of NGS 
in cohorts of patients with epilepsy in order to understand which are the most 
commonly-implicated genes. 
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3.2 Methods 
3.2.1 Identification of epilepsy-associated genes: 
Genes associated with epilepsy were identified through four routes, sequentially: 
1. Personal experience of encountering patients with genetic epilepsy and 
from reading papers describing cases 
2. Review of genes covered by epilepsy diagnostic testing in UK NHS 
laboratories and US commercial laboratories 
3. Search of the Online Mendelian Inheritance in Man (OMIM) resource (Johns 
Hopkins University, Baltimore, 2018) for using the term [epilepsy]. Search 
date February 5th 2018; 1064 results. 
4. Search of Medline [1860-2017] using the search terms ([epilepsy] or 
[seizure]) and [gene]. Search date April 18th 2018; 8534 results 
For each epilepsy-associated gene identified I reviewed the original research for 
quality and relevance. Any gene considered relevant to epilepsy was added to a 
database into which I systematically recorded phenotype features (age of onset, 
seizure types, comorbidities), mode of inheritance, and date of first published 
case or case series. I defined six functional groups for genes as follows, and 
categorised each gene into the group of best fit: 
• Metabolic: Genes encoding proteins involved in the transport and 
metabolism of intracellular small molecules, or mitochondrial function 
• Ion channel/G-protein: Genes whose products form ion channels, ion 
channel accessory proteins, or G-proteins 
• Cell growth and proliferation: Genes encoding regulators of cell growth 
and proliferation 
• Synaptic: Genes encoding proteins with specifically high expression at the 
synapse, or with key synaptic functions (excluding ion channels and G-
proteins)  
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• Regulatory: Genes thought to play a role in transcriptional regulation, 
translational regulation, or post-translational protein modification 
• Others: Miscellaneous, or unknown function 
3.2.2 Meta-analysis of diagnostic yield from epilepsy NGS studies 
Papers reporting the application of NGS to cohorts of patients with epilepsy were 
identified using a Medline literature search (date April 18th 2018) using the 
following terms:  
• [epilepsy] or [epileptic] or [seizure] and  
• [next generation sequencing] or [gene panel] or [exome] or [genome] 
Total results = 870 
Abstracts of these papers were reviewed to identify studies in which NGS 
technology (either a targeted gene panel, a whole exome, or a whole genome) had 
been applied in the diagnostic evaluation of a cohort of patients with epilepsy. 
Studies which did not include patients with epilepsy were excluded, as were those 
that did not report diagnostic results, or in which 10 or fewer patients were 
reported. Diagnostic results from each study were reviewed to check whether they 
satisfied the American College of Medical Genetics and Genomics criteria for 
pathogenicity (Richards et al., 2015). Variants that did not meet these criteria 
were removed from the results. Total number of diagnostic results involving each 
gene were summated for each paper. 
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3.3 Results 
3.3.1 Epilepsy-associated genes: discovery over time, and functional 
categories 
359 epilepsy-associated genes were added to the database. These genes fell into 
the following functional categories, in descending order of frequency (Figure 3.3a): 
• Metabolic: 116 (32%) 
• Cell growth and proliferation: 83 (23%) 
• Ion channel-G-protein: 66 (19%) 
• Regulatory: 48 (13%) 
• Synaptic: 32 (9%) 
• Others: 14 (4%) 
The proportionate increase in epilepsy gene discovery in each group between 2011 
and 2017 was as follows: 
• Metabolic: 59 to 116 (200%) 
• Cell growth and proliferation: 37 to 83 (220%) 
• Ion channel-G-protein: 35 to 66 (190%) 
• Regulatory: 17 to 48 (280%) 
• Synaptic: 9 to 32 (360%) 
• Others: 5 to 14 (360%) 
Since the arrival of NGS, there has been a greater proportionate increase in gene 
discovery within the regulatory and synaptic groups than within the metabolic, cell 
growth and proliferation and ion channel/G-protein groups.
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Figure 3.3a: Epilepsy gene discovery 1991-2017
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3.3.2 Meta-analysis of diagnostic yield from NGS epilepsy studies 
3.3.2.1 Most commonly implicated genes 
24 studies were included in the analysis. These are presented in table 3.3a. 
Diagnostic yield ranged from 3% to 50%.  
For 104/210 genes there was only a single patient with a diagnostic result 
reported. 
Figure 3.3a shows the genes recurrently implicated (four or more positive results). 
The most commonly implicated genes were SCN1A, KCNQ2, CDKL5, SCN2A, STXBP1, 
and PCDH19. These six genes were implicated in more than 50% of the diagnostic 
results. The 27 most commonly-implicated genes explained 80% of the diagnostic 
results. 
In order to adjust for the variability in size of panels I have also represented the 
most commonly implicated genes as a proportion of the total number of patients 
tested for variants in each respective gene (Figure 3.3c). Two papers did not 
report which genes were included in their panels (Zhang 2017 and Butler 2017) and 
one paper reported changing their panel mid-way through the study (Trump 2016), 
so these were excluded from this analysis. The most commonly implicated seven 
genes are exactly the same in both analyses but a few genes appear to gain 
significance (see GABRB3, CHD2, WWOX and NEXMIF). 
Figure 3.3d presents the number of diagnostic results in the functional category 
groups and compares these with the total number of known epilepsy-associated 
genes in each group (see Figure 3.3a). Although ion channel/G-protein genes 
represent under 20% of the total numerically, variants in these genes account for 
more than half of the diagnostic results. Metabolic genes – 32% of the total – 
account for just 11% of the diagnostic results. Genes involved in growth and 
proliferation make up 23% of the numbers but only 6% of the diagnostic results.
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3.3.2.2 Factors associated with diagnostic yield 
3.3.2.2.1 Number of genes selected (i.e. size of panel) 
Figure 3.3e takes the data from Table 3.3a and shows the relationship between the 
size of the panel, plotted on a logarithmic scale, and the diagnostic yield. There is 
a clear association between the number of genes selected for testing and the 
diagnostic yield, though this explains only about one fifth of the variance in yield 
observed (R2 = 0.225). Variation in patient selection between these studies may 
explain much of the remaining variance. The low diagnostic yield of 4% in the 
study by Hildebrand et al. may be due to the fact that most of the patients in this 
study had sporadic temporal lobe epilepsy. The current state of knowledge 
suggests that sporadic temporal lobe epilepsy is rarely monogenic. The low yield of 
3% in the Myers et al. study may be because most of the patients selected had 
already undergone extensive genetic investigation. 
3.3.2.2.2 Phenotypes 
Studies that recruited patients with childhood-onset severe epilepsies (e.g. 
Hamdan 2017, Tumiene 2017, Ko 2018) had higher diagnostic yield than those with 
broader inclusion (Trump 2015, Butler 2017). Moreover, within individual studies, 
age of onset was also associated with increased probability of receiving a 
diagnostic result. In the Trump et al. study (Trump et al., 2016) the odds ratio for 
a diagnostic result in the children aged less than two months was 5.0 (see table 
3.3b) and in Møller et al.’s study presentation in the first month of life was 
associated with an odds ratio of a diagnostic result of 5.7. Conversely in the Helbig 
et al. study, a significant difference for early-onset patients was not seen. Nor did 
Helbig et al. find significantly increased diagnostic yields in subgroups with 
infantile spasms or early onset epileptic encephalopathy (Helbig et al., 2016). An 
important difference is that the Helbig study used a panel of 4800 genes, whereas 
the Trump and Møller studies both used a more selective 46-gene panel. Trump et 
al. and Møller et al. are likely to have favoured genes associated with early onset 
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epilepsies. The Ko et al. study, using a 172 gene panel, found a significant 
association between drug-resistance and a diagnostic result (odds ratio: 3.5) (Ko et 
al., 2018). In summary, early onset, severe and drug-resistant epilepsies appear to 
be associated with increased diagnostic yield when relatively small gene panels are 
used, but this effect is not seen when larger panels are used.
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Table 3.3a: Summary of 24 NGS studies of epilepsy, involving 13,063 patients: 2012-2018 
Study Country/region Patient selection Platform Yield Reference 
Lemke 
2012 
Germany/ 
Switzerland 
Not specified – variable phenotypes 265 gene epilepsy panel  16/33 (48%) (Lemke et al., 2012) 
Kodera 
2013 
Japan Early onset epileptic encephalopathy 30 gene epilepsy panel 11/53 (21%) (Kodera et al., 2013) 
Della Mina 
2014 
Italy Not specified – variable phenotypes 67 gene epilepsy panel 9/19 (47%) (Mina et al., 2015) 
Carvill 
2014 
Global Infantile spasms or Lennox Gastaut 
Syndrome 
Trio Whole Exome Sequencing (WES) 51/356 (14%) 
 
(Carvill et al., 2014) 
Allen 2015 Ireland Unexplained early onset epileptic 
encephalopathy 
137 gene epilepsy panel 13/50 (26%) (Allen et al., 2016) 
Trump 
2015 
UK Tertiary referrals to Great Ormond 
Street Hospital 
46 gene epilepsy panel 58/323 (18%) (Trump et al., 2016) 
Zhang 2015 China Unexplained epilepsy and intellectual 
disability  
300 gene epilepsy panel 46/253 (18%) (Zhang et al., 2015) 
Møller 
2016 
Denmark, 
Estonia, the UK, 
Argentina, 
Pakistan 
Epileptic encephalopathies and 
familial epilepsies 
46 gene epilepsy panel 49/216 (23%) (Møller et al., 2016) 
Myers 2016 Global Unsolved epileptic encephalopathy 
cases 
27 candidate gene epilepsy panel 18/531 (3%) (Myers et al., 2016) 
Helbig 
2016 
USA Clinical referrals to diagnostic lab, all 
patients with seizures 
Diagnostic exome 119/314 (38%) (Helbig et al., 2016) 
Zhang 2016 China Early onset epileptic encephalopathy 17 gene epilepsy panel 56/175 (32%) (Zhang et al., 2017) 
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Parrini 
2016 
Italy Drug-resistant epilepsy (0-5 years) 95 gene epilepsy panel 71/349 (20%) (Parrini et al., 2017) 
Hildebrand 
2016 
Australia Focal epilepsy 11 gene epilepsy panel 11/251 (4%) (Hildebrand et al., 2016) 
de Kovel 
2016 
Europe Seizures and intellectual disability, 
onset <5 years 
26 gene epilepsy panel 31/360 (9%) (Kovel et al., 2016) 
Gokben 
2017 
Turkey Early-onset epileptic encephalopathy 16 gene panel 9/30 (30%) (Gokben et al., 2017) 
Butler 
2017 
USA Clinical referrals 110 gene epilepsy panel 58/339 (17%) (Butler et al., 2017) 
Hamdan 
2017 
Canada Developmental and epileptic 
encephalopathy 
Trio Whole Genome Sequencing (WGS) 63/197 (32%) (Hamdan et al., 2017) 
Ortega-
Moreno 
2017 
Spain Epilepsy and developmental delay 106 gene epilepsy panel 17/87 (20%) (Ortega-Moreno et al., 
2017) 
Newman 
2017 
USA Referrals to diagnostic lab. 100 gene epilepsy panel 36/166 (22%) (Newman et al., 2017) 
Tumiene 
2017 
Slovenia Epilepsy and developmental delay or 
dysmorphism 
Diagnostic exome (4813 genes) 40/86 (47%) (Tumienė et al., 2017) 
Ko 2018 South Korea Developmental and epileptic 
encephalopathy 
172 gene epilepsy panel 97/278 (35%) (Ko et al., 2018) 
Palmer 
2018 
Australia Epileptic encephalopathies Diagnostic exome 16/32 (50%) (Palmer et al., 2018) 
Lindy 2018 USA Clinical referrals 70 gene panel 1324/8565 
(15.5%) 
(Lindy et al., 2018) 
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Table 3.3b: Odds ratios for clinical predictors of diagnostic results within epilepsy NGS studies 
Study Clinical feature associated 
with diagnostic result 
Number with diagnostic 
result/Number with feature (%) 
Number with diagnostic 
result/Number without feature (%) 
Odds ratio (95% 
confidence intervals) 
and p value (Fisher’s 
exact test) 
Trump 2015 Presentation < 2 months 30/77 (39%) 28/246 (11%) 5.0 (2.7-9.1), p<0.0001 
Møller 2016 Presentation < 1 month 12/21 (57%) 37/195 (19%) 5.7 (2.2-14.5), p<0.001 
Helbig 2016 Presentation < 1 month 12/28 (43%) 107/276 (37%) 1.3 (0.6-2.8), n.s. 
Helbig 2016 Infantile spasms 16/41 (39%) 103/273 (38%) 1.4 (0.7-2.7), n.s. 
Helbig 2016 Early Onset Epileptic 
Encephalopathy 
28/67 (42%) 91/247 (37%) 1.2 (0.7-2.1), n.s. 
Ko 2018 Drug-resistant seizures 74/161 (46%) 23/118 (19%) 3.5 (2.0-6.1), p<0.0001 
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Figure 3.3b: Combined results from 24 NGS studies in epilepsy. Genes implicated on four or more occasions.
0
50
100
150
200
250
300
350
400
450
S
C
N
1
A
K
C
N
Q
2
C
D
K
L
5
S
C
N
2
A
S
T
X
B
P
1
P
C
D
H
1
9
P
R
R
T
2
S
C
N
8
A
M
E
C
P
2
S
L
C
2
A
1
U
B
E
3
A
T
S
C
2
G
A
B
R
G
2
G
R
IN
2
A
K
C
N
T
1
F
O
X
G
1
T
P
P
1
G
A
B
R
B
3
A
R
X
G
A
B
R
A
1
A
L
D
H
7
A
1
IQ
S
E
C
2
C
D
H
2
T
S
C
1
Z
E
B
2
C
H
R
N
A
4
D
N
M
1
P
O
L
G
S
L
C
9
A
6
S
Y
N
G
A
P
1
C
A
C
N
A
1
A
G
N
A
O
1
M
E
F
2
C
S
P
T
A
N
1
P
N
P
O
C
H
R
N
A
7
A
L
G
1
3
K
C
N
Q
3
T
C
F
4
C
L
N
5
K
C
N
B
1
T
B
C
1
D
2
4
A
T
P
1
A
2
A
T
P
1
A
3
C
A
S
K
E
E
F
1
A
2
E
P
M
2
A
G
R
IN
1
M
B
D
5
S
L
C
1
A
2
A
D
S
L
A
N
K
R
D
1
1
C
L
N
3
C
L
N
6
C
N
T
N
A
P
2
G
A
M
T
G
R
IN
2
B
K
A
N
S
L
1
K
C
N
A
2
K
C
N
J1
0
L
G
I1
M
F
S
D
8
P
N
K
P
S
L
C
2
5
A
2
2
S
Y
N
1
W
D
R
4
5
W
W
O
X
N
u
m
b
e
r 
o
f 
p
o
si
ti
v
e
 r
e
su
lt
s
Gene
Lemke 2012 Kodera 2013 Della Mina 2014 Carvill 2014 Allen 2015 Trump 2015
Zhang 2015 Møller 2016 Myres 2016 Helbig 2016 Zhang 2016 Parrini 2016
Hildebrand 2016 de Kovel 2016 Gokben 2017 Butler 2017 Hamdan 2017 Oretega-Moreno 2017
Newman 2017 Tumiene 2017 Ko 2018 Palmer 2018 Lindy 2018
59 
 
 
Figure 3.3c: Genes for which >0.2% of tests resulted in a diagnosis 
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Figure 3.3d: Gene functional groupings: comparison of the diagnostic results from NGS meta-analysis with the total number 
of epilepsy-associated genes in each group 
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Figure 3.3e: Relationship between diagnostic yield and size of panel in 24 epilepsy NGS studies
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3.3.3 Discussion 
In this chapter I have shown that there has been a progressive increase in the 
number of genes associated with epilepsy discovered each year. The first gene, 
GCSH was discovered in 1991. By 2017 there were more than 350. Ion channel 
genes constitute a minority of the total numerically (19%), but account for more 
than half of the diagnostic results from NGS panel testing (51%). Patients with 
epilepsy associated with pathogenic variants in genes involved in metabolic 
processes may be under-represented in NGS samples, since with these conditions 
there may be biochemical markers pointing towards a diagnosis. The same may be 
true for patients with variants in genes associated with growth and proliferation, 
since these patients may have diagnostic MRI scans precluding them from entry 
into diagnostic studies. To some extent the categorisation of genes into distinct 
functional groups is artificial, as will be discussed further in chapter 7. However, it 
is helpful when considering precision therapy, since evidence relating to ion 
channel and metabolic genes is strongest. 
The diagnostic yield when NGS is applied to epilepsy patients depends on three 
things: i) the genes selected for investigation; ii) the patients selected for testing, 
in relation to age of onset, severity of disease, and extent of previous testing; iii) 
the current state of knowledge about the significance of variants identified. 
This meta-analysis does not overcome these limitations, since panel sizes and 
patient selection have been highly variable between studies. Nonetheless, in 
tallying the cumulative number of diagnoses between 24 studies it becomes clear 
that the majority of currently achievable diagnoses lie in a relatively small number 
of genes. Some important genes will doubtless be underrepresented in this analysis 
either because patient cohorts selected have not focussed on phenotypes relating 
to those genes, or because prior testing of patients has excluded them from the 
testing platform used. 
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Diagnostic results in this analysis have been counted in a binary manner. The 
reality is less clear cut. The interpretation of results from NGS studies remains a 
challenge. As with all diagnostic tests, a balance must be struck between 
sensitivity and specificity. The information delivered by of large panel 
investigations is extensive, the human genome is highly variable between 
individuals, and every human being, healthy or otherwise, carries a large number 
of rare genetic variants, including variants in genes associated with disease. No 
single tool is reliable for predicting the pathogenicity of a genetic variant. 
Computer-based algorithms such as Polyphen (Adzhubei et al., 2010) and SIFT®  
(Kumar, Henikoff & Ng, 2009) use broad principles such as amino acid 
conservation, polarity, and pH change to predict the effect of genetic changes on 
protein function. These have been developed to assist variant interpretation but 
they have poor specificity (Flanagan, Patch & Ellard, 2010). Relying on the 
published literature for variant/disease association is complicated by the large 
number of false associations that have been claimed and published (Ioannidis, 
2003). 
The American College of Genetics and Genomic Medicine (ACGM) has produced 
guidelines on variant interpretation (Richards et al., 2015). Application of this 
guidance is not consistent (Amendola et al., 2016), relying heavily on interrogation 
of the published literature, public repositories of variant and phenotype data such 
as ClinVar (National Center for Biotechnology Information, 2018), and genomic 
datasets of healthy populations such as ExAC (Broad Institute Exome Aggregation 
Consortium, 2018) and gnomAD (Broad Institute gnomAD Browser, 2018). Even 
when applying the objective guidance of ACMG, specificity is dependent on the 
reliability of deposited/published data, and sensitivity depends on the extent to 
which any real associations have been published or deposited. Ongoing efforts to 
develop robust databases of genotypes and phenotypes, if successful, will help to 
overcome these limitations. 
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4. Systematic review of the existing evidence for genotype-
driven precision therapy in epilepsy 
4.1 Introduction 
In chapter I will appraise the current evidence for precision therapy in single gene 
epilepsies. 
The most rigorous way of assessing the effectiveness of any therapeutic 
intervention comes from the double blind randomised-controlled trial (RCT). A 
well-conducted RCT should be able to determine causality of any association, and 
full double blinding should overcome any bias that would result from placebo 
response. 
RCTs must have large enough numbers of subjects in both therapy and control arms 
in order to demonstrate and quantify any significant therapeutic effect. In epilepsy 
there is a huge amount of aetiological and phenotypic heterogeneity, so this also 
means that a trial group will typically be heterogenous.  
The majority of new anti-epileptic drugs (AEDs) that have been introduced to the 
market in the last 30 years have gained a licence by demonstrating in one or more 
RCTs that they are superior to placebo when added to existing therapy in patients 
whose seizures have proved resistant to previous therapeutic regimens. It must 
also be demonstrated that they do not cause an unacceptable rate, or severity, of 
adverse effects (Ferlazzo et al., 2017). While this substantial evidence base 
informs us that many anti-epileptic drugs are efficacious, at least insofar as they 
reduce seizure frequency when used as add-on therapy, it does not help clinicians 
to decide which AED to use in any specific clinical scenario, such as age of patient, 
clinical phenotype, whether or not there has been previous treatment, or genetic 
test results. 
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Attempts to answer this last question through RCTs have been few because the 
more specific the clinical scenario the more difficult it is to recruit sufficient 
numbers of subjects to demonstrate significance. The unblinded SANAD trials 
attempted to answer the question as to whether response to first AED differed 
between patients with focal and generalised epilepsy. These trials showed that in 
focal epilepsy, the best results, in relation to efficacy and toleration, were seen 
with Lamotrigine (Marson et al., 2007a), whereas in generalised epilepsy the best 
results were seen with Sodium Valproate (Marson et al., 2007b). In a double-blind 
RCT for initial treatment of childhood absence epilepsy, Ethosuximide gave the 
best results (Glauser et al., 2010). In initial treatment of West syndrome, an 
unblinded RCT demonstrated that combined treatment with corticosteroids and 
Vigabatrin controlled infantile spasms significantly more rapidly than 
corticosteroid treatment alone (O'Callaghan et al., 2017). 
The small extent of RCT success in defined epilepsy syndromes, along with high 
profile anecdotal evidence of dramatic treatment responses in certain highly 
specific scenarios, such as the case of Charlotte Figi’s response to Cannabidiol 
(Scientific American, 2017), has driven popular demand for a precision approach to 
epilepsy therapy (Berkovic et al., 2015). However the dilemma remains that the 
more precise you want treatment to be, the harder it is to find enough patients for 
trials to generate evidence.  
Since any individual single-gene epilepsy is very rare, generation of an evidence 
base for genotype-driven therapy is particularly challenging.  Various lower grade 
approaches to evidence generation have been taken and these will now be 
reviewed systematically.   
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4.2 Methods 
I used a Medline literature search for publications reporting precision therapy in 
epilepsy, by using the following search terms: 
([epilepsy] or [seizure]) and [gene]. Search date April 18th 2018; 8534 results  
Abstracts of papers whose titles suggested made reference to therapy response in 
a specific genetic epilepsy were reviewed.  
4.3 Results 
Of 7250 results from the search, 268 abstracts were reviewed, and 43 papers 
describing precision therapy were included in the review. Eight distinct categories 
of evidence were identified. At the weakest end of this evidence base were case 
reports and case series. At the strongest end were RCTs. It must be born in mind 
that some approaches that have little supporting evidence may in fact be the most 
important, for example in the treatment of epilepsies associated with inherited 
metabolic diseases. In many of these cases, precision therapy is so biologically 
plausible that no clinical evidence beyond case reports has been sought. 
4.3.1 Outstanding case reports and small case series 
There have been numerous reports documenting a relatively unexpected treatment 
success in a genetically determined epilepsy. Such reports are hugely vulnerable to 
publication bias since authors are more inclined to publish results of successes 
than failures. Nonetheless the reports of successes, particularly if biologically 
plausible, may inform more robust projects such as clinical trials, as did the 
Charlotte Figi Cannabidiol story, which triggered an RCT of Cannabidiol in Dravet 
syndrome. 
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Remarkable treatment successes in small numbers of cases could easily be 
coincidental, or even related to factors other than the genetic cause of the 
epilepsy. In some genetic epilepsies a dramatic change in seizure frequency may 
reflect the natural history of the condition rather than a treatment response. For 
example, in KCNQ2 encephalopathy, though the associated developmental 
impairment may be severe, seizures themselves are often self-limited. Seizure 
frequency will fluctuate in all patients, so it is important to consider the timing 
and persistence of reported seizure frequency changes.                     .
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Table 4.3.1: Precision-therapy evidence: case reports and small case series. 
Paper Gene (inheritance) 
Variant and phenotype 
Therapy Summary Benefit claimed beyond 
seizures 
Biological plausibility 
(Mahajnah et al., 
2016) 
ALDH7A1 (AR) 
Biallelic variants cause 
pyridoxine dependency 
Pyridoxine 
supplementation + 
Lysine restriction 
Patient diagnosed with ALDH7A1-
related pyridoxine dependency at 3 
months of age. Commenced pyridoxine 
supplementation and Lysine restriction 
and has been seizure free until the age 
of 44 months 
Yes. Normal development 
reported 
ALDH7A1 encodes 
antiquitin, deficiency of 
which leads to pyridoxine 
depletion and Lysine 
accumulation. 
(Byers et al., 
2016) 
CACNA1A (AD)  
De novo S1373L variant 
causing early onset 
developmenal and 
epileptic 
encephalopathy (EODEE) 
Lamotrigine 6 year old child with epileptic 
encephalopathy having experienced no 
benefit from 2 previous AEDs, had a 
“precipitous decrease in seizure 
frequency and severity”, which 
persisted over one year 
Yes. Improvement in 
activity level, interaction 
and alertness reported 
Unknown 
(Dilena et al., 
2016) 
STXBP1 (AD) 
De novo nonsense 
variant causing EODEE 
Levetiracetam 1 month old baby with epileptic 
encephalopathy and multiple clonic 
seizures per day, resistant to 
Phenobarbital and Phenytoin became 
seizure free with normalised EEG after 
starting Levetiracetam 
No. Patients had severe 
developmental delay at 33 
months of age 
Possible. Both syntaxin 
binding protein (product of 
STXBP1) and SV2A (the 
target of Levetiracetam) are 
involved in synaptic vesicle 
docking at the presynaptic 
membrane. 
(Bearden et al., 
2014) 
KCNT1 (AD) 
De novo R426Q variant 
causing epilepsy of 
infancy with migrating 
focal seizures 
Quinidine 2 year old child with drug-resistant 
focal epilepsy, having failed 9 previous 
AEDs, became seizure free after 
commencing Quinidine therapy 
Yes. Improved head 
control, increased 
spontaneous movements 
and alertness, and spoke 
her first words 
 
KCNT1 encodes a neuronal 
potassium channel. 
Quinidine is a potassium 
channel blocker. 
(Joshi et al., 
2016) 
 
PIGA (XLR)  
Maternally inherited 
N179Y variant causing 
EODEE 
 
Ketogenic Diet 2 brothers with epilepsy resistant to 
multiple AEDs achieved sustained 
seizure freedom on the Ketogenic Diet 
Yes. Some developmental 
progress reported. 
Unknown 
(Foster et al., 
2017) 
SCN2A (AD) 
De novo missense 
variants causing EODEE 
 
Mexiletine 2 unrelated cases with epilepsy 
resistant to multiple AEDs achieved 
improved seizure control on Mexiletine 
No. Severe developmental 
impairment reported in 
both cases 
SCN2A encodes a neuronal 
sodium channel. Mexiletine 
is a sodium channel blocker. 
(Higurashi et al., PCDH19 (XLRF) Intermittent 5 cases. Shorter seizure cluster No Unknown 
69 
 
2015) Epilepsy with cluster 
seizures and 
developmental delay 
corticosteroids duration was reported after single dose 
IV methylprednisolone on 16 occasions 
between 5 patients. 
(Boerma et al., 
2016) 
SCN8A (AD) 
De novo missense 
variants causing early 
onset epileptic 
encephalopathy 
Phenytoin 4 cases with drug-resistant epilepsy. 
3/4 became seizure free following 
introduction of Phenytoin. In 2 cases 
seizures recurred on withdrawal of 
Phenytoin. 
Yes. 2/4 reported to have 
developmental 
improvement 
SCN8A encodes a neuronal 
sodium channel. Phenytoin 
is a sodium channel blocker. 
Abbreviations – AR – autosomal recessive, AD – autosomal dominant, XLR – X-linked recessive, XLRF – X-linked restricted to females 
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4.3.2 Larger case series 
Larger case series that report treatment response provide more robust evidence 
than isolated case reports since at least they demonstrate effects that are 
reproducible. It is often a challenge to gather a cohort of patients with an 
extremely rare disease, so these reports typically describe a group of patients that 
is quite heterogenous in phenotype severity, previous AED treatment, and seizure 
frequency. Data for these series is invariably collected retrospectively, so follow-
up is non-standardised and seizure frequency data may be subjective. The clinical 
significance of positive results from treatment is difficult to quantify due to 
absence of controls. For example, where the use of Retigabine in KCNQ2-related 
epilepsy is reported, the seizure reduction rate of 36% (Millichap et al., 2016) may 
in fact be comparable to that which would be seen with a number of conventional 
AEDs. Where a significant proportion of cases experience a dramatic response in 
what is typically a drug-resistant epilepsy, as seen with Fenfluaramine in SCN1A-
related epilepsy, case series data can be very informative (Ceulemans et al., 
2012).
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Table 4.3.2: Precision-therapy evidence: larger case series 
Paper Gene (inheritance) 
Phenotype 
Therapy Number of 
patients 
Outcomes measured Effect seen Benefit claimed 
beyond seizures? 
Biological 
plausibility 
(Mercimek-
Mahmutoglu 
et al., 2006) 
GAMT (AR) 
Guanidinoacetate 
methyltransferase 
deficiency 
Creatinine 
supplementation 
27 Reported 
improvement in 
seizure control, by 
clinician 
19/27 had improved 
seizure control 
Movement disorder 
improved in most 
patients but 
intellectual disability 
remained unchanged 
GAMT deficiency 
results in impaired 
cerebral creatinine 
synthesis 
(Khaikin et 
al., 2018) 
GAMT (AR) 
Guanidinoacetate 
methyltransferase 
deficiency 
Creatinine and 
Ornithine 
supplementation 
16 Seizure freedom, 
reported by clincian  
10/16 became seizure -
free 
2/5: movement 
disorder reportedly 
improved 
2/16 cognition 
reportedly improved 
GAMT deficiency 
results in impaired 
cerebral creatinine 
synthesis 
(Mills et al., 
2014)  
PNPO (AR) 
Pyridoxal-
phosphate-
dependent seizures 
Pyridoxal-5-
phosphate 
10 Seizure freedom, 
reported by clinician 
8/10 were seizure free 
within 3 days 
Not clear. Most had 
developmental delay 
PNPO causes 
deficiency of 
pyridoxal-5-
phosphate 
(Crespel et 
al., 2017) 
CSTB (AR) 
Progressive 
myoclonus epilepsy 
(Unvericcht-
Lundborg disease) 
Perampanel 
 
11 Seizure type and 
frequency, and any 
other symptoms, as 
reported by clinician  
Of 5 patients with 
generalised tonic-
clonic seizures, all 
became seizure free on 
Perampanel therapy 
9 patients had “clear 
improvement in 
myoclonus”. 5 
patients had 
improvements in 
mobility 
Unknown 
(Lim et al., 
2017) 
CDKL5 (X-linked) 
Presents with early 
childhood onset 
epilepsy and 
developmental 
delay 
 
Ketogenic Diet 104 Reported perception 
of seizure reduction, 
by caregiver 
59% reported seizure 
reduction. 8% reported 
seizure exacerbation. 
36% had severe side-
effects 
Improvement in 
alertness in 18%.  
Unknown 
(Millichap et 
al., 2016)  
KCNQ2 (AD) 
Epileptic 
encephalopathy 
cases 
Retigabine 11 Reported perception 
of seizure reduction, 
by caregiver  
4/11 (36%) reported 
improvement in seizure 
control. 5/11 had 
urinary retention. 
 
5/11 (45%) reported 
improvement in 
development or 
alertness 
 
 
Retigabine is an 
opener of the same 
potassium channel 
that KCNQ2 
encodes 
(Kass et al., 
2016) 
SLC2A1 (AD) 
Glut1-deficiency 
Ketogenic Diet 82 Caregiver reported 
estimation of seizure 
38/82 (46%) had 
seizure freedom, 66/83 
84% reported that 
movements and/or 
Ketogenic Diet 
provided the brain 
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related epilepsy reduction (80%) had ≥90% seizure 
reduction, and 78 
(95%) had ≥50% seizure 
reduction at latest 
follow up 
cognition was much 
better 
with an alternative 
energy source to 
glucose 
(Ceulemans 
et al., 2012) 
SCN1A (AD) 
Dravet syndrome 
Fenfluramine 11 Clinician-reported 
seizure freedom.   
8/11 (73%) had 
complete seizure 
freedom. 
Not reported Unknown 
(Anagnostou 
et al., 2016) 
POLG1 (AR) Avoidance of 
Sodium Valproate 
43 Clinician-reported 
hepatotoxicity 
22/43 (51%) patients 
with POLG-related 
Alpers syndrome 
developed Sodium 
Valproate-related 
hepatotoxicity. 
N/A Unknown 
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4.3.3 Retrospective comparative efficacy analysis 
In these studies, clinical data from patients are typically collected from multiple 
centres and retrospective seizure response data is collated. As with all 
retrospective case series, response data is rarely objective and may rely purely on 
a vaguely recalled clinical impression. With retrospective comparative analysis all 
therapies are analysed on an essentially equal footing, so there is less 
ascertainment bias than with case series. However, there is likely to be recall bias 
in favour of treatments most recently tried, since these will have had less time to 
fail. Some AEDs are far more popular than others and it is difficult to determine 
from these studies the utility of a treatment that is used in a small number of 
patients, even if the response data is good in those patients for whom it was used. 
The critical impact that timing of data acquisition can have on results is illustrated 
in the study on CDKL5 by Müller et al. (Müller et al., 2016) which reported a 3-
month response rate to Vigabatrin of 8/25 (32%) and a 12-month response rate of 
1/25 (4%). Though these studies rarely quantify the effect of any given therapy, 
they can give a sense of which treatment may be relatively more useful or more 
harmful. The best evidence that sodium channel blocking medications frequently 
exacerbate seizures in SCN1A-related epilepsy comes from this type of study 
(Brunklaus et al., 2013), though this has recently been backed up by animal studies 
(Hawkins et al., 2017).
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Table 4.3.3: Precision-therapy evidence: retrospective comparative efficacy analysis  
Paper Gene 
(inheritance) 
Number of 
patients 
Outcomes measured Effect seen Biological plausibility 
(Ebrahimi-Fakhari 
et al., 2015) 
PRRT2 (AD) 24 Seizure freedom, reported by 
clinician 
23/24 (96%) cases became seizure 
free on treatment with 
Carbamazepine  
Unknown 
(Brunklaus et al., 
2012) 
SCN1A (AD) 60 Seizure exacerbation, reported 
by clinician 
In 36/60 (60%) there was a history of 
seizure exacerbation with 
Carbamazepine treatment 
In 26/60 (43%) there was a history of 
seizure exacerbation with 
Lamotrigine treatment 
SCN1A is preferentially expressed 
in inhibitory interneurons so 
blockade of these channels may 
exacerbate neuronal 
hyperexcitability 
(Lotte et al., 2017) PCDH19 (XLRF) 58 Seizure frequency reduction by 
≥50% at 3 months after 
commencing treatment, 
reported by clinician 
For treatments taken by more than 
20 patients, the greatest response 
rates were seen with Clobazam (68%) 
Sodium Valproate (44%) and 
Phenobarbital (40%) 
 
Unknown 
(Müller et al. 2016) CDKL5 (XLR) 39 Seizure frequency reduction at 
12 months after commencing 
treatment, reported by 
clinician 
For treatments taken by more than 
20 patients, the greatest response 
rates were seen with Sodium 
Valproate (9%) and Lamotrigine (8%) 
 
Unknown 
(Pisano et al., 
2015) 
KCNQ2 (AD) 15 Seizure freedom at 2 weeks 
after commencing treatment, 
reported by clinician 
6/15 (40%) of cases were seizure free 
on Carbamazepine treatment 
5/15 (33%) were seizure free on 
Phenytoin treatment 
 
 
Reduced sodium influx is likely to 
stabilise neuronal cell membranes 
that have reduced potassium 
efflux due to KCNQ2 loss-of-
function 
(Herbst et al., 
2016) 
PAFAH1B (AD) 22 Perception of benefit, reported 
by clinician and caregiver 
All 9 families whose child had been 
treated with Lamotrigine reported it 
to be beneficial as did 7/8 clinicians 
15/17 caregivers reported that 
Sodium Valproate was beneficial as 
did 11/12 clinicians 
 
 
Unknown 
(Wolff et al., 2017) SCN2A (AD) 201 Seizure freedom, reported by In cases with seizure onset before 3 Early onset cases of SCN2A-
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clinician (timing not specified) months of age 12/19 (63%) patients 
treated with sodium channel 
blocking medications were seizure 
free, compared with 6/86 (7%) of 
patients not treated with sodium 
channel blocking medications 
In cases with seizure onset after 3 
months of age 2/39 (5%) patients 
treated with sodium channel 
blocking medications were seizure 
free compared with 12/47 (26%) of 
patients not treated with sodium 
channel blocking medications 
related epilepsy are likely to be 
the result of gain-of-function 
variants 
Late onset cases are likely to be 
the result of loss-of-function 
variants 
(Johannesen et al., 
2018) 
SLC6A1 (AD) 34 Seizure freedom, reported by 
clinician (timing not specified) 
10/15 (67%) of patients treated with 
Sodium Valproate became seizure 
free 
SLC6A1 encodes a cerebral GABA-
transporter 
Sodium Valproate potentiates 
GABAergic neurotransmission 
Abbreviations – GABA – Gamma-amino-butyric acid 
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4.3.4  Single cell models 
For ion channel-related epilepsies single-cell models have become the gold 
standard for defining the functional effects of a genetic variant and proving 
pathogenicity. The most commonly used models involve transfecting cell lines (for 
example human embryonic kidney cells or Xenopus laevis oocytes) with the variant 
being investigated, and then using the patch clamp technique (Neher & Sakmann, 
1976) to measure the properties of ion currents compared with those in wild-type 
cells (Shalaby et al., 1997). In the same models, potential therapeutic agents can 
be introduced in vitro to investigate whether they normalise any electrophysiologic 
changes associated with specific genetic variants. In order to translate this back 
into practice, medications that are successful in vitro, if already licensed for use, 
may then be tried in vivo, typically in a small number of cases. At least as a proof-
of-concept this approach has been shown to yield useful information, as 
exemplified by GRIN2A, GRIN2D, KCNT1 and SCN8A. Different missense variants in 
the same gene can have divergent effects on ion channel function, so the 
translatability of one single cell-model success to other cases with different 
variants in the same gene is uncertain. The extent to which a single cell model is 
able to represent the functional effect of complex neuronal circuits also has to be 
questioned. 
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Table 4.3.4: Precision-therapy evidence: single cell models +/- translation to clinic 
Paper Gene (inheritance) 
Variant and phenotype 
Therapy/ies Model Effect seen in humans Benefit 
beyond 
seizures? 
Biological plausibility 
(Pierson et al., 
2014) 
GRIN2A (AD) 
De novo L812M variant 
Patient with severe drug-
resistant epilepsy with onset 
at 2 months and severe 
developmental delay 
Memantine Xenopus laevis oocyte model 
in which the L812M variant 
was transfected. Memantine 
inhibited excessive NMDA 
receptor activity.  
Yes 
Trial of Memantine in the 
patient resulted in a 
seizure reduction from an 
average of 11.1 episodes 
per week to 3.3  
No 
Cognitive 
ability 
remained 
unchanged 
GRIN2A encodes an 
NMDA receptor subunit 
and Memantine is an 
NMDA receptor 
antagonist  
(Li et al., 2016) 
 
GRIN2D (AD) 
De novo V667I variant in 2 
unrelated patients with 
infantile onset drug-resistant 
epilepsy and developmental 
delay 
Memantine 
Ketamine 
Magnesium 
Xenopus laevis oocyte model 
The V667I variant was 
transfected 
Memantine Ketamine and 
Magnesium inhibited excessive 
NMDAr activity 
Yes 
Trial of Memantine 
resulted in mild to 
moderate improvement in 
seizure burden in both 
patients 
Yes 
Improvement 
in 
development 
reported 
GRIN2D encodes an 
NMDA receptor subunit 
and Memantine is an 
NMDA receptor 
antagonist 
(Milligan et al., 
2014) 
KCNT1 (AD) 
7 different disease associated 
KCNT1 mutations from 
patients with either epilepsy 
of infancy with migrating focal 
seizures or autosomal 
dominant nocturnal frontal 
lobe epilepsy  
Quinidine Xenopus laevis oocyte model 
in which the 7 variants were 
transfected 
Gain-of-function properties 
associated with the variants 
were normalised by Quinidine 
Not tried 
 
N/A KCNT1 encodes a 
neuronal potassium 
channel 
Quinidine is a 
potassium channel 
blocker 
(Barker et al., 
2016) 
SCN8A 
De novo I1327V variant 
associated with EODEE 
Phenytoin Human dorsal root anglion 
ND7/23 cells transfected with 
the I1327V variant 
Gain-of-function properties 
associated with the variant 
were normalised by Phenytoin 
Not tried 
 
N/A SCN8A encodes a 
neuronal sodium 
channel 
Phenytoin is a sodium 
channel blocker 
Abbreviations - NMDAr – N-Methyl-D-Aspartate receptor 
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4.3.5  Whole organism models 
Whole organism models more accurately reflect both the complex effects of 
genetic variants on the brain and may also represent clinical phenotypes, though in 
fact it seems that many animal models of human genetic epilepsies do not have 
seizures. In two very rare recessively inherited epilepsies – ATAD1 and STRADA – 
successful treatment of a genetically modified mouse in which both functional 
copies of a gene have been removed has been followed by successful treatment in 
humans (Ahrens-Nicklas et al., 2017; Parker et al., 2013). This approach to 
precision treatment is highly resource intensive and may be difficult to apply to 
conditions where an animal model either does not exist, or does not express the 
desired phenotype.
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Table 4.3.5: Precision therapy evidence: whole organism models +/- translation to clinic 
Paper Gene (inheritace) 
Variant and phenotype 
Therapy Model and effect Effect seen in humans Benefit beyond 
seizures? 
Biological 
plausibility 
(Ahrens-
Nicklas et 
al., 2017) 
ATAD1 (AR) 
Patients with biallelic truncating 
variants present with neonatal 
onset progressive extreme 
hypertonia encephalopathy and 
seizures (reported in a 
consanguineous family with 
homozygous nonsense variants) 
Perampanel 
(AMPA 
receptor 
antagonist) 
Knockout mouse model 
Administration of 
Perampanel reversed 
behavioural effects, 
normalised brain MRI 
abnormalities prevented 
seizures and prolonged 
survival 
2 patients with homozygous 
nonsense started on Perampanel 
Effect on seizures not reported but 
in both cases EEG normalised and 
other AEDs were weaned 
Yes 
Both cases had 
temporary 
improvement in 
tone 
 
ATAD1 regulates 
AMPA receptor-
dependent synaptic 
plasticity (Zhang et 
al., 2012) 
(Parker et 
al., 2013) 
STRADA (AR) 
Patients with biallelic truncating 
variants present with PMSE 
(polyhydramnios megalencephaly 
symptomatic epilepsy) syndrome 
Rapamycin 
(mTOR 
inhibitor) 
Knockout mouse model 
Rapamyin rescued 
aberrant cortical 
lamination and 
heterotopia 
5 patients with STRADA-related PMSE 
treated with Rapamycin 
One case reducing from 180 seizures 
per year to seizure free 
No seizure exacerbation and no 
adverse effects reported in any cases 
Yes 
Improvement in 
receptive 
language  
STRADA encodes an 
upstream inhibitor 
of mTOR (Parker et 
al., 2013) 
(Marguet et 
al., 2015) 
KCNQ2 (AD) Bumetanide 
(NKCC1 
antagonist) 
Mutant mouse model 
Transient treatment 
with Bumetanide during 
neonatal period 
restored adult wildtype 
behaviour 
Not tested N/A NKCC1 blockade is 
likely to stabilise 
neuronal cell 
membranes that 
have reduced 
potassium efflux 
due to KCNQ2 loss 
of function 
(Hawkins et 
al., 2017) 
SCN1A (AD) Clobazam Heterozygous knockout 
mouse model 
Screening of 9 AEDs in a 
mouse model of Dravet 
syndrome 
Clobazam shown to be 
most effective 
Not in this study but Clobazam is a 
frequently used treatment in Dravet 
syndrome 
N/A SCN1A loss-of-
function is thought 
to 
disproportionately 
affect inhibitory 
GABAergic neurones 
Abbreviations – AMPA - α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; mTOR – mammalian target of Rapamycin
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4.3.6  High throughput screening 
High-throughput screening for medication response in either a whole organism 
model or single cell model of genetic epilepsy offers a system for identifying 
potentially therapeutic compounds in a largely hypothesis-free manner. In a 
zebrafish model of SCN1A-related epilepsy 320 food and drug administration (FDA) 
approved compounds were screened for effect on zebrafish seizures and 
behaviour. Surprisingly, the most efficacious medication was an antihistamine 
called Clemizole (Baraban, Dinday & Hortopan, 2013). If a trial were to 
demonstrate efficacy of Clemizole in humans this could be brought to market 
relatively rapidly since it is already an approved drug.                           .
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Table 4.3.6: Precision-therapy evidence: high throughput screening 
Paper Gene (inheritance) Model Results Effect seen in humans Biological 
plausibility 
(Baraban, Dinday & 
Hortopan, 2013) 
 
SCN1A (AD) Zebrafish mutant model of SCN1A in 
which the fish have spontaneous seizures 
Screening of 320 compounds for effect 
on zebrafish seizures 
18/350 compounds significantly 
inhibited spontaneous seizures 
The largest effect was seen with 
Clemizole (an antihistamine) 
Not tried Unknown 
(Atkin et al., 2018) SCN8A (AD) Human Embryonic Kidney cells 
expressing the disease-associated 
R1871Q variant demonstrated a leftward 
shift in sodium channel activation 
90 compounds screened for effect on 
channel function 
Amitryptypline, Carvedilol, 
Nivladipine and Carbamazepine all 
demonstrated concentration-
dependent inhibition of sodium 
currents 
Not tried Carbamazepine 
is a sodium 
channel 
blocker 
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4.3.7  Open-label trials 
There are situations where, for either practicality or safety and monitoring 
reasons, blinded trials cannot be performed and an open label approach is used, as 
with the SANAD trials. Often such trials still have a control group, but often one 
which is given either a different dose of the same treatment, or an alternative 
treatment. Placebo effect is less of a concern where the objective is to compare 
two treatments for which there is no pre-conceived idea as to which is likely to be 
more efficacious.                                               .
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Table 4.3.7: Precision-therapy evidence: open label trials 
Paper Gene  
Phenotype 
Therapy Number of 
patients 
Methodology Results Biological plausibility 
(Smith-Hicks et 
al., 2017) 
MECP2 (AD) 
Rett syndrome 
Dextramethorphan 
(NMDA receptor 
antagonist) 
38 Patients randomised to 3 
different doses of 
Dextramethorphan 
Seizure frequency at 6 
months compared with 
baseline 
Formal neuropsychology 
assessments carried out at 
baseline and 6 months 
Statistically 
significant dose-
dependent reduction 
in seizures receptive 
language and 
behaviour 
Patients with Rett syndrome 
demonstrate high levels of 
CSF glutamate (NMDAr 
agonist) (Lappalainen & 
Riikonen, 1996) 
(Krueger et al., 
2013) 
TSC1/TSC1 (AD) 
Tuberous 
Sclerosis 
Complex 
Everolimus 
(mTOR inhibitor) 
20 Open label uncontrolled 
trial 
Seizure frequency over 12 
week treatment period 
compared with 4 week 
baseline 
12/20 (60%) had a 
≥50% reduction in 
seizure frequency 
Statistically 
significant 
improvements in 
questionnaire 
measurements for 
child behaviour and 
quality of life 
TSC1 and TSC2 negatively 
regular mTOR  
Everolimus is an mTOR 
inhibitor 
 
(Hess et al., 2016) TSC1/TSC1 (AD) 
Tuberous 
Sclerosis 
Complex 
Cannabidiol 18 Open label uncontrolled 
trial 
Seizure frequency at 3 
months compared with 1 
month baseline 
9/18 (50%) had a 
≥50% reduction in 
seizure frequency 
7/18 (38% 
experienced seizure 
aggravation) 
13/18 (72%) had 
reported cognitive or 
behavioural 
improvements on 
treatment 
Unknown 
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4.3.8  Double blind RCTs 
Gold standard clinical evidence will always rely on double-blind RCTs. In genetic 
epilepsy there have been four to date. In Dravet syndrome, add on Stiripentol was 
shown to be significantly more efficacious than placebo though it is not known how 
many of these patients had an SCN1A variant (Chiron et al., 2000). In a larger RCT 
of Cannabidiol in which 93% of participants had a pathogenic SCN1A variant, a 
more modest response rate was seen in the intervention arm and a more 
significant placebo response was observed, though the difference was still 
significant (Devinsky et al., 2017). In tuberous sclerosis complex (TSC), caused by 
variants in the TSC1 or TSC2 genes, the mTOR inhibitor Everolimus has been shown 
in RCTs to be effective for treating subependymal giant cell astrocytoma (SEGA) 
(Krueger et al., 2010) and renal angiomyolipomata (AML) (Bissler et al., 2013) 
associated with TSC. The EXIST-3 trial demonstrated that in patients with TSC and 
drug-resistant epilepsy Everolimus was significantly more efficacious than placebo 
at reducing seizure frequency (French et al., 2016). This study neatly provided a 
proof-of-principal that a focus on treating the underlying cause can be effective in 
controlling seizures. Whilst EXIST-3 was not able to assess any impact of 
Everolimus on non-seizure aspects of TSC, a previous open label trial involving 20 
patients aged 2-21 years treated with Everolimus over 12 weeks demonstrated 
significant improvements in validated measures of behaviour (Nisonger Child 
Behavior Rating Form) and quality of life (Quality of Life in Childhood Epilepsy 
questionnaire, QOLCE) (Krueger et al., 2013) (reported in table 4.3.8). 
Mullen et al.’s crossover RCT of Quinidine in KCNT1-related epilepsy demonstrated 
that even with very small numbers of participants and short-term seizure 
measurements, trials can be sufficiently powered to generate evidence, provided 
baseline seizure frequency is high enough. Despite some encouraging evidence for 
the use of Quinidine in KCNT1-related epilepsy from case reports (Bearden et al., 
2014) and single cell models (Milligan et al., 2014), the more robust approach of 
the RCT demonstrated that, at least in an adult and teenager group with 
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autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), there was no 
detectable benefit from Quinidine treatment (Mullen et al., 2018).
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Table 4.3.8: Precision-therapy evidence: double blind RCTs 
Paper Gene 
Phenotype 
Therapy Number of 
patients 
Methodology Results Biological plausibility 
(Chiron et al., 
2000) 
SCN1A*(AD) 
Dravet syndrome 
Striripentol 41 (21 
Stiripentol 21 
placebo) 
Placebo-controlled RCT of add on 
Stiripentol to existing therapy 
Seizure frequency at 2 months 
compared with baseline 
71% of patients in the 
Stiripentol group had a ≥50% 
reduction in seizure frequency 
compared with 5% in the 
placebo group (p <0.05) 
Unknown 
(Devinsky et 
al., 2017) 
SCN1A ** (AD) 
Dravet syndrome 
Cannabidiol 120 (61 
Cannabidiol 59 
placebo) 
Placebo-controlled RCT of add on 
Cannabidiol to existing therapy 
Convulsive seizure frequency over 
14 week treatment period 
compared with 4 week baseline 
Median frequency of convulsive 
seizures per month reduced 
from 12.4 to 5.9 (39%) in the 
CBD group compared with 14.9 
to 14.1 (13%) in the placebo 
group (p = 0.01) 
Caregiver Global Impression of 
Change was significantly 
improved in the Cannabidiol 
group compared with the 
placebo group (62% v 34%, 
p<0.05)  
Possible 
cannabinoids shown to 
target sodium channels 
(Patel et al., 2016) 
(Mullen et al., 
2018) 
KCNT1 (AD) 
Autosomal 
dominant 
nocturnal frontal 
lobe epilepsy 
Quinidine 6 (crossover 
trial) 
Order-randomized blinded 
placebo-controlled, crossover trial 
Seizure frequency on continuous 
video-EEG monitoring measured 
No difference in seizure 
frequency observed between 
intervention period and 
placebo period 
2 cases developed prolonged 
QT interval on ECG 
N/A 
(French et al., 
2016) 
TSC1 and TSC2 
(AD) 
Tuberous 
Sclerosis 
Complex 
Everolimus 366 (130 high 
dose 117 low 
dose 119 
placebo) 
Random and double- blinded 
assignment to low dose Everolimus 
high dose Everolimus, or placebo 
Seizure frequency during 12 week 
maintenance period compared 
with baseline 
40% of patients in the high dose 
group, 28% in the low dose 
group, and 15% in the placebo 
group experienced a ≥50% 
seizure reduction (p <0.05)  
Everolimus is an mTOR 
inhibitor TSC1 and TSC2 
negatively regulate mTOR 
* Inclusion in this trial was based on a clinical diagnosis of Dravet syndrome. The number of cases with SCN1A mutations is not known 
** Inclusion in this trial was based on a clinical diagnosis of Dravet syndrome. 111/120 (93%) had pathogenic SCN1A variants
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4.3.9 Discussion 
Whilst the RCT is the gold standard for generating clinical evidence, it has not 
often been applied to the therapy in specific genetic epilepsies. Moreover, the 
small number of trials that have been conducted have had significant limitations. 
All single-gene epilepsies are extremely rare recruitment to genotype-specific 
RCTs will necessarily be challenging. In order to produce useful evidence with 
small numbers of participants, these participants need to have a consistently high 
frequency of seizures at baseline. It follows that participants in such RCTs typically 
have drug-resistant epilepsy and consequently the only question that is typically 
answered is whether a treatment is efficacious as an add-on therapy. A treatment 
that is shown to be efficacious as add-on therapy may not have the same benefit if 
used as a first line treatment. In both the Stiripentol and Cannabidiol trials for 
Dravet Syndrome, it is possible that some of the clinical effect seen in the 
intervention group was through drug interactions resulting in higher levels of 
Clobazam (Luszczki et al., 2010) and Clobazam metabolites respectively (Gaston et 
al., 2017). Another limitation of the RCTs done so far is that they have lacked 
control groups without the genetic diagnosis, so it is not possible to know whether 
any anti-epileptic effect is specific to the genotype or a more general anti-
epileptic effect. Cannabidiol in fact appears to be more efficacious in a group of 
drug-resistant patients without SCN1A variants than it was in the Dravet syndrome 
trial, so its effect is unlikely to be specific to SCN1A (Devinsky et al., 2018). 
The non-RCT evidence presented here also has major limitations, the most 
prominent of which are publication bias and ascertainment bias. Case reports and 
case series can be useful in terms of guiding efforts to generate more definitive 
evidence but must be used with great caution as evidence to guide treatment in 
themselves. 
Though the advent of NGS has heralded a substantial increase in the proportion of 
patients for whom a precise genetic cause can be identified, optimism that this 
will translate to more effective precision therapy approaches has not yet been 
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realised. In Dravet syndrome, establishment of the clinical phenotype appears to 
be as strong a predictor of Stiripentol response as the identification of an SCN1A 
mutation (Cho et al., 2018). Clinical factors such as seizure type and age of onset 
may override the importance of genetic aetiology in relation to the utility of 
specific therapies. 
The idea that identifying a genetic cause in itself is sufficient to guide treatment 
approach is likely to be over simplistic. Examples of cases that buck the trend of 
established evidence for a particular therapy include patients with SCN1A-related 
epilepsy who appear to benefit from sodium channel blocking treatments (Dalic et 
al., 2015, Takaori et al., 2017). 
Variables beyond the genetic diagnosis itself that are likely to influence treatment 
include the precise functional effects of a variant, the age of the patient at the 
time of treatment, and the impact of genetic modifiers. In SCN2A-related epilepsy, 
response to sodium channel blocking medications appears to be dependent on 
predicted functional effect of the SCN2A variant. Patients with gain-of-function 
variants benefit from these therapies and patients with loss-of-function variants do 
not. Age of seizure onset is a strong predictor of which functional class of variant a 
patient has (Wolff et al., 2017). In KCNT1-related epilepsy response to Quinidine 
appears to depend on the age of the patient at the time of treatment, with most 
treatment successes being in the younger group (Abdelnour et al., 2018). Age-
dependent treatment response is not surprising since many epilepsy-associated 
genes have a highly age-dependent expression profile. In KCNQ2-related epilepsy, 
mouse model evidence suggests that the ideal therapeutic window for treatment 
would appear to be the very early neonatal period (Marguet et al., 2015). 
When considering genetic modifiers, genetic influences on susceptibility to adverse 
drug reactions (Amstutz et al., 2014), as well as determinants of drug absorption, 
distribution, action, metabolism and elimination, are all relevant (Chen et al., 
2014; Shaheen et al., 2014; Löscher et al., 2009; Saygi et al., 2014; Thompson, 
Kahlig & George, 2011). To fully understand any relationship between genotype 
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and therapy response, a truly comprehensive approach to genotyping must be 
considered, taking into account all of the above variables. Because all these 
variables make an individual genotype unique, ultimately the best evidence may 
not come from RCTs but from longitudinal studies. If such studies are to be of any 
value, it is critical that clinical and genetic data are gathered objectively, 
comprehensively, and that this data is shared between groups in order to generate 
large datasets.  
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5. Prospective study of selected gene testing in a Scottish 
population-based cohort of children < 3 years with seizures 
5.1 Introduction 
As discussed in section 3.4, existing studies of genetic testing in epilepsy are 
limited in what they can tell us about the epidemiology of the monogenic 
epilepsies, since the cohorts studied have typically been selected via a referral 
process, rather than obtained from a population-based sample. Patients selected 
for inclusion in these studies may not represent the complete spectrum of 
epilepsies observed in the population due to conscious or unconscious biases of 
referrers, who may expect that those with more severe disease, early onset, or 
additional comorbidity to be more likely to have an identifiable genetic cause. 
Conversely, such cohorts may be depleted of patients with more common genetic 
causes of epilepsy due to such diagnoses having already been made through single 
gene (Sanger) sequencing. If we want to understand how patients may benefit 
from genetically stratified therapy we must first understand the epidemiology of 
the monogenic epilepsies. 
There have been previous attempts to estimate the incidence of two monogenic 
epilepsies: SCN1A and SLC2A1.  
Pathogenic SCN1A variants are associated with a spectrum of childhood-onset 
epilepsies and febrile-seizure disorders. At the severe end of this spectrum is a 
phenotype called Dravet syndrome. Though there remains to be an international 
consensus on an absolute clinical definition of Dravet syndrome, it is generally 
accepted that the following are essential components of the diagnosis: i) onset of 
febrile or afebrile seizures in the first 12 months of life; ii) developmental slowing 
or regression following seizure-onset; iii) progression to a drug-resistant epilepsy, 
with multiple seizure types (Wirrell et al., 2017). In 80% of Dravet syndrome cases, 
there is an associated pathogenic variant in SCN1A (Depienne et al., 2009; Zuberi 
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et al., 2011). Hence the clinical condition has verged on becoming synonymous 
with the gene.  
There have been two attempts to determine the incidence of SCN1A-related 
Dravet syndrome. Wu et al. reviewed the electronic notes of 125,547 infants born 
at Kaiser Permanente northern California from 2007-2010. Records of all those who 
had had two or more seizures before the age of 12 months and who were 
prescribed anti-epileptic medication by the age of 24 months were reviewed. 
Objective criteria for a diagnosis of Dravet syndrome were used and defined as 
follows: i) normal or near-normal cognitive and motor development before the 
onset of seizures; ii) seizure semiology consisting of myoclonic, hemiclonic, or 
generalised tonic-clonic seizures; iii) At least two seizures lasting longer than 10 
minutes; iv) failure to respond to first-line anti-epileptic medication; v) continued 
seizures after two years of age. From this cohort, the authors identified eight 
children who satisfied these diagnostic criteria for Dravet syndrome, six of whom 
had an associated SCN1A variant (the other two did undergo SCN1A gene analysis 
but were not found to have a causative variant). They estimated the incidence of 
Dravet syndrome to be 1 per 15,700 live births, and the incidence for SCN1A 
related Dravet syndrome to be 1 per 20,900 live births (Wu et al., 2015).  
The main limitation of this study relates to the clinical definition of Dravet 
syndrome, which has not been based on any international consensus opinion. 
SCN1A-related epilepsies present a spectrum of epilepsies which have multifaceted 
components, including age of seizure onset, seizure type(s), seizure duration, and 
developmental comorbidity. This encapsulates the challenge for epidemiological 
study of monogenic epilepsies.  At the mild end of the SCN1A-related epilepsy 
spectrum there are individuals who only have febrile seizures and who develop no 
associated comorbidities. At some undetermined point on the spectrum, the 
phenotype is deemed severe enough to merit the label “Dravet syndrome.” 
Patients with the “full house” of features may be easy to label as Dravet 
syndrome, but what about those who develop all the typical clinical features, but 
happen to present at little later than usual, say at 13 months of age? Or what 
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about those who achieve good seizure control, for example with the early 
application of the promising new medication Fenfluramine (Ceulemans et al., 
2012), but still develop the associated comorbidities? 
It with these complexities in mind that the epidemiological study reported in this 
chapter of the thesis has made every attempt not to be constrained by phenotype 
selection. The objective here is to identify every individual within a defined 
population presenting with epilepsy or complex febrile seizures and to ensure that 
as many as possible get genetic testing. In that way it should be possible to define 
the true incidence, and associated phenotypic spectrum of, each monogenic 
epilepsy. 
The incidence of SCN1A-related Dravet syndrome has been estimated in Denmark 
to be 1 per 22,000 live births (Allan, Helle & Møller, 2015). Semi- objective clinical 
criteria were used to define those who satisfied a diagnosis of Dravet syndrome: i) 
seizure onset before 12 months; ii) “mainly” fever triggered and “often” prolonged 
[inverted commas added]; iii) later occurrence of other seizure types including 
focal seizures, myoclonic seizures, atypical absences, and tonic-clonic seizures; iv) 
normal motor an cognitive development prior to seizure onset; v) subsequent 
plateauing or regression of skills. In addition to the same limitations in relation to 
clinical definition as identified in the Wu study, this study from Denmark is 
vulnerable to selection bias. All patients were identified from the single national 
tertiary epilepsy centre, making the assumption that all patients with this severity 
of epilepsy would be referred to that centre. The study in this chapter aims to 
overcome such bias by recruiting from 24 different paediatric departments across 
Scotland, not just tertiary centres. Similar, single tertiary centre approaches have 
been used to estimate the incidence of Glut1 deficiency syndrome, which is caused 
by pathogenic variants in the SLC2A1 gene. The quoted figures are 1 per 90,000 
live births in Queensland Australia (Coman et al., 2006), and 1 per 88,000 live 
births in Denmark (Larsen et al., 2015b). Selection bias is likely to be a bigger issue 
in relation to SCL2A1 than in relation to SCN1A, since this is more recently 
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described, and the full phenotypic spectrum of the disorder is therefore less likely 
to have been fully revealed.  
In addition to describing the epidemiology and clinical spectrum of the monogenic 
seizure disorders of early childhood, a secondary objective of this chapter is to 
determine in what proportion of all children presenting with epilepsy before their 
third birthday an underlying aetiology can be identified: including structural, 
metabolic, infectious, and immune causes. Thanks to advances in genetic, 
neuroimaging, and immunological investigations – coupled with an increased 
awareness among clinicians that these causes exist and can be investigated for – it 
is becoming increasingly possible to ascribe a precise aetiological cause to epilepsy 
in cases that would have previously been designated “idiopathic” or “cryptogenic.” 
Berg et al. reviewed the records of 775 children who were diagnosed with epilepsy 
before their third birthday. They were able to identify an aetiology in 227 patients 
(29.3%). These patients were identified from 17 epilepsy centres in the United 
States, but the sample was not population-based and the extent to which they 
were investigated for aetiology was limited – for example 448 of the patients did 
not undergo any form of genetic testing (Berg et al., 2017). With a more proactive 
approach to genetic testing, this chapter will investigate how much higher an 
aetiological yield can be obtained. 
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5.2 Methods 
5.2.1 Cohorts 
In this study I involved two overlapping cohorts. Both cohorts only included 
children who presented prior to their third birthday, and both cohorts only 
included those who presented between May 8th 2014 and May 7th 2017. The first 
cohort was a Scotland-wide cohort and the second cohort was a West of Scotland 
cohort, including only patients residing in the following Health Board regions: 
Ayrshire and Arran, Dumfries and Galloway, Forth Valley, Greater Glasgow and 
Clyde, and Lanarkshire. The majority of patients in Cohort 1 were identified 
prospectively through recruitment to the Genetic and Autoimmune Childhood 
Epilepsy (GACE) study (Symonds et al., 2019). The primary aim of the GACE study 
was to determine the diagnostic and clinical utility of genetic and autoantibody 
testing in patients with early childhood onset epilepsy of undetermined cause.  
Patients in the Cohort 2 were retrospectively identified through reviewing the case 
notes of all children who were investigated using electroencephalography (EEG) 
between January 1st 2014 to December 31st 2017 in the EEG departments serving 
the West of Scotland (Royal Hospital for Children [RHC] Glasgow, Crosshouse 
Hospital Kilmarnock, and Forth Valley Royal Hospital Larbert), n = 1174. 
Population and birth rate denominators for these cohorts were obtained from the 
National Records of Scotland, birth time series data (National Records of Scotland, 
2018b), and 2011 census data (National Records of Scotland, 2018a).  
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Table 5.2a: Summary of Cohort 1 and Cohort 2 
 Cohort 1 Cohort 2 
Inclusion criteria Presentation before the day of the third birthday 
and 
Presentation between May 8th 2014 and May 7th 2017 
and 
Any one the following: 
• 2nd afebrile unprovoked seizure 
• 2nd prolonged (>10 minute) febrile seizure 
• 1st episode of febrile or afebrile status epilepticus (>30 
minutes) 
• Cluster of two or more febrile or afebrile seizures within 
a 24-hour period 
Exclusion criteria 
 
An aetiology that would 
explain seizures/epilepsy 
already established by the 
time of presentation, or 
through neuroimaging or 
biochemical testing, shortly 
after presentation 
Not living in one of the following 
Health Board areas: 
Ayrshire and Arran,  
Dumfries and Galloway,  
Forth Valley,  
Greater Glasgow and Clyde,  
Lanarkshire 
Case identification Recruited to the GACE study 
and/or 
Referred for genetic testing 
through the national epilepsy 
genetic service 
In Cohort 1 
and/or 
EEG done at RHC Glasgow, 
Crosshouse or Forth Valley 
hospital between 01.01.2014 
and 31.12.2017 and < 4 years at 
the time of EEG 
Number of cases 322 313 
Cases in both cohorts 194 
5.2.2 Cohort 1: Methodology 
5.2.2.1 Introduction 
The Genetic and Autoimmune Childhood Epilepsy (GACE) study is a Scotland-wide 
multicentre prospective cohort study. The aim of the study is to identify all cases 
of new onset epilepsy without a cause already known at presentation and then to 
determine the diagnostic and clinical utility of genetic and anti-neuronal antibody 
testing in this group. All families recruited were offered genetic testing on a 104-
gene panel of epilepsy associated genes, and antibody testing for 10 antineuronal 
antibodies. Cases presenting with atypical febrile seizures (detailed in the 
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inclusion criteria above) or with either a single episode of afebrile status 
epilepticus or a single cluster of afebrile seizures within a 24-hour period were also 
eligible for inclusion. The rationale for including these additional cases was that it 
is recognised that some genetic epilepsies, most notably SCN1A-related epilepsy, 
present first with febrile seizures before the onset of unprovoked seizures 
(Brunklaus et al., 2012), and we did not wish to delay testing in such cases. 
5.2.2.2 Recruitment 
The GACE study was opened simultaneously in 11 of the 15 NHS Health Boards in 
Scotland (Figure 5.2a). Within those regions, participants could be recruited at all 
NHS health care facilities where it was anticipated that children presenting with 
seizures would be seen and assessed. This included four tertiary paediatric 
hospitals, 10 district general hospitals with paediatric inpatient services, and 10 
district general hospitals with community based paediatric facilities (see Figure 
5.2b). Though the study was not opened in NHS Orkney, NHS Shetland and NHS 
Western Isles, patients residing within these health board areas could be recruited 
to the study either following transfer to a secondary or tertiary paediatric unit, or 
on visiting outpatient assessment by a paediatric neurologist – a paediatric 
neurologist from Dundee does a regular clinic in both Orkney and Shetland. The 
Golden Jubilee Health Board does not provide either acute or outpatient paediatric 
services.  
Patients who were not recruited to the GACE study but who were referred for 
diagnostic genetic testing at the Scottish Genetic Epilepsy Service at the West of 
Scotland Regional Genetics Service were also included in Cohort 1. The Scottish 
Genetic Epilepsy service is nationally funded via the NHS Scotland National 
Services Division (NSD) (NHS Scotland, 2018). NSD services are free for all NHS 
Boards in Scotland to access and use. The Genetic Epilepsy Service is the only 
laboratory that provides diagnostic testing for sequence variants in epilepsy-
associated genes, so it is anticipated that few if any Scottish patients with epilepsy 
would receive a genetic diagnosis of a single gene cause of epilepsy elsewhere. 
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In order to facilitate maximum recruitment to the GACE study, a link clinician was 
identified in each Health Board. Each link clinician was sent a weekly reminder 
email about the study. All link clinicians were either paediatric neurologists or 
paediatricians with expertise in epilepsy. All link clinicians were active 
participants in the Scottish Paediatric Epilepsy Network (SPEN) (Scottish Paediatric 
Epilepsy Network, 2018), a Managed Clinical Network that is also supported 
through NSD. MCNs are defined as “linked groups of health professionals and 
organisations from primary, secondary and tertiary care, working in a co-ordinated 
manner, unconstrained by existing professional and Health Board boundaries, to 
ensure equitable provision of high quality clinically effective services” (NHS 
Education for Scotland, 2018). SPEN organises regular educational and training 
events for clinicians involved in the management of childhood epilepsy and 
supports the development of standards of care for children with epilepsy in 
Scotland. The GACE study was actively promoted at each SPEN meeting and in 
SPEN newsletters.  
There are eight EEG departments in Scotland that perform paediatric EEG (in 
Inverness, Aberdeen, Dundee, Kirkcaldy, Larbert, Edinburgh, Glasgow, and 
Kilmarnock).  A contact was identified in each of these EEG departments, and this 
person was sent a weekly reminder email about the study. 
There are 17 paediatric epilepsy specialist nurses in Scotland. Each was sent a 
weekly reminder about the study. 
Inclusion and exclusion criteria for Cohort 1 are detailed in table 5.2a.
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Figure 5.2a: Health Boards in Scotland
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Figure 5.2b: Recruitment sites for Cohort 1 
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5.2.2.3 Consent 
The carers of participants recruited to the GACE study were asked to give informed 
consent for the following: 
• Genetic testing on a 104-gene epilepsy panel at the West of Scotland 
Regional Genetics Service in Glasgow 
• Immune testing for 10 autoantibodies at the Nuffield Department of Clinical 
Neurosciences at the University of Oxford 
• To be sent a series of questionnaires two months after recruitment and a 
second set 12 months’ after 
• For the research team to discuss the participant’s clinical case with their 
hospital doctor or GP, and examine electronic and paper medical records 
• For the participant’s paediatrician to be sent follow-up questionnaires for a 
clinical update, and to enquire about the impact of genetic testing 
The Parent Information Sheet and Parent Consent Form for the study are supplied 
in Appendix 1 and 2 respectively. 
5.2.2.4 Ethical approval 
The GACE study was approved by the West of Scotland Research Ethics Service 
(WoSRES) on December 11th 2013 (REC number 13/WS/0299, IRAS ID 135019). 
A separate ethical approval for a genetic epilepsy research database was granted 
by WoSRES in 2012, and was updated on January 23rd 2017 (REC number 
16/WS/0203, IRAS ID 214468). This approval specifically permits the analysis of 
anonymised clinical and genetic data from patients referred to the National 
Genetic Epilepsy Service and therefore allows cases not included in the GACE study 
to be included in Cohort 1. 
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5.2.2.5 Initial clinical evaluation 
At the time of recruitment to the GACE study, the recruiting clinician was asked to 
complete a clinical detail proforma (Appendix 3). Details of age of onset, seizure 
types, relevant comorbidities, EEG findings, neuroimaging findings, family history 
and prior investigations were gathered for each patient. Within two months of 
recruitment parents of participants were sent standardised questionnaires, 
including the Adaptive Behaviour Assessment Tool II (ABAS II) questionnaire, which 
is a validated measure of adaptive behaviour in early childhood (Floyd et al., 
2015). It was hoped that the ABAS-II would provide a more sensitive and objective 
measure of any early developmental comorbidity that clinician impression alone. 
Parents were also sent standardised questionnaires to assess Health Related 
Quality of Life (ELDQOL or Peds-QL) and parental adjustment (Parent Stress Index 
and Strengths and Difficulties Questionnaire). 
For cases not recruited to the GACE study who are included in Cohort 1, a different 
clinical details proforma was completed (Appendix 4). This was a requirement 
before genetic testing was activated. Parental questionnaires were not sent out to 
these families. 
5.2.2.6 Follow-up clinical evaluation 
Six months after each participant’s genetic report was issued, the recruiting 
clinician was sent a clinical follow-up questionnaire (Appendix 5), along with a 
questionnaire asking them about the utility of genetic testing (Appendix 6). The 
clinical follow-up questionnaire asked for many of the same details as the initial 
clinical details proforma, recognising that since cases were recruited to the GACE 
study early in their presentation, further clinical features may have become 
apparent since recruitment. 
12 months after recruitment, provided genetic results had been fed back to 
families, parents were asked to complete a second set of questionnaires which was 
identical to the first set. 
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5.2.2.7 Case review 
The clinical details proformas of all cases recruited to the GACE study were 
reviewed by a panel of three paediatric neurologists, to ensure that each case 
satisfied the inclusion criteria, that clinical details were sufficiently complete, and 
to determine whether accelerated testing of any specific genes was indicated. 
5.2.2.8 Testing procedure and variant interpretation 
For all cases in Cohort 1, clinicians requesting genetic testing were asked to obtain 
a 4ml blood sample in an EDTA tube from each patient. This was sent to the 
Genetic Epilepsy Service for DNA extraction and sequencing. 
At the bottom of the clinical details proforma (Appendix 3) recruiting clinicians 
were asked if they wanted accelerated Sanger sequencing of one or more of 10 
genes to be carried out. For some of these genes dosage studies in the form of 
Multiplex Ligation Probe Amplification (MLPA) was carried out in tandem with 
Sanger sequencing (Appendix 7). Sanger sequencing could be carried out 
significantly more quickly than gene panel testing, MLPA can detect copy number 
losses and exonic deletions that would otherwise be missed on panel testing. 
In cases where no single gene testing was requested and cases where single gene 
testing did not return a diagnostic result, samples were tested on an Illumina 
MiSeq custom designed panel of 104 genes associated with epilepsy (Appendix 8).  
Variants identified were classified in accordance with the UK Association for 
Clinical Genetic Science (ACGS) guidelines (Association for Clinical Genetic 
Science, 2017) with reference to the American College of Genetics and Genomics 
(ACGM) guidelines on variant interpretation (Richards et al., 2015). According to 
these guidelines variants are classified as 1 – benign, 2 – likely benign, 3 – 
uncertain significance, 4 - likely pathogenic, and 5 – pathogenic. Any variants 
classified as 3, 4, or 5 were brought to a multidisciplinary discussion (MDD) 
involving paediatric neurologists, clinical geneticists and clinical scientists. At the 
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MDD, variant and clinical details were reviewed and a decision on final 
interpretation made. Outcomes from the MDD depend on the strength of the 
evidence supporting pathogenicity of the variant, inheritance pattern, and clinical 
phenotype information (see table 5.2b). 
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Table 5.2b: Workflow for genetic variants identified 
Outcome from genetic testing Workflow 
No class 3, 4 or 5 variants identified Case not taken to MDD. Negative report issued. No 
parental samples requested. 
Single heterozygous class 3, 4 or 5 variant 
identified in a gene associated with 
recessively-inherited disease 
Case taken to MDD.  
If in silico evidence for pathogenicity sufficiently 
strong and clinical phenotype in keeping with the 
published literature, consideration of further testing 
(e.g. array CGH) to look for a deletion affecting the 
other allele. Otherwise negative report issued and no 
parental samples requested. 
Homozygous class 3 variants identified in a 
gene associated with recessively-inherited 
disease 
Case taken to MDD.  
If in silico evidence for pathogenicity sufficiently 
strong and clinical phenotype in keeping with the 
published literature then upgrading variant to class 4 
considered. Parental samples requested to inform 
recurrence risk. 
 
Two or more heterozygous variants 
identified in a gene associated with 
recessively-inherited disease, at least one of 
which is a class 3 variant. 
Case taken to MDD.  
Parental samples requested to determine whether the 
variants are in cis or trans.  
If variants are in trans, in silico evidence for 
pathogenicity sufficiently strong, and clinical 
phenotype in keeping with the published literature 
then upgrading variant(s) to class 4 considered. 
Heterozygous class 3 variant identified in a 
gene associated with dominantly-inherited 
disease 
Case taken to MDD.  
If in silico evidence for pathogenicity sufficiently 
strong and clinical phenotype in keeping with the 
published literature then parental samples requested. 
Following parental testing, if the variant has been 
inherited from a similarly affected parent, or has 
arisen de novo in a gene commonly associated with de 
novo presentation, upgrading variant to class 4 
considered. 
Hemizygous class 3 variant identified in a 
gene associated with X-linked recessive 
inheritance 
Case taken to MDD.  
If in silico evidence for pathogenicity sufficiently 
strong and clinical phenotype in keeping with the 
published literature then parental samples requested. 
If the variant has been maternally inherited, 
upgrading variant to class 4 considered. 
Heterozygous class 3 variant identified in a 
gene associated with X-linked dominant 
inheritance 
Case taken to MDD.  
If in silico evidence for pathogenicity sufficiently 
strong and clinical phenotype in keeping with the 
published literature then parental samples requested. 
If the variant has arisen de novo or been inherited 
from a similarly affected mother, upgrading of 
variant to class 4 considered 
Homozygous class 4 or 5 variants identified 
in a gene associated with recessively-
inherited disease 
Case taken to MDD.  
Reported as causative unless phenotype is highly 
atypical. Parental samples requested to inform 
recurrence risk 
Two or more class 4 or 5 variants identified 
in a gene associated with recessively-
inherited disease 
Case taken to MDD.  
Parental samples requested to determine whether the 
variants are in cis or trans.  
If variants are in trans, variants reported as causative 
unless phenotype is highly atypical. 
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Heterozygous class 4 or 5 variant identified 
in a gene associated with dominantly 
inherited disease 
Case taken to MDD.  
Reported as causative unless phenotype is highly 
atypical. Parental samples requested to inform 
recurrence risk. 
Hemizygous class 4 or 5 variant identified in 
a gene associated with X-linked recessive 
inheritance 
Case taken to MDD.  
Reported as causative unless phenotype is highly 
atypical. Parental samples requested to inform 
recurrence risk. 
Heterozygous class 4 or 5 variant identified 
in a gene associated with X-linked dominant 
inheritance 
Case taken to MDD.  
Reported as causative unless phenotype is highly 
atypical. Parental samples requested to inform 
recurrence risk. 
All cases presenting at under four months of age who did not have a positive 
diagnosis on panel testing had MLPA for KCNQ2 carried out. 
For all patients, a final result from genetic testing was issued to the requesting 
clinician. Where variant interpretation was altered by the results of parental 
testing a second report was sent. 
5.2.3 Cohort 2: Methodology 
Because cases with established aetiology were excluded from the GACE study and 
would be unlikely to be referred for clinical genetic testing, analysis of Cohort 1 
will be uninformative in telling us about the overall incidence of epilepsy in the 
under three years age group. Moreover, Cohort 1 cannot tell us the incidence of all 
genetic epilepsies in this group, since some genetic aetiologies may have been 
established prior to presentation with seizures, or would be diagnosed through 
means other than single gene or panel testing. Array CGH testing is carried out at 
regional laboratories in Aberdeen, Dundee, and Edinburgh as well as Glasgow. 
For Cohort 2, patients were identified retrospectively through reviewing all 
referrals for EEG investigations at the Royal Hospital for Children (RHC) in 
Glasgow, Forth Valley Royal Hospital, and Crosshouse Hospital.  Postcodes were 
reviewed and checked against the National Records of Scotland list of postcodes 
covered by each of the 2014 Health Boards to determine the Health Board of 
residence of each patient.                 . 
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Departmental EEG registers of all patients who had undergone EEG investigation at 
RHC Glasgow, University Hospital Crosshouse and Forth Valley Royal Hospital were 
reviewed and filtered to include only those who were under the age of four years 
at the time of EEG and whose EEG was done between January 1st 2014 and 
December 31st 2017 inclusive. Medical notes of all of these cases were then 
reviewed to see if they satisfied the inclusion criteria in Table 5.2a.  
The following minimum dataset was collected in each case (Table 5.2c): 
Table 5.2c: Minimum dataset for Cohort 2 
Data point Categorical options 
Is the patient also in Cohort 1? Y 
N 
Health Board region Ayrshire and Arran,  
Dumfries and Galloway,  
Forth Valley  
Greater Glasgow and Clyde, 
Lanarkshire 
Date of birth dd/mm/yyyy 
Eligible for Cohort 1? Y 
N 
Date of inclusion seizure dd/mm/yyyy 
Inclusion seizure category Febrile status epilepticus (30 minutes or longer) 
Febrile seizure cluster (2 or more within 24 hours) 
2nd prolonged (>10 minute) febrile seizure 
Afebrile status (30 minutes or longer) 
Unprovoked cluster of afebrile seizures (2 or more within 
24 hours) 
Acute symptomatic afebrile seizures (record provoking 
factor) – single episode or recurrent 
2nd unprovoked seizure (i.e. epilepsy diagnosed) 
Inclusion seizure type  Generalised clonic or tonic clonic 
Absence 
Myoclonic 
Myoclonic absence 
Atonic 
Tonic 
Epileptic spasms 
Focal 
Unclassified 
Were epileptic spasms diagnosed? Y 
N 
Date of onset of spasms dd/mm/yyyy 
Date of most recent follow-up dd/mm/yyyy 
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Diagnosis at most recent follow-up 1.  Hypoxic ischaemic encephalopathy (HIE) 
1A. HIE – no seizures 
1B. HIE – seizures resolved 
1C. HIE – seizures continued beyond day 28 or patient 
remained on treatment 
2.  Febrile status 
2A. Single episode of febrile status 
2B. Recurrent episodes of febrile status 
2C. Febrile status plus other febrile seizures 
2D. Febrile status plus single afebrile seizure (status or 
otherwise)* 
3. Febrile clusters 
3A. Single cluster of febrile seizures (2 or more within 24 
hours) 
3B. Recurrent clusters of febrile seizures (2 or more within 
24 hours) 
3C. Single cluster of febrile seizures (2 or more within 24 
hours) plus other febrile seizures 
3D. Single cluster of febrile seizures (2 or more within 24 
hours) plus a single afebrile seizure (status or otherwise)* 
* febrile status plus recurrent afebrile seizures should be 
recorded as epilepsy 
4. Recurrent prolonged febrile seizures 
Recurrent prolonged febrile seizures (>10 minutes) 
5. Afebrile status or cluster  
5A. Single episode of afebrile status 
5B. Single cluster of unprovoked seizures 
6. Acute symptomatic seizures 
6A. Single episode of acute symptomatic seizures (clear 
cause identified**, seizures resolved within 28 days of 
event and treatment stopped***) 
6B. Recurrent episodes of acute symptomatic seizures 
** e.g. neonatal stroke, hypoglycaemia, gastroenteritis, 
ADEM etc.   
*** If seizures persisted beyond 28 days or remained on 
treatment, record as epilepsy (7.) 
7. Epilepsy 
Epilepsy (i.e. recurrent unprovoked seizures) 
MRI brain done? Y 
N 
MRI brain date dd/mm/yyyy 
MRI brain findings freetext 
Structural aetiology identified? Y 
N 
Structural aetiology details freetext 
Metabolic aetiology identified Y 
N 
Metabolic aetiology details freetext 
Genetic aetiology identified? Y 
N 
Genetic aetiology details freetext 
Immune aetiology identified? Y 
N 
Immune aetiology details freetext 
Infectious aetiology identified? Y 
N 
Infectious aetiology details freetext 
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Classification of epilepsy freetext 
Current treatment Never had regular AED therapy 
Previous AED therapy, now off medication 
Still on first AED monotherapy 
On second AED monotherapy (first did not control) 
On second AED monotherapy (first not tolerated) 
On second AED monotherapy (had come of first then 
seizures recurred) 
AED polytherapy (two or more AEDs at the same time) 
Other - freetext 
Drug-resistant epilepsy*? 
* defined as having moved onto 3rd 
AED for efficacy reasons or 
continuing to have at least one 
seizure in 6 months despite at 
least 6 months of treatment with 
a second AED 
Y 
N 
Current AEDs or other therapies freetext 
Current seizure frequency None in the last 6 months 
< 1 per month: At least one seizure in the last 6 months 
but an average of fewer than one per month 
Monthly: Average of at least one per month, but fewer 
than one per week 
Weekly: Average of at least one per week, but fewer than 
one per day 
Daily: Average of one or more per day 
Developmental status No concerns 
Global developmental delay 
Other concerns 
5.2.4 Whole Genome Sequencing 
Patients from Cohort 2 who had a diagnosis of drug-resistant epilepsy (see row 27. 
in Table 5.2b) or epileptic spasms (see row 8 in Table 5.2b) and for whom no 
aetiology explaining epilepsy had been identified were offered Whole Genome 
Sequencing (WGS). Methods are described in section 6.1  
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5.3 Results 
5.3.1 Cohort 1: Recruitment and estimation of under recruitment 
338 patients were recruited to the GACE study, of whom 49 were excluded from 
Cohort 1. 24 were excluded because their recruitment seizure occurred before May 
8th 2014, four were excluded because the recruitment seizure occurred after the 
3rd birthday, 16 were excluded because an aetiology had already been identified 
prior to the recruitment seizure, three were excluded because all events were 
determined to be non-epileptic, and two were excluded because no seizure 
satisfied the criteria for eligibility.  
An additional 33 eligible patients were identified through reviewing all 695 
referrals for genetic testing at the National Genetic Epilepsy Service between April 
1st 2014 and December 31st 2017. A total of 322 eligible patients were identified. 
DNA samples were obtained from 315 of these and tested in Glasgow (Figure 5.3a).
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Figure 5.3a: Recruitment flowchart for Cohort 1
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Because the study centre for the GACE study was in Glasgow it was expected that 
there would be a sampling bias, with a greater proportion of eligible cases 
recruited from the Greater Glasgow and Clyde Health Board than from other 
Health Boards. Total under 3 years population estimates for each Health Board 
region are based on 2011 census data (National Records of Scotland, 2018a) (see 
Table 5.3a). 
Table 5.3a: Under 3 years of age population estimate by year (National Records 
of Scotland, 2018a) 
 
Health Board 2011 2012 2013 2014 2015 2016 Mean % of 
total 
Ayrshire & Arran 11820 11710 11585 11159 10953 10971 11366 6.5 
Borders 3366 3344 3456 3501 3387 3328 3397 2.0 
Dumfries & Galloway 4570 4432 4266 4057 4005 3956 4214 2.4 
Fife 12661 12556 12304 11916 11806 11643 12148 7.0 
Forth Valley 9929 9868 9685 9532 9322 9248 9597 5.5 
Grampian 19508 19523 19349 19208 19083 19079 19292 11.1 
GG&C 38161 38794 39253 38516 37980 37643 38391 22.1 
Highland 9928 9682 9535 9257 9075 9107 9431 5.4 
Lanarkshire 22546 22336 22133 21514 21396 21211 21856 12.6 
Lothian 29898 29664 29814 29159 28908 28855 29383 16.9 
Orkney 658 640 630 587 580 558 609 0.4 
Shetland 847 821 822 782 767 737 796 0.5 
Tayside 12783 12828 12857 12626 12510 12217 12637 7.3 
Western Isles 751 733 735 756 720 712 735 0.4 
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Figure 5.3b: Recruitment to Cohort 1 by Health Board population
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Figure 5.3b compares the proportion of total patients in Cohort 1 with the 
proportion of < 3 years population in each Health Board. In the Greater Glasgow 
and Clyde and Tayside Health Boards the proportion of total cases recruited was 
significantly greater than the total proportion of the < 3 years population. If 
recruitment in all the other Health Boards had matched that of Greater Glasgow 
and Clyde and Tayside, additional 150 cases would have been expected, and would 
have made the total in Cohort 1 465. Figure 5.3c shows that recruitment to Cohort 
1 was consistent throughout the study period, though there were fewer 
presentations with febrile seizures in the months May to July.        .
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Figure 5.3c: Recruitment to Cohort 1 by month of presentation and type of presentation 
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5.3.2 Capture-recapture to estimate cases missing from Cohort 1 
The total number of patients identified in Cohort 2 was 313, of whom 194 had 
been recruited to Cohort 1.  
The majority of additional patients in Cohort 2 (83/119) picked up through review 
of EEG records were not eligible for Cohort 1, owing to the fact that an aetiology 
was established prior to, or immediately after, seizure presentation. However, 36 
patients in Cohort 2 were found to be eligible for Cohort 1 but had not been 
recruited to the cohort. Conversely, there were 53 patients in Cohort 1 who were 
not also identified through reviewing EEG requests (they had not had an EEG during 
the period of January 1st 2014 to December 31st 2017). Figure 5.3c shows the 
overlap between patients in Cohort 1 and patients in Cohort 2 that were eligible 
for Cohort 1 but were not included. 
 
Figure 5.3d: West of Scotland patients eligible for inclusion in Cohort 1 
according to whether they were recruited to the cohort, and whether they had 
been investigated with EEG between 01/01/2014 and 31/12/2017 
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Using a capture-recapture technique it is possible to estimate the number of 
additional “unidentified” patients that would have been eligible for Cohort 1 from 
the West of Scotland Health Boards.  Because patients who had received a 
diagnosis of epilepsy were more likely to be investigated with EEG than those who 
had not received a diagnosis of epilepsy, cases have been divided into two groups: 
those diagnosed with epilepsy and those not diagnosed with epilepsy. Figures 5.3e 
and 5.3f represent the data in Figure 5.2d with cases divided into epilepsy and 
non-epilepsy groups. 
 
Figure 5.3e: West of Scotland patients with epilepsy eligible for inclusion in 
Cohort 1 according to whether they were included in the cohort, and whether 
they were investigated with EEG between 01/01/2014 and 31/12/2017 
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Figure 5.3f: West of Scotland cases without epilepsy eligible for inclusion in 
Cohort 1 according to whether they were included in the cohort, and whether 
they were investigated with EEG between 01/01/2014 and 31/12/2017 
Figure 5.3e shows that of 136 patients with epilepsy who were recruited to Cohort 
1 119 (87.5%) had been investigated with EEG, and that an additional 13 patients 
with epilepsy were identified through EEG review. The expected additional number 
of unrecruited epilepsy patients that had not been investigated with EEG would 
therefore be 2 (13/0.875 – 13), making the expected total number of West of 
Scotland epilepsy patients eligible for Cohort 1 151.  
Figure 5.3f shows that of 58 patients without epilepsy who were recruited to 
Cohort 1 22 (37.9%) had been investigated with EEG, and that an additional 23 
patients were identified through EEG review. The expected additional number of 
unidentified non-epilepsy patients that had not been investigated with EEG would 
therefore be 38 (23/0.379– 23), making the expected total number of West of 
Scotland non-epilepsy patients eligible for Cohort 1 119. 
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Adding these figures up, there was an estimated under ascertainment of patients 
in the West of Scotland of 28% (76 patients). The expected total number of West of 
Scotland patients eligible for Cohort 1 is estimated to be 270 whilst the actual 
number included was just under three quarters of this figure, 194. Given that the 
West of Scotland Health Boards comprise 49.13% of the < 3 years population, and 
assuming that presentations with seizures are equally distributed geographically 
per head of the population, the expected total number of patients eligible for 
Cohort 1 nationally would be 550 (270/0.4913), whereas only 58% of this number 
were actually included in Cohort 1 (322). 
5.3.3 Single gene diagnoses made in Cohort 1 
315 patients in Cohort 1 underwent genetic testing. 183 patients had single gene 
sequencing of one or more genes (Sanger +/- MLPA) initially. Of these 22 (13.6%) 
had a diagnostic result. The 162 patients for whom single gene sequencing was 
requested without a diagnostic result, and the 133 for whom no single gene testing 
was requested, were tested on the 104 gene panel. Of the 295 patients tested on 
the panel, 50 (16.9%) had a diagnostic result. Panel diagnosis rates were marginally 
higher in the group that had not had prior single gene sequencing compared with 
those who had (19.5% v 14.8%) though this was not statistically significant (Fishers 
exact, p = 0.35). 32/50 (64%) diagnoses made on panel testing involved genes for 
which a single gene test was available in Glasgow, but had not been specifically 
requested. 21 patients had MLPA requested for one or more single genes following 
a negative panel result, and two of these resulted in a diagnostic finding (both in 
the KCNQ2 gene). Overall, 74/315 (23.5%) patients in Cohort 1 had a diagnostic 
result from Sanger, MLPA, or panel testing.  
Figure 5.3g shows the diagnostic results from Cohort 1, per gene. Diagnostic results 
were made in 20 different genes, and 55/74 (74%) of diagnoses were in the most 
frequently implicated eight genes. The shaded bars represent those genes for 
which there is some published evidence to support the concept that knowledge of 
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that genetic cause may inform treatment choice (Chapter 4). On this basis 62/74 
(84%) of genetic diagnoses made had potential treatment implications. 
Using the mean birth rate in Scotland (Table 5.3b) between 2011 and 2016 as a 
denominator for the birth rate in this cohort, the incidence of the more common 
single gene epilepsies can be estimated (Table 5.3d). 
Table 5.3b: Births in Scotland 2011-2016 (National Records of Scotland, 2018b)
Year Births Male births Female births 
2011 58,590 30,111 28,479 
2012 58,027 29,713 28,314 
2013 56,014 28,828 27,186 
2014 56,725 29,056 27,669 
2015 55,098 28,354 26,744 
2016 54,488 28,236 26,252 
Mean 56,490 29,050 27,440 
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Figure 5.3g: Genes in which diagnostic results were achieved from Cohort 1; shaded bars represent  genes for which 
there is published evidence to support a specific treatment approach (Chapter 4)
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Table 5.3c: Minimum incidence estimates for the more common monogenic 
seizure disorders of early childhood; incidence figures rounded up to three 
significant figures 
Genetic 
cause 
Number of 
patients in 
Cohort 1 
Estimated minimum 
incidence 
95% Confidence intervals (Poisson 
distribution) 
PRRT2 17 1 per 9,970 live births 1 per 6,300 to 1 per 17,200 
SCN1A 11 1 per 15,500 live births 1 per 8,630 to 1 per31,000 
KCNQ2 9 1 per 18,900 live births 1 per 9,940 to 1 per 41,300 
SLC2A1 6 1 per 28,300 live births 1 per 13,000 to 1 per 77,100 
CDKL5 4 1 per 42,400 live births 1 per 16,600 to 1 per 156,000 
PCDH19 4 1 per 20,600 live born females 1 per 8,040 to 1 per 1 per 75,600 
SLC6A1 4 1 per 42,400 live births 1 per 16,600 to 1 per 156,000 
DEPDC5 4 1 per 42,400 live births 1 per 16,600 to 1 per 156,000 
With 74 genetic diagnoses made in total, the estimated minimum incidence of all 
monogenic seizure disorders presenting before the age of three years is 1 per 2,290 
live births (95% confidence intervals: 1 per 1,830 to 1 per 2,930). By the European 
definition of rare disease (affecting fewer than one in 2000 individuals) these 
genetic seizure disorders would still qualify as rare (Rare Diseases Europe, 2018). 
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5.3.4 Associations between clinical features of presentation and 
genetic diagnosis 
Table 5.3d: Associations between clinical features of presentation and genetic 
diagnosis using Fisher’s exact test in Cohort 1 
 N (%) with genetic 
cause 
Two-tailed Fisher’s 
exact probability 
Odds ratio (95% 
confidence 
intervals) 
Total cohort 74/315 (23.5%)   
Age at presenting seizure 
< 6 months 34/86 (40.0%) p<0.001* 3.1 (1.8-5.4) 
6-12 months 19/76 (25.0%) p>0.05 1.1 (0.6-2.0) 
12-24 months 16/108 (14.8%) p<0.01 ψ 0.4 (0.2-0.8) 
24-36 months 5/52 (9.6%) p<0.005 ψ 0.2 (0.1-0.6) 
Presenting seizure  
Febrile generalised 1/37 (2.7%) p<0.005 ψ 0.1 (0.0-0.6) 
Febrile focal 2/9 (22.2%) p>0.05 0.9 (0.2-4.6) 
Febrile status  6/45 (13.3%) p>0.05 0.5 (0.2-1.1) 
Afebrile focal  37/97 (38.1%) p<0.001* 3.3 (1.9-5.7) 
Afebrile generalised (all, 
excluding spasms) ¥ 
20/90 (22.2%) p>0.05 1.0 (0.6-1.7) 
Afebrile generalised GTCS 10/48 (20.8%) p>0.05 0.9 (0.4-1.9) 
Afebrile generalised 
myoclonic 
3/19 (15.8%) p>0.05 0.6 (0.2-2.3) 
Afebrile generalised tonic 3/8 (37.5%) p>0.05 2.1 (0.5-9.2) 
Afebrile generalised atonic 1/4 (25.0%) p>0.05 1.2 (0.1-11.3) 
Afebrile generalised absence 3/11 (27.3%) p>0.05 1.3 (0.3-5.1) 
Afebrile status  2/17 (11.8%) p>0.05 0.9 (0.1-2.0) 
Infantile spasms 3/21 (14.3%) p>0.05 0.6 (0.2-2.0) 
Development, at recruitment  
Normal 47/213 (22.1%) p>0.05 0.7 (0.4-1.3) 
Not normal 27/102 (26.5%) p>0.05 1.4 (0.8-2.4) 
* Significant positive association; ψ Significant negative association 
¥ Combined group of all afebrile generalised seizures 
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Significant associations with genetic diagnosis in this cohort were: presentation at 
age under six months, and presentation with afebrile focal seizures. Older ages of 
presentation were associated with progressively reduced odds of genetic diagnosis. 
Interestingly the presence of abnormal development at presentation was not 
associated with genetic diagnosis. The absence of association here may reflect that 
a high proportion of patients with genetic diagnoses presented at a young age, and 
it is possible that developmental impairments had not become apparent at that 
stage. However, of 86 patients presenting before the age of six months, 25 (29.1%) 
did have developmental concerns highlighted which is a slightly higher proportion 
than in the total cohort (26.5%). Of those presenting before the age of six months 
who had developmental concerns at the time of recruitment, 11 (44%) had a 
genetic cause identified, so even in the early onset group, identification of 
developmental concerns did not associate with the finding of a genetic cause. 
Specific types of presentation appeared to be associated with particular genetic 
causes (Figure 5.3e): For example 33% of children presenting between 4 months of 
age and 12 months of age with afebrile focal seizures had a diagnostic PRRT2 
variant. 
5.3.4.1 Multivariate model 
Since age at presentation and type of presenting were associated with genetic 
aetiology in the univariate model, I put these variables into a multivariate model. 
Age at presentation was divided into three groups (< 6months, 6-12 months, and > 
12 months) and presenting seizure was divided into three groups (afebrile focal, 
afebrile generalised, and febrile). Both factors remained significant in the 
multivariate model. The model explained 15% of the variance (Nagelkerke R2 = 
0.15). 
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Table 5.3d-2: Binary logistic regression analysis for whether age at presentation 
and type of presenting seizure is associated with genetic diagnosis in Cohort 1 
(Hosmer and Lemeshow) 
 p value OR (95% confidence intervals) 
Age at presentation 
12-36 months (reference) 0.002 Reference category 
6-12 months 0.021 2.3 (1.1-4.7) 
< 6 months 0.001 3.1 (1.6-6.1) 
Presenting seizure 
Febrile (reference) 0.003 Reference category 
Afebrile generalised 0.214 1.7 (0.7-3.7) 
Afebrile focal 0.002 3.7 (1.6-8.4) 
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Table 5.3e: High yield phenotype groups for genetic diagnosis in Cohort 1 
Presentation Afebrile focal seizures 
≤4 months 
Afebrile focal seizures ≥4 
months and <12 months 
Febrile or afebrile status 
epilepticus <24 months 
Afebrile generalised seizures 
≥9 months and <24 months 
N 40 27 53 38 
Genetic diagnosis KCNQ2 9 (23%) PRRT2 9 (33%) SCN1A 4 (8%) SLC2A1 5 (13%) 
SCN1A 3 (8%) SCN1A 3 (11%) DEPDC5 1 (2%) CACNA1A 1 (2%) 
KCNQ3 2 (5%) KCNQ2 2 (7%) KCNA2 1 (2%) CHD2 1 (2%) 
CDKL5 2 (5%) PCDH19 1 (4%) POLG1 1 (2%) KCNA1 1 (2%) 
COL4A1 1 (2%) SLC2A1 1 (4%) PRRT2 1 (2%) PRRT2 1 (2%) 
KCNT1 1 (2%)   SCN1A 1 (2%) 
 PRRT1 1 (2%) 
 SCN2A 1 (2%) 
 STXBP1 1 (2%) 
TOTAL 21 (53%) 15 (59%) 9 (15%) 10 (26%) 
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5.3.5 Phenotypic spectrum of the monogenic seizure disorders 
For the genes in which there were four or more diagnostic results I calculated the 
mean, median, mode(s), and standard deviation of the age of presentation (table 
5.3d). Assuming a roughly normal distribution for age of presentation for each of 
monogenic seizure disorder, I extrapolated from this data to produce illustrative  
probabilistic distribution curves, where the x axis is the age of presentation and 
the y axis is a probability of a diagnosis involving that gene given presentation at 
age x (Figure 5.3h). The peak of each curve represents the mode, the slope is 
dependent on the standard deviation, and the curve has been skewed in order that 
the mean of the curve approximates the mean from the real data. Each curve has 
been scaled so that the area under the curve is equal to the total probability of a 
finding a diagnostic result in the gene from Cohort 1 (e.g. the area under the 
KCNQ2 curve equals 9/315 = 0.0286 and the area under the PRRT2 curve equals 
17/315 = 0.540). Figure 5.3h demonstrates that up to the age of four months, the 
most likely genetic diagnosis in a child presenting with seizures is KCNQ2-related. 
At all ages beyond four months the most likely diagnosis is PRRT2. These data are 
based on hypothetical extensions from the small number of cases associated with 
each genetic diagnosis in Cohort 1, and larger samples would be required to 
validate this model.  
Table 5.3f: Distribution of age of presentation for the eight most common 
monogenic seizure disorders in Cohort 1 
Gene N Age of presentation (months) 
Range Median Mode(s) Mean σ 
PRRT2 17 3-20 6 5 7.56 3.97 
SCN1A 11 1.5-25 6.5 4/7/11 7.75 7.24 
KCNQ2 9 0.1-4 0.59 0.16/1/4 1.43 1.62 
SLC2A1 6 11-19 14 12 14.67 3.44 
CDKL5 4 0.49-6 1.15 N/A 2.20 2.58 
PCDH19 4 6-18 12 N/A 12.00 4.97 
SLC6A1 4 14-31 21 N/A 21.75 7.41 
DEPDC5 4 2.5-26 19.5 N/A 16.86 10.73 
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Figure 5.3h: Hypothetical distributions of age of presentation for seven 
monogenic epilepsies, based on extrapolated data from Cohort 1
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5.3.5.1 PRRT2 
PRRT2 encodes a protein called proline-rich transmembrane protein 2. PRRT2 is 
highly expressed in brain. The transmembrane protein is believed to play a role in 
coupling Ca2+ sensing to synaptic vesicle fusion (Valente et al., 2016). PRRT2 was 
first associated with disease in 2011. Chen et al. reported three different 
frameshift mutations among eight Han Chinese families with a dominantly-
inherited non-epileptic movement disorder, Paroxysmal Kinesigenic Dyskinesia 
(PKD) (Chen et al., 2011).  
A variety of clinical phenotypes have since been associated with heterozygous 
PRRT2 variants, including PKD, self-limited familial and non-familial infantile 
seizures, febrile seizures and febrile seizures plus, hemiplegic migraine, migraine 
with aura, migraine without aura, and a phenotype termed Infantile Convulsions 
Choreoathetosis (ICCA) syndrome which is characterised by the presence of both 
infantile epilepsy and PKD in the same individual. Self-limited infantile seizures is 
the most common phenotype observed (Ebrahimi-Fakhari et al., 2015). There is no 
established relationship between genotype and phenotype, and often different 
phenotypes are observed within PRRT2-affected families. The majority of disease-
associated variants observed are frameshift truncating variants. This observation, 
along with experimental evidence showing that human lymphoblastoid cell lines 
carrying heterozygous PRRT2 frameshift variants undergo nonsense-medicated 
mRNA decay (Wu et al., 2014), supports the hypothesis that the primary 
mechanism in PRRT2-related disease involves haploinsufficiency.  
80%-90% of PRRT2-related disease is associated with the recurrent frameshift 
variant (c.649dup, p.Arg217Profs*8) accounting for 78.5% of published cases 
(Ebrahimi-Fakhari et al., 2015). 
There have been no previous incidence estimates for PRRT2-related disease. 
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Table 5.3g: PRRT2 gene summary from literature 
Chromosome locus 16p11.2 
Phenotype observed in microdeletion 
syndrome? 
Yes 
pLI Score~ 0.30 
Brain expression ratio* 5.47 
Localisation within brain Localises to α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor complexes (Schwenk 
et al., 2012) 
Proposed gene function Coupling Ca2+ sensing to synaptic vesicle fusion (Valente et al., 2016) 
Proposed genetic mechanism of pathogenicity Haploinsufficiency 
Yield in epilepsy NGS literature (Chapter 3) 67/13063 (0.5%), Rank: 7 
Previous incidence estimates None 
Previous clinical spectrum descriptions 38.7% PKD 
14.3% ICCA 
41.7% Self-limited infantile seizures 
5.3% other phenotypes (Ebrahimi-Fakhari et al., 2015) 
Previous age of onset descriptions Data form 401 cases. Mean onset was 6.0 months (Ebrahimi-Fakhari et al., 2015) 
Previous penetrance estimates 61% for PKD phenotype. Complete for PKD or infantile convulsions (van Vliet et al., 2012) 
Evidence for specific treatment Retrospective uncontrolled clinician-reported subjective treatment response analysis. N = 64.  
63/64 (99%) of patients with Paroxysmal Kinesigenic Dyskinesia treated with Carbamazepine had a good 
response (Huang et al., 2015). 
Retrospective uncontrolled clinician-reported subjective treatment response analysis. N = 24.  
23/24 (96%) experienced complete seizure control on Carbamazepine treatment (Ebrahimi-Fakhari et al., 
2015). 
~ From the Exome Aggregation Consortium (ExAC) dataset (Broad Institute Exome Aggregation Consortium, 2018) 
* From the GTEx Portal data, based on adult post-mortem tissue expression profiles (Aguet et al., 2017)
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Table 5.3h: Patients with PRRT2 variants from Cohort 1 
Yield 17/315 (5.4%), Rank: 1 
Case 
ID 
Age of 
presentation 
Presenting 
seizure 
Dev. delay at 
presentation > 
follow-up 
Age of 
follow-up 
Epilepsy 
diagnosis 
Seizure 
types 
observed 
Current 
seizure 
frequency 
Current treatment 
approach 
Current 
treatment 
Effective 
treatments 
Variant Inheritance Family history 
339 3 months Febrile 
generalised 
status 
No > No 11 
months 
Self-limited 
familial 
infantile 
epilepsy 
Feb-status 
Afeb-GTCS 
Afeb-focal 
None in 6 
months 
Still receiving first 
AED monotherapy 
LEV LEV c.649dup, 
p.Arg217Profs*8 
Unknown Father, mother, 
paternal uncle 
and maternal 
uncle all had 
febrile seizures 
344 4 months Afebrile focal No > Unknown N/A – 
moved 
abroad 
Unknown Afeb-focal Unknown Unknown Unknown LEV c.649dup, 
p.Arg217Profs*8 
Unknown Mother and 7 of 
her relatives had 
infantile 
seizures 
323 4 months Afebrile tonic No > No 11 
months 
Self-limited 
infantile 
epilepsy 
Afeb-tonic None in 6 
months 
Still receiving first 
AED monotherapy 
PB PB c.649dup, 
p.Arg217Profs*8 
De novo None 
200 5 months Afebrile focal No > No 30 
months 
Self-limited 
familial 
infantile 
epilepsy 
Afeb-focal None in 6 
months 
Still receiving first 
AED monotherapy 
CBZ CBZ c.649dup, 
p.Arg217Profs*8 
Paternal Father had 
infantile 
seizures; 
paternal aunt 
had childhood 
epilepsy and 
hemiplegic 
migraine 
82 5 months Afebrile focal No > Mild 23 
months 
Self-limited 
infantile 
epilepsy 
Afeb-focal None in 6 
months 
Previously received 
AED therapy – now 
off medication 
None CBZ c.564delG, 
p.Ala189Leufs*4
0 
Unknown None 
92 5 months Afebrile focal No > No 32 
months 
Self-limited 
infantile 
epilepsy 
Afeb-focal None in 6 
months 
Previously received 
AED therapy – now 
off medication 
None CBZ c.649dup, 
p.Arg217Profs*8 
Maternal Mother has PKD 
182 5 months Afebrile focal No > No 14 
months 
Self-limited 
infantile 
epilepsy 
Afeb-focal None in 6 
months 
Still receiving first 
AED monotherapy 
LEV LEV c.649dup, 
p.Arg217Profs*8 
Maternal Mother had 
febrile seizures. 
Maternal cousin 
had infantile 
seizures (case 
13). Maternal 
uncle had self-
limited infantile 
seizures 
281 5 months Febrile focal No > No 19 
months 
ICCA Feb-focal 
Spasms 
None in 6 
months 
Previously received 
AED therapy – now 
off medication 
None VGB c.896A>C, 
p.Gln299Pro 
Paternal Father had a 
seizure in his 
30s 
172 7 months Afebrile focal No > No 39 
months 
Self-limited 
infantile 
epilepsy 
Afeb-focal None in 6 
months 
Still receiving first 
AED monotherapy 
CBZ CBZ c.649dup, 
p.Arg217Profs*8 
Unknown None 
244 7 months Afebrile 
myoclonic 
No > No Not 
recorded 
Self-limited 
infantile 
epilepsy 
Afeb-Myo None in 6 
months 
Still receiving first 
AED monotherapy 
VPA VPA c.649dup, 
p.Arg217Profs*8 
Unknown Paternal cousin 
had infantile 
seizures 
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193 7 months Afebrile focal No > No 31 
months 
Self-limited 
infantile 
epilepsy 
Afeb-focal None in 6 
months 
Still receiving first 
AED monotherapy 
CBZ CBZ c.649dup, 
p.Arg217Profs*8 
Paternal Two paternal 
cousins had 
infantile 
seizures 
271 8 months Afebrile focal No > No 18 
months 
Self-limited 
infantile 
epilepsy 
Afeb-focal None in 6 
months 
Still receiving first 
AED monotherapy 
CBZ CBZ c.649dup, 
p.Arg217Profs*8 
Maternal Mother has JME 
88 9 months Afebrile focal No > No 48 
months 
Self-limited 
infantile 
epilepsy 
Afeb-focal None in 6 
months 
Previously received 
AED therapy – now 
off medication 
None LEV c.649dup, 
p.Arg217Profs*8 
Paternal Paternal cousin 
had infantile 
seizures (case 
7). Paternal 
uncle had self-
limited infantile 
seizures. 
Paternal aunt 
had febrile 
seizures. 
334 9 months Afebrile focal No > No 19 
months 
Self-limited 
familial 
infantile 
epilepsy 
Afeb-focal 
Afeb-GTCS 
None in 6 
months 
Still receiving first 
AED monotherapy 
LEV LEV c.942G>C, 
p.Lys314Asn 
Paternal Identical twin 
had recurrent 
febrile seizures 
117 10 months Afebrile focal No > No 36 
months 
Self-limited 
infantile 
epilepsy 
Afeb-focal None in 6 
months 
Previously received 
AED therapy – now 
off medication 
None VPA c.649dup, 
p.Arg217Profs*8 
Unknown None 
202 11 months Afebrile focal No > No 34 
months 
Self-limited 
infantile 
epilepsy 
Afeb-focal None in 6 
months 
Still receiving first 
AED monotherapy 
LEV LEV c.649dup, 
p.Arg217Profs*8 
Maternal None 
77 20 months Afebrile focal Severe > 
Severe 
55 
months 
Unclassified 
focal 
epilepsy 
Afeb-focal None in 6 
months 
Receiving a different 
AED monotherapy to 
the first one tried – 
initial therapy not 
effective 
CBZ (Prev. 
tried LEV) 
CBZ c.649dup, 
p.Arg217Profs*8 
De novo None 
Abbreviations used: GTCS – generalised tonic clonic seizure(s). Myo – myoclonic, Afeb – afebrile, Feb – febrile. AED – Anti-epileptic drug. LEV – Levetiracetam, PB – Phenobarbital. CBZ – Carbamazepine, VGB – Vigabatrin, VPA – 
Sodium Valproate, ICCA –Infantile Convulsions Choreoathetosis, PKD – Paroxysmal Kinesigenic Dyskinesia, JME – Juvenile Myoclonic Epilepsy,  
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Table 5.3i: Summary of patients with PRRT2 variants in Cohort 1 
Median age of presentation 6 months 
Development Normal at presentation: 16/17 (94%) 
Normal at latest follow-up: 15/17 (88%) 
Presenting seizure type Afebrile focal: 13/17 (76%) 
Afebrile tonic: 1/17 (6%) 
Afebrile myoclonic: 1/17 (6%) 
Febrile status: 1/17 (6%) 
Febrile focal: 1/17 (6%) 
Seizure types observed Afebrile focal: 14/17 (82%) 
Afebrile GTCS: 2/17 (12%) 
Afebrile myoclonic: 1/17 (6%) 
Afebrile tonic: 1/17 (6%) 
Afebrile spasms: 1/17 (6%) 
Febrile status: 1/17 (6%) 
Febrile focal: 1/17 (6%) 
Latest diagnosis Self-limited infantile epilepsy: 14/17 (82%) 
ICCA: 1/17 (6%) 
Unclassified or unknown: 2/17 (12%) 
Current seizure frequency None in 6 months: 16/17 (94%) 
Unknown: 1/17 (6%) 
Current treatment approach First AED monotherapy: 10/17 (59%) 
Off medication: 5/17 (29%) 
Monotherapy changed due to poor efficacy: 1/17 (6%) 
Unknown: 1 (6%) 
Effective treatments used Carbamazepine: 7/17 (41%) 
Levetiracetam: 6/17 (35%) 
Sodium Valproate: 2/17 (12%) 
Vigabatrin: 1/17 (6%) 
Phenobarbitone: 1/17 (6%) 
Variant type Frameshift: 15/17 (88%) 
Missense: 2/17 (12%) 
Variant inheritance From affected parent: 5/17 (29%) 
From unaffected parent with family history: 3/17 (18%) 
From unaffected parent without family history 1/17 (6%): 
Undetermined but with strong family history: 3/17 (18%) 
Undetermined, no family history: 3/17 (18%) 
De novo: 2/17 (12%) 
In this cohort, 15/17 (88%) of pathogenic PRRT2 variants were frameshift variants 
and two were missense. In 14/17 (82%) cases the pathogenic variant was the 
recurrent c.649dupC variant which is similar to that reported in previous cohorts 
(Ebrahimi-Fakhari et al., 2015). In nine cases parental samples were tested: with 
the variant de novo in two and inherited in seven. In three cases where the variant 
was inherited, it was inherited from an unaffected parent, but in two of those 
cases other family members on the transmitting parent’s side were affected. This 
suggests that the penetrance of PRRT2 is not complete, as has been previously 
suggested (van Vliet et al., 2012).  
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A relatively consistent picture of PRRT2-related epilepsy as a disorder emerged. 
This disorder is characterised by onset of focal seizures in the first two years of 
life, with good short-term seizure outcome. 
Presenting seizure was an afebrile focal seizure in 12/17 cases (76%) and 11/17 
(65%) had afebrile focal seizures only. 
15/17 patients had normal development at latest follow-up; one had mild delay, 
and one had severe delay. A beneficial therapy was reported in all cases: In seven 
this was Carbamazepine, in six it was Levetiracetam and in two it was Sodium 
Valproate. From this data it is difficult to come to any conclusions about whether 
any specific medication is associated with a positive response in PRRT2-related 
epilepsy since all patients, despite receiving a variety of treatments, had been 
seizure-free for at least 6 months at the most recent follow-up. This is likely to 
reflect the natural history of the condition. In only one case was AED therapy 
changed due to lack of efficacy (case 77), where initial therapy with 
Levetiracetam was ineffective so treatment was changed to Carbamazepine, with 
good response. None of these patients received AED polytherapy or developed 
drug-resistant epilepsy.  
The estimated incidence of PRRT2-related seizures from this cohort is 1 per 9,970 
live births. This is likely to be an underestimate since some patients with mild 
phenotypes will not have met inclusion criteria. For example, the identical twin of 
case 334 was found to have the same PRRT2 variant, but because she only had 
febrile seizures she was not eligible for inclusion in the cohort. Despite being the 
most frequently observed seizure-associated gene in Cohort 1, PRRT2 variants have 
much more rarely observed in the previous NGS studies (Chapter 3). A number of 
reasons could explain the relatively high yield for PRRT2 variants in Cohort 1 
compared with previous studies. First, because the seizure phenotype is often mild 
and self-limited, patients with PRRT2-associated phenotypes may not be 
considered ideal candidates for NGS since families and clinicians may not be 
invested in finding a cause. Second, PRRT2-related seizures may present in the 
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context of an established family history of PKD, in which case the PRRT2 cause 
may already be known, clinicians may have been directed towards single gene 
PRRT2 sequencing or a movement disorder gene panel. Third, since it was first 
established as a PKD gene rather than an epilepsy gene, PRRT2 was not included in 
some of the smaller panels.  
Patients with 16p11.2 microdeletion syndrome present with similar clinical 
features to those with PRRT2 loss of function variants, but are more likely to have 
additional clinical features, including intellectual disability, skin manifestations, 
and hypotonia. In the largest study of 16p11.2 deletion carriers, involving 136 
individuals, 27% had unprovoked seizures and 7% had febrile seizures (Steinman et 
al., 2016). Finally, since >80% of PRRT2 variants in this cohort were inherited, it is 
possible that there is a population-specific effect of PRRT2-related disorders in 
Scotland. 
5.3.5.2 SCN1A 
SCN1A encodes the neuronal voltage-gated sodium channel Nav1.1. Opening of this 
channel leads to rapid efflux of sodium from neuronal cells and brings about 
depolarisation associated with axonal signal propagation.  Experimental studies in 
mice and expression studies un humans suggest that Nav1.1 preferentially localises 
to inhibitory interneurons (Ogiwara et al., 2007;), leading to the hypothesis that 
loss of Nav1.1 function leads to decreased excitability of inhibitory neurones, and 
thereby contributes to an overall network hyperexcitability. De novo pathogenic 
variants in SCN1A are typically associated with Dravet syndrome, a severe epilepsy 
that typically presents with prolonged febrile seizures in infancy and evolves to a 
drug-resistant polymorphic epilepsy with associated developmental impairment 
(Claes et al., 2001).  Inherited variants are often associated with milder 
phenotypes including Genetic Epilepsy with Febrile Seizures Plus (GEFS+) (Escayg 
et al., 2000), and non-epilepsy neurological phenotypes including Familial 
Hemiplegic Migraine (FHM) (Dichgans et al., 2005). Patients with de novo variants 
and relatively mild phenotypes are reported (Myers et al., 2017b) and so too have 
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severely affected individuals within families where other members have had mild 
phenotypes (Nabbout et al., 2003).  
The incidence of SCN1A-related Dravet syndrome has previously been estimated in 
Northern California (Wu et al., 2015). The authors interrogated the case notes of 
all infants born at Kaiser Peramanente Northern California from 2007 to 2010 to 
identify those with a clinical picture of Dravet syndrome. They identified eight 
infants, six of whom had a de novo pathogenic SCN1A variant. This was from a 
population base of 125,547 births so they estimated the incidence of SCN1A-
related Dravet syndrome to be 1 per 20,900 live births. A similar incidence figure 
of 1 per 22,000 has been quoted in Denmark, though this study was based on the 
assumption that all cases of SCN1A-related Dravet syndrome would have been seen 
at a single centre (Allan, Helle & Møller, 2015).                        .
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Table 5.3j: SCN1A gene summary from the literature 
Chromosome locus 2q24.3 
Phenotype observed in microdeletion syndrome? Yes. 2q24.3 deletion, often involving other sodium channel genes SCN2A, SCN3A, SCN7A, and SCN9A is 
associated with a severe epilepsy and developmental disorder (Lim et al., 2015) 
pLI Score~ 1.0 
Brain expression ratio* 80.1 
Localisation within brain Preferentially localises to the axons of inhibitory interneurons (Ogiwara et al., 2007) 
Proposed gene function Encodes a neuronal voltage-gated sodium channel, opening of the channel leads to depolarisation 
during the action potential 
Proposed genetic mechanism of pathogenicity Haploinsufficiency 
Yield in epilepsy NGS literature (Chapter 3) 423/13063 = 3.2%, Rank: 1 
Previous incidence estimates Estimated incidence of SCN1A positive-Dravet syndrome in California: 1 per 20,900 live births (Wu et 
al., 2015) 
Estimated incidence of SCN1A positive-Dravet syndrome in in Denmark: 1 per 22,000 live births (Allan, 
Helle & Møller, 2015) 
Previous clinical spectrum descriptions 87% Dravet syndrome 
5% Febrile seizures plus 
7% other epilepsies (Zuberi et al., 2011) 
Also associated with a non-epilepsy phenotype, familial hemiplegic migraine (Dichgans M et al., 2005) 
Previous age of onset descriptions Median 6.5 months (Harkin et al., 2007) 
Median 6 months (Brunklaus et al., 2012) 
Previous penetrance estimates Incomplete penetrance in familial cases reported (Mhanni et al., 2011) 
Evidence for specific treatment RCT evidence to support use of Cannabidiol to treat seizures in Dravet syndrome (Devinsky et al., 
2017) 
RCT evidence to support use of Stiripentol to treat seizures in Dravet syndrome Chiron 2000 (Chiron et 
al., 2000) 
Retrospective data suggests avoidance of Carbamazpeine and Lamotrigine (Brunklaus et al., 2012) 
~ From the Exome Aggregation Consortium (ExAC) dataset (The Broad Institute Exome Aggregation Consortium, 2018) 
* From the GTEx Portal data, based on adult post-mortem tissue expression profiles (Aguet et al., 2017)
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Table 5.3k: Patients with SCN1A variants from Cohort 1 
Yield 11/315 (3.5%), Rank: 2 
Case 
ID 
Age of 
presentatio
n 
Presenting seizure Dev. delay at 
presentation > 
follow-up 
Age of 
follow-
up 
Epilepsy 
diagnosis 
Seizure types 
observed 
Current 
seizure 
frequency 
Current treatment 
approach 
Current 
treatment 
Effective 
treatments 
Variant Inheritan
ce 
Family 
history 
135 1.5 months Febrile focal 
status 
No > Moderate 37 
months 
Dravet syndrome Afeb-GTCS 
Afeb-tonic 
Afeb-Myo 
Afeb-AA 
Feb-status 
Daily Receiving AED 
polytherapy 
Stiripentol, 
Fenfluramine, 
CLB, LEV, ESM 
Fenfluramine c.2875T>G, 
p.Cys959Gly 
De novo None 
212 3 months Afebrile focal Mild > Mild 19 
months 
Dravet syndrome Afeb-focal < 1 per 
month 
Receiving AED 
polytherapy 
VPA, CLB, 
Stiripentol 
Stiripentol c.4055T>G, 
p.Leu1352Arg 
De novo None 
58 4 months Afebrile focal Mild > Moderate 37 
months 
Dravet syndrome Afeb-focal 
Afeb-GTCS 
Feb-focal 
Monthly  Receiving AED 
polytherapy 
CBZ and VPA CBZ c.4441G>A, 
p.Val1481Ile 
De novo None 
218 4 months Afebrile focal Mild > Mild 21 
months 
Dravet syndrome Afeb-status 
Afeb-GTCS 
Afeb-Myo 
Afeb-focal 
Monthly  Receiving AED 
polytherapy 
VPA, 
Nitrazepam, 
Stiripentol 
PB c.2290delG, 
p.Val764Leufs
*2 
De novo None 
290 6 months Febrile 
generalised status 
No > No 20 
months 
Dravet syndrome Afeb-Myo 
Afeb-focal 
Feb-status 
Daily  Receiving AED 
polytherapy 
VPA, CLB, 
Stiripentol 
Stiripentol c.4933C>T, 
p.Arg1645* 
De novo None 
90 7 months Afebrile focal No > No 35 
months 
Febrile seizures 
plus 
Afeb-focal 
Afeb-GTCS 
 
< 1 per 
month 
Receiving a different 
AED monotherapy to 
the first one tried – 
initial therapy not 
tolerated 
LMT (prev. 
tried LEV) 
None reported c.5171C>T, 
p.Ala1724Val 
De novo None 
123 7 months Febrile focal No > Moderate 44 
months 
Dravet syndrome Afeb-GTCS 
Afeb-Myo 
Afeb-AA 
Afeb-atonic 
Feb-GTCS 
Weekly Receiving AED 
polytherapy 
VPA and CLB Stiripentol c.4822G>T, 
p.Asp1608Tyr 
De novo None 
65 11 months Afebrile absence No > Moderate 23 
months 
Dravet syndrome Afeb-absence 
Afeb-GTCS 
Monthly Receiving AED 
polytherapy 
VPA and CLB None reported c.2619G>C, 
p.Trp873Cys 
De novo None 
180 19 months Afebrile focal 
status 
Mild > Mild 32 
months 
Dravet syndrome Afeb-Myo 
Afeb-GTCS 
Afeb-focal 
Afeb-status 
Feb-status 
Feb-GTCS 
Monthly Receiving AED 
polytherapy 
VPA, CLB, 
Stiripentol 
VPA c.1663-9A>G Not 
maternal 
None 
317 19 months Febrile focal 
status 
No > No 29 
months 
Recurrent 
prolonged 
febrile seizures 
Feb-status 
Feb-GTCS 
< 1 per 
month 
Never had regular 
AED 
None N/A c.4091T>C, 
p.Met1364Thr 
Unknown  None 
5 25 months Febrile unknown No > No 40 
months 
Recurrent 
febrile seizures 
Feb-GTCS None in 6 
months 
Never had regular 
AED 
None N/A c.2176+2T>C Paternal Father had 
febrile 
seizures 
Abbreviations used: GTCS – generalised tonic clonic seizure(s). Myo – myoclonic, AA – Atypical absence, Afeb – afebrile, Feb – febrile. GEFS+ - Genetic epilepsy with febrile seizures plus; AED – Anti-epileptic drug. LEV – Levetiracetam, 
CBZ – Carbamazepine, VPA – Sodium Valproate, CLB – clobazam, PB – Phenobarbitone, ESM – Ethosuximide, LMT – Lamotrigine 
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Table 5.3l: Summary of patients with SCN1A variants in Cohort 1 
Median age of presentation 6.5 months 
Development Normal at presentation: 7/11 (64%) 
Normal at latest follow-up: 4/11 (36%) 
Presenting seizure type Afebrile: 6/11 (55%) 
Afebrile focal: 5/11 (45%) 
Afebrile focal status: 1/11 (9%) 
Afebrile absence 1/11 (9%) 
Febrile: 5/11 (45%) 
Febrile focal: 3/11 (27%) 
Febrile focal status: 2/11 (18%) 
Febrile generalised status: 1/11 (9%) 
Febrile unknown: 1/11 (9%) 
Status: 4/11 (36%) 
Seizure types observed Afebrile GTCS: 7/11 (64%) 
Afebrile focal: 6/11 (55%) 
Afebrile myoclonic: 5/11 (45%) 
Afebrile atypical absence: 2/11 (18%) 
Afebrile tonic: 1/11 (9%) 
Afebrile atonic: 1/11 (9%) 
Afebrile status: 2/11 (18%) 
Febrile status: 3/11 (27%) 
Febrile GTCS: 3/11 (27%) 
Febrile focal: 1/11 (9%) 
 
Febrile seizures at any time: 7/11 (64%) 
Status at any time: 5/11 (45%) 
Multiple seizure types observed: 8/11 (73%) 
Latest diagnosis Dravet syndrome: 8/11 (73%) 
Febrile seizures or febrile seizures plus: 3/11 (27%) 
Current seizure frequency Seizures at least once per day: 2/11 (18%) 
Seizure at least once per week: 3/11 (27%) 
Seizures at least once per month: 7/11 (64%) 
< 1 seizure per month: 3/11 (27%) 
None in last 6 months: 1/11 (9%) 
Current treatment approach AED polytherapy: 8/11 (73%) 
Second AED monotherapy (initial treatment not 
tolerated): 1/11 (9%) 
Never had a regular AED: 2/11 (18%) 
Effective treatments used Stiripentol: 3/11 (27%) 
Carbamazepine: 1/11 (9%) 
Sodium Valproate: 1/11 (9%) 
Phenobarbitone: 1/11 (9%) 
Variant type Missense: 7/11 (64%) 
Frameshift/nonsense/splice-site: 4/11 (36%) 
Variant inheritance De novo: 8/11 (73%) 
From affected parent: 1/11 (9%) 
Unknown: 2/11 (18%) 
Among the 11 patients with a pathogenic SCN1A variant identified in Cohort 1, 
eight had been diagnosed with Dravet syndrome at the time that the follow-up 
questionnaire was completed, making the estimated incidence of SCN1A-related 
Dravet syndrome in this population 1 per 21,200 live births – a very similar figure 
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to that obtained by Wu et al. and Bayat et al. All of the patients diagnosed with 
Dravet syndrome had a de novo SCN1A variant apart from one patient (case 180) 
for whom the variant was not maternally-inherited, but a paternal sample was not 
available. Dravet syndrome has been characterised as a severe drug-resistant 
epilepsy which typically presents initially with febrile seizures, before progressing 
to a severe drug-resistant epilepsy with frequent seizures of multiple types. 
Developmental stagnation or regression is seen from the second year of life and is 
hypothesised to be partly due to uncontrolled seizure activity (Brunklaus et al., 
2012).  
Cross-sectional data from patients with Dravet syndrome suggests that by the end 
of the second year of life, 40% of patients have normal development, 30% have 
mild learning disability, 20% have moderate learning disability, and 10 have severe 
learning disability (Brunklaus et al., 2012). At most recent follow-up, at a median 
age of 32 months (range 19 to 44) 36% of patients with SCN1A variants in Cohort 1 
had normal development, which would be consistent with this literature.  
Seizure control in this group was good compared with historical cohorts. Though 
just one patient was seizure-free, only 3/11 (27%) of these patients were having 
seizures at least once per week. Due to small numbers it is difficult to determine 
whether seizure control was related to early initiation of specific treatment in the 
group. All three patients who were experiencing seizures at least once per week 
were on highly specific treatments for Dravet syndrome (two Stiripentol, and one 
Fenfluramine). 
5.3.5.3 KCNQ2 
KCNQ2 encodes the neuronal voltage-gated potassium channel, Kv7.1. This is a 
slowly activating and deactivating potassium conductance that plays a critical role 
in determining the subthreshold electroexcitability of neurons as well as the 
responsiveness to synaptic inputs. Variants in KCNQ2 were first described in 
families with self-limited familial neonatal seizures (Singh et al., 1998) but have 
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since also been associated with severe early-onset epileptic encephalopathy 
(Dedek et al., 2003) and with myokymia (Dedek et al., 2001) – a non-epileptic 
movement disorder. Milder phenotypes are associated with truncating variants 
(Soldovieri et al., 2014; Claes et al., 2004) and whole gene deletions (Heron et al., 
2007; Kurahashi H et al., 2009) and more severe phenotypes are associated with 
missense variants (Kato et al., 2013; Olson et al., 2017; Weckhuysen et al., 2012). 
In vitro functional studies have demonstrated that missense KCNQ2 variants 
associated with severe phenotypes exhibit gain of function properties (Millichap et 
al., 2017) suggesting that both loss-of-function and gain-of-function may play a 
role in KCNQ2-related seizures, with perhaps gain-of-function variants having a 
more detrimental consequence.                                            .
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Table 5.3m: KCNQ2 gene summary from the literature 
Chromosome locus 20q.13.33 
Phenotype observed in microdeletion syndrome? Yes – neonatal seizures often observed in 20q13.3 deletion syndrome (Akihisa et al., 2015) 
pLI Score~ 1.0 
Brain expression ratio* 30.2 
Localisation within brain High expression in hippocampus, temporal cortex, cerebellar cortex, and medulla (Kanaumi et 
al., 2008) 
Proposed gene function Slowly activating and deactivating neuronal potassium channel. 
Proposed genetic mechanism of pathogenicity Both gain-of-function and loss-of-function mechanism likely 
Yield in epilepsy NGS literature (Chapter 3) 231/13063 (1.8%), Rank: 2 
Previous incidence estimates None 
Previous clinical spectrum descriptions No unselected cohorts published. Can present as self-limited neonatal seizures or as a severe 
neonatal-onset epileptic encephalopathy. 
Also associated with a non-epilepsy phenotype, peripheral nerve hyperexcitability (Wuttke et al., 
2007) 
Previous age of onset descriptions Mean 1.8 days in encephalopathy cases (Olson et al., 2017; Millichap et al., 2016) 
First week of life in all familial cases (Soldovieri et al., 2014) 
Previous penetrance estimates Complete penetrance in all families reported, though phenotype can be variable (de Haan et al., 
2006; Hewson, Puka & Mercimek‐Mahmutoglu, 2017) 
Evidence for specific treatment Retrospective uncontrolled clinician report of seizure-freedom. N = 15.  
6/15 (40%) of cases with KCNQ2 encephalopathy achieved seizure-freedom within two weeks of 
commencing Carbamazepine. 
Retrospective uncontrolled clinician report of seizure-freedom. N = 15.  
5/15 (33%) of cases with KCNQ2 encephalopathy achieved seizure-freedom within two weeks of 
commencing Phenytoin (Pisano et al., 2015). 
~ From the Exome Aggregation Consortium (ExAC) dataset (The Broad Institute Exome Aggregation Consortium, 2018) 
* From the GTEx Portal data, based on adult post-mortem tissue expression profiles (Aguet et al., 2017)
142 
 
Table 5.2n: Patients with KCNQ2 variants from Cohort 1 
Yield 9/315 (2.9%), Rank: 3 
Case 
ID 
Age of 
presentation 
Presenting 
seizure 
Dev. delay at 
presentation > 
follow-up 
Age of 
follow-up 
Epilepsy 
diagnosis 
Seizure types 
observed 
Current seizure 
frequency 
Current 
treatment 
approach 
Current 
treatment 
Effective 
treatments 
Variant Inheritance Family 
history 
336 3 days Afebrile 
focal 
No > No 12 months Self-limited 
neonatal 
seizures 
Afeb-focal None in 6 months Previously 
received AED 
therapy – now 
off medication 
None CBZ Whole gene 
deletion 
Unknown None 
302 5 days Afebrile 
focal 
No > No 13 months Self-limited 
familial 
neonatal 
seizures 
Afeb-focal None in 6 months Still receiving 
first AED 
monotherapy 
PB PB c.1918delC, 
p.Leu640fs 
Unknown Mother has 
history of 
neonatal 
seizures 
293 5 days Afebrile 
focal 
No > No 12 months Self-limited 
familial 
neonatal 
seizures 
Afeb-focal None in 6 months Never had a 
regular AED 
None N/A Duplication of 
Exons 2-12 
Paternal Father has 
history of 
neonatal 
seizures 
279 9 days Afebrile 
focal 
No > No 13 months Self-limited 
familial 
neonatal 
seizures 
Afeb-focal None in 6 months Previously 
received AED 
therapy – now 
off medication 
None CBZ Duplication of 
Exons 2-12 
Maternal Mother has 
history of 
neonatal 
seizures 
338 19 days Afebrile 
focal 
No > No 14 months Self-limited 
familial 
neonatal 
seizures 
Afeb-focal None in 6 months Previously 
received AED 
therapy – now 
off medication 
None CBZ c.1874_1880del, 
p.Lys625Argfs*15 
Unknown Paternal 
cousin had 
neonatal 
seizures 
294 1 month Afebrile 
focal 
Moderate > 
Moderate 
13 months Early infantile-
onset 
developmental 
and epileptic 
encephalopathy 
Afeb-focal 
Afeb-tonic 
None in 6 months Receiving a 
different AED 
monotherapy 
to the first 
one tried – 
initial therapy 
not effective 
CBZ CBZ c.1657C>T, 
p.Arg553Trp 
De novo None 
46 3 months Afebrile 
focal 
No > Mild 40 months Unclassified 
focal epilepsy 
Afeb-focal Daily seizures Receiving AED 
polytherapy 
VPA and 
CBZ 
CBZ c.1116C>G, 
p.Tyr372* 
De novo None 
177 4 months Afebrile 
focal 
Severe > 
Profound 
31 months Early infantile-
onset 
developmental 
and epileptic 
encephalopathy 
Afeb-focal None in 6 months Receiving a 
different AED 
monotherapy 
to the first 
one tried – 
initial therapy 
not effective 
CBZ CBZ Whole gene 
deletion 
Paternal Father has 
history of 
neonatal 
seizures 
326 4 months Afebrile 
focal 
No > No 17 months Self-limited 
infantile 
seizures 
Afeb-focal None in 6 months Previously 
received AED 
therapy – now 
off medication 
None CBZ c.1106_1118+6del
TGCCCATGTACAG
GTACCG, 
p.Pro370Argfs*15 
Unknown None 
Abbreviations used: GTCS – generalised tonic-clonic; Afeb – afebrile, Feb-febrile, AED – anti-epileptic drug, CBZ – Carbamazepine, VPA – Sodium Valproate, PB - Phenobarbitone 
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Table 5.3o: Summary of patients with KCNQ2 variants in Cohort 1 
Median age of presentation 18 days 
Development Normal at presentation: 7/9 (78%) 
Normal at latest follow-up: 7/9 (78%) 
Presenting seizure type Afebrile focal: 9/9 (100%) 
Seizure types observed Afebrile focal: 9/9 (100%) 
Afebrile tonic: 1/9 (11%) 
Latest diagnosis Self-limited neonatal seizures: 5/9 (56%) 
Early infantile-onset developmental and epileptic 
encephalopathy: 2/9 (22%) 
Unclassified focal epilepsy 1/9 (11%) 
Self-limited infantile seizures: 1/9 (11%) 
Current seizure frequency None: 8/9 (89%) 
At least one seizure per day: 1/9 (11%) 
Current treatment approach Off medication: 4/9 (44%) 
Monotherapy changed due to poor efficacy: 2/9 (22%) 
First AED monotherapy: 1/9 (11%) 
Never had AED treatment: 1/9 (11%) 
AED polytherapy: 1/9 (11%) 
Effective treatments used Carbamazepine: 7/9 (78%) 
Phenobarbitone: 1/9 (11%) 
Variant type Frameshift/nonsense/splice-site: 4/9 (44%) 
Whole gene deletion: 2/9 (22%) 
Duplication of exons 2-12: 2/9 (22%) 
Missense: 1/9 (11%) 
Variant inheritance From affected parent: 3/9 (33%) 
De novo: 2/9 (22%) 
Unknown: 4/9 (44%) 
The literature would suggest that it is very rare for KCNQ2-related epilepsy to 
present beyond the neonatal period (Zhang et al., 2017; Millichap et al., 2016; 
Olson et al., 2017; Millichap et al., 2017; Allen et al., 2014). In this cohort 4/9 
cases presented at one month or over, perhaps suggesting an ascertainment bias in 
the literature. The findings within this KCNQ2 cohort are at also odds with the 
literature which has indicated that inherited variants and missense variants are 
associated with more severe phenotypes. The most severely affected individual 
(case 177) – the only one with severe or profound cognitive impairment – had an 
inherited gene deletion from his father who had a personal and family history of 
self-limited familial neonatal seizures. The only case who developed drug-resistant 
epilepsy (case 46) had a de novo nonsense variant. All patients with KCNQ2 
variants presented with focal seizures, and only one patient (case 294) developed 
any other seizure type (tonic seizures). Seizure outcomes in this group of patients 
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were good, with 8/9 patients seizure-free for at least six months at the time of 
most recent follow-up. 
5.3.5.4 SCL2A1 
SLC2A1 encodes GLUT1, the major glucose transporter in brain, placenta and 
erythrocytes. Dysfunction of blood-to-brain glucose transport was initially 
postulated as the cause of a disorder identified in three unrelated patients who 
presented with early infantile onset drug-resistant myoclonic seizures, 
developmental delay, microcephaly, and low cerebrospinal fluid (CSF) but normal 
serum glucose levels (de Vivo et al., 1991). Subsequently, de novo loss of function 
variants (one whole gene deletion and two nonsense variants) of the SLC2A1 gene 
were identified in these three patients (Seidner et al., 1998). 
Subsequent reports have significantly expanded the phenotype associated with 
SLC2A1 variants to include a broad range of clinical presentations, including 
various paroxysmal and static movement disorders – including dystonia, exercise-
induced dystonia, ataxia, spasticity, and chorea – (Hully et al., 2015; Suls et al., 
2008). The majority of affected individuals have epileptic seizures before the age 
of three years, yet seizure types and outcomes vary, as do developmental and 
cognitive profiles of affected individuals (Hully et al., 2015). Despite this wide 
phenotypic variability, a consistent finding is that affected individuals have a low 
CSF to plasma glucose ratio (de Giorgis & Veggiotti, 2013). 
The finding that patients with GLUT1 deficiency (Glut1-D) often present with early 
childhood-onset absence or myoclonic seizures has prompted some groups to 
screen for SLC2A1 variants in patients presenting with these seizure types. Larsen 
et al. screened 50 children presenting with absence seizures between six months 
and six years and identified pathogenic SLC2A1 variants in five of these (10%). 
Those with SLC2A1 variants presented at a wide range of ages, between three 
weeks and five years (Larsen et al., 2015b). Arsov et al. screened 89 patients with 
early onset absence seizures (before four years of age) and identified 11 (12%) with 
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pathogenic SCL2A1 variants (Arsov et al., 2012).  Mullen et al. screened 84 children 
with myoclonic-atonic seizures and identified four with pathogenic SLC2A1 variants 
(5%) (Mullen et al., 2011). In the Larsen, Arsov and Mullen papers, more detailed 
description of the phenotypes reveals that the majority of affected patients do in 
fact have additional features, typically developmental delay and ataxia, though 
these may be subtle. 
More severe Glut1-D phenotypes are observed with truncating variants than with 
missense variants, but no other genotype-phenotype correlations have been 
described (Hully et al., 2015; de Giorgis & Veggiotti, 2013).                . 
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Table 5.3p: SLC2A1 gene summary from the literature 
Chromosome locus 1p34.2 
Phenotype observed in microdeletion syndrome? Yes – features of Glut1-D observed in patients with deletions involving SLC2A1 (Vermeer et al., 2007) 
pLI Score~ 0.94 
Brain expression ratio* 1.0 
Localisation within brain Choroid plexus, ependyma, and glia (Vannucci et al., 1998) 
Proposed gene function Actively transports glucose across the blood-brain barrier 
Proposed genetic mechanism of pathogenicity Haploinsufficiency 
Yield in epilepsy NGS literature (Chapter 3) 52/13063 (0.4%), Rank: 10 
Previous incidence estimates Estimated as 1 per 90,000 live births in Queensland, Australia (Coman David et al., 2006) and 1 per 
83,000 in Denmark (Larsen et al., 2015b) 
Previous clinical spectrum descriptions No unselected cohorts published. 
Associated phenotypes include infantile onset epileptic encephalopathy (de Vivo et al., 1991; Seidner 
et al., 1998), early onset absence epilepsy (Agostinelli et al., 2013), epilepsy with myoclonic-atonic 
seizures (Agostinelli et al., 2013), generalised epilepsy with comorbid movement disorder (Larsen et 
al., 2015b), and exercise-induced dystonia without epileptic seizures (Schneider et al., 2009). 
Previous age of onset descriptions Range 3 months to 8 years (Hully et al., 2015; Larsen et al., 2015b) 
Previous penetrance estimates None. Occasional families with incomplete penetrance reported (Striano et al., 2012) 
Evidence for specific treatment Retrospective uncontrolled family-reported subjective treatment response analysis. N = 82. 38/82 
(46%) had seizure-freedom, 66/83 (80%) had ≥90% seizure-reduction, and 78 (95%) had ≥50% seizure-
reduction at latest follow up (range 1 month-20 years, median 5.5 years) (Kass et al., 2016). 
~ From the Exome Aggregation Consortium (ExAC) dataset (The Broad Institute Exome Aggregation Consortium, 2018) 
* From the GTEx Portal data, based on adult post-mortem tissue expression profiles (Aguet et al., 2017)
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Table 5.3q: Patients with SLC2A1 variants from Cohort 1 
Yield 6/315 (1.9%), Rank: 4 
Case 
ID 
Age of 
presentation 
Presenting 
seizure 
Dev. delay at 
presentation > 
follow-up 
Age of 
follow-up 
Epilepsy 
diagnosis 
Seizure 
types 
observed 
Additional 
features 
Current 
seizure 
frequency 
Current 
treatment 
approach 
Current 
treatment 
Effective 
treatments 
Variant Inheritance Family 
history 
119 11 months Afebrile 
focal 
No > Mild 42 months Unclassified 
generalised 
and focal 
epilepsy 
Afeb-focal 
Afeb-GTCS 
Afeb-atonic 
Mild gait 
ataxia 
None in 6 
months 
Receiving 
AED 
polytherapy 
and 
Ketogenic 
Diet 
LEV, CBZ 
KD 
Unknown – 
KD just 
started 
c.497_499delTCG, 
p.Val166del 
De novo None 
167 12 months Afebrile 
myoclonic 
Mild > No 36 months Myoclonic 
epilepsy 
Afeb-myo Mild gait 
ataxia 
None in 6 
months 
Never had 
regular AED 
Ketogenic 
Diet 
KD KD c.736_739delGAAG
, p.Glu246fs 
De novo Paternal 
uncle has 
epilepsy 
139 12 months Afebrile 
absence 
No > No 44 months Epilepsy with 
myoclonic-
atonic 
seizures 
Afeb-
absence 
Afeb-myo 
Afeb-atonic 
Mild gait 
ataxia 
None in 6 
months 
Receiving a 
different 
AED 
monotherap
y to the first 
one tried – 
initial 
therapy not 
effective 
Ketogenic 
Diet 
VPA 
KD 
VPA 
KD 
c.277C>T, 
p.Arg93Trp 
Unknown - 
adopted 
Biological 
mother 
has 
learning 
difficulties 
and history 
of epilepsy 
87 16 months Afebrile 
GTCS 
Mild > Mild 50 months Unclassified 
generalised 
epilepsy 
Afeb-status 
Afeb-GTCS 
Mild gait 
ataxia 
< 1 per 
month 
Never had 
regular AED 
Ketogenic 
Diet 
KD KD c.940G>A, 
p.Gly314Ser 
Paternal Father has 
exercise-
induced 
dystonia 
50 18 months Afebrile 
GTCS 
Mild > No 57 months Unclassified 
generalised 
epilepsy 
Feb-GTCS 
Afeb-status 
Afeb-GTCS 
Severe 4-
limb 
dystonia 
(resolved on 
KD) 
None in 6 
months 
Previously 
received 
AED therapy 
– now off 
medication 
Ketogenic 
Diet 
KD KD c.505_507delCTC, 
p.Leu169del 
De novo None 
156 19 months Afebrile 
GTCS 
No > Mild 41 months Unclassified 
generalised 
epilepsy 
Afeb-GTCS Mild gait 
ataxia 
None in 6 
months 
Never had 
regular AED 
Ketogenic 
Diet 
KD KD c.929C>G, 
p.Thr310Ser 
De novo None 
Abbreviations used: GTCS – generalised tonic-clonic; myo – myoclonic, Afeb – afebrile, Feb-febrile, AED – anti-epileptic drug, LEV – Levetiracetam, CBZ – Carbamazepine, VPA – Sodium Valproate, KD – Ketogenic Diet 
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Table 5.3r: Summary of patients with SCL2A1 variants in Cohort 1 
Median age of presentation 12 months 
Development Normal at presentation: 3/6 (50%) 
Normal at latest follow-up: 3/6 (50%) 
Presenting seizure type Afebrile GTCS: 3/6 (50%) 
Afebrile myoclonic: 1/6 (17%) 
Afebrile absence: 1/6 (17%) 
Afebrile focal: 1/6 (17%) 
Seizure types observed Afebrile GTCS: 4/6 (67%) 
Afebrile status: 2/6 (33%) 
Afebrile myoclonic: 2/6 (33%) 
Afebrile atonic: 2/6 (33%) 
Afebrile absence: 1/6 (17%) 
Afebrile focal: 1/6 (17%) 
Febrile GTCS: 1/6 (17%) 
Latest diagnosis Unclassified generalised epilepsy: 3/6 (50%) 
Unclassified generalised and focal epilepsy: 1/6 (17%) 
Epilepsy with myoclonic-atonic seizures: 1/6 (17%) 
Myoclonic epilepsy: 1/6 (17%) 
Current seizure frequency None in last 6 months: 5/6 (83%) 
< 1 seizure per month: 1/6 (17%) 
Current treatment approach Never had regular AED, on Ketogenic Diet: 3/6 (50%) 
AED polytherapy and Ketogenic Diet: 1/6 (17%) 
Monotherapy changed due to poor efficacy and Ketogenic 
Diet: 1/6 (17%) 
Off medication, on Ketogenic Diet: 1/6 (17%) 
Effective treatments used Ketogenic Diet: 5/6 (83%) 
Sodium Valproate: 1/6 (17%) 
Variant type Missense: 3/6 (50%) 
In-frame deletion: 2/6 (33%) 
Frameshift: 1/6 (17%) 
Variant inheritance De novo: 4/6 (67%) 
From affected parent: 1/6 (17%) 
Unknown: 1/6 (17%) 
Though there has been no previous large cohort of unselected children with 
seizures tested for variants in SLC2A1, a surprising finding in this cohort is that age 
of presentation appears to be later than suggested by the published literature. In 
the largest published series of SLC2A1 cases, from France, 16/38 cases had 
epileptic seizures, and for those who had seizures, the median age of presentation 
with seizures was 6 months (range 1.5 to 60 months) (Hully et al., 2015). In Cohort 
1 the median age of presentation was 12 months (range 11-19 months). Seizures in 
Glut1-D can present at a wide range of ages, so that fact that no early-infantile-
onset cases were captured in Cohort 1 is likely to reflect chance and small 
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numbers. There has been a perception from previous case reports of Glut1-D that 
patients are likely to present with, or develop, absence seizures or myoclonic 
seizures. In Cohort 1 the most commonly observed seizure type was GTCS, and 4/6 
(67%) patients had neither myoclonic nor absence seizures. Seizure-outcomes in 
this group were good, with 5/6 (83%) patients having had no seizures for six 
months or more at the time of their most recent follow-up. Short term 
developmental outcomes were also good with three patients having mild delay, 
and three having normal development at latest follow-up. In common with 
previous studies investigating SLC2A1 variants and epilepsy, all the patients 
identified in Cohort 1 had a movement disorder as well as seizures (ataxia or 
dystonia), though in 5/6 patients this manifested just as just mild gait ataxia. 
The incidence of Glut1-D has previously been estimated as 1 per 90,000 live births 
in Queensland (Coman et al., 2006) and 1 per 83,000 live births in Denmark (Larsen 
et al., 2015b). These estimates have been based upon the fact that both 
Queensland and Denmark had single centres for SLC2A1 testing, but because there 
was no active recruitment strategy for these studies there are likely to be a 
number of undiagnosed cases within those populations. The data from Cohort 1 
suggests that Glut1-D is far more common than these previous estimates (1 per 
28,000 live births) and that in cases where Ketogenic Diet is initiated early, the 
short-term outcomes are good. 1 per 28,000 is likely to be a significant 
underestimate of the incidence of Glut1-D since previous studies have shown that 
it may present without seizures, or with seizures after the age of three years (Kass 
et al., 2016; Coman et al., 2006; Hully et al., 2015; de Giorgis & Veggiotti, 2013; 
Larsen et al., 2015b). From the small number of cases identified in Cohort 1 it is 
not possible to assess genotype-phenotype correlation, though it is worthy of note 
that the one case with a truncating variant (case 167) was seizure-free and had 
normal development at most recent assessment (36 months). 
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5.3.5.5 Other genetic diagnoses made in Cohort 1 
Between them four genes - PRRT2, SCN1A, KCNQ2, and SLC2A1 - account for 43/74 
(58%) of single gene diagnoses made in Cohort 1.    For the other single gene 
diagnoses made in Cohort 1, the numbers are too small to draw conclusions about 
the clinical spectrum of each, and the confidence intervals for incidence estimates 
are broad (Figure 5.3c). There were four cases each of CDKL5, PCDH19, SLC6A1, 
and DEPDC5. These genes appear third, sixth, equal 68th respectively, in the list of 
genes most commonly implicated in diagnoses made on epilepsy panels (Chapter 
3). The incidence of SLC6A1-related epilepsy is likely to be an over-estimate since 
three of the four patients in Cohort 1 were siblings. The figures in Chapter 3 are 
likely to underestimate the relative yield of SLC6A1 and DEPDC5-related epilepsy 
because these genes were not included in the largest gene panel study by Lindy et 
al. (Lindy et al., 2018). 
5.3.5.6 Diagnosing genetic epilepsies with treatment implications 
Figure 5.3g highlighted those genetic diagnoses made in Cohort 1 for which there 
was some clinical or experimental evidence to support a specific treatment 
approach, or “precision medicine.” 85% (63/74) of genetic diagnoses fell into this 
category and 20% (63/315) of the entire cohort were diagnosed with a genetic 
cause that had potential treatment implications. 
I looked at what proportion of patients in Cohort 1 had in fact been treated with a 
specific therapeutic approach as supported by the evidence presented in Chapter 4 
(table 5.3s). This shows that although 63 patients in this cohort had diagnoses 
involving genes for which there was some support for a specific therapeutic 
approach, only 36 patients did in fact receive such an approach.  There are likely 
to be a number of reasons why not all “eligible” patients received precision 
therapy. First, four of these patients never in fact received any anti-epileptic 
therapy, because seizures were febrile or self-limited. Second, empirical therapy 
may have been started prior to knowledge of genetic result, and if this was 
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effective and tolerated, there would have been no incentive for the clinician to 
change treatment strategy. Third, clinicians may not have been aware of the 
evidence base, or had judged it too weak, to inform their treatment decisions. 
Finally, the timing of follow-up data was variable, so some patients may have been 
yet to start one of the evidence-based treatments. 
The “clinician reported benefit” from treatment used here is a crude and 
subjective measure of treatment efficacy. Clinician reports of relative therapeutic 
efficacy could be partially validated by asking for reports from parents as well. 
The most objective method of determining treatment benefit would be to ask 
parents to keep prospective diaries of seizure frequencies, though this would be 
time intense for families.  Additional benefits of therapy could be measured 
though prospectively accrued developmental, behavioural and quality of life 
questionnaires, though for patients on serial monotherapies or polytherapy it 
would be difficult to tease out the relative effects of different therapies. 
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Table 5.3s: Patients treated with precision therapy in Cohort 1 
Gene Proposed precision treatment(s) (Chapter 4) Number of 
patients in 
Cohort 1 
Number of 
treated patients 
in Cohort 1 
Number of treated patients currently on, 
or reported to have previously benefited 
from, precision therapy 
PRRT2 Carbamazepine 17 17 7/17 (41%) 
SCN1A Stiripentol 
Cannabidiol 
Fenfluramine 
Avoidance of Carbamazepine and Lamotrigine 
11 9 8/9 (89%) 
5 Stiripentol, 1 Fenfluramine, 8 never 
treated with CBZ or LMT 
KCNQ2 Carbamazepine 9 8 7/8 (88%) 
SCL2A1 Ketogenic Diet 6 6 6/6 (100%) 
CDKL5 Ketogenic Diet 
Sodium Valproate 
Lamotrigine 
4 4 3/4 (75%) 
2 Ketogenic diet, 1 VPA 
PCDH19  Intermittent corticosteroids 
Clobazam 
4 4 2/4 (50%) 
1 Intermittent corticosteroids, 1 Clobazam 
SLC6A1 Sodium Valproate 4 4 0/4 
CACNA1A Lamotrigine 2 1 0/1 
MECP2 Dextramethorphan 1 1 0/1 
POLG Avoidance of Sodium Valproate 1 1 1/1 (100%)  
SCN8A Phenytoin 1 1 0/1 
SCN2A Carbamazepine, Lamotrigine or Phenytoin 1 1 1/1 (100%) CBZ 
STXPB1 Levetiracetam 1 1 0/1 
KCNT1 Quinidine 1 1 1/1 (100%) 
TOTAL  63 59 36/59 (61%) 
Abbreviations used: CBZ – Carbamazepine; LMT – Lamotrigine; VPA – Sodium Valproate 
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What table 5.3s does show is that a very high proportion of genetic diagnoses do 
involve genes for which at least attempts have been made to make a case for 
precision therapy. In order to see if the same was true for genetic diagnosis as a 
whole in epilepsy I looked back at the data in Figure 3.2b which shows the 
cumulative results from 24 NGS studies in epilepsy.  Genes for which diagnosis may 
have therapeutic implications are shaded black – this includes all of the top 10 
genes, and 1571/2219 (71%) of all diagnoses made.  A ten gene epilepsy panel 
which included SCN1A, KCNQ2, CDKL5, SCN2A, STXBP1, PCDH19, PRRT2, SCN8A, 
MECP2, and SLC2A1 would theoretically capture 62% of all diagnoses, and 91% of 
diagnoses with treatment implications.                               .
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Figure 5.3i: Cumulative totals of genetic diagnoses made from 24 NGS studies (genes with 4 or more hits); Genes for which 
there is some evidence to support a precision approach are shaded black 
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Figure 5.3j: Theoretical relationship between number of genes covered and % of cases diagnosable, based on data 
extrapolated from 24 NGS studies; a 10 gene panel would diagnose 62% of cases, and 91% of cases in which the genetic 
diagnosis had treatment implications                                          .
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5.3.5.7 Limitations of the data from Cohort 1 
Cohort 1 was a prospective national population-based cohort study in which the 
aim was to recruit all children presenting before the age of three years with 
seizure phenotypes ranging form the mild (a single cluster of afebrile seizures 
within 24 hours) to the severe (drug-resistant epilepsies). By having broad inclusion 
criteria this cohort was able to overcome the ascertainment biases inherent in 
previous NGS studies which have preferentially recruited patients with severe 
and/or pharmaco-resistant epilepsies. It is likely that because of the broad 
inclusion criteria, Cohort 1 has shown a higher yield for PRRT2-related epilepsy (a 
typically mild and self-limited condition) than previous NGS studies. The incidence 
of SLC2A1-related epilepsy is higher, and the phenotype milder, than has been 
suggested by previous studies, which is also likely to reflect ascertainment of 
milder cases that would not have been otherwise identified. Interestingly the 
cohort did not identify many mild SCN1A cases and did not show a greater 
incidence of Dravet syndrome than previous studies, suggesting that the 
established epidemiology and described clinical spectrum of SCN1A-related 
seizures is already quite accurate.  
Despite having broader inclusion criteria than previous studies, Cohort 1 was still 
selective. Patients with very mild phenotypes such as single seizures, or recurrent 
short-duration febrile seizures were not included. Since these presentations may 
also have a genetic basis, it is possible that cohort 1 has underestimated the 
incidence of monogenic seizure disorders. Indeed, the twin sister of case 334 had 
the same PPRT2 variant but was not included in cohort 1 because she did not meet 
eligibility criteria (all her seizures were febrile and <10 minutes). The cohort was 
also selective on age, and number of genetic epilepsies that were tested for in the 
study. Particularly, SLC2A1, DEPDC5, POLG, and KCNT1 can present with seizures 
in later childhood and adulthood, so the incidences of these may have also been 
underestimated. In order to determine the true incidence of monogenic seizure 
disorders, a truly unselected birth cohort would have to be followed up for life, 
and whenever an individual from the cohort presented with a seizure of any type 
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they would be offered comprehensive genetic testing. Such as study would be 
costly and practically challenging. 
Cohort 1 did not have complete recruitment, with capture-recapture methodology 
suggesting that an estimated eligible 229 cases were not recruited. This figure is 
based on the assumptions that the rate eligible presentations in the rest of 
Scotland would be equal to that in the West of Scotland Health Boards (Greater 
Glasgow and Clyde, Lanarkshire, Forth Valley, Ayrshire and Arran, Dumfries and 
Galloway), and that recruited patients and non-recruited patients were equally 
likely to have been investigated with EEG. These limitations notwithstanding, it is 
likely that patients with monogenic seizure disorders presented to health care but 
were not recruited to the cohort. It is also possible that patients presented to 
health care services outwith the Scottish NHS (to English services or to private 
providers) or to facilities in the three small Health Boards not included in the study 
(Western Isles, Orkney, Shetland). The limitation of potential under recruitment 
can be qualified by quoting the incidences as “minimum” incidences. However, 
because the numbers in each gene group are relatively small the confidence 
intervals for each incidence estimate are wide, as shown in table 5.3c. A study 
with a larger population, or over a longer time period would help narrow these 
confidence intervals and help define the incidence of some of the rarer monogenic 
seizure disorders. 
Eligibility for inclusion was not based on year of birth but on age at presentation 
and date of presentation. This was a practical decision since it allowed 300 cases 
to be recruited in half of the time that it would have taken had a birth cohort 
approach been taken. The drawback of this approach is that it limited the 
accuracy of the denominator. Patients included in the cohort could have been born 
between May 9th 2011 and May 7th 2017. In the absence of a true denominator 
three times the mean number of births in Scotland between the years 2011 and 
2016 inclusive has been used as a denominator. Since this birth rate remained 
relatively stable, it is unlikely to have significantly affected the accuracy of the 
incidence estimates. 
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Some of the data presented in this section is limited in its precision. For example, 
information on developmental status and at most recent follow-up is based on 
clinician-reported impression, which will be less accurate than formal 
developmental assessment. Though parents were given ABASII questionnaires which 
provide a proxy measure of child development, the low return rate on these has 
limited their application to analysis of the cohort. Impression of development may 
also change over time, but for practical reasons, follow-up data was not obtained 
at a standard age for all patients.  
All patients in Cohort 1 were tested for pathogenic variants in 104 genes, yet this 
list of 104 does not represent all known epilepsy-associated genes, and it is 
possible that further diagnoses could have been made had a more extensive 
platform been used. Other genetic diagnoses, involving chromosomal 
microduplications and microdeletions may have been made had chromosomal 
microarray been part of the genetic testing protocol. Chromosomal microarray was 
not included as part of the testing protocol because this is a test that is was 
already available in the four regional genetics departments in Scotland. In reality 
some patients with chromosomal microdeletions and microduplications were in 
fact included in cohort 1 because their particular Copy Number Variant (CNV) was 
picked up through MLPA testing of a single gene (cases 336 177 with KCNQ2 
deletion and cases 293 and 279 with KCNQ2 duplication). Other patients with CNVs 
may have never been recruited to Cohort 1 if this was known about before 
presentation with seizures, for example if the child had already been investigated 
for developmental delay. In order to understand the relative importance of single 
gene variants, CNVs and other aetiologies in the under three years group 
presenting with seizures another cohort, in which patients were not excluded on 
the basis of having an established aetiology, was required. This was Cohort 2. 
5.3.6 Cohort 2: Epidemiology 
Patients in Cohort 2 were identified through two independent routes: i) Being in 
cohort 1; and ii) Review the notes of all children who had an EEG done in NHS 
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Forth Valley, NHS Greater Glasgow and Clyde or NHS Ayrshire and Arran between 
January 1st 2014 and December 31st 2017, and who were younger than four years at 
the time of the EEG. The numbers identified in Cohort 2 have already been 
referred to in section 2.3.2 when estimating the number of missing cases from 
Cohort 1.  
208 patients in Cohort 2 had been diagnosed with epilepsy by the time of their 
most recent follow-up. Of these, 136 had been included in Cohort 1, and 191 were 
identified through EEG records, with an overlap of 119. 
 
Figure 5.3k: Patients with a diagnosis of epilepsy in Cohort 2, according to 
whether they were in Cohort 1 and whether they were identified through EEG 
review 
Figure 5.3k shows that of 136 patients with epilepsy who were recruited to Cohort 
1. 119 (87.5%) had been investigated with EEG, and that an additional 72 patients 
with epilepsy were identified through EEG review. The expected additional number 
of patients with epilepsy that had not been investigated with EEG would therefore 
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be 10 (72/0.875 – 72), making the expected total number of West of Scotland 
patients with epilepsy 218.  
Table 5.3t: Births in West of Scotland Health Boards, 2011-2016 
Year Total Births A&A D&G Forth Valley GG&C Lanarkshire 
2011 29,000 3,887 1,396 3,154 13,068 7,495 
2012 28,558 3,701 1,390 3,254 13,098 7,115 
2013 27,592 3,647 1,327 3,025 12,583 7,010 
2014 27,880 3,571 1,286 3,114 12,788 7,121 
2015 26,983 3,612 1,256 2,939 12,275 6,901 
2016 26,598 3,495 1,318 2,887 12,082 6,826 
Mean 27,769      
The mean number of births in West of Scotland Health Boards from 2011-2016 
inclusive was 27,769, making the estimated denominator for this population 83,307 
live births. The estimated incidence of epilepsy of onset before three years is 
therefore 1 per 383 live births.  Wirrell et al. previously estimated the incidence of 
epilepsy of onset before 36 months of age to be 1 per 614 live births (Wirrell et al., 
2012).  
Incidence rates were higher at younger ages, as shown in figure 5.3l. Estimated 
incidence of epilepsy in the under 12 months age group in this cohort was 1 per 
705 live births, which is significantly greater than previous population-based 
estimates from Minnesota (1 per 893) (Wirrell et al., 2011), Nova Scotia (Camfield 
et al., 1996) (1 per 848), Helsinki (Gaily et al., 2016) (1 per 807) and London (Eltze 
et al., 2013) (1 per 1,220).                      .
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Figure 5.3l: Age-specific incidence of epilepsy in Scotland using data from Cohort 2, with 95% confidence intervals
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5.3.7 Cohort 2: Presentation and investigation 
54.3% of Cohort 2 presented in the first 12 months of life. 50.5% presented with 
focal seizures, 35.5% with generalised seizures, and 13.0% with infantile spasms. 
At the time of most recent follow-up, 51% of the cohort had an aetiology 
identified. Investigations performed in order to determine aetiology included CT 
brain scan (49 patients), MRI brain scan (184 patients), karyotype (7 patients) 
chromosomal microarray (109 patients), Sanger sequencing and or MLPA for single 
genes (92 patients), and gene panel testing (151 patients). 11 patients in the 
cohort had no identified aetiology but had not undergone gene panel testing 
(Figure 5.3m). The diagnostic yields shown in Figure 5.3m reflects a priori 
diagnostic suspicion. Due to radiation risks, patients are only likely to undergo 
urgent CT when there is a strong clinical suspicion of a structural lesion. Similarly, 
single gene testing and microarray were only likely to be requested where the 
suspicion of a genetic diagnosis was relatively high, whereas gene panel testing 
was offered in all cases for whom aetiology had not been determined. In a 
hypothetical scenario in which neuroimaging but no genetic testing were available, 
an aetiological diagnosis could be made in 23.1% of patients. Chromosomal studies 
(karyotype and microarray) would increase diagnostic yield by 38%, and single gene 
studies would increase the yield by a further 77% (Figure 5.3n). 
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Table 5.3u: Descriptive data from Cohort 2 
Age of presentation N % 
< 6 months 63 30.3% 
6-12 months 50 24.0% 
12-18 months 27 13.0% 
18-24 months 25 12.0% 
24-30 months 16 7.7% 
30-36 months 27 13.0% 
 
Presenting seizure type N % 
Focal 105 50.5% 
GTCS 56 26.9% 
Absence 5 2.4% 
Atonic 2 1.0% 
Myoclonic 8 3.8% 
Myoclonic absence 1 0.5% 
Spasms 27 13.0% 
Tonic 2 1.0% 
Unclassified 2 1.0% 
 
Aetiology N % 
Structural 27 13.0% 
Genetic 52 25.0% 
Trisomy 4 1.9% 
Microdeletion or duplication 11 5.3% 
Single gene variant 37 17.8% 
Metabolic 2 1.0% 
Aetiology in more than one group 25 12.0% 
Unknown 102 49.0% 
 
Antiepileptic therapy at latest follow-up N % 
Never had a regular AED 32 15.4% 
Off treatment 35 16.8% 
First monotherapy 53 25.5% 
Second third or fourth monotherapy 14 6.7% 
Monotherapy having previously received polytherapy 5 2.4% 
Polytherapy 62 29.8% 
Deceased 6 2.9% 
Unknown 1 0.5% 
 
Seizure frequency at latest follow-up N % 
None in 6 months 108 51.9% 
< 1 per month 31 14.9% 
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Monthly 9 4.3% 
Weekly 16 7.7% 
Daily 31 14.9% 
Deceased 6 2.9% 
Unknown 7 3.4% 
 
Seizure-frequency and treatment at latest follow-up Number % 
Not seizure-free 87 41.8% 
Seizure-free on therapy 48 23.1% 
Seizure-free off therapy 60 28.8% 
Deceased 6 2.9% 
Unknown 7 3.4% 
 
Development at latest follow-up Number % 
Normal 95 45.7% 
Global developmental delay 104 50.0% 
Other concerns (ASD features, attention or behavioural 
difficulties) 
8 3.8% 
Unknown 1 0.5% 
 
Epilepsy classification at latest follow-up N % 
Unclassified focal epilepsy 71 34.1% 
Unclassified focal and generalised epilepsy 11 5.3% 
Unclassified generalised epilepsy 3 1.4% 
Unclassified epilepsy 51 24.5% 
West syndrome 15 7.2% 
Infantile spasms (without hypsarryhthmia) 8 3.8% 
Self-limited familial neonatal seizures 3 1.4% 
Self-limited infantile seizures 12 5.8% 
Early onset developmental and epileptic encephalopathy 6 2.9% 
Epilepsy with myoclonic-atonic seizures 5 2.4% 
Absences with eyelid myoclonia 1 0.5% 
Alper's Huttenlocher syndrome 1 0.5% 
Dravet syndrome 2 1.0% 
Early onset absence epilepsy 4 1.9% 
Epilepsy with GTCS only 1 0.5% 
Epilepsy with myoclonic absences 1 0.5% 
Familial focal epilepsy 1 0.5% 
Febrile seizures plus 5 2.4% 
Unclassified myoclonic epilepsy 4 1.9% 
Myoclonic epilepsy of infancy 1 0.5% 
Panayiotopoulos syndrome 1 0.5% 
Unknown 1 0.5% 
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Figure 5.3m: Diagnostic investigations performed in Cohort 2
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Figure 5.3n: Proportionate increase in diagnostic yield achieved from genetic 
testing in Cohort 2 
5.3.8 Cohort 2: Aetiology 
51% of the cohort had an aetiology identified. 69 (33%) had a genetic cause 
identified, 48 (23%) a structural cause, 8 (4%) a metabolic cause, and 2 (1%) and 
infectious cause. 21 patients (10%) had an aetiology that fell into more than one of 
these categories (Figure 2.3o). Of 102 patients with no aetiology determined 91 
(89%) had been tested on the 104 gene panel and 84 (83%) had been investigated 
with MRI brain. 
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Figure 5.3o: Aetiological diagnoses made in Cohort 2 
Table 5.3v: Aetiologies in Cohort 2, by category 
Structural causes (n = 48) 
 Brain malformations (n = 18) 
  Cystic encephalomalacia (n =6) 
  Congenital hydrocephalus (n = 3) 
  Complex congenital brain malformation (n = 3) 
  Lissencephaly (n = 2) 
  Mesial temporal sclerosis (n = 2) 
  Aicardi syndrome (n =1) 
  Periventricular heterotopia (n = 1) 
  Bilateral perisylvian polymicrogyria (n = 1) 
 
Perinatal hypoxic-ischaemic injury (n = 5) 
 Traumatic brain injury (n = 4) 
  Non-accidental (n = 2) 
  Accidental (n = 1) 
  Unknown (n = 1) 
 Vascular (n = 4) 
  Neonatal cerebral infarction (n = 2) 
  Haemorrhagic stroke (n= 2) 
  Subdural haemorrhage (n = 1) 
  Developmental cerebral venous anomaly (n = 1) 
 
Tuberous sclerosis (n = 4) 
 Preterm with periventricular leukomalacia (n = 3) 
 Encephalitis (n = 2) 
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  NMDA receptor encephalitis, following HSV (n = 1) 
  Cerebellitis due to lead toxicity (n = 1) 
 
Hypoglycaemia-related cortical damage (n = 2) 
 Sturge-Weber syndrome (n = 2) 
 Periventricular leukomalacia from presumed antenatal insult (n = 1) 
Metabolic causes (n = 8) 
 Neonatal hypoglycaemia (n = 2) 
 Hyperinsulinism (n = 1) 
 Glycine encephalopathy (n = 1) 
 Farber disease (n = 1) 
 Alpers-Huttenlocher disease (n = 1) 
 Lead toxicity (n =1) 
 Mitochondrial disease, suspected (n = 1) 
Infectious causes (n = 2) 
 
Herpes Simplex Virus encephalitis (n= 1) 
 Congenital parvovirus infection (n = 1) 
Immune causes (n = 1) 
 NMDA receptor encephalitis, following HSV (n = 1) 
Genetic causes (n = 69) 
 Trisomy (n = 7) 
  Trisomy 21 (n = 5) 
  Trisomy 13 (n = 1) 
  Trisomy 18 (n = 1) 
 
Subchromosomal structural change (n = 16) 
  De novo 16p11.2 deletion (n = 3) 
  Angelman Syndrome (maternally-inherited 15q11.2-13.1 deletion) 
  De novo 16p13.11 deletion (n = 1) 
  De novo 17p13.3 deletion (Miller Dieker syndrome) (n = 1) 
  De novo 17q12 deletion (n = 1) 
  De novo 1p36 deletion (n = 1) 
  De novo 4p deletion (Wolff-Hirschhorn syndrome) (n = 1) 
  De novo 7q deletion (Williams syndrome) (n = 1) 
  De novo Xp22.31 deletion (n = 1) 
  De novo 16p.11.2 duplication (n = 1) 
  De novo 7p deletion and 7q duplication (n = 1) 
  De novo Idiodicentric chromosome 15 (n = 1) 
  De novo Marker chromosome 20 (n = 1) 
 
Single gene variant (n = 46) (see figure 2.3p) 
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Table 5.3w: Aetiologies in Cohort 2 which fell into multiple categories 
Metabolic and genetic diagnoses (n =2) 
 Farber disease due to homozygous ASAH1 variants  
 Alpers-Huttenlocher disease due to compound heterozygous POLG1 variants 
Metabolic, structural and genetic diagnoses (n = 1) 
 Glycine encephalopathy due to compound heterozygous AMT variants, with 
associated lissencephaly 
Metabolic and structural diagnoses (n = 3) 
 Hypoglycaemia-related cortical damage (n = 2) 
 Cerebellitis due to lead toxicity 
Structural and genetic diagnoses (n = 13) 
 Trisomy 13 and complex brain malformation 
 Trisomy 18 and complex brain malformation 
 Trisomy 21 and perinatal hypoxic ischaemic event 
 Tuberous Sclerosis due to TSC2 variant (n =3) 
 7p deletion and 7q duplication and perinatal hypoxic ischaemic event 
 16p13.11 deletion and MRI findings suggestive of Tuberous Sclerosis 
 1p36 deletion and bilateral perisylvian polymicrogyria 
 17p13.1 deletion and lissencephaly 
 KCNQ2 deletion and traumatic brain injury 
 KCNQ2 deletion and cystic encephalomalacia 
 Subdural haemorrhage and MAF1 variant 
Structural and infectious diagnoses (n = 1) 
 Congenital parvovirus and periventricular leukomalacia 
Structural, infectious and immune diagnoses (n = 1) 
 Herpes simplex virus encephalitis complicated by NMDA receptor encephalitis 
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Figure 5.3p: Single gene diagnoses made in Cohort 2 
As with Cohort 1, the majority of single gene diagnoses were clustered in a small 
number of genes, with 30/46 (65%) in the most frequently implicated seven genes. 
7/16 (44%) genetic diagnoses that were identified in just a single patient were 
made not through the genetic epilepsy service but through specific single gene 
testing targeted due to phenotype (AMT, ASAH1, COL4A1, FOXG1, MAF1, POLG1 
and WT1). For example, a patient with glycine encephalopathy was tested for 
variants in the two most commonly implicated genes in this condition (AMT and 
GLDC). 
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Aetiology was more commonly identified in patients who presented at a young age. 
In the <12 months group 62% had an identified aetiology, falling to 40% in the 12-24 
months group and to 37% in the 24-36 months group. The proportion of cases 
attributable to purely structural causes did not fall significantly with increasing 
age of presentation but the proportion attributable to genetic causes did (Figure 
5.3q). However, mean age at presentation was no different between those with 
structural causes and those with genetic causes (11.7 months v 11.2 months, two-
tailed t-test p>0.05). 
 
Figure 5.3q: Aetiological diagnoses in Cohort 2, by age of presentation
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Table 5.3x: Associations between clinical features and aetiology in Cohort 2, 
using Fisher’s Exact test 
 N (%) with 
aetiology  
Two-tailed 
Fisher’s exact 
probability 
Odds ratio (95% 
confidence 
intervals) 
Total cohort 106/208 (50.1%)   
Age at presenting seizure 
<12 months 69/113 (61.1%) < 0.005* 2.4 (1.4-4.3) 
12-24 months 21/52 (40.3%) > 0.05 0.6 (0.3-1.1) 
24-36 months 16/43 (37.2%) > 0.05 0.5 (0.2-1.0) 
Presenting seizure  
Focal 59/105 (56.2%) > 0.05 1.5 (0.9-2.6) 
Generalised 26/74 (35.1%) < 0.005 ψ 0.4 (0.2-0.7) 
Spasms 19/27 (70.4%) < 0.05* 2.6 (1.1-6.2) 
Additional features 
Spasms present at any age 29/43 (67.4%) < 0.05* 2.4 (1.2-4.8) 
Outcomes at latest follow-up    
Seizure-free 50/108 (46.3%) > 0.05 0.7 (0.4-1.2) 
Drug-resistant epilepsy (DRE) 53/71 (74.6%) < 0.005* 4.7 (2.5-8.8) 
Global developmental delay (GDD) 70/104 (67.3%) < 0.005* 3.9 (2.2-6.9) 
DRE and GDD 44/59 (74.6%) < 0.005* 4.1 (2.1-8.0) 
Death 6/6 (100%) < 0.05* N/A 
* Significant positive association; ψ Significant negative association 
Table 5.3x shows factors that were associated with identifying an aetiology. The 
strongest associations were with early age of presentation (under 12 months), 
presentation with epileptic spasms, the development of drug-resistant epilepsy 
(DRE), and the presence of global developmental delay (GDD). 
I then used a binary logistic regression model incorporating age of presentation (< 
12 months, 12-24 months, 24-36 months), presenting seizure (focal, generalised, or 
spasms), DRE (present or absent), and GDD (present or absent). In this multivariate 
model, type of presenting seizure was no longer significant (Table 5.3x-2). The 
development of DRE had the strongest association with having aetiology identified. 
Overall the multivariate model explained >25% of the variance (Nagelkerke R2 = 
0.267) and was able to predict whether aetiology was identified or not with 61.3% 
sensitivity and 73.5% specificity (Table 5.3x-3). 
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Table 5.3x-2: Multivariate model for associations with identified aetiology in 
Cohort 2 (Hosmer and Lemeshow) 
 p. OR (95% confidence intervals) 
Age at presentation 
24-36 months (reference) 0.036 N/A 
12-24 months 0.476 1.4 (0.5-3.5) 
< 12 months 0.017 2.8 (1.2-6.3) 
Presenting seizure 
Generalised (reference) 0.158 N/A 
Focal 0.055 1.9 (1.0-3.8) 
Spasms 0.387 1.6 (0.5-5.0) 
Outcomes 
GDD present 0.017 2.4 (1.2-4.8) 
DRE present 0.002 3.2 (1.6-6.7) 
Table 5.3x-3: Sensitivity and specificity of multivariate model for associations 
with aetiology in Cohort 2 (Hosmer and Lemeshow) 
Observed Predicted 
 Any cause Percentage Correct 
Absent Present 
Any aetiology 
identified 
Absent 75 27 73.5 
Present 41 65 61.3 
Overall Percentage   67.3 
Previous population-based studies of epilepsy in early childhood have identified a 
higher proportion of structural causes compared with what was found in Cohort 2. 
In Gaily et al’s. Finnish study 35% of those presenting at <12 months had a 
structural cause identified, compared with 33/113 (29%) in Cohort 2 (Gaily et al., 
2016). In those presenting at under 24 months, Eltze et al. reported that a 
structural cause was identified in 35%, compared with 40/165 (24%) in Cohort 2 
(Eltze et al., 2013). Since the overall incidences found in both the Gaily and Eltze 
studies were less than in Cohort 2, it is possible that their studies were affected by 
ascertainment bias, with patients with structural causes more likely to be 
identified and referred to the tertiary centres where the studies were based. 
At most recent follow-up 136/208 (65%) had an unclassified epilepsy syndrome 
which is a significantly more than the number who did not have an established 
aetiology (49%), suggesting that in this age group aetiological classification of 
epilepsy may be more relevant than clinical “syndrome” classification. 
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5.3.9 Predictors of short-term outcomes in Cohort 2 
The primary outcomes of interest in this cohort were: 1. the presence or absence 
or global developmental delay (GDD) and 2. the presence or absence of drug-
resistant epilepsy (DRE). DRE was defined as ongoing seizures (at least one seizure 
in the last 6 months) despite two adequately trialled and tolerated AED regimens. I 
also looked at the outcome of seizure-freedom for >6 months at most recent 
follow-up. 
Because follow-up data was not gathered at a consistent time point for all 
patients, it was important to test that duration and age of follow-up did not 
influence GDD and DRE outcomes. Table 5.3x shows that there were no differences 
in the mean duration of follow-up, nor in age at most recent follow-up, between 
those with and without GDD and DRE respectively. 
Table 5.3y: Differences in mean duration of follow-up and age at follow-up 
between GDD and DRE groups in Cohort 2 
 Mean age at most 
recent follow-up 
Mean duration of 
follow-up 
GDD present 39.8 months 25.9 months 
GDD absent 38.6 months 23.4 months 
Two-tailed t-test* for difference in means (GDD) p >0.05 p >0.05 
DRE present 39.2 months 27.0 months 
DRE absent 39.2 months 23.4 months 
Two-tailed t-test* for difference in means (DRE) p >0.05 p >0.05 
* Both samples were normally distributed 
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Table 5.3z: Associations between clinical features, aetiology, and outcomes in Cohort 2, using Fisher’s Exact test 
Outcome  Seizure-free for > 6 months GDD DRE 
 N (%) with 
outcome 
Two-tailed 
Fisher’s exact 
probability 
Odds ratio (95% 
confidence 
intervals) 
N (%) with 
outcome 
Two-tailed 
Fisher’s exact 
probability 
Odds ratio (95% 
confidence 
intervals) 
N (%) with 
outcome 
Two-tailed 
Fisher’s exact 
probability 
Odds ratio (95% 
confidence 
intervals) 
Total cohort 108/201 
(53.7%) 
 104/208 
(50.0%) 
 71/201 
(35.3%) 
 
Age at presenting seizure 
<12 months 60/107 
(53.1%) 
>0.05 0.8 (0.4-1.4) 60/113 
(53.1%) 
>0.05 1.3 (0.8-2.3) 44/107 
(41.1%) 
>0.05 1.7 (1.0-3.1) 
12-24 months 31/52 (60.0%) >0.05 1.4 (0.7-2.6) 22/52 (42.3%) >0.05 0.7 (0.4-1.2) 15/52 (28.8%) >0.05 0.7 (0.3-1.3) 
24-36 months 17/42 (40.5%) >0.05 1.0 (0.5-2.1) 22/43 (51.2%) >0.05 1.1 (0.5-2.1) 12/42 (28.6%) >0.05 0.7 (0.3-1.4) 
Presenting seizure 
Focal 54/102 
(52.3%) 
>0.05 0.9 (0.5-1.6) 53/105 
(50.5%) 
>0.05 1.0 (0.6-1.8) 34/102 
(33.3%) 
>0.05 0.8 (0.4-1.4) 
Generalised 38/72 (52.8%) >0.05 0.9 (0.5-1.7) 27/76 (35.5%) <0.005 ψ 0.4 (0.2-0.7) 24/72 (33.3%) >0.05 0.9 (0.5-1.6) 
GTCS 26/53 (49.1%) >0.05 0.8 (0.4-1.5) 15/56 (26.8%) <0.005 ψ 0.3 (0.1-0.5) 15/53 (28.3%) >0.05 0.6 (0.3-1.3) 
Other generalised seizure 12/19 (63.2%) >0.05 1.5 (0.3-4.1) 12/20 (60.0%) >0.05 1.6 (0.6-4.0) 9/19 (47.4%) >0.05 1.7 (0.7-4.5) 
Spasms 16/27 (59.3) >0.05 1.3 (0.6-3.0) 24/27 (88.9%) <0.005* 10.1 (2.9-34.8) 13/27 (48.1%) >0.05 1.8 (0.8-4.2) 
Aetiology 
Structural 24/46 (52.2%) >0.05 0.9 (0.5-1.8) 34/48 (70.8%) <0.005* 30.1 (1.6-6.3) 19/46 (41.3%) >0.05 1.4 (0.7-2.7) 
Genetic 33/69 (47.8%) >0.05 0.7 (0.4-1.3) 45/69 (65.2%) <0.005* 2.5 (1.4-4.6) 39/69 (56.5%) <0.005* 4.1 (2.2-7.6) 
Any cause 50/104 
(48.1%) 
>0.05 0.6 (0.4-1.1) 70/106 
(66.0%) 
<0.005* 3.9 (2.2-6.9) 53/104 
(51.0%) 
<0.005* 4.6 (2.4-8.7) 
Outcome 
GDD 44/102 
(43.1%) 
<0.005 ψ 0.4 (0.2-0.7)  59/102 
(57.8%) 
<0.005* 9.9 (4.8-20.4) 
DRE  59/71 (83.1%) <0.005* 10.1 (4.9-20.6)  
* Significant positive association; ψ Significant negative association 
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Table 5.3z supports the findings from previous studies that the most significant 
determinant of outcomes in childhood-onset epilepsy is the identification of an 
aetiology (Eltze et al., 2013; Gaily et al., 2016, Wirrell et al., 2012; O'Callaghan et 
al. 2017; Datta & Wirrell, 2000; Rantala & Ingalsuo, 1999). Identification of 
structural aetiology, genetic aetiology or any aetiology was associated with GDD. 
Identification of genetic aetiology, but not structural aetiology was associated with 
DRE. 
Age of presentation was not significantly associated with any of the outcomes 
investigated, a finding which contrasts with the study by Wirrell et al. which 
reported that presentation before 12 months of age was associated with the 
development of drug-resistant seizures (OR 6.8, 95% CI 2.0-22.8) but is consistent 
with the findings of Rantala et al. who reported no difference in seizure-remission 
rates between children presenting at 0-12 months compared with those presenting 
at 12-24 months (Rantala & Ingalsuo, 1999).  
Type of presenting seizure was associated with developmental outcome but not 
with epilepsy outcome. Children presenting with GTCS were significantly less likely 
to have GDD at most recent follow-up whilst those presenting with infantile spasms 
were significantly more likely to have GDD – a finding that is also consistent with 
previous studies (Gaily et al., 2016; Datta & Wirrell, 2000). The association 
between presentation infantile spasms on developmental outcome did not seem to 
be confounded by aetiology, since 8/8 (100%) patients with no identified aetiology 
had GDD, compared with 16/19 (84%) of those with an identified aetiology. 
There was a strong association between the two outcomes themselves: DRE and 
GDD. This association did appear to be influenced by aetiology. 44/59 (75%) of 
patients with both DRE and GDD had an identified aetiology compared with 27/92 
(29%) of those who had neither DRE nor GDD. 
177 
 
5.3.9.1 Multivariate models: 
For prediction of GDD as an outcome, I used a multivariate binary logistic model 
with the following inputs: type of presenting seizure (focal, generalised, or 
spasms); aetiology (any identified or none identified); and DRE (present or absent). 
The strongest associations with GDD were presentation with epileptic spasms, and 
the presence of DRE. The model was able to predict >40% of the variance 
(Nagelkerke R2 = 0.440) and predicted GDD with 72.1% sensitivity and 85.6% 
specificity (Table 5.3z-3) 
Table 5.3z-2: Multivariate model for associations with GDD in Cohort 2 (Hosmer 
and Lemeshow) 
 p. OR (95% confidence intervals) 
Age at presentation 
24-36 months (reference) 0.070 N/A 
12-24 months 0.190 0.5 (0.2-1.4) 
< 12 months 0.021 0.3 (0.1-0.9) 
Presenting seizure 
Generalised (reference) 0.000 N/A 
Focal 0.044 2.2 (1.0-4.6) 
Spasms 0.000 22.2 (5.1-96.1) 
Aetiology 
Any aetiology identified 0.020 2.4 (1.1-4.9) 
Outcomes 
DRE present 0.000 9.9 (4.4-22.0) 
Table 5.3z-3: Sensitivity and specificity of multivariate model for asscociation 
with GDD in Cohort 2 (Hosmer and Lemeshow) 
Observed Predicted 
Development Percentage Correct 
Absent Present 
GDD Absent 89 15 85.6 
Present 29 75 72.1 
Overall Percentage   78.8 
For prediction of DRE as an outcome, I used a multivariate model using just 
identification of a genetic aetiology (true or false) and GDD (present or absent) 
since these were the only significant predictors in univariate analysis. Both factors 
remained significant in the model (Table 5.3z-4). The model was able to predict 
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>35% of the variance (Nagelkerke R2 = 0.367) and predicted DRE with 45.1% 
sensitivity and 90.5% specificity (Table 5.3z-5) 
Table 5.3z-4: Multivariate model for associations with DRE in Cohort 2 (Hosmer 
and Lemeshow) 
 p. OR (95% confidence intervals) 
Aetiology 
Genetic aetiology identified 0.000 3.7 (1.8-7.4) 
Outcomes 
GDD present 0.000 9.1 (4.3-19.0) 
Table 5.3z-5: Sensitivity and specificity of multivariate model for associations 
with DRE (Hosmer and Lemeshow) 
Observed Predicted 
DRE Percentage Correct 
Absent Present 
DRE Absent 124 13 90.5 
Present 39 32 45.1 
Overall Percentage   75.0 
5.3.10 Whole genome sequencing 
Because the presence of epileptic spasms, and the development of DRE were but 
associated with a high chance of identifying an aetiology (Table 5.3x), and with 
adverse developmental outcome (Table 5.3z), cases with either of these two 
features who remained without a diagnosis were offered Whole Genome 
Sequencing (WGS). 
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Figure 5.3r: Aetiological findings from patients in Cohort 2 with DRE and 
epileptic spasms, before and after WGS 
In total 85 patients in the cohort had either DRE or infantile spasms. Of these the 
majority (74%) had an aetiology identified through neuroimaging or clinical genetic 
testing. Of the 22 patients who remained without and aetiological diagnosis, WGS 
was offered to all. Three families did not take up the offer of WGS and 19 
underwent testing. For 6 patients a diagnostic or strong candidate genetic cause 
was identified through WGS. The methodology of testing, and results from WGS 
will be described and discussed in detail in chapter 6 of this thesis.  
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5.4 Discussion 
In this chapter, I have described the establishment and follow-up two overlapping 
cohorts of children presenting with seizures in the first three years of life. Since 
these cohorts have been ascertained through independent mechanisms, it has been 
possible to use a capture-recapture technique to estimate how many patients may 
have been missed. Using this technique, alongside Scottish national birth record 
data, I have been able to calculate the incidence of epilepsy in the < 3 year age 
group as 1 per 383 live births. This is significantly more common than the previous 
estimate or 1 per 614 live births.  
Because these cohorts were extensively investigated for aetiology, and particularly 
for single gene causes, this study has made it possible to estimate the incidence, 
and more objectively describe the phenotypic spectrum, of a number of single 
gene seizure disorders or early childhood, including PRRT2, SCN1A, KCNQ2, and 
SCL2A1. Apart from SCN1A-related epilepsy, all of these are more common than 
suggested by previous reports. 
As well as enabling capture-recapture analysis, the development of Cohort 2 
overcame some of the limitations of Cohort 1, which are discussed in detail in 
section 5.3.6. Perhaps most importantly, because Cohort 1 focused on patients for 
whom there was no immediately apparent aetiology it was depleted of patients 
with already established structural causes (e.g. neonatal stroke) and genetic 
causes (e.g. trisomy 21). Cohort 2 permitted the inclusion of such patients and 
therefore reflected more accurately the overall aetiologies involved in early 
childhood-onset epilepsy.  Overall more than half of children presenting with 
epilepsy before their third birthday were found to have an aetiology. The majority 
of these aetiologies fell into “structural” or “genetic” groups.  
So far all evidence relating to aetiology-specific therapy in epilepsy relates to 
patients with single gene causes, though it would be perfectly reasonable to carry 
out a trial of therapy in patients with other causes, such as trisomy 21 or one of 
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the more common microdeletion syndromes. It is well accepted that for epilepsies 
in which there is a well delineated structural cause such as focal cortical dysplasia, 
epilepsy surgery offers the best hope of seizure control (Wiebe et al., 2001). Only 
one patient from these cohorts had undergone epilepsy surgery by the time of 
most recent follow-up. This was a patient in Cohort 1 from Lothian who had an 
area of cortical dysplasia in the right occipital lobe. This region was resected and 
subsequently he has been seizure-free. 
The largest aetiological group in both cohorts was the “monogenic” cause. 
Between one fifth and one quarter of the patients in these cohorts had such a 
single gene cause though this is likely to underestimate since the genetic testing 
was largely limited to a panel of 104 genes. With a larger platform further single 
gene diagnoses would be made, as demonstrated by the application of Whole 
Genome Sequencing (WGS) to selected patients within this cohort.  
Looking at the potential scope for therapy to be guided specifically by the 
knowledge of a single gene cause, this is likely to be the case for a significant 
minority of children with early-onset seizure disorders. 23.0% (74/322) of Cohort 1 
and 22.1% (46/208) of Cohort 2 had a single gene cause identified. Of the 74 single 
gene diagnoses made in Cohort 1 63 (85.1%) had potential treatment implications, 
and of the 46 single gene diagnoses made in Cohort 2 37 (80.4%) had potential 
treatment implications, based on evidence reviewed in chapter 4 of this thesis. 
These figures suggest that approximately 17-20% of all children diagnosed with 
epilepsy before their third birthday stand to benefit from a genetic diagnosis that 
may inform therapeutic choice. Since the incidence of epilepsy in the first three 
years of life is 1 per 383 live births, it can also be said that between 1 in 2,000 and 
1 in 2,300 of all children born are likely to have a genetic abnormality causing 
epilepsy for which there is currently available some evidence for a specific 
treatment choice. 
The significant limitations of the evidence in support of “gene-informed” 
treatment choices are discussed in section 4.4 of this thesis. It must be born in 
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mind however that when the clinician is faced with a patient presenting with 
frequent and intrusive seizures they will frequently come to the decision alongside 
families that they would like to start, or change, anti-epileptic therapy. The 
decision in this circumstance is therefore not one of “whether” to treat but of 
“what” specific therapy to use. In the absence of strong evidence to support a 
specific choice the clinician is faced with various options: i) reflect on their own 
previous experience of similar cases (phenotypically or aetiologically); ii) pick the 
therapy that they are most familiar with and which they feel is well-tolerated; iii) 
be guided by the side-effect profile of the medication and the concerns of the 
family in relation to these; iv) use the existing evidence from the literature, 
limited though it may be. In reality the best decision is likely to be informed by all 
of the above points. It was interesting to note that in Cohort 1 only 36/63 (57%) of 
patients with genetic diagnoses that had treatment implications had actually been 
treated with one of the therapies that the medical literature would suggest to be a 
good choice. As more evidence is generated and the results of studies 
disseminated, clinicians may be increasingly influenced by point iv). 
By performing WGS in patients with drug-resistant seizures and/or infantile spasms 
who remained without an aetiological diagnosis after gene panel testing, I have 
shown that extremely rare genetic diagnoses continue to be made in these 
patients. The rarity of these diagnoses presents a significant challenge to those 
trying to progress precision medicine. To gather sufficient numbers of patients to 
perform well-powered cohort studies or therapeutic trials is likely to be a major 
challenge, though not unsurmountable with multi-centre collaboration. 
An additional finding from Cohort 2 is that there is a strong association between 
identification of any aetiology and the presence of global developmental delay 
(GDD) and drug-resistant epilepsy (DRE) (table 5.3x). In a clinical context in which 
aetiological investigations, including imaging and genetic testing, are concluded 
rapidly, this data could potentially be used to reassure families. For example, of 
the 208 patients in Cohort 2, 97 had no identified cause. Of these 97, 28 (28.9%) 
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had GDD at most recent follow-up, 14 (14.4%) had DRE, and the majority (67, 
69.1%) had neither GDD nor DRE. 
There are a number of limitations of the data included in this chapter. Due to the 
large numbers in each cohort and the limited time available to gather phenotypic 
information (most collaborating clinicians contributed data in their own personal 
time), the depth of phenotype information has been limited and at times reduced 
to major categories. Increasing the resolution of phenotypic information may 
provide further insights into the nature of these epilepsies. For example, most of 
the patients in these cohorts had electroencephalogram (EEG) recordings but data 
from these have not been analysed. Similarly, the families in Cohort 1 were all 
sent the validated questionnaire Adaptive Behavioural Assessment Scale II (ABASII) 
as a measure of developmental progress. These data may have provided a greater 
depth of information that was obtained from the clinicians’ assessments of 
development, but due to the relatively low return rate these haven’t been 
included. 
Analyses performed in section 5.3.9. were dependent on data obtained at most 
recent clinical follow-up, specifically focussing on whether GDD or DRE had been 
diagnosed by that time. The time point at which the latest clinical update was 
obtained for each patient varied from one year after initial presentation to four 
years after initial presentation. Longer term follow-up and reanalysis of all 
patients in these cohorts, ideally at consistent time points, would be invaluable. 
Some patients may go on to develop developmental comorbidity and/or drug-
resistance despite having neither at the most recent follow-up.  
The aim of this thesis is to investigate the scope for genetically-guided precision 
medicine in epilepsy and, since as discussed in chapter 1.3, seizure control may 
not be the most important aspect of their child’s quality of life, long-term 
developmental and quality of life questionnaire data from these cohorts would add 
great value to this investigation, particularly if correlations between genetic 
diagnosis, therapeutic approach, and these outcomes can be investigated. In 
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SCN1A-related epilepsy it has previously been shown that early implementation of 
recommended therapy is associated with improved medium-term cognitive 
outcomes (Lange et al., 2018). Our research group aims to continue to follow-up 
these cohorts, gathering clinical and questionnaire data, and investigate for 
relationships between aetiology, treatment approach and long-term outcomes. The 
outcome of interest are seizure control, developmental comorbidity, and quality of 
life. 
A major challenge for the progression of precision therapy in single gene epilepsies 
is the large number of different single gene causes, each of which may require a 
different treatment approach. The patients most in need of a precision approach 
are those whose seizures are not currently being controlled by current 
management. In Cohort 2 there were 71 patients identified with drug-resistant 
epilepsy, of whom 28 (39.4%) had a single gene cause identified. Among these 28 
cases a total of 22 different genes were implicated. What this tells us is that most 
monogenic drug-resistant epilepsies of early childhood are extremely rare 
disorders. 
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6. Prospective study of Whole Genome Sequencing in a cohort 
of children with complex epilepsy from the West of 
Scotland 
6.1 Introduction 
As discussed in chapter 3, a great number of genes have been associated with 
epilepsy and there is currently no hint at a deceleration in epilepsy gene 
discovery. Data from Next Generation Sequencing (NGS) studies suggests that once 
the most frequently associated 50 genes have been excluded as cause, there 
remain still three times that number of known possible genetic causes (Figure 
1.6d), with the likelihood of each one being extremely low (average probability of 
a diagnostic result = 0.01% per gene). With such a large number of extremely rare 
possible genetic causes, targeted testing using a gene panel approach, though 
useful, has limitations.  It is therefore not surprising that the highest yields from 
NGS testing in epilepsy have come from approaches that have not restricted the 
number of genes tested. Three different approaches to untargeted sequencing are 
currently used: Clinical Exome or Mendeliome sequencing, Whole Exome 
Sequencing (WES), and Whole Genome Sequencing (WGS). The Mendeliome aims to 
capture all known disease-associated genes (n = c. 4,800), WES aims to capture all 
coding sequence, and WGS aims to capture all DNA, including intronic and 
intragenic regions. The precise limitations of each approach depend on the 
technology used, but broadly, the advantage of WES over Mendeliome is that it has 
the potential to identify variants in genes not hitherto associated with disease and 
the advantage of WGS over WES is that it may detect disease causing variants in 
intronic or intragenic regions, though many of these remain to be characterised. 
WGS also provides better coverage of the coding regions than WES (Belkadi et al., 
2015). 
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In this chapter I will investigate the diagnostic utility of WGS in severe childhood-
onset epilepsies and investigate how often diagnoses made using this technique 
have the potential to guide therapy choice.  
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6.2 Methods 
6.2.1 Recruitment 
Patients were recruited from the West of Scotland. Four key phenotypes were 
defined, and paediatric neurologists were asked to refer cases whom they thought 
were eligible and whose families would be interested in participating. 
Potential participants were invited by letter (Appendix 9) enquiring about their 
interest in the study. Interested families were then contacted by telephone to 
offer them further information and a recruitment visit. Prior to recruitment visits 
families were sent Information Sheets and Consent Forms. Information was 
discussed, and consent was taken, at the recruitment visit. 
6.2.2 Consent 
Consent was taken for the following: 
• Clinical history taking and examination 
• Medical note review 
• Contact with the patient’s paediatrician/neurologist to discuss clinical 
aspects of the case 
• Blood sample for DNA extraction in Glasgow 
• Whole Genome Sequencing outwith Glasgow 
• Sharing of anonymised clinical details with other research groups 
• Future contact if additional information or biological samples required 
• To be sent questionnaires about development, quality of life, and 
experience of genetic testing 
Participants were offered to be informed of any relevant genetic findings that 
emerged from the research, and were advised that they would not be informed of 
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any genetic findings that were not of relevance to epilepsy – for example if 
variants associated with cancer susceptibility were identified. 
Separate information sheets and consent forms were produced for Parents, Young 
People, Adult participants able to consent for themselves, and for Welfare 
Guardians of adult (over 16 years) participants unable to consent for themselves 
(see Appendix 10 and 11). 
6.2.3 Ethical Approval 
The study was approved by the Scotland A Research Ethics Committee on April 15th 
2016 (REC number 16/SS/0054, Protocol number GN15NE178, IRAS ID 170749). 
6.2.4 Clinical evaluation 
I carried out detailed phenotyping in each case. Parents and child were offered a 
90 minute appointment at the Glasgow Clinical Research Facility (CRF) during 
which structured history taking and physical examination took place (see Appendix 
12). Three generation family history was taken from both parents (see section 
3.2.5). Electronic and paper case notes were reviewed in each case for further 
clinical details and investigation results including EEG, MRI and previous genetic 
testing. Clinical and investigation finding were coded, where possible, using 
Human Phenotype Ontology (HPO) terms (Kӧhler et al., 2017). For an example 
phenotype summary see Appendix 13. 
Participants were asked to complete five validated questionnaires and two 
unvalidated questionnaires asking about their expectations and experience of 
genetic testing (Table 3.2 and 14). 
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Table 6.2a: Questionnaires used in phenotyping patients recruited for whole 
genome sequencing 
Questionnaires (and age groups) given at 
recruitment 
Questionnaires given six months after test 
results communicated 
ABAS II (Adaptive Behaviour Assessment Scale) 
< 5 years 
5-21 years 
Parent/Carer Experience of Genetic Testing * 
unvalidated (See Appendix 14) 
SDQ (Strength and Difficulties Questionnaire) 
2-4 years 
4-17 years 
17+ years 
 
PSI (Parental Stress Index) 
Peds QL (Pediatric Quality of Life) 
2-4 years 
5-7 years 
8-12 years 
13-18 years 
19-25 years 
> 26 years 
ELDQOL (Epilepsy with Learning Disability 
Quality of Life) 
Parent/Carer Expectations of Genetic Testing * 
unvalidated (See Appendix 14) 
6.2.5 Family history scores 
In order to have an objective measure of the strength of family history on both the 
maternal and paternal sides of the family, I devised a family history score. The 
score was attributed to each parent based on the presence of epilepsy and/or 
epilepsy-associated phenotypes in other family members on each side of the 
family. Where siblings of the patient were affected scores were applied to both 
parents equally.  
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Table 6.2b: Family history scores applied to each parent in the WGS study 
Relative (to parent) Phenotype Score 
Self Same phenotype 80 
Epilepsy (different phenotype) 40 
Related disorder: learning disability, migraine, 
schizophrenia, autism, Asperger’s, febrile seizures 
24 
(Another) child Same phenotype 40 
Epilepsy (different phenotype) 20 
Related disorder: learning disability, migraine, 
schizophrenia, autism, Asperger’s, febrile seizures 
12 
1st degree relative 
(parent, sibling) 
Same phenotype 20 
Epilepsy (different phenotype) 10 
Related disorder: learning disability, migraine, 
schizophrenia, autism, Asperger’s, febrile seizures 
6 
2nd degree relative 
(grandparent, uncle, 
aunt, niece or nephew) 
Same phenotype 10 
Epilepsy (different phenotype) 5 
Related disorder: learning disability, migraine, 
schizophrenia, autism, Asperger’s, febrile seizures 
3 
6.2.6 Pre-screening 
Participants who had already been extensively investigated were preferentially 
contacted for recruitment to the study. Recruitment to the study began prior to 
the setting up of the 104 gene epilepsy panel in Glasgow, so not all cases had been 
pre-screened on the 104 gene panel prior to WGS. A note was made of which cases 
had been pre-screened on the panel so that the difference in yield between the 
pre-screened group and the not pre-screened group could be analysed. 
6.2.7 Sequencing, filtering and analysis 
DNA samples were obtained from the proband and both parents (where available) 
and tested using Illumina’s HiSeq X Ten platform (Illumina, 2018). Mapping was 
performed using Stampy (Wellcome Trust Centre for Human Genetics, 2018). Data 
were provided from the sequencing laboratory in FASTQ format. Reeds were then 
mapped to make BAM files. Duplicates were removed and sequences were 
realigned around indels. Variants were called using the GATK best practice pipeline 
(DePristo et al., 2011), in reference to the GRCh37 human genome assembly. 
Variant files were saved in VCF format. Variants were filtered according to quality 
(IGV score > 100), rarity (heterozygous variants frequency in the ExAC database 
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(Broad Institute Exome Aggregation Consortium, 2018) of <0.0001 for heterozygous 
variants and <0.003 for biallelic variants) and predicted deleteriousness (Polyphen-
2 (Adzhubei et al., 2010) score >0.45 for coding missense variants and PhyloP score 
(Pollard et al., 2009) >4 for non-coding variants). All variants that were predicated 
to lead to truncation of the gene product were included. Additional information 
gathered for each variant were the GTEx relative brain expression ratio (Aguet et 
al., 2017) and pLI score (Lek et al., 2016) for the gene involved. Variants which 
survived this filtering were imported onto an excel spreadsheet and were then 
reviewed manually. Variants of interest were imported into Alamut® software in 
order to review in silico predictions. De novo and biallelic variants considered first 
in all cases. Inherited variants were considered if inherited from a parent with a 
large family history score (>30). For male patients, X-linked maternally-inherited 
variants were considered. Literature-based reviews were undertaken to gather 
additional supporting evidence for gene candidacy, with particular note taken of 
genes that had previously been associated with neurodevelopmental disorders such 
as intellectual disability, autism, or schizophrenia.  
In a parallel analysis, conducted by the bioinformatic team at UCB Pharma, 
phenotypic fatures coded for each patient using Human Phenotype Ontology (HPO) 
terms were uploaded onto the SpatientiaTM platform and analysed using the 
Phenomizer tool which prioritises variants in genes that have been associated with 
closely matching phenotypes (Kӧhler et al., 2017). At the end of the study 
candidate variant identified by both proceses were discussed and a final list of 
best candidates was produced. 
All variants that were considered strong candidates were confirmed by Sanger 
sequencing and discussed within a multidisciplinary team of professionals (Clinical 
scientists, Clinical Geneticists and Paediatric Neurologists) in order to determine 
further course of action required. Potential further courses of action were:  
1. For findings considered diagnostic – report the finding and invite the family to 
clinic to discuss 
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2. For variants considered strong candidates – gather additional supporting 
evidence, for example: 
• Any additional diagnostic tests from the patient that would support the 
genetic finding 
• Use online gene-matchmaker systems such as Decipher (Firth et al., 2009), 
Gene Matcher (Sobreira et al., 2015), and Phenome Central (Buske et al., 
2015) to contact other research groups who have identified patients with 
variants in the same gene 
• Obtain additional DNA samples from other affected or unaffected family 
members 
6.2.8 Defining novel candidate genes 
A list of 359 genes previously associated with epilepsy was collated based on 
literature review (Chapter 3). Variants identified involving any of these genes were 
considered. Variants in genes previously implicated with other neurodevelopmental 
disorders such as intellectual disability, autism, schizophrenia or migraine were 
also considered. Because there is no online public library of such genes, these 
were reviewed and identified ad hoc using literature search and the Online 
Mendelian Inheritance in Man (OMIM) resource (Johns Hopkins University, 
Baltimore, 2018). 
Additionally, novel candidate dominant epilepsy genes were selected from the 
filtered results based on GTEx ratio measure of relative brain expression, and pLI 
score of loss of function intolerance. In order to define sensitive and specific cut 
offs for GTEx and pLI values the 45 most commonly identified autosomal dominant 
genes (see chapter 3 and Appendix 15) were compared with the same values for all 
characterised human genes. Combinations of GTEx and pLI that would select just 
5% of characterised genes were tested for their sensitivity to select genes 
associated with dominant epilepsy. The highest sensitivity (73.8%) was achieved 
using script which used a multiple of log pLI and GTEx ratio (see table 6.2c). 
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Variants in candidate genes were considered if the allele frequency was <0.0001 in 
the gnomAD database and either predicated to result in truncation or, for missense 
variants, had a Polyphen-2 score of >0.8. 
Table 6.2c: Sensitivity of GTEx and pLI filters for selecting established 
dominant epilepsy genes 
Cut off to achieve 95% specificity (only 5% of 
all genes selected) 
Sensitivity (% of autosomal dominant 
epilepsy genes captured) 
GTEx ratio > 7.9 22/45 (48.9%) 
pLI > 0.9996 19/45 (42.2%) 
pLI > 0.7 and GTEx > 1.7 26/45 (57.8%) 
pLI > 0.8 and GTEx > 1.5 26/45 (57.8%) 
pLI > 0.9 and GTEx > 1.2 27/45 (60.0%) 
GTEx * Log2[0-Log9(1-pLI)] > 2.0 32/45 (71.1%) 
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6.3 Results 
6.3.1 Total recruitment, pre-screening and family testing 
A total of 79 patients from 72 families were recruited – including four families with 
two affected children, and one family with three affected children. 
Pre-screening, using the 104 gene epilepsy panel in Glasgow, was carried out for 44 
patients from 40 families (56%). 
In all cases DNA from the affected proband and both parents underwent WGS, 
apart from in one case where the proband, who presented with infantile spasms, 
had an extensive family history of focal epilepsy which appeared to follow a 
dominant inheritance pattern. In this family the proband and the most distantly-
related affected relative, but not the proband’s parents, were tested. In three of 
the families in which there was more than one affected sibling, just one of the 
siblings was tested with the other(s) sequenced later using the Sanger method to 
specifically look for the presence of any strong candidate variants. 
6.3.2 Phenotypes 
The four key phenotypes were defined following discussion with local paediatric 
neurologists about the phenotypes that were relatively common and were felt to 
have a likely genetic basis. These were: 
1. Drug-resistant myoclonic epilepsy (DRM), n = 35 
Definition:  
• Onset of epilepsy with myoclonic seizures before the 6th birthday and 
• Ongoing myoclonic seizures despite adequate trials of two 
appropriately chosen and tolerated anti-epileptic therapy regimens 
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2. Infantile-onset developmental and epileptic encephalopathy (IODEE). N = 36 
Definition:  
• Onset of epilepsy before 18 months of age and 
• Developmental stagnation or regression reported in association with 
seizure onset 
 
3. Landau-Kleffner Syndrome Spectrum (LKSS), n = 37 
Definition: 
• Onset of focal seizures before 10th birthday and 
• Comorbid autism diagnosis or significant sleep activation/electrical 
status epilepticus in slow wave sleep (ESES) reported on EEG 
 
4. Comorbid paroxysmal movement disorder (PMD), n = 13 
Definition:  
• Epilepsy of onset before 10th birthday and 
• Comorbid paroxysmal non-epileptic movement disorder such as 
chorea, myoclonus, or dystonia 
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Figure 6.3a: Key phenotypes, and overlap between them; patients in the WGS 
study 
As illustrated in figure 6.3a, there was significant overlap between the four key 
phenotype groups, with 47% of patients falling into more than one group. 
A total of 47980 variants survived the filtering pipeline and were analysed on the 
excel spreadsheet, representing an average of 607 variants per individual. 76 
variants were de novo.  
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Figure 6.3b: Phenotypic features of the WGS cohort
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6.3.3 Overall findings 
Table 6.3: Diagnostic and candidate findings among the entire WGS cohort 
Family Patient Phenotype Pre-
screened? 
Diagnostic finding Candidate finding 
2 P-2 PMD N   
4 P-4 DRM+LKSS Y   
5 P-5 IODEE+PMD N SCN8A (de novo)*  
7 P-7 LKSS N   
11 P-11 LKSS Y   
13 P-13 DRM+PMD N  TRIM46 (de novo) 
14 P-14 DRM+LKSS N   
16 P-16 LKSS N   
22 P-22 IODEE+LKSS N GNAO1 (de novo)  
24 P-24 DRM+IODEE+PMD Y  POLR1A (de novo) 
25 P-25 DRM+LKSS N   
29 P-29 DRM+IODEE N SCL35A2 (de novo)  
30 P-30 DRM Y   
31 P-31 DRM+LKSS N   
49 P-49 DRM+IODEE N   
106 P-106 IODEE Y   
115 P-115 LKSS Y   
120 P-120 DRM+IODEE+LKSS N   
137 P-137 IODEE Y   
B-137 IODEE Y   
143 P-143 DRM+IODEE N GABRA1 (de novo)*  
152 P-152 LKSS+PMD N   
173 P-173 IODEE Y   
183 P-183 DRM+IODEE+LKSS Y   
185 P-185 IODEE Y   
195 P-195 DRM N SCN2A (de novo)*   
B-195 DRM N   
263 P-263 IODEE+PMD Y SCN1A (de novo)*   
278 P-278 DRM Y  MAP2 (de novo) 
309 P-309 IODEE N   
321 P-321 IODEE Y   
361 P-361 IODEE Y  TRIO (maternal) 
412 P-412 DRM+LKSS N   
431 P-431 IODEE+LKSS N ROGDI (compound het.)  
437 P-437 LKSS Y   
B-437 LKSS N   
463 P-463 DRM+IODEE Y   
B-463 IODEE Y   
475 P-475 IODEE+LKSS Y   
506 P-506 IODEE N SMC1A (de novo)  
527 P-527 DRM+PMD Y   
S-527 DRM+PMD Y   
540 P-540 LKSS Y   
570 P-570 DRM+LKSS+PMD N   
597 P-597 DRM+LKSS N  MED13 (de novo) 
621 P-621 IODEE Y   
622 P-622 IODEE Y  RASL10B (de novo) 
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699 P-699 IODEE+LKSS Y   
722 P-722 IODEE Y  CACNA1G (de 
novo) 
755 P-755 DRM+IODEE Y   
765 P-765 LKSS N GRIN2A (paternal)*   
B-765 LKSS N GRIN2A (paternal)*   
S-765 LKSS N GRIN2A (paternal)*   
772 P-772 DRM+IODEE Y  CNTNAP1 
(compound het.) 
773 P-773 LKSS N   
780 P-780 DRM+LKSS N   
818 P-818 DRM+LKSS Y   
825 P-825 DRM+LKSS N   
830 P-830 DRM+PMD Y   
835 P-835 PMD Y   
838 P-838 LKSS Y   
847 P-847 DRM+IODEE+LKSS Y   
913 P-913 IODEE+LKSS N   
948 P-948 IODEE Y NEXMIF (de novo)  
951 P-951 PMD+LKSS N   
955 P-955 DRM+IODEE Y   
957 P-957 PMD N   
958 P-958 DRM N  LRP8 (compound 
het.) 
962 P-962 DRM Y  NIPBL (de novo) 
965 P-965 DRM Y   
969 P-969 DRM+LKSS N   
971 P-971 LKSS Y   
976 P-976 LKSS N STX1B (maternal)*  
979 P-979 DRM+IODEE Y   
981 P-981 IODEE Y   
989 P-989 IODEE Y   
991  P-991  LKSS Y   
994 P-994 LKSS+PMD Y   
999 P-999 IODEE Y   
* = gene included in 104 gene panel 
Overall, 13 patients from 11 families had a genetic finding that was considered 
diagnostic by the MDD. Another 10 patients from 10 families had a genetic finding 
that was considered a strong candidate, according to the criteria defined in 
section 6.2.8.  
Families who had not undergone pre-screening with the 104 gene panel were more 
likely to have a diagnostic finding (9/31 = 19.4%) than those who had undergone 
pre-screening (2/41 = 4.8%) [Fisher’s exact, p value = 0.007). This can be explained 
by the fact that 6/8 diagnostic results involved genes that were included in the 
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gene panel test. Families who had not undergone pre-screening were no more 
likely to have a candidate genetic cause (5/31 = 16.1%) than those who had been 
pre-screened (5/41 = 12.2%) [Fisher’s exact p value = 0.74]. Associations between 
clinical features and genetic findings will be reported in section 6.3.6. In just 4/72 
families (5.6%) was a genetic diagnosis with potential therapeutic implications 
made, and in all four cases this was a gene included on the 104 gene panel. 
6.3.4 Diagnostic results from WGS 
6.3.4.1 GABRA1 
Female, born 2013. Phenotype: DRM+IODEE 
P-143 was born at term plus 10 days by emergency Caesarean section for failure to 
progress. The pregnancy had been complicated by severe hyperemesis gravidarum 
during the first 20 weeks. Antenatal ultrasound scans and fetal movements has 
been normal. Birth weight was 3460g (+ 0.21 SD). No neonatal resuscitation was 
required. 
There were no parental concerns about development until the age of two months. 
She had developed a social smile at six weeks of age. The first seizure occurred at 
aged two months. It was early in the morning and she was awake following a breast 
feed. Her eyes turned to the left and her head followed, and then she began 
making “clucking sounds” with her throat. The whole episode lasted 60-90 
seconds. Very similar episodes continued to occur approximately twice per week. 
An EEG was performed at three months of age, during which a typical event was 
captured. This began with a focal epileptiform discharge in the right occipital 
area. This focal epileptiform discharge remained for about four minutes, before 
spreading to the left hemisphere. Only when the discharge spread to the left was 
there any detectable clinical change, which was head and eye deviation to the 
left, accompanied by facial flushing, and followed by a cry. Interictally there was 
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slowing and runs of high amplitude spikes, predominantly over the right occipital 
area. 
From the age of two months onwards, parents had concerns about developmental 
progress. She seemed poorly responsive to both verbal and visual cues, and she 
developed a pervasive habit of stimulating her own vision by waving her left arm 
up and down in front of her eyes. She went on to develop several further seizure 
types including bilateral clonic seizures from aged 4.5 months, and both tonic 
seizures and myoclonic seizures from aged 1 year. Interictal EEGs continued to 
show multifocal and migrating epileptiform activity and her development 
plateaued. At the time of assessment she was 3 years old and she had profound 
cognitive impairment, with no independent mobility, no expressive or receptive 
communication and no meaningful use of her hands. She had central hypotonia, 
and cerebral visual impairment. Both height and head circumference were within 
normal range for age. 
Beneficial treatments reported by the family were the Ketogenic Diet, Lorazepam 
for prolonged seizures, and Levetiracetam for focal seizures. Carbamazepine and 
Clobazam were both thought to have aggravated seizures. At the time of 
assessment she was having daily atypical absence seizures, myoclonic seizures 
every two days, and focal seizures between one and eight times per month.  
MRI brain scan at the age of 4 months demonstrated a slightly thin corpus callosum 
and delayed myelination. Repeat MRI brain at 13 months demonstrated a 
progression of myelination which was now within normal limits. 12 lead ECG 
demonstrated a prolonged QT interval of 480-490ms. She had an implantable 
cardiac loop recorder inserted at the age of 2.5 years. No arrhythmia has ever 
been captured on this. 
There was no family history on either side of epilepsy, febrile seizures, 
developmental disorder, mental ill health, or migraine.  
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Table 6.3b: GABRA1 variant in P-143 
GABRA1 gene details 
Function Neuronal GABA-A receptor, alpha 1 subunit 
Relative brain expression (GTEx ratio) 1755 
Missense constraint (ExAC) z = 3.53 
LoF constraint (ExAC) pLI = 0.963866 
Published cases of a similar phenotype Yes (Johannesen et al., 2016; Kodera H. et 
al., 2016)  
Frequency in previous NGS studies (Chapter 3) 0.015%. Rank 18 =  
Variant details 
Inheritance De novo 
Genomic location Chr5(GRCh37): g.161318039C>T 
HGVSc. NM_000806.5(GABRA1): c.839C>T 
HGVSp. p.Pro280Leu 
Region of the protein affected Second transmembrane segment (Johannesen 
et al., 2016) 
Population frequency Not in gnomAD or UK10K 
Previously reported No 
SIFT Deleterious (score: 0.04) 
Mutation Taster Disease causing (p-value: 1) 
Polyphen 2  1.00 (HumDiv) 1.00 (HumVar) 
MDD conclusion Causative 
WGS revealed a de novo missense variant in the GABRA1 gene. This was a novel 
variant, not found in the gnomAD or UK10K databases, and not previously reported 
in association with disease. 
GABRA1 encodes a subunit of the dominant CNS receptor for the inhibitory 
neurotransmitter, Gamma-Aminobutyric Acid (GABA). De novo GABRA1 variants 
have previously been associated with severe infantile onset epilepsies (Johannesen 
et al., 2016; Kodera et al., 2016), and since all in silico tools suggested 
pathogenicity, the MDD came to the conclusion that this variant was causative of 
P-143’s phenotype. The spectrum of epilepsies that have been associated with 
GABRA1 variants is broad, ranging from drug-responsive generalised epilepsies with 
onset in later childhood with good developmental outcomes, to severe neonatal 
onset epilepsies. No genotype-phenotype relationships have been identified. Only 
two of the previously reported cases presented at an earlier age than P-143 
(Kodera et al., 2016). Interestingly P-143 had a second de novo frameshift variant 
in a gene with a high pLI score (SNX13) which encodes a regulator of G-protein 
signalling (Zheng et al., 2001), though due to relatively low brain expression this 
did not reach candidacy criteria for a novel epilepsy gene.  
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Table 6.3c: SNX13 variant in P-143 
SNX13 gene details 
Function Regulator of G-protein signalling (Zheng et al., 
2001). 
Relative brain expression (GTEx ratio) 0.729 
Missense constraint (ExAC) z = 1.55 
LoF constraint (ExAC) pLI = 0.985322 
Published cases of a similar phenotype No 
Cases in public databases Yes. One case from the DDD study with a de novo 
missense variant (phenotype: abnormality of nervous 
system) 
Variant details 
Inheritance De novo 
Genomic location Chr7(GRCh37): g.17915341_17915344del 
HGVSc. NM_001350862.1(SNX13):c.510_513del 
HGVSp. p.Val171Serfs*8 
Population frequency Not in gnomAD or UK10K 
MDD conclusion Uncertain significance 
6.3.4.2 SCN2A 
Female, born 2003. Phenotype: DRM 
P-195 was born by normal delivery at term + 12 days following an uncomplicated 
pregnancy, with normal antenatal scans. Birth weight was 3500g (+0.3 SD). No 
neonatal resuscitation was required. Developmental concerns were evident prior to 
epilepsy onset in that she never rolled over or crawled. At the age of two years she 
had a few single words. She presented with a cluster of seven bilateral tonic-clonic 
seizures in a 24 hour period at 22 months of age. During these episodes her eyes 
rolled back, all four limbs stiffened and then began jerking for less than one 
minute. Within five weeks of that cluster of seizures she was having hundreds of 
absence seizures per day. These were characterised by loss of contact, 
accompanied by clicking sounds of the tongue and fluttering of the eyelids. Further 
seizure types that developed were focal motor seizures which involved right foot 
clonus, myoclonic seizures, atonic drop seizures, tonic seizures, episodes of non-
convulsive status, and epileptic spasms which where untypically late in onset at 13 
years. These were the predominant seizure type at most recent follow-up with 
more than 30 episodes per day. She has clusters of bilateral clonic seizures 
approximately every 6 months. EEG at the age of two years demonstrated irregular 
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bisynchronous slow spike and wave activity. MRI brain was normal at the age of 2 
years and again at the age of 7 years. The most effective antiepileptic treatment 
she had used was the Ketogenic Diet which was associated with a dramatic 
reduction in the frequency of absence seizures. 
There was a clear regression in language skills after onset of epilepsy. At the age 
of 14 years she communicates through single words and gestures. Other areas or 
development were delayed. She started walking at 3.5 years of age. From the age 
of 5 years she developed ritualistic and repetitive behaviours. She has short 
stature (- 2.07 SD) but a normal head circumference (+ 0.35 SD). 
P-195 has a brother (B-195), who was also recruited to this study. He presented at 
three years of age with a simple febrile convulsion. From the age of 3.5 years he 
had frequent myoclonic and atonic seizures (up to five per day) and from the age 
of four years he experienced clusters of brief bilateral clonic seizures two to three 
times per week. Seizures were resistant to therapy with Sodium Valproate, 
Nitrazepam and Clobazam, but responded to a combination of Levetiracetam and 
the Ketogenic Diet. His myoclonic and atonic seizures remitted at the age of five 
years of age, and the bilateral clonic seizures stopped at six years of age. At the 
time of assessment he had been seizure-free and off medication for four years and 
had normal cognitive ability. His EEGs showed frequent irregular bisynchronous 
polyspike and wave activity, which became more prominent during sleep. His 
height was 173cm at 16 years (+0.07 SD) and head circumference was 57.0cm (+ 
0.3 SD). He had pectus excavatum and had been investigated for possible Marfan 
syndrome. The father of both P-195 and B-195 had a single febrile convulsion as a 
child and has macrocephaly (OFC 62.5cm) but normal height (173cm). 
  
205 
 
Table 6.3d: SCN2A variant in P-195 
SCN2A gene details 
Function Neuronal voltage-gated sodium channel 
subunit, type alpha 2 (Nav1.2) 
Relative brain expression (GTEx ratio) 61.279 
Missense constraint (ExAC) z = 6.58 
LoF constraint (ExAC) pLI = 1.000000 
Published cases of a similar phenotype Yes (Wolff et al., 2017) 
Frequency in previous NGS studies (Chapter 3) 1.13%. Rank: 4 
Variant details 
Inheritance De novo 
Genomic location Chr2(GRCh37): g.166245588A>T 
HGVSc. NM_021007.2(SCN2A): c.5272A>T  
HGVSp. p.Ser1758Cys 
Region of the protein affected (Uniprot) Segment 6 of repeat IV (transmembrane) 
Population frequency Not in UK10K or gnomAD 
Previously reported No 
SIFT Deleterious (Score: 0) 
Mutation Taster Disease causing (p-value: 1) 
Polyphen 2  1.00 (HumDiv) 0.999 (HumVar) 
MDD conclusion Causative of the phenotype 
Because P-195 and B-195 both had a history of drug-resistant epilepsy, there was 
an expectation that they would have a shared genetic cause. However, the most 
likely candidate variant in this family was a de novo variant in SCN2A in patient P-
195 which was not shared by her brother. 
SCN2A encodes the α2 subunit of the neuronal voltage-gated sodium channel. 
SCN2A variants have been associated with a variety of epilepsy phenotypes, 
including patients with very similar phenotypes to P-195 - epilepsy onset at 1-3 
years of age, late-onset epileptic spasms, drug-resistant myoclonic seizures, non-
convulsive status epilepticus, bisynchronous slow spike and wave on EEG, and 
associated severe cognitive impairment (Wolff et al., 2017).  In the largest 
published series of cases, age of seizure onset ranged from one day to over eight 
years. Patients who presented in the first three months of life were significantly 
more likely to have missense variants whilst those presenting after three months 
were significantly more likely to have truncating variants (Wolff et al., 2017). 
The explanation for B-195’s epilepsy remained undetermined. Because the father 
had a history of febrile convulsion, paternally-inherited candidate variants were 
considered. There were no variants in epilepsy-associated genes. There were 
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variants in two novel candidate genes, the most interesting of which was thought 
to be CHD4 (Table 6.3e). De novo missense variants in CHD4 have been associated 
with a neurodevelopmental disorder called Sifrim-Hitz-Weiss syndrome, with 12 
individuals described in two publications. Affected individuals presented with 
developmental delay, facial dysmorphism, macrocephaly, and congenital cardiac 
defects (Sifrim et al., 2016; Weiss et al., 2016). None of these features were 
prominent in family 195, though it was noted that the father had macrocephaly. 
Neither epilepsy nor febrile seizures were reported features in the published 
cases. Interestingly the Epi4k study identified a patient with Lennox-Gastaut 
syndrome who had de novo variants in both SCN2A and CHD4 (Allen et al., 2013).  
Table 6.3e: CHD4 variant in family 195 (present in both P-195 and B-195) 
CHD4 gene details 
Function Encodes a chromodomain-containing protein 
that catalyzes ATP-dependent chromatin 
remodelling as a core component of the 
nucleosome remodelling and histone 
deacetylase repressor complex, which is 
involved in epigenetic regulation of gene 
transcription, DNA repair, and cell cycle 
progression (Sifrim et al., 2016; Weiss et al., 
2016). 
Relative brain expression (GTEx ratio) 0.636 
Missense constraint (ExAC) z = 7.05 
LoF constraint (ExAC) pLI = 1.000000 
Published phenotype Developmental delay, dysmorphism, 
macrocephaly, congenital cardiac defects 
(Sifrim et al., 2016; Weiss et al., 2016). 
Frequency in previous NGS studies (Chapter 3) None 
Variant details 
Inheritance Paternal (father had a history of febrile 
seizure) 
Genomic location Chr12(GRCh37): g.6709784T>A 
HGVSc. NM_001297553.1(CHD4) c.958A>T 
HGVSp. p.Asn320Tyr 
Population frequency Not in gnomAD or UK10K 
Previously reported No 
SIFT Deleterious (Score: 0) 
Mutation Taster Disease causing (p-value: 1) 
Polyphen 2  0.981 (HumDiv) 0.312 (HumVar) 
MDD conclusion Candidate variant for familial phenotype 
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6.3.4.3 SCN8A 
Male, born 2014. Phenotype: PMD+IODEE 
P-5 was born by SVD at term following an uncomplicated pregnancy. Parents had 
no concerns until the age of 3.5 months when he “curled up and went blue.” He 
was taken to his local paediatric unit where he was witnessed to have recurrent 
tonic seizures with accompanying desaturation and cyanosis. He subsequently 
developed infantile spasms and focal motor seizures. Through seizures were never 
captured on EEG, the inter ictal record demonstrated frequent spike and wave and 
polyspike and wave activity over both posterior occipital regions. MRI brain 
revealed delayed myelination, and abnormal signal in the globi pallidi, midbrain, 
pons and medulla. MR spectroscopy was normal. Following onset of seizures he had 
developmental stagnation. He developed a generalised choreoathetoid movement 
disorder and laryngomalacia. Seizure control was never achieved but the frequency 
of seizures was felt to reduce following introduction of Triple Bromide treatment. 
He died suddenly at the age of 22 months, with probable SUDEP as the cause. 
There was no family history of epilepsy but a maternal great uncle had had three 
sons who had all died in infancy of a condition which involved hydrocephalus. 
Table 6.3f: SCN8A variant in P-5 
SCN8A gene details 
Function Neuronal voltage-gated sodium channel 
subunit, type alpha 8 (Nav1.6) 
Relative brain expression (GTEx ratio) 7.270 
Missense constraint (ExAC) z = 7.71 
LoF constraint (ExAC) pLI = 1.000000 
Published cases of a similar phenotype Yes (Larsen et al., 2015a) 
Frequency in previous NGS studies (Chapter 3) 0.51%. Rank: 7= 
Variant details 
Inheritance De novo 
Genomic location Chr12(GRCh37): g.52159459G>A 
HGVSc. NM_014191.3(SCN8A): c.2549G>A 
HGVSp. p.Arg850Gln 
Region of the protein affected (Uniprot) Segment 4 of repeat II (transmembrane) 
Population frequency Not in gnomAD or UK10K 
Previously reported No 
SIFT Deleterious (Score: 0) 
Mutation Taster Disease causing (p-value:1) 
Polyphen 2  1.00 (HumDiv) 0.999 (HumVar) 
MDD conclusion Causative of the phenotype 
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P-5 was found to have a de novo variant in SCN8A which was felt to explain his 
phenotype. 
SCN8A encodes the α8 subunit of the neuronal voltage-gated sodium channel. De 
novo SCN8A variants have been reported in association with early onset epileptic 
encephalopathy with a prominent movement disorder described. Disease-
associated variants cluster in the transmembrane-encoding regions (Larsen et al., 
2015a). Only missense variants have been described and in vitro functional studies 
have suggested that disease-associated variants confer gain-of-function properties 
on the Nav1.6 channel (Barker et al., 2016). It has therefore been suggested that 
patients with SCN8A variants may respond better to sodium channel blocking 
medications than other classes of anti-epileptic drug, though evidence to support 
this remains anecdotal (Boerma et al., 2016).  P-5 was never tried on a sodium 
channel blocking AED, and he died prior to his WGS result. 
6.3.4.4 STX1B 
Male, born 2007. Phenotype: LKSS 
P-976 was born by forceps delivery following induction of labour at 38 weeks. His 
mother had gestational diabetes and had been on insulin since the 28th week. 
Antenatal scans had been normal and there had been no concerns about fetal 
movements. His birth weight was 3200g (-0.59 SD). There were no parental 
concerns about childhood development in the first 15 months of life. He walked at 
14 months, and he had several single words with meaning at 12 months.  
At 15 months of age he had a febrile convulsion. The family had taken him to the 
GP because of a temperature of 39.8 degrees. In the clinic room his eyes suddenly 
rolled back and all four limbs began jerking for about five minutes. 150 minutes 
after this first event he had a second convulsion of a similar nature. From that 
point onwards he had daily episodes in which his face would grimace, the right side 
of his mouth would lift, his eyelids would flutter, his pupils would dilate, and he 
would be unresponsive. 
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Following the febrile convulsion at 15 months there was an abrupt change in his 
developmental trajectory. He stopped speaking altogether for three months and 
made slow progress thereafter. At the age of nine years he can communicate with 
single words only. He also has difficulty with motor skills and is unsteady on his 
feet. He is unable to read or write. His cognitive ability has been assessed as 
severe learning disability.  He was diagnosed with autism at the age of three years, 
and he has major difficulty with attention and concentration. MRI brain scan at the 
age of 3 years was normal. EEG shows right-sided and bilateral spike and slow 
wave and polyspike and slow wave discharges during sleep. Current seizure 
frequency is 3-4 per month, and the family feel that seizure-control has benefitted 
from the combination of Perampanel, Clobazam and Triple Bromide. 
P-976’s father has 5 female cousins. Each of those cousins has a son with epilepsy. 
The paternal grandmother was thought to have undiagnosed autism. P-976’s 
mother has a history of a single febrile convulsion. 
Table 6.3g: STX1B variant in P-976 
STX1B gene details 
Function Pre-synaptic receptor for transport vesicles 
(Schubert et al., 2014) 
Relative brain expression (GTEx ratio) 39.95 
Missense constraint (ExAC) z = 3.63 
LoF constraint (ExAC) pLI = 0.944475 
Published cases of a similar phenotype Yes (Schubert et al., 2014; Vlaskamp et al., 
2016) 
Frequency in previous NGS studies (Chapter 3) 0.015%. Rank: 82= 
Variant details 
Inheritance Maternal (mother had a history of febrile 
seizure) 
Genomic location Chr16(GRCh37): g.31012515C>A 
HGVSc. NM_052874.4(STX1B): c.106-1G>T (Essential 
splice-site interference) 
HGVSp. N/A 
Region of the protein affected (Uniprot) N/A 
Population frequency Not in gnomAD or UK10K 
Previously reported No 
MDD conclusion Contributory to the phenotype 
P-976 had a maternally inherited essential splice-site variant in STX1B. STX1B 
encodes a pre-synaptic protein which has a potential role in neurotransmitter 
release (Schubert et al., 2014).  Variants in STX1B have been described in families 
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with dominantly-inherited epilepsy and/or febrile seizures. Penetrance of STX1B 
for phenotype appears to be variable within families, with some affected 
individuals having febrile seizures only, and others having drug-resistant epilepsy 
with comorbid intellectual disability (Schubert et al., 2014). The predicted effect 
of the STX1B variant in case P-976 was complete abolishment of the natural splice-
site. Since truncating variants in this gene are heavily constrained in ExAC but have 
been observed in families with fever-sensitive epilepsies, the MDT was confident 
that the STX1B variant was relevant in this family. The reason for the disparity in 
phenotype between mother and son was not clear. Interestingly there was a 
paternally-inherited variant in the candidate gene UNC13A which also encodes a 
pre-synaptic protein with a role in synaptic vesicle priming (Rossner et al., 2004). 
Due to the absence of any established association with human disease, the 
significance of this variant was uncertain. 
Table 6.3h: UNC13A variant in P-976 
UNC13A gene details 
Function Essential role in synaptic vesicle priming 
(from rodent studies) (Rossner et al., 2004) 
Relative brain expression (GTEx ratio) 17.08 
Missense constraint (ExAC) z = 5.89 
LoF constraint (ExAC) pLI = 0.999987 
Published cases of a similar phenotype No 
Cases in public databases No 
Frequency in previous NGS studies (Chapter 3) Not reported 
Variant details 
Inheritance Paternal (extensive family history of 
childhood onset epilepsy) 
Genomic location Chr19(GRCh37): g.17756625G>C 
HGVSc. NM_001080421.2(UNC13A): c.2214C>G 
HGVSp. p.Ile738Met 
Population frequency Not in gnomAD or UK10K 
Previously reported No 
SIFT Deleterious (Score: 0) 
Mutation Taster Disease causing (p-value:1) 
Polyphen 2  1.00 (HumDiv) 0.999 (HumVar) 
MDD conclusion Candidate modifier variant 
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6.3.4.5 GNAO1 
Female, born 1997. Phenotype: IODEE + LKSS 
P-22 was born by SVD at terms following an uncomplicated pregnancy. Birth weight 
was 3500g (+0.3 SD). Her parents had no concerns until the age of nine weeks 
when she began having prominent startle reactions in response to sudden noises. 
These were subsequently diagnosed as startle-induced reflex tonic seizures. Her 
whole body would become tense, her eyes would roll back, and her fists would 
clench. Ictal EEG performed at the time demonstrated rhythmic build-up of 
moderate voltage 4-5 per second theta activity over the left temporal area, 
spreading to all areas and becoming high voltage regular fast spiking. Inter ictal 
EEG showed left temporal sharp waves. Seizures remained resistant to medication 
until the age of four months when she was started on Sodium Valproate. She then 
became seizure-free until the age of four years when she began having generalised 
myoclonic seizures. From the age of 10 years she has had focal motor seizures 
arising from sleep, mostly in the early hours of the morning, and often triggered by 
noise. During a seizure her legs will stiffen with her toes pointing in plantar 
flexion. She will grab a pillow and appear frightened. She is usually responsive 
during events and can sometimes converse. She is currently having an average of 
two seizures per night and is taking three AEDs: Oxcarbazepine, Clobazam, and 
Sulthiame. Development has been considerably delayed. She has a diagnosis of 
autism. At the age of 20 years she cannot read or write and she mostly 
communicates with single words. She walks with a stooped gait. Her height and 
head circumference are within normal range. MRI brain scan was normal at the age 
of 13 years. There is no family history of epilepsy or any other neurodevelopmental 
disorders.  
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Table 6.3i: GNAO1 variant in P-22 
GNAO1 gene details 
Function G-protein-coupled receptor subunit (Feng et 
al., 2017).  
Relative brain expression (GTEx ratio) 13.888 
Missense constraint (ExAC) z = 3.49 
LoF constraint (ExAC) pLI = 0.984288 
Published cases of a similar phenotype Yes (Nakamura et al., 2013) 
Frequency in previous NGS studies (Chapter 3) 0.084%. Rank: 31= 
Variant details 
Inheritance De novo 
Genomic location Chr16(GRCh37): g.56385384A>G 
HGVSc. NM_020988.2(GNAO1): c.812A>G 
HGVSp. p.Lys271Arg 
Region of the protein affected (Uniprot) Nucleotide binding site 
Population frequency Not in gnomAD or UK10K 
Previously reported No 
SIFT Deleterious (score: 0) 
Mutation Taster Disease causing (p-value: 1) 
Polyphen 2  0.891 (HumDiv) 0.869 (HumVar) 
MDD conclusion Causative of the phenotype 
A de novo variant was found in GNAO1. GNAO1 encodes a subunit of highly brain 
expressed G-protein coupled receptor which is believed to play a role in mediation 
of signals at multiple neuroreceptor sites (Feng et al., 2017). De novo variants in 
this gene have been associated with early-onset developmental and epileptic 
encephalopathy (DEE) (Nakamura et al., 2013) and with an apparently distinct 
developmental disorder characterised by developmental delay, infrequent 
epileptic seizures, and a paroxysmal choreoathetoid movement disorder (Marcé-
Grau et al., 2016; Saitsu et al., 2016; Kulkarni et al., 2015; Ananth et al., 2016). 
There is an apparent clustering of the DEE-associated variants at codons 40-45, 
174-203, and 270-279, though exactly what function these domains represent has 
not been delineated. The variant in P-22, codon 271, was between two other 
published DEE-associated variants (Myers et al.,2016). 
6.3.4.6 GRIN2A 
Male, born 2009. Phenotype: LKSS 
P-765 was born by SVD at term following an uncomplicated pregnancy. Birth weight 
was 4700g (+ 2.4 SD). He was admitted to the Special Care Baby Unit for 48 hours 
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because of tachypnoea but there were no other neonatal concerns. His mother had 
no concerns about his early development. By the age of 22 months he was able to 
walk independently and communicate with single words. By the age of four years 
he had fluent speech and was fully toilet trained.  
At the age of five years during a diarrhoea and vomiting illness he had a bilateral 
clonic seizure during his sleep. There was associated hypersalivation. The following 
morning his mother noticed an abrupt change. He became completely non-verbal 
and could no longer follow simple instructions. He was admitted to hospital for 
investigation. MRI brain scan was normal but EEG demonstrated frequent 
multifocal spike wave and polyspike wave complexes which became continuous 
during sleep, consistent with a diagnosis of Epileptic Encephalopathy with 
Continuous Spike Waves During Slow Wave Sleep (ESES). He was treated with a 
course of high dose steroids which resulted in normalisation of the EEG, and a 
return of his previous language skills. Since then he has had multiple episodes of 
focal seizures, occurring in clusters and associated with abrupt change in language 
skills and behaviour. Therapeutic trials of Clobazam, Sodium Valproate, Ketamine, 
and Sulthiame were not effective at preventing these clusters.  
P-765 has an older sister (S-765) and an older brother (B-765). B-765 had global 
developmental delay and demonstrated autistic features from the age of 18 
months. He was diagnosed with autism at the age of four years. At the age of nine 
years he began having focal seizure characterised by behavioural arrest, facial 
twitching and drooling. Seizures were drug-resistant and came in clusters. His EEG 
demonstrated continuous right sided centrotemporal discharges seen during 
wakefulness and a clear deterioration during sleep to continuous generalised spike 
wave and polyspike wave complexes (Figure 6.3c).  
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Figure 6.3c: Sleep EEG from P-765, demonstrating continuous spike wave 
without clinical accompaniment  
S-765 was thought to have normal development until the age of two years, at 
which point her mother felt that she “suddenly withdrew into herself” and stopped 
all forms of imaginative play. She was diagnosed with autism at the age of five 
years. She began having focal seizures at the age of nine years. Seizures have been 
controlled with Sodium Valproate and Sulthiame. The father of all three children 
has learning disability and a possible history of language regression in early 
childhood, but no history of seizures. 
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Table 6.3j: GRIN2A variant in family 765 (Present in P-765, S-765 and B-765) 
GRIN2A gene details 
Function NMDA receptor subunit, 2A 
Relative brain expression (GTEx ratio) 16.58 
Missense constraint (ExAC) z = 3.80 
LoF constraint (ExAC) pLI = 0.998045 
Published cases of a similar phenotype Yes (Carvill et al., 2013; Endele et al., 2010; 
Lesca et al., 2013) 
Frequency in previous NGS studies (Chapter 3) 0.21%. Rank: 13= 
Variant details 
Inheritance Paternal 
Genomic location Chr16(GRCh37): g.9934590A>C  
HGVSc. NM_001134407.1(GRIN2A): c.1565T>G  
HGVSp. p.Val522Gly 
Region of the protein affected Agonist binding domain S1 (Swanger et al., 
2016) 
Population frequency Not in gnomAD or UK10K 
Previously reported No 
SIFT Deleterious (score: 0) 
Mutation Taster Disease causing (p-value: 1) 
Polyphen 2  0.999 (HumDiv) 0.999 (HumVar) 
MDD conclusion Causative of the familial phenotype 
P-765 inherited a variant in GRIN2A from his father. Sanger sequencing confirmed 
that S-765 and B-765 also carried the variant. The phenotype observed in this 
family is consistent with previously published cases of GRIN2A-related epilepsy, a 
condition which is characterised by the coexistence of focal epileptic seizures, 
abnormal language development, and a predisposition to ESES (Carvill et al., 2013; 
Endele et al., 2010; Lesca et al., 2013).  
GRIN2A encodes a key subunit of the excitatory glutamatergic NMDA receptor. 
Disease-associated variants in GRIN2A are usually missense, and cluster in the 
regions of the gene that encode the agonist binding domains and transmembrane 
regions of the receptor. In vitro functional studies show that epilepsy-associated 
missense variants in GRIN2A can be both gain-of-function and loss-of-function 
(Swanger et al., 2016). Pierson et al. demonstrated that in a Xenopus ooyte cell 
model, the epilepsy-associated Leu825Met variant resulted in increased agonist 
potency, and that this could be corrected with the NMDAr antagonist Memantine. 
They then treated a patient with [GRIN2A] Leu825Met-associated epilepsy with 
Memantine and reported a significant reduction in seizure frequency (Pierson et 
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al., 2014). In P-765 we trialled therapy with the NMDAr antagonist Ketamine but 
did not observe a reduction in seizure frequency. 
6.3.4.7 SLC35A2 
Female, born 2009. Phenotype: DRM + IODEE 
P-29 was born by SVD following induction of labour at term +13 days. There were 
no antenatal or neonatal complications. Birth weight was 3710g (+ 0.74 SD). There 
were no parental concerns until six weeks of age when she had a seizure involving 
clonic jerking of all four limbs, lasting about 60 seconds. Four hours later she had a 
second seizure of the same nature, followed by several more over the next few 
hours. For the next two weeks she remained a hospital inpatient, during which 
time seizure control was not achieved despite multiple AEDs. At eight weeks of age 
she began having typical infantile spasms. EEG demonstrated hypsarrhythmia. 
Spasms, occurring in clusters were resistant to treatment, and continued until the 
age of two years. Further seizure types included myoclonic seizures, tonic 
seizures, and absence seizures from two years, and frequent periods of non-
convulsive status epilepticus from four years. Seizures have been resistant to 
therapeutic trials of multiple AEDs, and surgical interventions in the form of Vagus 
Nerve Stimulation (VNS) and corpus callosotomy.  
Development has been severely impaired. At the age of eight years she has truncal 
hypotonia, is non-ambulant and non-verbal. She can hold a bottle with both hands 
but has no pincer grasp. She has microcephaly (OFC 49.0cm, -2.85 SD) but MRI 
shows her brain to be structurally normal. The only family history is that a 
maternal third cousin also had a severe developmental and epileptic 
encephalopathy (P-321 in this study). 
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Table 6.3k: SLC35A2 variant in P-29 
SLC35A2 gene details 
Function UDP-galactose transporter. Transfers 
nucleotide sugars from cytosol to Golgi 
apparatus for glycosylation (Miura et al., 
1996) 
Relative brain expression (GTEx ratio) 0.546 
Missense constraint (ExAC) z = 2.33 
LoF constraint (ExAC) pLI = 0.780526 
Published cases of a similar phenotype Yes (Kodera et al., 2013; Ng et al., 2013) 
Frequency in previous NGS studies (Chapter 3) 0.015%. Rank: 82= 
Variant details 
Inheritance De novo 
Genomic location ChrX(GRCh37): g.48762569del 
HGVSc. NM_005660.2(SLC35A2): c.617del 
HGVSp. p.Val206Alafs*143 
Population frequency Not in gnomAD or UK10K 
Previously reported No 
MDD conclusion Causative of the phenotype 
A de novo frameshift variant was found in the X-linked gene SLC35A2. Truncating 
and missense variants in this gene have been previously reported in females with 
severe neurodevelopmental disorders (Kodera et al., 2013; Ng et al., 2013). Since 
truncating variants are not observed in males, hemizygosity for truncation is 
thought to be non-viable. SLC35A2 encodes a UDP-galactose transporter involved in 
the glycosylation pathway, so this has been considered a Congenital Disorder of 
Glycosylation (CDG), though the typical biochemical signature of this group of 
disorders – abnormal transferrin isoforms – is often absent (Ng et al., 2013). 
Epilepsy is a frequently observed feature of most CDGs (Fiumara et al., 2016) and 
is present in 12/13 (92%) of published SLC35A2-CDG cases. Epileptic spasms are the 
most frequently observed seizure type (Allen et al., 2014; Bosch et al., 2016; 
Kimizu et al., 2017; Lopes et al., 2016; Dorre et al., 2015; Evers et al., 2017). >70% 
of cases are reported to have microcephaly and >60% have hypotonia – both 
present in P-29. Variable dysmorphism and skeletal abnormalities are also 
frequently reported, but were not present in P-29. Following consultation with a 
leading expert in CDGs, P-29 is starting a diet with D-galactose supplementation. 
This treatment has not previously been tried in SLC35A2-realted CDG, but has been 
shown to be tolerated and effective at normalising biochemical markers of disease 
in another genetic CDG, PGM1-CDG (Wong et al., 2017) 
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6.3.4.8 ROGDI 
Female, born 2011. Phenotype: IODEE + LKSS 
P-431 was born by SVD at 36 weeks gestation following induction of labour for 
cholestasis of pregnancy. Antenatal ultrasound scans and fetal movements had 
been normal. Birth weight was 3200g (+ 1.28 SD) and there were no neonatal 
complications. There were parental concerns about her behaviour from about four 
months of age. She did not smile, laugh or interact with her parents. At eight 
months of age she was starting to sit independently. Her first seizure occurred at 
8.5 months of age. Her mother heard a scream in the middle of the night and 
found her in the cot blue and floppy with her eyes rolled back. There was no 
stiffness or jerking noted. A second episode occurred one hour later. On this 
occasion she had stiffening of the right arm and the right leg, her eyes were rolled 
up and to the right, she was making lip smacking noises and her lips were blue. 
There were a few brief jerks of the right arm and leg. The entire episode, as with 
all subsequent seizures, was between three and six minutes duration. Identical 
seizures occurred every hour for the next two days but settled one she was started 
on regular Phenytoin. The Phenytoin was reduced and her focal seizures returned 
but this time did not settle when Phenytoin was restarted. She then had a four-
month period of frequent seizures. Seizures would occur in clusters of typically 
three seizures per hour with between one and six clusters per day. These were 
refractory to multiple medications (Sodium Valproate, Carbamazepine, and 
Nitrazepam) but eventually stopped when she was established on Levetiracetam. 
At the age of four years seizures recurred during a trial of Levetiracetam 
withdrawal and stopped again when Levetiracetam was re-introduced. EEGs 
demonstrated multifocal spike waves and sharp wave discharges. MRI brain was 
normal at the age of 9 months. 
Her development is delayed, at the age of five years she can hold a pencil and 
scribble but not draw, she has about 50 single words, she has very little 
imaginative play and extremely challenging behaviour including violent head 
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banging. She was diagnosed with autism at the age of five years. She has short 
stature (101cm, -2.1 SD) and microcephaly (49.5cm, -2.5 SD). She has prominent 
yellow discolouration and abnormal shape of her teeth (Figure 6.3B). 
There was no family history of epilepsy or any other neurodevelopmental 
disorders. 
Table 6.3l: ROGDI variants in P-431 
ROGDI gene details 
Function Unknown 
Relative brain expression (GTEx ratio) 3.840 
Missense constraint (ExAC) z = -1.50 
LoF constraint (ExAC) pLI = 0.000000 
Published cases of a similar phenotype Yes (Schossig et al., 2012; Tucci et al., 2013) 
Frequency in previous NGS studies (Chapter 3) Not reported 
Variant 1 details 
Inheritance Paternal 
Genomic location Chr16(GRCh37):g.4848186C>T 
HGVSc. NM_024589.2(ROGDI): c.532-1G>A (Essential 
splice-site interference) 
HGVSp. N/A 
Population frequency Not in gnomAD or UK10K 
Previously reported No 
Variant 2 details 
Inheritance Maternal 
Genomic location Chr16(GRCh37): g.4851551G>GC,  
HGVSc. NM_024589.2(ROGDI): c.153dup 
HGVSp. p.Thr52Hisfs*2 
Population frequency Not in gnomAD or UK10K 
Previously reported No 
MDD conclusion Causative of the phenotype 
P-431 had two variants in ROGDI, one inherited from each parent. Both variants 
are predicted to result in truncation, with the paternally inherited variant 
abolishing the splice site and the maternally-inherited variant resulting in 
frameshift. Biallelic truncating ROGDI variants have been previously identified as a 
cause of Kohlschütter-Tönz Syndrome (KTS) (Schossig et al., 2012), a condition first 
described in 1974 (Kohlschutter et al., 1974) characterised by epilepsy, 
intellectual disability, and yellow discolouration of the teeth with enamel 
hypoplasia. To date 16 patients with KTS due to ROGDI variants have been 
reported (Schossig et al., 2012; Tucci et al., 2013). All have epilepsy, with median 
age of seizure onset at 9 months (range 2-22) and yellow discolouration of the 
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teeth. Short stature and microcephaly are also reported. Treatment efficacy is not 
reported in many cases: two were reported to respond well to Levetiracetam, one 
to Sodium Valproate, one to Clobazam, and one to a combination of 
Phenobarbitone and Vigabatrin.  
 
Figure 6.3d: P-431 teeth 
6.3.4.9 SMC1A 
Female, born 2000. Phenotype: IODEE 
P-506 was born by elective caesarean section at 38 weeks gestation because of a 
previous caesarean section. Fetal movements and antenatal ultrasound scans were 
normal. Birth weight was 3600g (+ 0.51 SD) and there were no neonatal problems. 
Her parents first became concerned at five months of age because of poor head 
control. At about 5.5 months of age she had a seizure whilst she was with her 
mother at the hairdresser but this was not witnessed by the mother since she was 
out of the room at the time. The mother recalls her being very floppy following 
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the event. One week later she had a second event which was witnessed by the 
mother. All four limbs went stiff then began jerking, her eyes rolled backwards 
and her lips turned blue. Following that she began having epileptic spasms. This 
was her predominant seizure type until about 12 months of age. For the past ten 
years all of her seizures have been bilateral tonic clonic seizures. These have a 
striking clustering pattern. She will go for 8-12 weeks without any seizures at all, 
but then has 7-10 seizures per day for 48-72 hours. Interictal EEGs demonstrate 
multifocal sharp wave discharges. MRI brain at the age of 11 years demonstrated 
mild asymmetric posterior white matter volume loss. She has short stature (height 
141.0cm, -3.9 SD) and microcephaly (48.0cm, -5.3 SD). She has profound cognitive 
impairment. She has never been ambulant, has never had any speech, nor any 
bowel or bladder control. She communicates through babbling noises, smiles, and 
laughs. She has cerebral visual impairment. 
A maternal cousin has Asperger’s syndrome but there is no other family history of 
note. 
Table 6.3m: SMC1A variant in P-506 
SMC1A gene details 
Function Forms part of the Cohesin complex, believed 
to play a major role in transcriptional 
regulation (Mannini et al., 2015) 
Relative brain expression (GTEx ratio) 0.650 
Missense constraint (ExAC) z = 6.59 
LoF constraint (ExAC) pLI = 0.999988 
Published cases of a similar phenotype Yes (Lebrun et al., 2015; Goldstein et al., 
2015; Jansen et al., 2016) 
Frequency in previous NGS studies (Chapter 3) 0.0077%. Rank: 108= 
Variant details 
Inheritance De novo 
Genomic location ChrX(GRCh37):g.53421748G>A 
HGVSc. NM_006306.2(SMC1A): c.2923C>T 
HGVSp. p.Arg975* 
Population frequency Not in gnomAD or UK10K 
Previously reported No 
MDD conclusion Causative of the phenotype 
A de novo nonsense variant was found in SMC1A which was considered to be 
causative of the phenotype. SMC1A-related epilepsy will be discussed in more 
detail in chapter 7. 
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6.3.4.10 SCN1A 
Male, born 2010. Phenotype: IODEE + PMD 
P-263 was born by SVD at term weighing 3.6kg (+ 0.2 SD). There had been no 
concerns arising from routine fetal ultrasound scans and no concerns about fetal 
movements. He was born at a Community Midwifery Unit and discharged home on 
the day of his birth.  
At 2 days of age, his mother noticed a subtle change in breathing pattern. The 
same thing happened on day 4 of life. On day 10 of life he had an episode where 
both his eyes simultaneously abducted, his arms both abducted at the shoulders 
and his colour turned blue. He was admitted to his local district general hospital 
for observation then transferred to the regional tertiary neonatal unit. Seizures 
were captured on EEG monitoring. These were characterised by extension of all 
four limbs, followed by a cry, then a run of twitching movements of the right side 
of his face. On EEG there was a run of bilateral fast activity followed by a marked 
bradycardia (Figure 6.3d). 
 
Figure 6.3e: EEG in P-263 capturing ictal bradycardia on ECG lead 
MRI brain revealed linear T2 high signal within midbrain. He was started on 
Carbamazepine and his seizures stopped until 3 months of age when he had a focal 
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seizure following his second set of immunisations. He developed a stridor at 3 
months of age and was referred for ENT evaluation. At 5 months of age he was 
found dead in his car seat when returning from an outpatient appointment. 
Prior to his death there had been signs of developmental delay. He had poor head 
control and always held his hands in a clasped position. There were no concerns 
about his vision, he had a varied repertoire of babble, and responded to verbal 
cues. 
Post mortem examination demonstrated metabolic injury (red cell change, 
shrunken nuclei and eosinophilic cytoplasm) involving the basal ganglia, dentate 
nucleus brainstem (midbrain, pons and medulla), and spinal cord (within anterior 
horn cells). These findings were thought to be suggestive of Leigh Syndrome. With 
this in mind a muscle biopsy was assessed for respiratory chain enzymes (normal), 
and genetic tests were preformed for POLG1, MTATP6, and MTATP8 (all negative). 
Urine amino acids, plasma amino acids, and plasma organic acids were all also 
normal. There is no family history of epilepsy or neurodevelopmental disorders. 
Table 6.3n: SCN1A variant in P-263 
SCN1A gene details 
Function Neuronal voltage-gated sodium channel (type 
1.1) 
Relative brain expression (GTEx ratio) 80.1 
Missense constraint (ExAC) z = 5.61 
LoF constraint (ExAC) pLI = 1.00 
Published cases of a similar phenotype No 
Frequency in previous NGS studies (Chapter 3) 423/13063 = 3.2% 
Rank: 1 
Variant details 
Inheritance De novo 
Genomic location Chr2(GRCh37):g.166852611 A>G 
HGVSc. NM_001165963.1 (SCN1A): c.4493T>C 
HGVSp. p.Ile1498Thr 
Region of the protein affected “IFMT” motif between repeat III and repeat IV 
(cytoplasmic loop) 
Population frequency Not in gnomAD or UK10K 
Previously reported No 
SIFT Deleterious (score: 0) 
Mutation Taster Disease causing (p-value: 1) 
Polyphen 2  0.999 (HumDiv) 0.968 (HumVar) 
MDD conclusion Causative of the phenotype 
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The SCN1A missense variant identified in P-263 was considered to be pathogenic at 
the MDD. Though not previously associated with disease in the literature, this 
variant was absent from healthy population databases and was predicated to be 
damaging by all in silico tools. A different amino acid substitution at the same 
residue has been recurrently identified in association with the rare SCN1A-related 
phenotype, familial hemiplegic migraine (FHM) (Weller et al., 2014; de Vries et al., 
2013). A highly conserved four amino acid motif (IFMT, 1498-1501) in this loop of 
the Nav1.1 protein between repeat II and repeat IV acts as a hinged lid that blocks 
the pore when the channel is in fast inactivated states (Catterall, 2014). It is 
hypothesised that variants in this region impair this blocking process and thereby 
confer gain-of-function properties on the ion channel. Gain-of-function properties 
of variants are observed in other FHM-associated SCN1A variants (Dhifallah et al., 
2018). This contrasts with most epilepsy-associated SCN1A variants which result in 
loss-of-function (Escayg & Goldin, 2010). Further evidence in support of the 
p.Ile1498Thr variant conferring gain-of-function properties comes from reviewing 
the literature relating to variants affecting paralogous residues in other sodium 
channels. These are: SCN2A (p.Ile1488Asn), a mosaic variant associated with 
epilepsy and intellectual disability (Stosser et al., 2017); SCN9A (p.Ile1461Thr), a 
recurrent variant demonstrated experimentally to impair channel inactivation and 
associated with paroxysmal extreme pain disorder (Fertleman et al., 2006; Drenth 
& Waxman, 2007); SCN8A (p.Ile1479Met), presentation with drug-resistant epilepsy 
from 4 months of age (Larsen et al., 2015a) ; and SCN5A (p.Ile1485Val), associated 
with Brugada syndrome (National Center for Biotechnology Information: Bethesda, 
2018). 
The role of SCN1A variants in childhood-onset epilepsies has been discussed in 
detail in chapter 5. Patients with SCN1A-related epilepsy typically present 
between 6 weeks of age and 25 months of age with a median age of presentation 
of around 6 months (Harkin et al., 2007; Brunklaus et al., 2012). Around half of 
patients present initially with febrile seizures, which are often prolonged. Most 
patients will progress to a severe drug-resistant epilepsy with comorbid cognitive 
difficulties and ataxia (Dravet syndrome). Developmental impairment is typically 
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not apparent before one year of age (Brunklaus et al., 2012). Atypical cases of 
SCN1A related epilepsy have been recently described. These patients differ from 
those with Dravet syndrome or GEFS+ in that they all present relatively early, 
before three months of age, and they develop an early onset hyperkinetic 
movement disorder and early profound developmental impairment (Sadleir et al., 
2017). It is well-established that the diagnosis of Dravet syndrome, and the 
presence of a pathogenic SCN1A variant, is associated with early mortality, with 
half of deaths caused by SUDEP (Shmuely et al., 2016). 
The presentation with seizures in the neonatal period seen in P-263 has not been 
reported before. Pathogenic SCN1A variants have been identified in patients 
without epilepsy who have had Sudden Unexpected Death in Infancy however 
(Brownstein et al., 2018). 
In view of the atypical phenotype it was worth looking for any potential genetic 
modifiers in P-263. A second de novo variant was found in CHN1 gene (p. 
Leu84Ser), though due to a relatively low pLI score this gene was not considered a 
candidate for epilepsy. CHN1 variants have been associated with dominantly-
inherited Duane retraction syndrome (Chan et al., 2011; Miyake et al., 2008). 
6.3.4.11 NEXMIF 
Male, born 2015. Phenotype: IODEE 
P-948 was born by SVD at 35 weeks gestation with a birth weight of 2.23kg (- 1.51 
SD). Head circumference at birth was 30.0cm (- 2.38 SD). On the first day of life he 
had an apnoea and was found to be hypotonic. He was treated for early-onset 
sepsis, though blood cultures were negative. Due to a weak suck he required 
nasogastric feeding for the first three weeks of life.  
At 4 months of age he presented with his first seizures. These were characterised 
by apnoea and desaturation but little in the way of motor features. No events were 
captured, but interictal EEG demonstrated multifocal epileptiform discharges. He 
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was started on Levetiracetam and his seizures stopped. He remained seizure-free 
until the age of 14 months. He then began having clusters of events on wakening in 
which his eyes rolled back, his arms flexed, and his legs stiffened, lasting just 
under one second. These were felt to be best described as epileptic spasms. 
Levetiracetam was restarted and these events ceased. EEG was not available until 
three days after restarting Levetiracetam. No events were captured on EEG at that 
time but the interictal EEG showed low to moderate amplitude mixed frequency 
background of theta and delta activity and rhythmical 4-5Hz theta activity 
intermittently over the posterior regions in brief runs.  This activity became more 
marked and widespread during drowsiness. 
He has global developmental delay. At 37 months of age he is non-ambulant and 
has global hyptonia. He mobilises by bottom shuffling and rolling and can sit 
without support. He has cerebral visual impairment and severe gastro-oesophageal 
reflux. He is non-verbal and does not respond to his own name or any other verbal 
cues. 
He has microcephaly (OFC 45.3cm, -2.78 SD) and short stature (height 79.5cm, -
4.08 SD). 
MRI brain was normal at 7 months of age. His mother has a history of mild learning 
disability. 
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Table 6.3o: NEXMIF variant in P-948 
NEXMIF gene details 
Function Involved in neurite outgrowth by regulating 
cell-cell adhesion via the N-cadherin 
signalling pathway (Van Maldergem et al., 
2013) 
Relative brain expression (GTEx ratio) 3.08 
Missense constraint (ExAC) z = 0.55 
LoF constraint (ExAC) pLI = 0.95 
Published cases of a similar phenotype Van Maldergem 2013(Van Maldergem et al., 
2013) 
Kuroda 2015 (Kuroda et al., 2015) 
de Lange 2016 (de Lange et al., 2016) 
Webster 2016 (Webster et al., 2017) 
Lorenzo 2018 (Lorenzo et al., 2018) 
Frequency in previous NGS studies (Chapter 3) 3/13063 = 0.023%.  
Variant details 
Inheritance De novo 
Genomic location ChrX (GRCh37):g.73963510 G>T 
HGVSc. NM_001008537.2 (NEXMIF) c.882C>A 
HGVSp. p.Tyr294* 
Population frequency Not in gnomAD or UK10K 
Previously reported No 
MDD conclusion Causative of the phenotype 
P-948 had a de novo truncating variant in NEXMIF. Variants in this gene, which is 
located on the X chromosome, are associated with a neurodevelopmental disorder. 
37 patients with NEXMIF-associated disorders have been reported in the literature. 
17/37 (46%) are male. The majority of male patients have inherited duplications, 
translocations, or microdeletions involving all or part of NEXMIF, which have been 
inherited from unaffected mothers. All reported females have de novo variants, 
the majority of which are frameshift or nonsense variants (Van Maldergem et al., 
2013; Kuroda et al., 2015; de Lange et al., 2016; Webster et al., 2017; Lorenzo et 
al., 2018). Only one male with a de novo truncating variant has been reported 
(Lorenzo et al., 2018). 
24/37 (65%) patients have epileptic seizures and 19/37 (51%) are reported to have 
dysmorphic features, though these vary markedly between patients. Only 4 
patients (11%) are reported to have microcephaly (Van Maldergem et al., 2013; 
Kuroda et al., 2015; de Lange et al., 2016; Webster et al., 2017; Lorenzo et al., 
2018). 
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Knockdown of NEXMIF in rat cortex results in altered neuronal migration and 
dendritic growth (Van Maldergem et al., 2013; Gilbert & Man, 2016), but the 
specific function of NEXMIF is not understood. 
6.3.5 Novel candidate epilepsy genes 
In section 6.3.5 I will present the phenotypes and genotypes of those patients who 
had strong candidate genetic variants identified through WGS. 
6.3.5.1 TRIO 
Male, born 2000. Phenotype: IODEE. 
P-361 was born by SVD at term, weighing 3100g (- 0.8 SD). His mother, who had a 
history of temporal lobe epilepsy, took Phenobarbitone throughout pregnancy but 
did not have any seizures. At birth it was noted that he had hypertelorism, which 
was in common with other family members. There were no neonatal 
complications. There were no parental concerns about development in infancy. He 
was crawling at nine months, and was using several single words at 13 months.  
Shortly after MMR vaccination at 13 months, he began having epileptic spasms. 
These presented as clusters of episodes in which his head and arms would flex. He 
would have 10-20 spasms in a cluster and 5-10 clusters per day. Despite multiple 
therapeutic trials of AED treatment, the spasms were not controlled for five 
months. Spasms were eventually controlled when he was started on Vigabatrin. 
Once spasms were controlled he remained seizure-free. During the period of 
uncontrolled spasms, his family noticed a marked change in his development. He 
stopped talking and stopped taking an interest in his surroundings. He became 
irritable and slept a lot more than he had previously. EEG demonstrated bursts of 
high amplitude spike and wave and polyspike and wave activity over all areas at 1-
2Hz as well as prolonged runs of generalised irregular slow spike/polyspike and 
wave. Once the spasms were controlled he began to gain skills again. He went on 
to attend mainstream school with learning support. He has difficulties with short-
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term memory, attention and concentration. As a teenager he has been diagnosed 
with Asperger’s syndrome. 
There is an extensive family history of focal epilepsy and migraine with aura on his 
mother’s side of the family, shown in Figure 6.3f and Table 6.3q.  
Because of the extensive family history, variant filtering in family 361 represented 
a departure from the methodology used in the other families in this study. Three 
affected family members underwent WGS (GENIE-P-361, GENIE-G-361, and GENIE-
E-361). Variants present in all three were further filtered on rarity (< 0.003 in 
gnomAD), and on whether they were either missense or truncating. A total of 
seven variants survived this filtering.  DNA from subsequent family members, 
affected and not affected, was then sequenced using the Sanger method in order 
to isolate variants that were segregating with epilepsy within the family. Table 
6.3p demonstrates the segregation of the seven candidate variants, with only the 
variant in TRIO demonstrating complete segregation among the first seven family 
members sequenced.       ……………………………………………………………………………………..
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Table 6.3p: Candidate variant segregation in family 361 
Family 
member 
Affected (Y/N) Gene and variant (Variant present Y/N) 
BEGAIN 
V356L 
DYNC2H1 
Frameshift 
EIF2D 
M391V 
ITPKC 
Y316N 
NPM1 
Codon loss 
SREBF2 
V369I 
TRIO 
K2036N 
P Y Y Y Y Y Y Y Y 
E Y Y Y Y Y Y Y Y 
G Y Y Y Y Y Y Y Y 
C N Y N Y Y N Y N 
D N Y N N Y Y N N 
J Y Y N Y Y N N Y 
R Y Y N Y N N N Y 
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Table 6.3q: Phenotypes and genotypes in family 361; colour coding Orange = genotype/phenotype present. Blue = 
genotype/phenotype absent 
Family 
member 
Current age 
(2018) 
Phenotype TRIO Genotype 
A 18 years No history of epilepsy or migraine WT/WT 
B 21 years No history of epilepsy or migraine Unknown 
C 42 years No history of epilepsy or migraine WT/WT 
D 47 years No history of epilepsy or migraine WT/WT 
E 73 years Focal seizures from aged 16 years.  Intense déjà vu sensation and a burning rubber smell lasting 2-3 
minutes, up to five times per day. Now controlled on Carbamazepine 
Interictal EEG (2008): Slow complexes occur over the left temporal area. These reverse in phase at the 
site of electrodes F7-T3 and can occur in the form of short runs 
MRI brain: normal 
K2036N/WT 
F 51 years No history of epilepsy or migraine WT/WT 
G 45 years Focal seizures from aged 13 years. Intense déjà vu sensation and a burning rubber. Currently seizure-
free for 25 years and off medication 
Onset of migraine in her 40s. Begins with a “kaleidoscope” visual aura then progresses to severe 
headache. Takes regular Amitriptyline 
K2036N/WT 
H 70 years No history of epilepsy or migraine WT/WT 
I 23 years No history of epilepsy or migraine Unknown 
J 22 years Recurrent episodes of absence status aged 12-13 years. Currently seizure-free off medication for 7 years K2036N/WT 
K Died aged 66 years Focal seizures from aged 15 years. Intense déjà vu episodes. EEG demonstrated focal sharp waves in the 
right mid and posterior temporal regions. 
K2036N/WT 
L 48 years Focal seizures from aged 16 years. Intense déjà vu sensation and olfactory aura.  K2036N/WT 
M 45 years Focal seizures from aged 15 years. Intense déjà vu sensation and olfactory aura of burning rubber and 
tomato soup, progressing to a “feeling like [her] whole head was slowly turning all the way round and 
[she] couldn’t control it”. Frequent seizures like this as well as others with secondary generalisation to 
bilateral clonic movements. Currently on Carbamazepine and Phenobarbitone and seizure-free for 12 
years. EEG demonstrates left frontal-temporal sharp waves. MRI brain normal. 
K2036N/WT 
N Unknown No history of epilepsy or migraine Unknown 
O 21 years No history of epilepsy or migraine Unknown 
P 18 years Infantile spasms and abnormal EEG. Asperger’s syndrome K2036N/WT 
Q Unknown No history of epilepsy or migraine Unknown 
R 50 years 4 convulsive seizures in her late 20s. Seizure-free for 20 years on Lamotrigine  K2036N/WT 
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S 16 years Hemiplegic migraines with visual flashing and right arm weakness from aged 17 years K2036N/WT 
T 48 years Migraine from aged 11 years. Visual aura of flickering lights rapidly followed by severe headache lasting 
24 hours. At worst 3-4/month 
K2036N/WT 
U 24 years No history of epilepsy or migraine Unknown 
V 40 years No history of epilepsy or migraine WT/WT 
W Died aged 72 years Generalised tonic-clonic seizures from aged 15 years. None since aged 18 years. K2036N/WT 
X 44 years Onset of intense déjà vu sensation in her mid-teens, occasionally accompanied by a feeling as if she is 
“about to pass out” and a “tingly” fleeing in one or other hand. No EEG data available. 
K2036N/WT 
Y Unknown No history of epilepsy or migraine Unknown 
Z 23 years No history of epilepsy or migraine Unknown 
α 20 years Febrile convulsion aged 2 years. Single unprovoked GTCS aged 4 years. Migraine with visual aura from 
aged 9 years. Attacks currently occur twice per year. 
WT/WT 
β 21 years Severe migraine attacks once per week from aged 5 years. No aura. Vomiting ++ and bilateral frontal 
headache. On Pizotifen. Attacks currently occur twice per year. 
WT/WT 
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Figure 6.3f: Family 361 pedigree 
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Table 6.3r: TRIO variant in family 361 
TRIO gene details 
Function Postulated to play a role in several signalling 
pathways that control cell proliferation 
(Ferraro et al., 2007). 
Relative brain expression (GTEx ratio) 0.931 
Missense constraint (ExAC) z = 6.29 
LoF constraint (ExAC) pLI = 1.000000 
Published cases of a similar phenotype No, but is associated with intellectual 
disability (Pengelly et al., 2016) 
Frequency in previous NGS studies (Chapter 3) Not reported 
Variant details 
Inheritance Maternal in all affected individuals 
Genomic location Chr5(GRCh37): g.14477027G>C  
HGVSc. NM_007118.3(TRIO): c.6108G>C 
HGVSp. p.Lys2036Asn 
Region of the protein affected GEF2 domain (Katrancha et al., 2017) 
Population frequency Not in gnomAD or UK10K 
Previously reported No 
SIFT Tolerated (Score: 0.2) 
Mutation Taster Not available 
Polyphen 2  0.863 (HumDiv) 0.565 (HumVar) 
MDD conclusion Strong candidate variant for the familial 
phenotype 
TRIO encodes a Rho GTPase which has been shown in Drosophila to be involved in 
axon guidance and dendritic arborisation (Newsome et al., 2000; Iyer et al., 2012; 
Shivalkar; Giniger, 2012). Expression of TRIO in rat hippocampal cells is high in the 
early postnatal period but rapidly falls after birth, suggesting a role for TRIO in 
early neuronal development (Ba et al., 2016). 
De novo variants in TRIO have been associated with intellectual disability, 
microcephaly, and subtle dysmorphic features (Ba et al., 2016; Pengelly et al., 
2016) and with autism (Iossifov et al., 2014; Samocha et al., 2014). Two patients 
with epilepsy and de novo TRIO mutations have been reported in the literature. 
One was included in the series of six patients with intellectual disability by 
Pengelly et al. (Pengelly et al., 2016) – a nine year old female with developmental 
delay, gait ataxia and nocturnal tonic-clonic seizures (p.Asn1080Ile). The other was 
included in the Epi4K consortium paper of patients with Lennox-Gastaut Syndrome 
(p.Thr2945Met) (Allen et al., 2013). In the majority of published cases disease-
associated TRIO variants are not associated with epilepsy. It is possible that 
different TRIO mutations have opposing functional effects.  
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Ba et al. investigated the functional consequence of TRIO inhibition (using Trio 
shRNA) in Pup hippocampal neurones and demonstrated significantly increased 
AMPAr-mediated but not NMDAr-mediated transmission compared with controls 
which would suggest that TRIO loss-of-function would predispose to reduced, not 
increased cortical excitability. The same finding was reproduced by Sadybekov et 
al. Using HEK293 cells they demonstrated that a truncating variant had identical 
functional consequences on AMPAr-mediated potentials as Trio shRNA (Sadybekov 
et al., 2017). 
The variant in family 361 is predicted to disrupt an evolutionarily conserved 
Glu2033-Lys2036 hydrogen bond within the GEF2 domain of the protein, which 
might lead to destabilisation. 
6.3.5.2 MED13 
Male, born 2006. Phenotype: DRM + LKSS 
P-597 was born by SVD at 35 weeks gestation following a pregnancy complicated by 
pre-eclampsia. Birth weight was 2600g (+ 0.25 SD). There were no neonatal 
complications. There were no concerns about his early childhood development. He 
began walking before his first birthday and had good speech by the age of four 
years. At the age of four years he had his first seizure. He was at nursery at the 
time. Nursery staff described whole body stiffening and four limb jerking, lasting 
several minutes. From then on he had frequent generalised myoclonic seizures, 
often causing him to fall. By the age of 4.5 years he was having hundreds of 
myoclonic and absence seizures per day, as well as up to 20 tonic-clonic 
convulsions. He lost ambulation and stopped learning and interacting. Seizures 
remained resistant to multiple therapeutic trials of AEDs, but dramatically 
responded to the Ketogenic Diet when introduced at the age of 5.5 years, which 
resulted in complete seizure freedom for eight months. He continues to have tonic 
seizures during sleep on most nights but all other seizure types have resolved.  He 
stopped the Ketogenic Diet at the age of seven years but continues to take regular 
236 
 
Rufinamide and Topiramate. Since seizure control improved he has started 
regaining skills, and now attends main stream education with 1:1 learning support. 
EEGs have shown bilateral electrical status epilepticus in slow wave sleep (ESES), 
as well as frequent runs of bisynchronous spike/polyspike and wave activity during 
wakefulness, without clinical accompaniment. Serial MRI brain scans demonstrate 
a consistent area of abnormal cortical signal in the left occipital lobe. Since 
seizures and EEGs have always been consistent with a generalised epilepsy the 
significance of this is unclear. Height and head circumference are both within 
normal range. He has a younger half-brother to his father with language delay, but 
there is no other family history of developmental disorders. 
Table 6.3s: MED13 variant in P-597 
MED13 gene details 
Function Subunit of the large Mediator complex that 
functions with DNA-binding transcription 
factors and RNA polymerase II (Snijders Blok 
et al., 2018) 
Relative brain expression (GTEx ratio) 0.591 
Missense constraint (ExAC) z = 1.18 
LoF constraint (ExAC) pLI = 1.000000 
Published cases of a similar phenotype No 
Frequency in previous NGS studies (Chapter 3) Not reported 
Variant details 
Inheritance De novo 
Genomic location Chr17(GRCh37): g.60088260G>T 
HGVSc. NM_005121.2(MED13) :c.1618C>A 
HGVSp. p.Pro540Thr 
Population frequency Not in gnomAD or UK10K 
Previously reported No 
SIFT Tolerated (Score: 1) 
Mutation Taster Disease causing (p-value: 1) 
Polyphen 2  0.999 (HumDiv) 0.915 (HumVar) 
MDD conclusion Strong candidate variant for the phenotype 
Due to its high LoF constraint in ExAC, high Polyphen-2 score, and because it had 
arisen de novo this variant in MED13 was considered a strong candidate as the 
cause of P-597’s epilepsy. Two other patients with de novo MED13 variants had 
been identified through the Deciphering Developmental Disorders (DDD) study with 
clinical and genotypic information deposited on the Decipher website (Firth et al., 
2009), both of who had “abnormality of the nervous system” as a phenotypic 
feature. I made contact with the referrers of these cases and was subsequently put 
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in contact with a group in the Netherlands who were collecting genotypic and 
phenotypic data on patients with de novo MED13 variants in order to characterise a 
new genetic syndrome. P-597 appears as patient H in their paper (Snijders Blok et 
al., 2018). 11 patients were described in total. Four had truncating variants, six 
had missense variants, and one had an in-frame deletion of a single amino acid.  
All 11 patients had cognitive impairment, ranging from borderline to moderate. 
Additional phenotypic features in this group were highly variable: two had Duane 
anomaly (a type of congenital strabismus), two had congenital cardiac anomalies, 
and three had hypotonia. Only P-597 had epilepsy. 
The authors reported that the Pro540Thr variant identified in P-597 lies within a 
highly conserved linear motif and results in the high probability of formation of a 
Casein Kinase 1 phosphorylation motif. They hypothesised that this could lead to 
additional interaction with proteins containing forkhead domains (Dinkel et al., 
2016). 
6.3.5.3 POLR1A 
Male, born 2013. Phenotype: DRM + IODEE + PMD 
P-24 was born at term by planned caesarean section due to previous emergency 
caesarean section for placental abruption resulting in stillbirth. Birth weight was 
2960g (- 1.08 SD). He was noted to be hypotonic from the first day of life and 
required supplementary nasogastric feeding for three weeks. Gross motor 
development was delayed. He first rolled over at 10 months and at the age of 
three years is currently unable to sit independently, has no pincer grasp, no 
expressive language and makes no response to verbal cues. His swallow is safe but 
his oral intake is poor so he receives supplemental nasogastric feeding. He has 
peripheral hypertonia in all four limbs and wears ankle food orthoses. He smiles 
and enjoys holding hands with others.  
At the age of 12 months he began having clusters of epileptic spasms. Shortly after 
that he developed bilateral clonic seizures, generalised myoclonic seizures, and 
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absence seizures. He continued to have multiple seizures per day despite 
therapeutic trials of multiple AEDs. At the age of 3.5 years he was started on the 
Ketogenic Diet and the response was significant. He went from having >50 seizures 
per day to fewer than five. 
As well as his epilepsy P-24 has episodes of whole body stiffening which have been 
captured on EEG and shown to be non-epileptic.  
EEG during epileptic spasms demonstrated high amplitude bisynchronous spikes 
followed by suppression but not hypsarrhythmia. Background EEG is dominated by 
high voltage spike/sharp and slow waves. MRI brain at the age of 18 months 
demonstrated a symmetrical high T2 signal in the periventricular white matter 
around the posterior body and trigone of both lateral ventricles. MR spectroscopy 
was normal. He has short stature (86.7cm, -2.14 SD) and microcephaly (46.1cm, -
2.32 SD). He has subtle dysmorphic features: hypertelorism, thin upper lip and 
carp-shaped mouth. His joints are hypermobile. 
 
Figure 6.3d: T2-weighted axial MRI slice from P-24 showing high signal in the 
periventricular white matter  
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Table 6.3t: POLR1A variant in P-24 
POLR1A gene details 
Function Catalyses DNA-dependent synthesis of 
ribosomal RNA (Weaver et al., 2015). 
Relative brain expression (GTEx ratio) 0.668 
Missense constraint (ExAC) z = 3.00 
LoF constraint (ExAC) pLI = 0.999862 
Published cases of a similar phenotype No 
Frequency in previous NGS studies (Chapter 3) Not reported 
Variant details 
Inheritance De novo 
Genomic location Chr2(GRCh37): g.86257413C>A 
HGVSc. NM_015425.4(POLR1A): c.4685G>T 
HGVSp. p.Cys1562Phe 
Population frequency Not in gnomAD or UK10K 
Previously reported No 
SIFT Deleterious (Score: 0) 
Mutation Taster Not available 
Polyphen 2 0.999 (HumDiv) 0.977 (HumVar) 
MDD conclusion Strong candidate variant for the phenotype 
A de novo missense variant in POLR1A was found. This was considered a strong 
candidate due to high Polyphen-2 score, absence from gnomAD, and significant 
constraint of variation in ExAC. However, de novo variants in POLR1A had already 
been published in association with an apparently quite different phenotype than 
that of P-24, involving severe mandibulofacial dysostosis and no epilepsy (Weaver 
et al., 2015). Using Gene Matcher (Sobreira et al., 2015). I was able to identify 
another patient in the USA with exactly the same variant as P-24, also arising de 
novo. This patient did not have acrofacial dysostosis, but presented with severe 
hypotonia in infancy, developed infantile spasms and had hypertelorism and 
flexion contractures of the limbs. That these two patients should have such similar 
phenotype, and one so different from other patients with de novo POLR1A variants 
is intriguing. POLR1A encodes a protein essential for ribosome biogenesis a 
ubiquitous process required by all cells in the body (Weaver et al., 2015). In theory 
distinct POLR1A missense alleles may uniquely alter lineage-specific translational 
regulation of protein expression, leading to tissue-specific phenotypes in affected 
individuals. 
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6.3.5.4 NIPBL 
Female, born 2013. Phenotype: DRM 
P-962 was born by SVD at term following an uncomplicated pregnancy with normal 
antenatal scans. Birth weight was 3500g (+ 0.3 SD). There were no parental 
concerns about development until prior to onset of seizures. At the age of 2.5 
years she was in a supermarket café with her mother when both her arms 
stiffened, her eyes rolled back, her back extended and she became unresponsive. 
She remained like this for just over two minutes. She was then drowsy for a further 
2.5 hours. Three days later she began having myoclonic jerks and four days after 
that she began having drop seizures. Tonic, atonic, and myoclonic seizures 
occurred every day for the next 21 months, despite trials of multiple AEDs, VNS, 
and the Ketogenic Diet. From the age of two years and nine months she also 
developed absence seizures, occurring 3-4 times per week. She first began having 
days without seizures at the age of four years and three months, which coincided 
with the parents starting her on a self-sourced Cannabinoid-based therapy. Though 
she continued to gain skills since onset of seizures, there was a slowing of her 
language development, reduced interaction with others, easy frustration, and 
clumsiness to her gait and fine motor skills. All of these improved when her 
seizure-control improved. She is due to start mainstream primary school. Formal 
neuropsychological assessment at the age of 3 years and 5 months using the 
Wechsler Preschool and Primary Scale of Intelligence – Third UK Edition (WPPSI-III) 
showed that her general intelligence scores fell within the average range.  
EEGs demonstrate frequent generalised bursts of spike/polyspike wave interictally, 
and bisynchronous 2-3Hz spike wave activity during myoclonic seizures. MRI brain 
at the age of 2.5 years showed minimal ventricular asymmetry only. 
At the age of 5 years she has short stature (height 98.4cm, - 2.56 SD) and 
microcephaly (OFC 49.0cm, -2.52 SD). There is no family history of epilepsy or 
other neurodevelopmental disorders.  
241 
 
Table 6.3u: NIPBL variant in P-962 
NIPBL gene details 
Function Regulator of the cohesin complex (Watrin et 
al., 2006) 
Relative brain expression (GTEx ratio) 0.521 
Missense constraint (ExAC) z = 5.04 
LoF constraint (ExAC) pLI = 1.000000 
Published cases of a similar phenotype One case reported with a de novo NIPBL 
variant epilepsy, and no features of Cornelia 
de Lange syndrome (Parenti et al., 2017) 
Frequency in previous NGS studies (Chapter 3) Not reported 
Variant details 
Inheritance De novo 
Genomic location Ch5 (GRCh37): g.37026336A>T 
HGVSc. NM_133433.3(NIPBL): c.5715A>T 
HGVSp. p.Lys1906Phe 
Region of the protein affected Between Heat Repeat 2 and Heat Repeat 3 
(Selicorni et al., 2007) 
Population frequency Not in gnomAD or UK10K 
Previously reported No 
SIFT Deleterious (Score: 0) 
Mutation Taster Disease causing (p-value: 1) 
Polyphen 2 1.000 (HumDiv) 1.000 (HumVar) 
MDD conclusion Strong candidate variant for the phenotype 
A de novo variant was found in NIPBL. Variants in this gene are associated with 
Cornelia de Lange syndrome (CdLS), a multisystem developmental disorder 
characterised by: microcephaly; pre- and postnatal growth restriction often 
associated with feeding difficulties and gastro-oesophageal reflux; characteristic 
facial appearance with fine arched eyebrows, synophrys, long philtrum, thin upper 
vermilion and low set posteriorly rotated ears; and variable presence of 
malformations (limb, cardiac, diaphragmatic, gastrointestinal and genitourinary) 
(Boyle et al., 2015). CdLS has been associated with variants in six genes (NIPBL, 
SMC1A, SMC3, RAD21, and HDAC8, and BRD4) all of which are structural 
components of, or regulators of the cohesin complex (Olley et al., 2018; Mannini et 
al., 2013) a structure which binds chromatin and plays a key role in transcriptional 
regulation (Mannini et al., 2015). Epilepsy prevalence in case series of CdLS ranges 
from 4% to 80%, but the epilepsy phenotype appears to be highly heterogenous 
(Pavlidis et al., 2014). In an Italian series of 62 patients with CdLS, 26 had NIPBL 
variants, of whom three had epilepsy (Selicorni et al., 2007). There is a single case 
in the literature of a patient with a de novo NIPBL variant (p.Ser2296Gly) and a 
non-CdLS phenotype. This is a German female of Turkish ancestry who presented 
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with clinical features of Coffin-Siris Syndrome (CSS), including coarse facies, 
frontal bossing, thick eyebrows, broad nasal tip, anteverted nares, wide mouth, 
thin upper lip, thick everted lower lip, and hypoplastic nails. This patient was 
reported to have seizures, but further details of the epilepsy phenotype were not 
described (Parenti et al., 2017). The only features of CSS or CdLS present in P-962 
are short stature and microcephaly. Patients with variants in another CdLS-
associated gene, SMC1A can present with severe epilepsy but no dysmorphisim 
(Symonds et al., 2017). 
6.3.5.5 TRIM46 
Male, born 2006. Phenotype: DRM and PMD 
P-13 was born by SVD at term following an uncomplicated pregnancy. Birth weight 
was 3700g (+ 0.4 SD) and head circumference was 37.2cm at 12 days of age (+ 1.65 
SD). His parents had no concerns about his early development. 
He walked at 10 months, could ride a bike at three years, and could write his own 
name at four years. From the age of four years his language became less fluent and 
more disjointed, and from five years his rate of skill acquisition slowed down. 
Gradually he lost motor skills so that by the age of ten years he was unable to walk 
and could no longer use a pencil. His swallow became unsafe and he required 
salivary gland excision for excessive salivation.  
His first seizure occurred at the age of seven years. His head turned to the left, 
and became locked in a tonic posture. His eyes were deviated upwards and to the 
left. The whole episode lasted 30-60 seconds. Subsequent seizures had the same 
semiology and duration. From the age of 10 years he developed generalised 
myoclonic seizures, which appeared to be triggered by bright lights. Seizures come 
in clusters. He can have months without any seizures then have several days of 
multiple seizures per day. He continues to have seizures despite AED polytherapy 
with Levetiracetam, Sodium Valproate, and Clobazam. Seizures appear to be 
frequently triggered by bright sunlight. 
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In addition to his seizures he also has an episodic non-epileptic movement disorder 
characterised by tremor and stiffening of the right leg. He has progressive 
pyramidal, extrapyramidal signs, and cerebellar ataxia. 
 
Figure 6.3d: MRI images from P-13 showing cerebral and cerebellar volume loss 
EEGs have shown generalised abnormalities. Myoclonic seizures have been 
captured and are accompanied by generalised spike/polyspike and slow wave 
discharges. Interictally the EEG shows runs of bifrontal rhythmic slows, sometimes 
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with sharp wave accompaniment; and intermittent isolated bursts of generalised 
spike wave in the resting record and during photic stimulation. Visual Evoked 
Potentials (VEP), aged 11 years, had an amplitude at the upper range of normal. 
Electroretinogram (ERG) was present but at a subnormal amplitude. 
MRI brain at seven years of age showed delayed myelination mild cerebral and 
cerebellar atrophy and increased peri-trigonal T2 signal. Repeat MRI at the age of 
12 years demonstrated non-progression of the abnormal signal, but progressive 
atrophy of the deep white matter of the parietal lobes bilaterally. 
At most recent assessment, aged 10 years, P-13 had normal height (141cm, -0.18 
SD) but microcephaly (50.8cm, -2.39 SD). There was no family history of epilepsy 
or other neurodevelopmental disorders. 
Table 6.3v: TRIM46 variant in P-13 
TRIM46 gene details 
Function Required for neuronal polarity and axon 
specification (van Beuningen et al., 2015) 
Relative brain expression (GTEx ratio) 8.421 
Missense constraint (ExAC) z = 3.87 
LoF constraint (ExAC) pLI = 0.998652 
Published cases of a similar phenotype No 
Cases in public databases No 
Frequency in previous NGS studies (Chapter 3) Not reported 
Variant details 
Inheritance De novo 
Genomic location Chr1(GRCh37): g.155152916C>T 
HGVSc. NM_001282379.1(TRIM46): c.1594C>T 
HGVSp. p.Gln532* 
Population frequency Not in gnomAD or UK10K 
Previously reported No 
MDD conclusion Strong candidate variant for the phenotype 
There was a de novo nonsense variant in TRIM46. This gene has high expression in 
brain compared with other tissues. TRIM46 protein localises to the proximal axon 
where it is involved in microtubule binding. Knockout of TRIM46 results in 
disorganised microtubule binding (van Beuningen et al., 2015). No truncating 
variants in this gene are observed among the >60,000 individuals in the ExAC 
dataset. Recently antibodies to TRIM46 have been reported in three patients with 
small-cell lung cancer and paraneoplastic neurological syndromes (van 
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Coevorden‐Hameete et al., 2017). Affected individuals presented with gait 
disturbance, focal seizures, cerebellar signs, and cognitive decline. 
6.3.5.6 LRP8 
Male, born 2002. Phenotype: DRM 
P-958 was born by elective caesarean section at term following an uncomplicated 
pregnancy. His mother was taking the antidepressants Venflafaxine and Fluoxetine 
for the first 12 weeks of pregnancy. Birth weight was 4200g (+ 1.4 SD). There were 
no neonatal complications. His parents had no concerns about his early 
development. He crawled at 12 months, walked at 16 months, and could speak in 
sentences by the age of three years.  
His first seizure was at 3.5 years of age. His mother heard a gurgling noise, and 
found him grinding his teeth and jaw, eyes rolled back, and unresponsive for two 
minutes. He went on to have frequent focal seizures, characterised by loss of 
contact, and eye deviation upwards and to the right. Occasionally seizures would 
progress to involve clonic jerking of all four limbs. He went on to develop multiple 
seizure types, including tonic-clonic seizures without focal onset, generalised 
myoclonic seizures, drop attacks, tonic seizures, typical absence seizures. At most 
recent assessment, aged 14 years, he was having 1-2 nocturnal bilateral clonic 
seizures per night, and focal seizures with right eye deviation every day. Seizures 
have been resistant to multiple AEDs. Introduction of the Ketogenic Diet was 
associated with cessation of drop attacks, and a reduction in frequency of 
myoclonic seizures. Vagal Nerve Stimulation was associated with reduced 
frequency of daytime seizures. When he was tried on Carbamazepine all seizure 
types became more frequent. 
Onset of seizures was associated with a marked change in his developmental 
trajectory, and particularly with a change in his social communication skills. At the 
age of 14 years his drawing skills are the level of a seven year old. He 
communicates verbally but with the language skills of a five year old. He was 
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diagnosed with autism at the age of 10 years. EEGs have always been abnormal. 
When absence seizures have been captured EEG shows 1.5-2.5 per second slow 
spike and wave, which has been more pronounced over the left hemisphere at 
times. Interictal EEGs are poorly organised and slow. MRI brain at the age of four 
years was normal. Height and head circumference at the age of 14 years are within 
normal range. 
There is no family history of epilepsy. His mother has a history of depression, his 
mother’s father has autism spectrum disorder, and his mother’s father’s sister had 
schizophrenia. 
Table 6.3v: LRP8 variants in P-958 
LRP8 gene details 
Function Encodes the Reelin receptor, required for 
developmental layering of neurones within the 
cortex (Trommsdorff et al., 1999) 
Relative brain expression (GTEx ratio) 2.353 
Missense constraint (ExAC) z = 2.77 
LoF constraint (ExAC) pLI = 0.999986 
Published cases of a similar phenotype No 
Cases in public databases No 
Frequency in previous NGS studies (Chapter 3) Not reported 
Variant 1 details 
Inheritance Paternal 
Genomic location Chr1(GRCh37): g.53736706C>A 
HGVSc. NM_004631.4(LRP8):c.1246G>T 
HGVSp. p.Ala416Ser 
Population frequency 0.00005772 in gnomAD. Not in UK10K 
Previously reported No 
SIFT Deleterious (Score: 0) 
Mutation Taster Disease causing (p-value: 1) 
Polyphen 2 (HumVar) 0.9992 (HumDiv) 0.998 (HumVar)  
Variant 2 details 
Inheritance Maternal 
Genomic location Chr1(GRCh37): g.53741411G>A 
HGVSc. NM_004631.4(LRP8):c.898C>T 
HGVSp. p.Arg300Cys 
Population frequency 0.000004065 in gnomAD, Not in UK10K 
Previously reported No 
SIFT Deleterious (Score: 0) 
Mutation Taster Disease causing (p-value: 1) 
Polyphen 2 (HumVar) 0.887 (HumDiv) 0.849 (HumVar) 
MDD conclusion Strong candidate variants 
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Compound heterozygous variants missense were identified in LRP8. Based on GTEx 
ratio and pLI score this was considered a candidate gene. Both variants were 
considered candidates due to their rarity (>0.001 in gnomAD) and predicated 
deleteriousness (>0.8 Polyphen Score).  
LRP8 encodes a cortical reelin receptor. Reelin is, encoded by RELN, is a large 
secreted glycoprotein which is produced by cells within the developing brain. 
Reelin activates a signalling pathway in postmitotic migrating neurons, which is 
essential for positioning of neurons within laminated nervous system parenchyma 
(Maha et al., 2007). Biallelic loss of function RELN variants are associated with 
lissencephaly in humans. Lissencephaly is a developmental cortical malformation 
syndrome resulting in a smooth appearance to the brain surface, and is associated 
with drug-resistant epilepsy and cognitive impairment (Hong et al., 2000). 
Additionally, heterozygous missense variants in RELN have been associated with 
dominantly-inherited familial lateral temporal lobe epilepsy (Dazzo et al., 2015). 
In a mouse model, biallelic knockout of LRP8 does not result in a detectable 
phenotype, unless combined with knockout of VLDLR which encodes another 
cortical Reelin receptor. Knockout of both LRP8 and VLDLR results in a clinical and 
neuropathological phenotype which mimicks that of the biallelic RELN knockout 
mouse (Trommsdorff et al., 1999). 
6.3.5.7 CNTNAP1 
Female, born 2014. Phenotype: DRM + IODEE 
P-772 was born at 37 weeks by emergency caesarean section following induction of 
labour for polyhydramnios. Antenatal scans had been otherwise normal. Birth 
weight was 3130g (- 0.49 SD). She was in poor condition at birth requiring bag and 
mask ventilation for poor respiratory effort. She was intubated and ventilated from 
20 minutes of age, due to severe respiratory distress. Her neonatal course was 
complicated by an episode of severe E. coli sepsis, pharyngomalacia, for which she 
had a tracheostomy at five weeks of age, and severe gastroesophageal reflux for 
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which she had gastrostomy and fundoplication at three months of age. She was 
discharged home from neonatal care at the age of six months. She has been able to 
self-ventilate via tracheostomy. 
From birth she was noted to be hypotonic. She had an extended posture to her 
spine, a flexed posture to her wrists, and made very little spontaneous movement. 
She had bulbar and facial palsies bilaterally, exhibiting no facial movements and 
having no gag reflex. Facial features noted from early infancy were micrognathia, 
bilateral ptosis, and an upturned nose. She had investigations based on a suspicion 
of congenital myopathy. She had a normal creatine kinase level and negative 
genetic tests for spinal muscular atrophy, congenital myotonic dystrophy, and 
pyruvate dehydrogenase deficiency. 
She began having epileptic spasms at two months of age. These involved 
symmetrical flexion at the elbows and eye deviation. The spasms were captured on 
EEG and were accompanied by bilateral suppressions followed by runs of right-
sided sharp waves. The EEG background did not initially show hypsarrhythmia but 
progressively deteriorated over time and showed hypsarrhythmia by the age of 
three years. Epileptic spasms were resistant to multiple AEDs. She also developed 
generalised myoclonic seizures. Both Topiramate and Levetiracetam was 
associated with a reduction in seizure frequency. 
Serial MRI brain scans at 12 days, one month, and two months, showed progressive 
cortical volume loss and delayed myelination of the cerebral and cerebellar 
hemispheres. 
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Figure 6.3e: MRI scan (aged 2 months) from P-772 showing cerebral atrophy 
and hypomyelination 
At the age of four years she has profound developmental delay. She is unable to sit 
independently, unable to swallow, and has no verbal or non-verbal communication. 
She has cerebral visual impairment. Head circumference and height are within 
normal range. There is no family history of epilepsy or other neurodevelopmental 
disorders. 
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Table 6.3x: CNTNAP1 variants in P-772 
CNTNAP1 gene details 
Function Component of complex at neuronal paranodal 
complex, required for high velocity nerve 
conduction (Bhat et al., 2001) 
Relative brain expression (GTEx ratio) 4.184 
Missense constraint (ExAC) z = 4.50 
LoF constraint (ExAC) pLI = 0.004109 
Published cases of a similar phenotype Yes. Similar in other phenotypic features, but 
none previously reported with epilepsy (Low et 
al., 2018; Nizon et al., 2016; Laquérriere et al., 2014) 
Frequency in previous NGS studies (Chapter 3) Not reported 
Variant 1 details 
Inheritance Paternal 
Genomic location Chr17 (GRCh37): g.40838099C>A 
HGVSc. NM_003632.2(CNTNAP1): c.840C>A 
HGVSp. p.Asp280Glu 
Population frequency 0.00001624  in gnomAD. Not in UK10K 
Previously reported No 
SIFT Deleterious (Score: 0) 
Mutation Taster Polymorphism (p-value: 0.686) 
Polyphen 2 (HumVar) 1.00 
Splicing predications Predicated new splice acceptor site 
Variant 2 details 
Inheritance Maternal 
Genomic location Chr17 (GRCh37): g. 40842225-229 GGTAA>G 
HGVSc. NM_003632.2(CNTNAP1) :c.1855+3_1855+6del 
HGVSp. N/A - intronic 
Population frequency Not in gnonmAD or UK10K 
Previously reported No 
Splicing predictions Predicted loss of splice donor site 
MDD conclusion Causative of the phenotype 
Biallelic variants in CNTNAP1 were identified, both of which were predicated to 
have an impact on splicing. 
CNTNAP1 encodes caspr, an essential component of a multiprotein complex which 
locates to the nodes of Ranvier in myelinated nerve cells (Laquérriere et al., 
2014). In a homozygous knockout mouse model, lack of caspr results in a 
phenotype of hypomotility, tremor, wide-based gait, and generalised motor paresis 
(Bhat et al., 2001). In humans, biallelic frameshift variants were first described by 
Laquerriere et al. They reported seven patients, from four unrelated families. 
Affected individuals present with severe congenital arthrogryposis and a 
pronounced motor neuropathy. All seven reported patients died in the first three 
months of life (Laquérriere et al., 2014). Nizon et al. subsequently described two 
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siblings with homozygous nonsense variants who had a very similar clinical picture 
but without arthrogryposis. Sural nerve biopsy demonstrated peripheral nerve 
hypomyelination (Nizon et al., 2016). Features common to all nine patients were 
polyhydramnios, severe neonatal hypotonia, facial diplegia, and absence of 
spontaneous swallowing or breathing. 
Subsequently, a non-lethal form of recessive CNTNAP1-related disease was 
described by Low et al. Unlike the previously reported variants some of these were 
missense variants. All patients had a severe neurological phenotype, including 
orobulbar dysfunction, facial nerve weakness, vocal cord paresis, severe 
gastroeosophageal reflux, brain hypomyelination, and severe developmental delay. 
The patients with missense variants had a milder phenotype, with survival up to 15 
years observed. The authors proposed that hypomorphic missense variants partially 
ameliorate the phenotype (Low et al., 2018). 
The only reported patients with CNTNAP1 variants and seizures are among seven 
patients from two families reported by Hengel et al. In one of these families, a 
large consanguineous Palestinian pedigree carrying a nonsense variant, two of 
three affected individuals survived to nine and 12 years old and had developed 
tonic-clonic seizures. In the second family, an Irish family in which affected 
individuals were compound heterozygous for one nonsense and one missense 
variant, one of two affected individuals developed clonic, brief tonic, and 
myoclonic seizures from the age of 10 weeks, and died at the age of four months 
(Hengel et al., 2017). 
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6.3.5.8 MAP2.  
Male, born 2014. Phenotype: DRM. 
P-278 was born by SVD at term weighing 4250g (+ 1.5 SD). There had been no 
concerns during the pregnancy, with normal routine fetal ultrasound and normal 
fetal movements reported. He was discharged home on day 1 of life. There were 
no concerns about his early infantile development, but by 12 months of age his 
mother had concerns about his motor development because he was unable to sit 
unsupported. He made developmental progress in other domains. By the age of 2 
years he was able to scribble and had several single words, including “Daddy” 
“Hiya” and “Bye”. His started having seizures at the age of 22 months. These 
involved rapid jerks of both arms and both legs with rapid drops of the head. These 
occurred very frequently (up 100 per day). EEG during these events demonstrated 
bursts of bisynchronous frontally-predominant polyspike wave. He was started on 
Levetiracetam, which was associated with a reduction in seizure frequency to 20 
per day, but was also associated with a change in mood and cessation of verbal 
communication. His treatment was changed to Sodium Valproate and he continued 
to have about 20 myoclonic seizures per day, but regained his words. From the age 
of 35 months he began having episodes every few weeks where he would become 
unresponsive for about 30-60 seconds, then giggle for a couple of seconds, then 
continue what he was doing. 
MRI brain scan at the age of 30 months was normal. At the age of 4 years he has 
global developmental delay. He is unable to sit independently, he can transfer toys 
between hands and scribble with a pencil but not draw anything, he has single 
word language and appears to follow conversations. He is content and sociable and 
enjoys giving “High 5’s”. On examination OFC is 46.9cm (-2.67 SD) and height is 
89.4cm (-1.56 SD). He has bilateral symmetrical lower limb hypertonia, with 
hyperreflexia and clonus. He has bilateral choroidoretinopathy. 
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Table 6.3y: MAP2 variant in P-278 
MAP2 gene details 
Function Stimulates microtubule proliferation in 
dendrites (Fontaine-Lenoir et al., 2006) 
Relative brain expression (GTEx ratio) 22.7 
Missense constraint (ExAC) z = 0.36 
LoF constraint (ExAC) pLI = 0.9999833 
Published cases of a similar phenotype None 
Cases in public databases 4 in Decipher – all with abnormality of the 
nervous system 
Frequency in previous NGS studies (Chapter 3) Not reported 
Variant details 
Inheritance De novo 
Genomic location Chr2 (GRCh37): g.210565051 G>A 
HGVSc. NM_002374.3(MAP2): c.4573G>A 
HGVSp. p.Asp1525Asn 
Population frequency Not in gnomAD or UK10K 
Previously reported No 
SIFT Deleterious (score 0.02) 
Mutation Taster Disease causing (prob: 0.997) 
Polyphen 2 0.998 (HumDiv), 0.859 (HumVar) 
MDD conclusion Strong candidate variant 
P-278 has a de novo variant in MAP2. MAP2 is highly expressed in the neuronal 
dendrites and encodes a 280-kD protein, MAP2. In vitro experiments in rat brain 
samples demonstrate that MAP2 is a receptor for the neurosteroid pregnenolone. 
Decreasing MAP2 expression results in loss of the stimulatory effects of 
pregnenolone on neurite extension (Fontaine-Lenoir et al., 2006). There are no 
published reports of human disease in association with variants in MAP2.  However, 
I identified four patients from the Deciphering Developmental Disorders (DDD) 
study with de novo variants in this gene, all of whom had a phenotype of 
“abnormality of the nervous system” (Firth et al., 2009). 
In addition to the MAP2 variant, P-278 also has a maternally inherited nonsense 
variant (p.Arg581*) in SPAST, a gene associated with hereditary spastic paraparesis 
(HSP) (Hazan et al., 1999). Most HSP-related SPAST variants are truncating. The 
phenotype presents with progressive lower limb spasticity and weakness in the 
absence of other neurological signs or symptoms. First symptoms can present at 
any age between the first year of life and 77 years of age (mean = 28.7 years), and 
penetrance is not complete in that a minority mutation carriers, identified through 
family studies, are asymptomatic. Penetrance is lower in females (0.88) than in 
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males (0.94) (Parodi et al., 2018). It is possible that the lower limb hypertonia 
observed in P-278 is related to this SPAST variant, and that his mother is currently 
asymptomatic for this. It is unlikely that the other phenotypic features observed in 
P-278 are related to the SPAST variant since epilepsy, developmental delay, and 
choroidoretinopathy are not reported features of this condition, nor are they 
present in his mother. 
6.3.5.9 RAS10LB 
Male, born 2014. Phenotype: IODEE 
P-621 was born by SVD at 39 weeks gestation. There were no concerns prior to 
birth in relation to fetal movements or ultrasound scans. Birth weight was 2500g (-
1.99 SD) and head circumference was 29.3cm (-3.61 SD). At birth he was found to 
have an everted left ear and absent 12th ribs. Newborn hearing screening (auditory 
brainstem responses) demonstrated bilateral sensorineural hearing loss. He had 
some respiratory distress at birth and was treated with oxygen for 24 hours. He 
struggled to feed and required supplemental nasogastric feeding for the first 6 
weeks of life. 
He presented with epileptic spasms at the age of 17 months. These presented as 
clusters of 3-4 spasms once or twice per day. After 2 weeks of these events he had 
an EEG which demonstrated modified hypsarrhythmia (Figure 6.3h). He was started 
on Vigabatrin and the spasms stopped after 5 days. After 3 months of treatment 
the Vigabatrin was stopped. He remained seizure-free until the age of 25 months 
when he had a single cluster of spasms associated with intercurrent illness. MRI 
brain scans done at 1 year of age and 3 years of age demonstrated a structurally 
normal brain.  
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Figure 6.3h: EEG in P-621 showing modified hypsarrhythmia 
At the age of 3 years he has global developmental delay. He has hypotonia, and 
has never been able to sit without support. He can hold a toy in a palmar grasp but 
cannot transfer toys or use a pincer grasp. He is non-verbal and responds only to 
his name. He enjoys music and makes attempts to sing. Head circumference is 
42.5cm (-4.8 SD), height is 78.9cm (-3.98 SD), and weight is 10.1kg (-2.46 SD). 
There is no family history of epilepsy or other neurodevelopmental disorder. 
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Table 6.3z: RASL10B variant in P-621 
RASL10B gene details 
Function Regulator of dense-core vesicle secretion. 
Biallelic knockout mice are viable and fertile 
but have small atrial cardiomyocytes and high 
blood pressure (Rybkin et al., 2007)  
Relative brain expression (GTEx ratio) 5.52 
Missense constraint (ExAC) z = 3.14 
LoF constraint (ExAC) pLI = 0.03679261 
Published cases of a similar phenotype None 
Cases in public databases None 
Frequency in previous NGS studies (Chapter 3) Not reported 
Variant details 
Inheritance De novo 
Genomic location Chr17 (GRCh37): g. 34067458 C>T 
HGVSc. NM_033315.3 (RASL10B): c.247C>T 
HGVSp. p.Arg83Trp 
Population frequency Not in gnomAD or UK10K 
Previously reported No 
SIFT Deleterious (score: 0) 
Mutation Taster Disease causing (prob:1) 
Polyphen 2 1.00 (HumDiv) 0.999 (HumVar) 
MDD conclusion Strong candidate variant 
There was a de novo variant in RASL10B, a that has high brain expression and 
encodes the protein Ras-related protein 7, RRP7. RRP7 interacts with the C-
terminal region of CAPS1, a regulator of vesicle secretion. The role of RRP7 in 
neurones has not been studied. In rat cardiomyocytes increased RASL10B 
expression results in elevated levels of atrial natriuretic peptide (Rybkin et al., 
2007).  
6.3.5.10 CACNA1G 
Male, born 2016. Phenotype: IODEE 
P-722 was born by SVD at term weighing 3410g (-0.18 SD) and with a head 
circumference of 35.5cm (+0.37 SD). There were no antenatal concerns in relation 
to routine ultrasound scans or fetal movements. On day 2 of life he was reviewed 
for poor feeding and was found to have central hypotonia. He was admitted to the 
neonatal unit for feeding support and supplemental oxygen for 2 weeks. At 3 
months of age he presented with clusters of seizures characterised by symmetrical 
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extensor spasms of the arms, eye opening and staring, going red in the face, and 
trembling at the jaw. 
EEG during these demonstrated a build-up of rhythmic slow waves with intermixed 
irregular polyfocal spikes (Figure 6.3i). Seizures continued despite treatment with 
initially Vigabatrin then Carbamazepine, then Levetiracetam. 
MRI brain at the age of 5 months demonstrated a structurally normal brain with 
some enlargement of the subarachnoid spaces. 
 
Figure 6.3i: Ictal EEG in P-722, showing irregular polyfocal spikes and muscle 
artefact of jaw trembling 
At the age of 14 months he has global developmental delay and generalised 
hypotonia. He is unable to roll or sit. His hands come to the midline but he is 
unable to hold a toy. He responds to verbal cues with laughs and giggles, but has 
no words. His height is 72.4cm (-0.39 SD) and his head circumference is 45.2cm (-
0.44 SD). There is no family history of epilepsy or other neurodevelopmental 
disorder. 
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Table 6.3α: CACNA1G variant in P-722 
CACNA1G gene details 
Function Subunit of T-type voltage-gated calcium 
channel 
Relative brain expression (GTEx ratio) 4.71 
Missense constraint (ExAC) z = 4.97 
LoF constraint (ExAC) pLI = 0.999997 
Published cases of a similar phenotype 4 patients reported with  de novo missense 
variants, presenting with cerebellar 
hypoplasia/atrophy, developmental delay, and 
hand/digital anomalies. 2/4 had neonatal-
onset seizures (Chemin et al., 2018). 
Cases in public databases None 
Frequency in previous NGS studies (Chapter 3) Not reported 
Variant details 
Inheritance De novo 
Genomic location Chr17 (GRCh37): g. 48695666 C>T 
HGVSc. NM_018896.4 (CACNA1G): c. 5389C>T 
HGVSp. p.Arg1797* 
Population frequency Not in gnomAD or UK10K 
Previously reported No 
MDD conclusion Strong candidate variant for the phenotype 
There was a de novo nonsense variant in the CACNA1G gene. This gene encodes a 
subunit of the neuronal T-type calcium channel. T-type channels are thought to be 
involved in pacemaker activity, low-threshold calcium spikes, neuronal oscillations 
and resonance, and rebound burst firing (Perez-Reyes et al., 1998). De novo 
missense variants in CACNA1G have been reported in 4 individuals presenting with 
childhood-onset cerebellar atrophy. All 4 had severe or profound intellectual 
disability and hypotonia. 2/4 presented with seizures in the first 2 weeks of life 
and were described as having an epileptic encephalopathy, whilst the other 2 had 
not had any seizures reported by the time of most recent follow up (8 years and 
11.5 years). MRI scans in all 4 demonstrated cerebellar atrophy but with a normal 
cerebral cortex and normal brainstem. All 4 had anomalies involving the hands, 
including clinodactyly, short hands and feet, syndactyly, and broad thumbs. 
Functional characterisation of 2 of these missense variants was carried out by 
transfecting the variants into human embryonic kidney cells (HEK-293T) and using 
patch clamp current recording techniques. Both variants impaired channel 
inactivation, and effect that was fully-blocked by a selective T-type calcium 
channel blocker TTA-P2 (Chemin et al., 2018). 
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Truncating variants in CACNA1G have not been reported in association with 
neurological disease, but since these variants are heavily constrained in ExAC (pLI 
= 1.00), the nonsense variant identified in P-722 is a strong candidate cause. In 
contrast the published gain-of-function variants reported by Chemin et al. it is 
likely that calcium channel blocking medications, including the anti-epileptic drugs 
Topiramate, Ethosuximide, Zonisamide, and Acetazolamide, may exacerbate 
symptoms by further impairing calcium channel function, though this would have 
to be tested experimentally. 
6.3.6 Associations between phenotypic features and the identification 
of diagnostic/strong candidate findings 
6.3.6.1 Age of first seizure presentation 
In order to assess whether age of first seizure presentation was associated with the 
finding of a diagnostic or candidate genetic variant, I performed two sample t-
tests comparing the mean age of presentation between those families with 
diagnostic/candidate findings and those without. There were no significant 
differences between the groups. 
Table 6.3β: Differences between mean age at first seizure between groups with 
and without diagnostic/candidate variants in the WGS cohort (2-tailed t-test) 
Group Number Mean age at first 
seizure 
P-value 
Diagnostic finding 11 11.2 months 0.17 (n.s.) 
No diagnostic finding 61 22.4 months 
Diagnostic or candidate finding 21 17.2 months 0.44 (n.s.) 
No diagnostic or candidate 
finding 
51 22.1 months 
6.3.6.2 Family history scores 
I wanted to test a hypothesis that patients without de novo causative or candidate 
variant would have higher family history scores than those with a de novo 
causative or candidate variant, since this would suggest that these patients had a 
more significant polygenic contribution to their epilepsy. The mean family history 
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score was higher in both the group without a de novo diagnostic variant and the 
group without a de novo diagnostic or candidate variant, but neither of these 
differences reached statistical significance. It is possible that this study was 
underpowered to detect significant differences. It would be interesting to repeat 
this analysis with a larger sample. 
Table 6.3γ: Differences between mean Family History Scores between group 
with and without diagnostic/candidate variants in the WGS cohort (2-tailed t-
test) 
Group Number Mean Family History score P-value 
de novo Diagnostic finding 8 23 0.46 (n.s.) 
No de novo diagnostic finding 64 28.2 
de novo Diagnostic or 
candidate finding 
15 11.4 0.08 (n.s.) 
No de novo diagnostic or 
candidate finding 
57 31.1 
6.3.6.3 Phenotypic features 
Table 6.3Δ reports the % of patients who had a diagnostic or candidate genetic 
variant according to the presence or absence of clinical features. The only clinical 
features that were significantly associated with the presence of either a diagnostic 
or a candidate variant were: i) the presence of moderate to profound cognitive 
impairment; and ii) the presence of microcephaly (>2 SD below the mean).
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Table 6.3Δ: Associations between phenotypic features and diagnostic or candidate findings in the WGS cohort 
Feature Total number 
with feature 
Number with 
diagnostic 
variant 
% with 
diagnostic 
variant 
p-value 
(Fisher’s 
exact) 
Number with 
diagnostic or 
candidate 
variant 
% with 
diagnostic or 
candidate 
variant 
p-value 
(Fisher’s 
exact) 
Seizure types 
Myoclonic 37 3 8.1% >0.05 10 27.0% >0.05 
Generalised clonic/tonic-clonic 31 4 12.9% >0.05 7 22.6% >0.05 
Focal 39 8 20.5% >0.05 12 30.8% >0.05 
Drop 22 1 4.5% >0.05 4 18.2% >0.05 
Absence 21 2 9.5% >0.05 7 33.3% >0.05 
Atypical absence  16 2 12.5% >0.05 5 31.2% >0.05 
Tonic 20 5 25.0% >0.05 8 40.0% >0.05 
Spasms 27 5 18.5% >0.05 10 37.0% >0.05 
Status 20 4 20.0% >0.05 5 25.0% >0.05 
Cognitive impairment 
Mild-normal 29 0 0.0% 0.0072* 3 10.3% <0.001* 
Moderate-profound 42 10 23.8% 0.017* 17 40.5% <0.001* 
Unknown 1 1 100.0% >0.05 1 100.0% >0.05 
Additional features 
Autistic features 31 6 19.3% >0.05 8 25.8% >0.05 
Drug-resistant seizures 53 8 15.1% >0.05 15 28.3% >0.05 
Microcephaly (<2 SD below mean) 16 4 25.0% >0.05 9 56.3% 0.012* 
Any abnormality on MRI scan 23 4 17.4% >0.05 8 34.8% >0.05 
Any organ anomaly or deformity 15 3 20.0% >0.05 5 33.3% >0.05 
Phenotype group 
DRM 33 3 9.1% >0.05 10 30.3% >0.05 
IODEE 34 8 23.5% >0.05 13 38.2% >0.05 
LKSS 34 4 11.8% >0.05 5 14.7% >0.05 
PMD 12 2 16.7% >0.05 2 16.7% >0.05 
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6.4 Discussion 
In this chapter I have investigated the utility of Whole Genome Sequencing (WGS) 
in a cohort of patients from 72 families. These patients presented with a broad 
range of epilepsy phenotypes, but all could be considered to fall into at least one 
of four phenotype categories, namely drug-resistant myoclonic epilepsy, infantile-
onset developmental and epileptic encephalopathy, Landau-Kleffner spectrum, 
and comorbid paroxysmal movement disorder. Despite the WGS platform being 
significantly larger than the 104 gene panel described in chapter 5, the yield of 
diagnostic results from WGS was significantly lower than was obtained from panel 
testing in the unselected < 3 years cohorts. From WGS, 11/72 (15.3%) families had 
a diagnostic result. This relatively low yield almost certainly reflects that fact that 
this cohort had already been extensively investigated and was therefore depleted 
of patients with the more common genetic causes. When looking just at patients in 
this cohort who had not been pre-screened by testing on the 104 gene panel the 
yield of diagnostic results from WGS among was similar to the figures in chapter 5 
at 19.4% (9/31), whilst among those who had been pre-screened the yield was just 
4.8% (2/41). What this demonstrates is that once the more common genetic causes 
have been excluded, only a tiny minority of patients will have an identifiable 
genetic cause even when tested on the largest platform available. So what does 
explain these severe epilepsies with no identifiable cause despite WGS? There are 
a number of possibilities: 
• The first possibility is that one of the candidate genetic causes identified 
(Table 6.3a) is in fact causative. Once you move into the realm of 
increasingly rare genetic diseases there is often little published literature on 
the phenotypic spectrum of any given condition. Thus it becomes 
increasingly challenging to make a judgement as to whether a genetic 
finding is truly “causative.” It was for this reason that the methodology for 
this chapter involved in depth multidisciplinary discussion with a panel of 
experts in clinical genetics, laboratory genetics, and epilepsy. Whether 
genetic findings were designated “diagnostic” or “candidate” came down to 
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the consensus opinion at each multidisciplinary discussion. For example, 
though the CNTNAP1 variants identified in family 772 were considered 
“candidate” they were thought to be sufficiently strong to justify offering 
pre-natal testing to the family in future pregnancy, particularly since, as a 
recessive condition the chance of recurrence was not insignificant (25%). 
• A second possibility is that there is genetic cause within the WGS data that 
has not been identified as a candidate because of the limitations of the 
methodology used in this study. The criteria for variant candidacy were 
necessarily restrictive in order to keep the number of candidate variants to 
a manageable number and to maintain specificity. For a variant to be 
considered as a candidate it had to be in a gene with a high brain expression 
ratio and a low tolerance for haploinsufficiency (i.e. a high pLI score). 
Furthermore, the variant itself had to be rare (found in less than 1 in 
100,000 individuals), coding (within exons), and with either predicted loss of 
function effect, or with a strong prediction of deleteriousness according to 
Polyphen-2 (score >0.8). Finally, the variant had to be inherited in a manner 
in keeping with the family history (de novo, X-linked in a male, recessive, or 
inherited from an affected parent). Each of these filters may have 
inadvertently thrown out potentially causative variants. The gene filter, 
based on an algorithm using brain expression and tolerance of 
haploinsufficiency, used to select candidate genes was only 71.1% sensitive 
when tested against the 45 most commonly-implicated autosomal dominant 
epilepsy-associated genes. Examples of epilepsy-associated genes that are 
not selected by this filter include KCNA2 and KCNT1, both of which have 
relatively low pLI scores and so are predicted to tolerate haploinsufficiency. 
The low pLI score is explained by the fact that epilepsy-associated variants 
in these genes are always missense variants with predicted gain-of-function 
properties (Barcia et al., 2012; Milligan et al., 2014; Lim et al., 2016; Syrbe 
et al., 2015). Other epilepsy-associated genes may have low pLI scores 
because they are associated with mild phenotypes and therefore deleterious 
variants have not been selected out of the population: examples include 
PRRT2 and CHRNA2. Some other epilepsy-associated genes were missed by 
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the filter because they are ubiquitously expressed and therefore have a 
relatively low brain expression ratio (GTEx). Examples of this include 
DYRK1A and SLC2A1.  
Moving onto genes associated with disorder that have recessive inheritance 
patterns, the chance that they would be filtered out increases markedly, 
principally because these genes tend to have low pLI scores: they tolerate 
loss of function of one allele and only cause disease when both alleles are 
affected. One of the most compelling diagnostic findings in this chapter 
were the recessive ROGDI variants identified in family 431. These were 
considered diagnostic since both variants were predicated to result in loss of 
function and because the phenotype of P-431, including amelogenesis 
imperfecta, was fully in keeping with the published cases. The ROGDI gene 
has a very low pLI score of 3.2x10-12, since carriers of truncating variants, 
like the parents of P-431, are expected to be healthy. 
It is possible that intronic variants identified through WGS may have been 
causative. Intronic variants may lead to disease through a variety of 
mechanisms, the best understood of which are the disruption of 
transcription regulatory motifs, and the activation of non-canonical splice-
sites, leading to pseudo exon inclusion (Vaz-Drago, Custódio & Carmo-
Fonseca, 2017).  Recently seven de novo deep intronic variants in SCN1A 
have been described in patients with Dravet syndrome. Using real time 
qualitive Polymerase Chain Reaction (RT-qPCR) the authors were able to 
demonstrate that these variants resulted in the inclusion of an additional 
“poison” exon to the SCN1A gene transcript which likely lead to loss of 
function of the allele (Carvill et al., 2018). I looked for possible causative 
intronic variants in the patients in this cohort, but there were no de novo 
intronic variants identified within established epilepsy-associated or 
neurodevelopmental disorder-associated genes.  
Excluding variants on the basis that they were inherited from an unaffected 
parent may also have filtered out causative variants, since some epilepsy-
associated genes are have incomplete or variable penetrance. For example, 
asymptomatic individuals carrying deleterious variants in TSC1 or TSC2 have 
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parented children with severe phenotypes of tuberous sclerosis (Staley, Vail 
& Thiele, 2011). In family 976 a maternally-inherited essential splice site 
variant in STX1B was identified. The proband had a severe focal epilepsy, 
whilst his mother had a history of a single febrile convulsion. Variable 
penetrance is well-described in this gene (Schubert et al., 2014). 
Finally, all the tools used here to filter variants have their own specificity, 
sensitivity, and technical limitations. Alternative tools with the same 
objectives exist to the ones I have used, such as the Haploinsufficiency 
Index (HI) as an alternative to the pLI score (Firth et al., 2009); Combined 
Annotation Dependent Depletion (CADD) score (Rentzsch et al., 2019) and 
Provean (Choi & Chan 2015) as an alternatives to Polyphen-2; and Brain 
Cloud as an alternative to GTEx ratio (Colantuoni et al., 2011). In the 
absence of gold standard definitions of diagnostic results, it is very difficult 
to appraise the relative merits of these various tools. 
• A third possibility is that there is a genetic cause not easily identified 
though standard WGS analysis, such as a copy number variant (CNV). Large 
CNVs were excluded in this cohort by ensuring that all patients had had 
array CGH testing, yet the technology used was only sensitive to a copy 
number variant size of 1 kilobase. It is possible to use tools to interrogate 
WGS data for small CNVs and this analysis is ongoing at present. 
• A fourth possibility is that there is a non-Mendelian genetic cause such as 
oligogenic or polygenic inheritance, or epigenetic factors. 
• A fifth possibility is that there is no genetic cause at all, and that some 
unidentified environmental factor explains the epilepsy, such as an 
infectious process, or environmentally triggered immune process. 
In reality the aetiology for most patients with epilepsy will be a blend of the above 
possibilities. Every patient with epilepsy is likely to have, to varying and possibly 
unquantifiable degrees, some environmental and some non-Mendelian genetic 
contributors to their phenotype. Some will also have Mendelian genetic 
contributors as well, though it remains a minority in which such be identified. WGS 
does have the capacity to identify Mendelian causes after a large gene panel has 
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failed to do so, but with a relatively low yield. In this study I showed that two 
factors were associated with an increased likelihood of identification of a 
Mendelian genetic cause and these are the presence of microcephaly and the 
presence of moderate to profound cognitive impairment.   
At present I have been unable to demonstrate that diagnostic results obtained 
though WGS after gene panel testing have direct implications for therapy choice, 
though this partly reflects the fact that the Glasgow 104 gene panel was designed 
to include as many “treatable” genetic epilepsies as possible. It is important to 
recognise however that there may be therapeutic value for families in connecting 
with other families affected by a rare genetic disorder. 
In addition to the diagnostic results obtained through WGS, a number of promising 
new candidate epilepsy genes were identified: POLR1A, MED13, TRIO, CACNA1G, 
CNTNAP1, and NIPBL are all genes have been associated with neurodevelopmental 
disorders but typically without epilepsy as a prominent feature of the established 
phenotype. These findings lend support to the conceptualisation epilepsy as a 
symptom of multiple rare genetic brain disorders, rather than a disease in itself. 
The candidate variants in TRIM46, MAP2, RASL10B, and LRP8 are all in completely 
novel genes and now efforts are underway to identify more patients with 
potentially pathogenic variants in these genes through linking with other research 
groups. 
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7. Detailed phenotyping and therapy response in cohort of 
children with a newly-identified genetic epilepsy, SMC1A 
7.1 Introduction 
Genes that have been associated with epilepsy can be broadly divided into five 
groups, based on the function of the protein encoded: 
• Metabolic: Genes encoding proteins involved in the transport and 
metabolism of intracellular small molecules, or mitochondrial function 
• Ion channel/G-protein: Genes whose products form ion channels, ion 
channel accessory proteins, or G-proteins 
• Cell growth and proliferation: Genes encoding regulators of cell growth 
and proliferation 
• Synaptic: Genes encoding proteins with key synaptic functions (excluding 
ion channels and G-proteins)  
• Regulatory: Genes thought to play a role in transcriptional regulation, 
translational regulation, or post-translational protein modification 
• Others: Miscellaneous, or unknown function 
7.1.1 Metabolic genes 
An inherited metabolic disease (IMD) is a condition in which the body produces 
insufficient quantities of a key enzyme or cofactor that is involved in the transport 
or metabolism of one or more small molecules (e.g. sugars, amino acids, lipids) 
within the cell. The root cause of most IMDs is one or more pathogenic variant in 
the gene encoding the relevant enzyme. The majority of IMDs are recessively 
inherited since one working copy of a gene is usually sufficient to produce 
sufficient quantities of most enzymes. Because enzymes function within complex 
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and intersecting pathways, most IMD have both upstream and downstream effects. 
Symptoms relating to IMDs can be described in relation to three broad 
mechanisms: over accumulation of a toxic metabolite; insufficient production of a 
key substrate; and failure of energy supply. Epileptic seizures are common in 
patients with IMDs and all three of these mechanisms are likely to play a role in 
seizure predisposition in affected patients. Examples of each are given below: 
7.1.1.1 Overaccumulation of a toxic metabolite:  
e.g. Glycine encephalopathy, associated with recessively-inherited variants in 
genes (GLDC, AMT, GCSH) encoding components of the glycine cleavage complex. 
Results in accumulation of glycine within the CNS. Glycine is an agonist at 
excitatory NMDA receptors. Seizures observed in glycine encephalopathy are 
believed to be largely as a consequence of NMDA activation. 
7.1.1.2 Insufficient supply of a key substrate: 
e.g. Biotinidase deficiency, associated with recessively-inherited variants in BTD 
which encodes the biotinidase enzyme. Biotinidase releases biotin from protein in 
the diet. Biotin is a critical cofactor in a number of carboxylation reactions.  
7.1.1.3 Failure of energy supply: 
e.g. disorders of mitochondrial function, which may be associated with variants in 
nuclear DNA, or in mitochondrial DNA. 
Distinction between these three mechanisms is not always clear cut. For example, 
in a patient with glucose 1 transporter deficiency (Glut1-D) this can be conceived 
of as both an insufficient supply of a key substrate (glucose to the CNS) and as a 
failure of energy supply. In many IMDs an single enzyme deficiency will result both 
overaccumulation of toxic metabolites and in insufficient supply of key substrates, 
and it is not always possible to tell which if these is the main factor driving a 
predisposition to seizures.  
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7.1.2 Ion channel and G-protein disorders 
Ion channels and G-protein coupled receptors are transmembrane receptor 
proteins that are present in all cell membranes in the body and permit 
extracellular influences to transmit signals into the cell. Ion channels do this 
through opening pores which specifically allow charged ions to pass through the 
membrane, thereby causing a shift in charge. G-proteins act by triggering an 
intracellular cascade of interactions in response to extracellular binding of a 
ligand. Both ion channels and G-proteins have hundreds of subtypes which confer 
tissue and cell-specific functional properties. Some have critical roles within the 
CNS while others do not. Though ion channels and G-proteins are functionally quite 
different I have included them here in a single category because within the CNS, 
many neurotransmitters act as ligands at both types of receptor. For example, the 
GABA-A receptor is a chloride ion channel and the GABA-B receptor is a G-protein, 
but both receptors are agonised by GABA. CNS ion channels can be broadly divided 
into those that are triggered by electrical charge (voltage-gated) and those that 
are triggered by neurotransmitters (ligand-gated). Some ion channels have both 
properties. Voltage-gated ion channels are critical for the rapid transmission of 
electrical signals along neurones……………………………………………………………………………..
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Table 7.1a: Examples of ion channels and G-protein-coupled receptors associated with epilepsy 
Type of transmembrane 
receptor 
Gene Receptor and function Epilepsy phenotype(s) Reference 
Voltage-gated ion 
channel 
SCN1A Voltage-gated sodium channel. Allows 
membrane depolarisation during 
action potential 
Dravet syndrome and fever sensitive 
seizures 
(Claes et al., 2001) 
Ligand-gated ion channel GABRA1 GABA-sensitive chloride channel. 
GABA binding allows chloride entry 
into the neurone leading to 
hyperpolarisation and reduced 
excitability 
Wide range of phenotypes associated: 
rom severe neonatal-onset 
developmental and epileptic 
encephalopathy to adult onset 
generalised epilepsies  
(Johannesen et al., 2016) 
G-protein coupled 
receptor 
GABBR2 GABA-sensitive G-protein coupled 
receptor. 
Infantile spasms (Hamdan et al., 2017) 
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7.1.3 Growth and proliferation genes 
Developmental organisation of the brain structure is a process that relies on 
multiple cellular and intracellular signalling pathways. Variants in many of the 
genes involved in these pathways have been associated with epilepsy. Some of the 
best characterised are those with roles in cortical development, a process which 
involves the migration of neurones from the centre of the brain to the outer 
cortex. Disruption of this process can lead to characteristic malformations which 
may be identified on neuroimaging. Examples include the PAFAH1B1 (Saillour et 
al., 2009), DCX (Gleeson et al., 1998), and TUBA1A (Jansen et al., 2011). Variants 
in all these genes are associated with lissencephaly – a cerebral cortex with an 
absence of normal gyration – and epileptic seizures.  
Variants in other genes may result in disruption of neuronal growth and 
proliferation at a later stage in development. The mTOR pathway is a ubiquitous 
intracellular signalling pathway which is linked to the insulin receptor. Disruption 
of the mTOR pathway has been associated with a wide variety of metabolic, 
neoplastic and developmental disorders. Certain proteins within the mTOR 
pathway appear to be specifically important in CNS tissue, and variants in genes 
encoding these proteins associate with epilepsy. Examples include hamartin and 
tuberin (encoded by TSC1 and TSC2 respectively) which are associated with 
tuberous sclerosis, and Dep-domain containing protein 5 (DEPDC5) which is 
associated with focal epilepsies, not all of which have associated neuroimaging 
abnormalities (Lal et al., 2014). 
7.1.4 Synaptic genes 
The fully developed human central nervous system has an estimated 100 billion 
neurones, and 1,000 trillion synapses, which equates to an average of 10,000 
synapses per neurone. This extraordinary degree of connectivity is what gives the 
human brain a processing power that is unparalleled by even the most powerful of 
computers (Kunkel et al., 2014). In this context, it is not surprising that 
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orchestration of synaptic function is a highly complex process which is regulated by 
many genes, proteins and pathways. Ion channels and G-proteins are of critical 
importance at the synapse and these have been discussed. Other key functions of 
the synapse, including neurotransmitter release, synaptic vesicle recycling, and 
postsynaptic membrane organisation, underpin many genetic epilepsies. For 
example, docking and fusion of pre-synaptic vesicles is disrupted by variants in 
STXBP1, which encodes Syntaxin binding protein 1, and are associated with 
developmental and epileptic encephalopathy (Saitsu et al., 2008).  
7.1.5 Regulatory genes 
The final category of epilepsy-associated genes are those that are influence the 
expression of other genes through an effect on transcription, translation, or post-
translational modification. Many of these are transcription factors which bind to 
DNA and control (activating or repressing) which genes are transcribed within a 
particular cell type (Spitz & Furlong, 2012). The most well-known epilepsy-
associated transcription factor is MeCP2, a protein encoded by MECP2.  MeCP2 can 
both activate and repress transcription. Variants in MECP2 are associated with Rett 
Syndrome, an X-linked neurodevelopmental disorder characterised by cognitive 
impairment, drug-resistant seizures, and stereotypic hand wringing movements 
(Swanberg et al., 2009). Other epilepsy-associated transcription factors include 
TCF4 (associated with Pitt-Hopkins syndrome) (Rosenfeld JA et al., 2009) and ZEB2 
(Mowat-Wilson syndrome) (Dastot-Le Moal et al., 2007).  
The second major mechanism by which gene translation is regulated is through 
chromatin remodelling. Most of the time DNA is wrapped tightly around histone 
protein complexes to form chromatin. DNA must be exposed from the histone 
complex for transcription to take place. This is predominantly achieved through 
either covalent histone modification, or through ATP-dependent complexes which 
move, eject or restructure nucleosomes, the primary repeating unit of chromatin 
which consists of a segment of DNA sequence wrapped around eight histone cores 
(Saha, Wittmeyer & Cairns, 2006). Variants in genes encoding chromatin 
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remodelling proteins have been also been associated with epilepsy: Variants in 
CHD2 are associated with a developmental and epileptic encephalopathy with 
marked photosensitivity (Galizia et al., 2015), and variants in KANSL1, are 
associated with Koolen de Vries syndrome, a multi-organ malformation syndrome 
in which half of affected patients have epilepsy (Koolen et al., 2012; Myers et al., 
2017a). 
7.1.6 Blurring of boundaries 
Sections 7.1.1-5 present five categories of epilepsy-associated genes as if they are 
distinct and exclusive. Though this is helpful conceptually, the reality is no so clear 
cut. Some genes have multiple functions, some have functions that can be 
conceptualised in multiple ways, and others have not been fully characterised. 
Many IMDs, “ion channelopathies”, and “synaptopathies” are likely to have an 
impact on neuronal growth and proliferation as evidenced the neuroimaging 
findings that can be associated with these conditions. At times the distinction 
between “metabolic” and “ion channel” becomes challenging. For example, 
SLC6A1 encodes a transmembrane transporter of the small peptide GABA which 
removes GABA from the synaptic cleft. SLC6A1 related epilepsy could be 
considered a metabolic disorder (disrupted transport of small molecules) or an ion 
channel disorder, since the direct consequence of excess GABA within the synaptic 
cleft is likely to be an over activation of GABA receptors. 
The distinction between Ion Channel/G-protein disorders and Synapse-related 
disorders is particularly artificial since there is so much interaction between 
multiple ion channels, G-proteins and other synaptic proteins at every synapse. 
Nonetheless, because the ion channel disorders have been relatively well-
characterised, and because most examples of genetically driven precision therapy 
in epilepsy relate to this group, it is helpful to consider these disorders separately 
from the other synaptopathies. 
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7.1.7 Precision therapy 
In metabolic epilepsies, treatments can be targeted at the biochemical 
abnormality (e.g. replace the enzyme, restrict the diet, or supplement the 
deficient substrate). In ion channel disorders there is scope to modify neuronal ion 
channels with targeted therapy (e.g. sodium channel blocking drugs in SCN8A-
related seizures). In disorders of growth and proliferation pathways can be 
modified therapeutically (e.g. mTOR suppression with Everolimus for tuberous 
sclerosis). Though there as yet no examples of success, it is conceivable that 
therapeutic agents could be developed to target specific synapse-related 
epilepsies once the molecular pathways involved have been characterised. For 
epilepsies relating to disorders of transcriptional regulation precision therapy 
presents a particular challenge since there are no cellular pathways to target. 
Even targeting the underlying cause (the genetic defect) through gene therapy has 
proved challenging since transcriptional regulation involves a complex and fine 
balance between promotion and repression.  In MECP2-related Rett Syndrome gene 
therapy in mice has been hampered by the detrimental effects of over expression 
of MECP2 (Sinnett & Gray, 2017). Perhaps a first step to precision therapy in the 
disorders of transcriptional regulation is to understand what the key downstream 
regulated genes are, what the impact of the disease is on these, and whether any 
targetable pathways are revealed. 
7.1.8 SMC1A 
In chapter 6 (section 6.4.3.9) I identified a de novo nonsense mutation in SMC1A. 
This gene encodes a structural component of the cohesin ring, which is thought to 
be involved in transcriptional regulation through binding to chromatin. Through 
gene matching systems I was able to identify another 15 patients with epilepsy and 
loss of function variants in this gene as well as nine published cases. The aim of 
this chapter is to describe the phenotype of this condition and explore the 
potential for precision therapy for patients with epilepsy associated with variants 
in this gene.  
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7.2 Methods 
7.2.1 Case ascertainment 
The Deciphering Developmental Disorders study (DDD) is a UK-wide multicentre 
project involving 23 recruitment centres which encompass all regional genetics 
departments within the UK NHS. Inclusion criteria for this study were any one of 
the following: 
- Neurodevelopmental disorder 
- Congenital anomalies 
- Abnormal growth parameters (weight, height, head circumference) 
- Dysmorphic features 
- Unusual behavioural phenotype 
- Genetic disorder for which the molecular basis is unknown 
Most participants to DDD were recruited as “trios” (both patents and affected 
proband). Basic phenotype information was collected and coded in Human 
Phenotype Ontology (HPO) terms (Kӧhler et al., 2017). Genetic testing involved 
Whole Exome Sequencing, which was carried out at the Hinxton Sanger Institute in 
Cambridge (Firth et al., 2011). 
Though personal correspondence with the DDD project leaders at the Sanger 
Institute I was given the contact details of eight clinical geneticists who had 
recruited patients to the DDD study in whom de novo truncating variants in the 
SMC1A gene had been identified among the first 4,293 families analysed (McRae et 
al., 2017). All of these patients were females with epilepsy. Because this was 
deemed to be a novel genotype-phenotype association I was granted a 
“Complementary Analysis Protocol (CAP)” which, within the overall protocol and 
ethical framework of the DDD study, permitted me to collect additional phenotype 
information directly from clinicians. 
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I published genotype and phenotype details of these patients in February 2017 
(Symonds et al., 2017).  Following this publication, I received personal 
correspondence about another six patients. I identified a further patient through 
my WGS study, described in section 6.3.4.9. There are also nine patients with 
SMC1A truncation variants published elsewhere (Helbig et al., 2016; Lebrun et al., 
2015, Goldstein et al., 2015; Jansen et al., 2016; Hansen et al., 2013; Gorman et 
al., 2017).    
7.2.2 Ethical approval 
The Deciphering Developmental Disorders (DDD) study has United Kingdom 
Research Ethics Committee approval (10/H0305/83, granted by the Cambridge 
South REC). 
7.2.3 Clinical information 
I created a structured phenotype form, which was sent to both the clinical 
geneticist and the paediatric neurologist involved in each case (Appendix 16). 
7.2.4 Genetic information 
Original genetic reports were requested. SMC1A variants were described with 
reference to human genome build GRCh37 (Hg19) SMC1A transcript 0066306.3, 
which is the canonical transcript. 
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7.3 Results 
7.3.1 Cases and ascertainment 
25 patients were identified in total (16 new and nine published, see table 7.3a). 
Patients 1-8 were from the DDD study. As per the protocol of that study, the 
SMC1A variants in these cases were detected by trio Whole Exome Sequencing. 
Patient 9 was the affected sister of patient 8. She died at the age of 11 months 
and was tested, by Sanger method, for the variant present in her sister post 
mortem. Patient 11 was recruited to the Whole Genome Sequencing (WGS) study 
described in chapter 6 of this thesis, and patients 10, 12, 13, 14, 15, and 16 all had 
their SMC1A variants identified in different clinical or research laboratories. 
7.3.2 Estimated incidence of SMC1A-related epilepsy 
Analysing the first 4,293 families in the DDD study, the authors estimated that 42% 
of the cohort carried a disease causing de novo variant. They estimated that a de 
novo variant can be expected to result in a developmental disorder in between 1 in 
213 and 1 in 448 births. Since eight patients with SMC1A-related epilepsy were 
among these 4,293 families, extrapolating from their estimates, the incidence of 
SMC1A-related epilepsy would be expected to be between 1 per 50,000 and 1 per 
100,000 births. 
7.3.3 Genetic findings 
SMC1A encodes a 1,233 amino acid protein called smc1 (structural maintenance of 
chromosomes 1), which is a structural component of the cohesin ring (Rocques et 
al., 1995). 
All 25 variants were novel, and all were predicated to result in truncation of the 
smc1 protein: 10 nonsense, 10 frameshift, and five splice interference. De novo 
status of the variant was demonstrated in 23/25 patients.……
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Table 7.3a: Summary of the phenotypic features of 16 new patients and the 9 published patients with SMC1A truncations 
Patient Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 
SMC1A variant c.1591C>T 
p.Gln531Ter 
 
Nonsense 
c.3145C>T 
p.Arg1049Ter 
 
Nonsense 
c.549G>A 
pGlu183Glu 
 
Splice interference 
c.2197G>T 
p.Glu733Ter 
 
Nonsense 
c.3326_3330delATGG
C insC 
p.Asp1109AlafsTer102 
Frameshift 
c.2923C>T 
p.Arg975Ter 
 
Nonsense 
c.511C>T 
p.Arg171Ter 
 
Nonsense 
c.2477delA 
p.Asn826Thrfs*3 
 
Frameshift 
Inheritance of 
variant 
De novo De novo De novo De novo De novo De novo De novo De novo 
Method of testing DDD study DDD study DDD study DDD study DDD study DDD study DDD study DDD study 
Age at completion 
of phenotype form 
6 years 6 years 3 years 8 years 10 years 5 years 4 years 14 years 
Birth OFC Z-score/ 
most recent OFC 
Z-score 
-0.8/-3.5 -1.5/-4.5 -1.6/-0.8 -2.0/-2.5 -1.2/-2.0 Unknown/-3.0 Unknown/-2.0 Unknown/-2.0 
Most recent height 
Z-score 
-2.3 -2.6 0.06 -2.6 -4.5 -3.2 -2.5 -3.7 
Tone Hypotonia Hypotonia Axial hypotonia, 
peripheral 
hypertonia 
Hypotonia Hypotonia Hypotonia Hypotonia, with 
increased dynamic 
tone at ankles 
Unknown 
Cognitive ability Moderate – severe 
impairment 
Severe impairment Severe impairment Severe impairment Severe impairment Moderate – 
severe 
impairment 
Moderate – severe 
impairment 
Moderate – severe 
impairment 
Gross motor 
development 
Can run with 
unsteady gait 
Unable to sit 
without support 
Unable to sit 
without support 
Non-ambulant Unable to sit without 
support 
Walking from 30 
months 
Can take a couple 
of steps with 
support 
Walking from 2.5 
years. Unsteady on 
feet with frequent 
falls, aged 7 
Speech Non-verbal. Smiles 
and makes hand 
gestures 
Non-verbal. Non-verbal Non-verbal Non-verbal Lost speech 
aged 3 years 
following SE 
Non-verbal. Coos, 
laughs, cries 
appropriately 
Non-verbal. 
Communicates 
through signing 
Autism - - - + - - - + 
Age at first 
seizure 
15 months 5-6 weeks 4 months 5 months 6 months 5 months 4 weeks 28 months 
First seizure 
semiology 
Cluster of GTCS GTCS Generalised tonic Focal→bilateral 
clonic 
Cluster of GTCS Focal→bilateral 
tonic 
Bilateral clonic FS 
Further seizure 
types 
GTCS, hemiclonic, 
drop attacks, 
atypical absence 
Focal FS, CSE, focal, 
myoclonic, spasms, 
atypical absence 
Focal, generalised 
tonic 
GTCS, myoclonic, 
atypical absence, 
tonic, spasms, NCSE, 
reflex sensory 
Focal→bilateral 
tonic 
focal→bilateral 
clonic 
GTCS, hemiclonic GTCS 
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Patient Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 
Seizure clusters? + - + + + + + + 
Seizure freedom? No Yes, aged 5 years No Yes, aged 7 years No For 1 year then 
recurred 
No No 
Therapies tried PHT, VPA, LEV, 
LMT, CLB, TPM, 
CBZ 
CBZ, VPA, TPM, 
CLB, RUF, LEV, 
GBP KD, VNS 
GBP, AZA, CZP, 
LZP, VPA, LEV, 
Pyridoxine, STP 
VPA, LMT, CBZ, 
TPM, LEV, PHT, 
CLB, PB 
PB, CBZ, CLB, VPA, 
LMT, TPM, LEV, 
Pyridoxine, KD 
CBZ, VPA, TPM, 
PB, LEV, KD 
TPM, VPA, LEV, 
CBZ 
PB, LEV, TPM, LMT, 
CBZ, CLB, VNS, KD 
Beneficial 
therapies 
VPA, PHT, CBZ GBP (seizure-free) STP PB (seizure-free) CLB, KD LEV (seizure-
free for 1 year), 
KD 
None KD 
EEG Independent left 
and right sided 
epileptiform 
abnormalities 
Diffusely slow with 
sharp transients 
seen over both 
temporal regions 
High amplitude 
background 
activity with 
epileptiform 
discharges over 
left and 
occasionally right 
hemisphere 
Multifocal epileptic 
activity 
Continuous high 
voltage waves 
without epileptiform 
discharges 
High voltage 
slow background 
Frequent multi-
spike and slow 
right centro-
temporal region 
Right-sided spike 
and slow wave 
abnormalities 
MRI(s) Normal Cerebral volume 
loss 
Small hemorrhage 
along the posterior 
falx and tentorium 
Normal Small cavum septum 
vergae 
Normal  Normal Normal 
Dysmorphisms and 
skeletal anomalies 
Mild facial 
asymmetry with 
the right side of 
the face appearing 
fuller than the 
left; mild left 
ptosis; short, 
slightly up-turned 
nose; thin upper 
lip; shallow 
philtrum; small 
hands and feet 
Bitemporal 
narrowing; 
upslanting 
palpebral fissures; 
thin, straight 
eyebrows; mildly 
posteriorly rotated 
ears; tapering of 
digits; short 5th 
fingers; short 
broad halluces; 
overlapping 2ndand 
3rd toes 
Hirsutism of the 
forehead, back, 
arms and upper lip; 
bitemporal 
narrowing with low 
anterior hairline; 
long eyelashes; 
downturned corner 
of mouth with 
midline groove of 
the lower lip 
Small widely 
spaced teeth; 
deep-set eyes; 
downward sloping 
palpebral fissures; 
short, slightly up-
turned nose; 
shallow philtrum; 
low-set posteriorly 
rotated ears; 
syndactyly of the 
1st and 2nd toes 
Deviation of both 
halluces at the 
metatarso-phalangeal 
joint; left 3rd finger 
camptodactyly; left 
5th finger clinodactyly 
Puffy eyes; right 
nasal deviation; 
small over-
folded right 
pinna; short, 
slightly upturned 
nose; thin upper 
lip; shallow 
philtrum; 
clinodactyly of 
the middle toes 
of both feet; 
central incisor. 
None None 
Malformations None Bilateral 
congenital hip 
dysplasia; bilateral 
talipes; bifid T8 
vertebra 
Cleft palate; 
multiple small 
cysts in kidneys 
ASD; VSD Bifid T6 vertebra; 
ASD; choanal atresia 
Cleft palate None None 
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Patient Patient 9 Patient 10 Patient 11 Patient 12 Patient 13 Patient 14 Patient 15 Patient 16 
SMC1A variant c.2477delA 
p.Asn826Thrfs*3 
 
Frameshift 
c.3115C>T 
p.Gln1039Ter 
 
Nonsense 
c.2923C>T 
p.Arg975Ter 
 
Nonsense 
 
 
 
Frameshift 
c.615G>A 
p.Glu205Glu 
 
Splice interference 
c.1495C>T 
p.Arg488Ter 
 
Nonsense 
c.3305_3312del 
p. Asn1102ArgfsTer53 
 
Frameshift 
c.3321C>A 
p.Tyr1107Ter 
 
Nonsense 
Inheritance of 
variant 
De novo De novo De novo De novo De novo Absent from 
mother 
De novo Unknown 
Method of 
testing 
Sanger testing for 
variant identified 
in sibling (Patient 
8) 
Clinical Exome 
Testing (Germany) 
Whole Genome 
Sequencing 
(Chapter 6) 
Cornelia de Lange 
gene panel 
(Edinburgh) 
71 gene epilepsy 
panel (USA) 
WGS (Ireland) Clinical Exome Testing 
(India) 
Clinical Exome 
Testing (UK) 
Age at 
completion of 
phenotype 
form 
Died aged 11 
months 
Died aged 9 years 2 
months 
16 years 7 years 6 months 10 years 4 years 2 years 7 months 25 years 
Birth OFC Z-
score/most 
recent OFC Z-
score 
-1.7/Unknown -1.3/-6.3 Unknown/-5.3 -1.9/-7.8 Unknown/unknown 
(reportedly normal) 
Unknown/-2.1 Unknown/-2.71 Unknown/Unkno
wn 
Most recent 
height Z-score 
Unknown -5.0 -3.59 -4.0 Unknow (reportedly 
normal) 
Unknown 0.00 Unknown 
Tone Unknown Neonatal hypotonia 
 
Axial hypotonia, 
peripheral 
hypertonia 
Hypotonia Axial hypotonia, 
peripheral 
hypertonia 
Axial hypotonia, 
peripheral 
hypertonia 
Hypotonia Normal 
Cognitive 
ability 
Profound 
impairment 
Severe impairment Profound 
impairment 
Profound 
impairment 
Severe impairment Moderate – severe 
impairment 
Profound impairment Borderline 
impairment 
Gross motor 
development 
No head control Unable to sit Can sit 
independently 
Never able to walk 
Unable to sit  Walked at 13 
months. Ataxic gait 
Walked at 3 years. 
Ambulant now. 
Ataxia 
Ambulant. Ataxia Normal 
development. 
Bilateral pes 
cavus 
Speech N/A Non-verbal Non-verbal Non-verbal Loss of all language 
at 18 months. Now 
non-verbal 
Non-verbal One word with 
meaning 
Normal 
Autism - - - - + - + - 
Age at first 
seizure 
< 1 month 2 months 5 months 3 weeks 13 months 3 years 10 months 12 years 
First seizure 
semiology 
Unknown GTCS GTCS GTCS Focal Focal Infantile spasms Focal 
Patient Patient 9 Patient 10 Patient 11 Patient 12 Patient 13 Patient 14 Patient 15 Patient 16 
Further seizure 
types 
Unknown Myoclonic, CSE Spasms, atypical 
absence 
Focal, myoclonic  GTCS, Atonic Focal GTCS, 
myoclonic, CSE 
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Seizure 
clusters? 
- - + + + - - + 
Seizure 
freedom? 
No No No No No No No No 
Therapies tried Unknown TPM, VPA, LEV, 
RUF 
LEV, VPA, NZP CBZ, VPA, PHT, 
LEV, TPM, LMT, 
PRP 
VPA, LMT, ZNS, KD, 
VNS 
OXC, TPM, VPA, 
LCS, CLB 
VGB, VPA, ZNS, TPM, 
LEV, ACTH, KD 
CLB, TPM, VPA, 
CBZ, LEV, PHT, 
LMT, LCS, PRP, 
PB 
Beneficial 
therapies 
Unknown None LEV, VPA None LEV, KD, VNS VPA, LCS, CLB ACTH, VGB LEV, PHT 
EEG Unknown Multifocal 
epileptogenic 
activity, more 
often over the right 
hemisphere 
Focal 
frontotemporal 
sharp waves 
Focal sharp waved 
independently on 
left and right 
Left temporal 
epileptiform spike 
discharges, 
spreading to the 
right during a 
seizure 
Focal epileptiform 
discharges 
Bisynchronous bursts 
of spike-wave activity 
Right anterior 
focal 
epileptiform 
discharges 
MRI(s) Semilobar 
holoprosencephaly 
Thin abnormally 
shaped corpus 
callosum and 
minimal cerebral 
atrophy 
Mild asymmetric 
posterior white 
matter volume loss 
Normal  Normal T2 hyperintensity 
in the posterior 
periventricular 
white matter 
without volume 
loss. Slightly 
immature 
myelination 
Normal Normal 
Dysmorphisms 
and skeletal 
anomalies 
Hypotelorism; small 
low-set posteriorly 
rotated ears; 
bilateral 5th finger 
clinodactyly; 
overlapping 4th and 
5th fingers; left 
rockerbottom foot; 
hypoplastic nails of 
the 4th and 5th toes 
Expressionless 
face, straight 
eyebrows; short, 
upturned nose; 
flattened midface; 
short philtrum; 
downturned 
corners of the 
mouth; small hands 
with tapering 
fingers 
None Low anterior 
hairline 
None None Short neck, high nasal 
bridge, upturned nose, 
long eyelashes, 
flattened midface, 
shallow philtrum, 
small hands 
None 
Malformations Partial anomalous 
pulmonary venous 
drainage 
ASD; VSD None None None None None None 
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Paper and case Hansen 
(Hansen et al., 
2013) 
Lebrun 
(Lebrun et al., 
2015) 
Goldstein 1 
(Goldstein et 
al., 2015) 
Goldstein 2 
(Goldstein et al., 
2015) 
Jansen 1 
(Jansen et al., 
2016) 
Jansen 2 
(Jansen et al., 2016) 
Helbig 
(Helbig et al., 
2016) 
Gorman 1 
(Gorman et 
al., 2017) 
Gorman 2 
(Gorman et al., 
2017) 
SMC1A variant c.1731G>A 
p.Asp577Asp 
 
Splice 
interference 
c.1911+1G>T 
 
 
Splice 
interference 
c.2853_2856delT
CAG 
p.Ser951Argfs*12 
Frameshift 
c.3549_3552dupG
GCC 
P.Ile1185Glyfs*23 
Frameshift 
c.2364del 
Asn788Lysfs*10 
 
Frameshift 
c.2421_2562del 
Leu808Argfs*6 
 
Frameshift 
c.3549_3552d
upGGCC 
p.I1185Gfs*23 
Frameshift 
c.1114delG 
p.Val372Ter 
 
Nonsense 
c.1113+1G?A 
 
 
Splice 
interference 
Inheritance of 
variant 
De novo De novo De novo De novo De novo De novo De novo De novo De novo 
Method of 
testing 
323 gene 
epilepsy panel 
(Germany) 
Whole Exome 
Sequencing 
(France) 
Whole Exome 
Sequencing 
(USA) 
Whole Exome 
Sequencing (USA) 
Whole Genome 
Sequencing 
(Netherlands) 
Whole Genome 
Sequencing 
(Netherlands) 
Not reported Whole Exome 
Sequencing 
(Ireland) 
Whole Exome 
Sequencing 
(Ireland) 
Current age 
(age at report) 
11 years 7 years 4 years 3 years 46 years 14 years Not reported Died at 9 
months 
Died at 3 years 
Birth OFC Z-
score/most 
recent OFC Z-
score 
Unknown/-2.5 -3.9/-2.5 Unknown/-2.0 -1.0/0.0 Unknown/-2.5 Unknown/-1.7 Not reported 0.00/-2.5 Unknown/-2.5 
Most recent 
height Z-score 
-0.5 -2.0 Unknown -0.05 -2.5 -2.0 Not reported Not reported Not reported 
Tone Not reported Axial hypotonia, 
peripheral 
hypertonia 
Axial hypotonia, 
peripheral 
hypertonia 
Not reported Axial hypotonia, 
peripheral 
hypertonia 
Normal Not reported Profound 
hypotonia 
Profound 
hypotonia 
Cognitive ability Impairment, but 
not qualified 
Severe 
impairment 
Severe 
impairment 
Severe 
impairment 
Severe 
impairment 
Severe impairment Not reported N/A Severe 
impairment 
Gross motor 
development 
Walked at 18 
months 
Delayed Non-ambulant Walked at 12 
months 
Never crawled 
or walked 
Walked at 2y; 
suddenly stopped 
walking at 5 years 
Not reported No head 
control at 9 
months 
Non-ambulant 
Speech First words at 30 
months 
Non-verbal Non-verbal Non-verbal. Coos, 
interacts. 
Non-verbal Non-verbal Not reported N/A Non-verbal 
Autism - - - - - - Not reported N/A N/A 
Age at first 
seizure 
3 months < 1 month 4 months 17 months 9 months 2 years Not reported 17 weeks 7 weeks 
First seizure 
semiology 
GTCS Focal with eyelid 
myoclonia 
Generalised 
tonic 
Focal/atypical 
absence, GTCS 
GTCS GTCS Not reported Focal Focal 
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Paper and case Hansen 
(Hansen et al., 
2013) 
Lebrun 
(Lebrun et al., 
2015) 
Goldstein 1 
(Goldstein et 
al., 2015) 
Goldstein 2 
(Goldstein et al., 
2015) 
Jansen 1 
(Jansen et al., 
2016) 
Jansen 2 
(Jansen et al., 2016) 
Helbig 
(Helbig et al., 
2016) 
Gorman 1 
(Gorman et 
al., 2017) 
Gorman 2 
(Gorman et al., 
2017) 
Further seizure 
types 
Focal Focal, spasms Tonic, 
focal→bilateral 
clonic, CSE 
Focal/atypical 
absence, GTCS 
GTCS GTCS Not reported  Tonic, spasms, 
GTCS,  
Seizure 
clusters? 
+ - + + + + Not reported - + 
Seizure 
freedom? 
Not reported No No Yes No No Not reported No No 
Therapies tried Not reported Unknown PB, LEV, CLB, 
TPM, CZP, VPA, 
KD 
LEV, TPM, OXC, 
VPA, PB 
PHT, PB, CBZ, 
VPA, VGB, CZP 
LMT, TPM, CBZ, CLB, 
LEV, CZP, OXC, 
Carnitine, Pyridoxine, 
KD, Oestrogen 
Not reported VPA, CBZ, 
TPM, PHT, KD 
Not reported 
Beneficial 
therapies 
Unknown Unknown None None None Oestrogen Not reported None None 
EEG Nonspecific 
monomorphic 
generalized 
slow-wave 
activity with 
rare spikes 
Hypsarrhythmia 
(when presented 
with infantile 
spasms) 
Multifocal 
epileptiform 
discharges 
Generalised 
epileptiform 
activity or 
occipital 
abnormalities 
“centrencephali
c” epilepsy 
Unknown Not reported Multifocal 
migrating 
epileptiform 
discharges 
Slow 
background, left 
temporal 
epileptiform 
discharges 
MRI(s) Not reported Thin corpus 
callosum 
Mild symmetric 
T2 
hyperintensities 
in the periatrial 
white matter on 
FLAIR sequencing 
with possible 
thickening of the 
insular cortex 
Mild enlargement 
of extra-axial 
spaces; slight 
thinning of the 
corpus callosum. 
Temporal lobes 
prominent sulci 
and hippocampi 
round and 
somewhat 
smaller. 
Slightly 
enlarged 
ventricles, 
hypotrophy 
cerebellar 
vermis 
Mild periventricular 
white matter 
abnormalities 
Not reported Not reported Not reported 
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Paper and case Hansen 
(Hansen et al., 
2013) 
Lebrun 
(Lebrun et al., 
2015) 
Goldstein 1 
(Goldstein et 
al., 2015) 
Goldstein 2 
(Goldstein et al., 
2015) 
Jansen 1 
(Jansen et al., 
2016) 
Jansen 2 
(Jansen et al., 2016) 
Helbig 
(Helbig et al., 
2016) 
Gorman 1 
(Gorman et 
al., 2017) 
Gorman 2 
(Gorman et al., 
2017) 
Dysmorphisms 
and skeletal 
anomalies 
Round face with 
arched 
eyebrows; short 
nose; upslanting 
palpebral 
fissures; 
smoothed 
philtrum; mild 
retrognathia; 
crowded 
teeth; flattened 
midface; 
clinodactyly of 
the fifth 
fingers; 
camptodactyly 
of the fifth 
finger on the 
right 
Mild synophrys; 
small hands; 
small feet; thin 
nose and upper 
lip; retrognathia; 
triangular face 
Long eyelashes; 
short nose; 
hirsutism on legs 
and back 
None Low anterior 
hairline; flat 
midface; 
straight 
eyebrows with 
deep set eyes; 
small and 
elongated ears 
with a 
prominent anti-
helix; long 
nose; short 
philtrum; 
eversion of the 
lower lip; 
disorganized 
dentition; 
small, narrow 
hands with 
tapering 
fingers; 
syndactyly of 
the 2nd and 3rd 
toes and a 
mildly broad 
first toe 
Mild trigonocephaly; 
mildly up slanting 
palpebral fissures with 
blepharophimosis; 
posteriorly rotated 
Ears; full cheeks, full 
lips and short 
philtrum; hands small 
with slender fingers 
Not reported None Small hands and 
feet; incomplete 
single palmar 
creases; big 
hallux bilaterally 
extended 
Malformations Diaphragmatic 
hernia 
None None None Cleft palate None Not reported None ASD 
Abbreviations: GTCS – generalised tonic-clonic seizure; FS – Febrile Seizure; CSE – Convulsive Status Epilepticus; NCSE – Non-Convulsive Status Epilepticus; PHT – Phenytoin; VPA – Sodium Valproate; 
LEV – Levetiracetam; LMT – Lamotrigine; CLB – Clobazam; TPM – Topiramate; CBZ – Carbamazepine;  RUF – Rufinamide; GBP – Gabapentin; ZNS – Zonisamide;  KD – Ketogenic Diet; VNS – Vagal Nerve 
Stimulation; PB – Phenobarbitone; OXC – Oxcarbazepine; VGB – Vigabatrin; CZP – Clonazepam; ACTH – Adrenocorticotrophic hormone; OXC – Oxcarbazepine; LCS – Lacosamide; PRP – Perampanel; ASD - 
Atrial Septal Defect; VSD – Ventricular Septal Defect 
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7.3.4 Phenotype 
7.3.4.1 Seizures 
Patients presented with a variety of seizure types (generalised in 12, focal in nine, 
epileptic spasms in one, unknown in three). 17 patients developed multiple seizure 
types. Age of seizure onset ranged from the neonatal period to 12 years of age 
(median five months). Distribution of age at first seizure is shown in figure 7.3a. 
Patient 16, who presented at 12 years of age, was a clear outlier. 
 
Figure 7.3a: Distribution of age at first seizure for patients with SMC1A 
truncations 
Seizure types observed were: focal (n = 15), GTCS (n = 15), epileptic spasms (n = 
6), atypical absence (n = 5), myoclonic (n = 6), tonic (n = 5), convulsive status 
epilepticus (n = 4) and drop/atonic (n = 3). Epileptic spasms, though the presenting 
seizure type in just one case, developed following other seizure types in four 
cases. This pattern is slightly unusual. For most children who develop epileptic 
spasms this is their first seizure type. Among 43 patients who had epileptic spasms 
in cohort 2 (chapter 5), for 27 (63%) spasms were the presenting seizure type. 
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Though there was wide variability in the seizure types observed in this cohort, a 
specific feature of the seizures that was noted as a common theme was the 
tendency for seizures to occur in clusters. For 16/22 patients for whom seizure 
characteristics were described a clustering pattern to seizures was reported. For 
some of the patients I was able to obtain a more detailed description of the 
seizure clustering: 
• Patient 6: 3-10 focal-onset seizures occur over a 24 hour period every 10-21 
days, with complete seizure-freedom between clusters. 
• Patient 8: 15-25 GTCS occur over a 2-3 day period every 2-3 weeks, with 
complete seizure freedom between clusters. During the seizure clustering 
period she is unable to communicate or mobilise and she stops eating. 
• Patient 11: 14-20 seizures over a 2-3 day period every 8-12 weeks, with 
complete seizure freedom between clusters. 
• Patient 12: Clusters of focal-onset seizures with many per day over a 3-5 
days period, with weeks or months of seizure-freedom between clusters. 
Among the published cases too there are descriptions of seizure clustering: 
• Hansen et al.: “The girl had generalized tonic–clonic seizures, occasionally 
occurring in impressive clusters lasting 24–48 h as well as clusters of seizures 
with secondary generalization” (Hansen et al., 2013). 
• Goldstein et al., patient 1: “By 4 years of age, her seizure frequency 
consisted of clusters of 6-7 seizures every one to two weeks” (Goldstein et 
al., 2015). 
• Jansen et al. Both patients reported to have “clusters of GTCS” 
• Gorman et al. Both patients reported to have “clusters of focal seizures” 
(Gorman et al., 2017).  
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7.3.4.2 Electroencephalogram (EEG) 
For 22 patients, EEG recordings, reports, or summaries were available. Though 
there was not a consistent EEG signature. Sixteen patients had at least one EEG 
demonstrating focal or multifocal epileptiform discharges. For two patients 
(patient 15 and the patient reported by Lebrun et al. the only EEG data provided 
was during an episode of infantile spasms, and this demonstrated generalised 
epileptiform abnormalities. Illustrative EEG recordings are shown in Figure 7.3b. 
7.3.4.3 Development and cognition 
Developmental impairment was reported in 24/25 patients for whom information 
was available. In all cases, apart from those with neonatal-onset seizures, 
concerns about development were present prior to presentation with seizures. In 
21/24 cases development was assessed as being moderately, severely, or 
profoundly impaired. Specifically, verbal communication appeared to be affected, 
with 19/22 of the patients who survived to the age of usual speech acquisition 
having no verbal communication. Gross motor development was also affected in 
most cases: nine patients were non-ambulant.    
For four patients I was able to gather evidence of developmental or cognitive 
regression, though this did not clearly relate to seizure onset. Patient 6 lost her 
ability to speak following an episode of convulsive status epilepticus at the age of 
three years, the second patient reported by Jansen et al. had an abrupt loss of 
ambulation at the age of five years. The parents of Patient 13 noticed a rapid 
decline in development from the age of 18 months. She had complete loss of 
language skills, having had a number of single words prior to that. Patient 16 is 
exceptional in that she presented at the age of 12 years and there had been no 
concerns about her early childhood development. She completed mainstream 
school education and went to university. She has clusters of GTCS once per month, 
often resulting in admissions to the Intensive Care Unit, and there has been a 
gradual decline in her cognitive functioning to borderline-low levels. 
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Figure 7.3b: Illustrative EEGs of 
patients with SMC1A truncations 
(A) Inter ictal sleep EEG from Patient 
1: showing generalised irregular 
spike/sharp and slow activity in sleep 
without any clinical accompaniment; 
(B) Inter ictal EEG from Patient 6: 
showing short bursts of mixed spike 
and slow waves with a bilateral but 
asymmetric distribution; (C) Ictal EEG 
from Patient 6 during a focal-onset 
seizure: showing generalized spike and 
slow wave activity; (D) Inter ictal EEG 
from Patient 10: showing irregular 
spike/sharp and slow wave activity, 
more prominent in the left temporal 
and occipital region; (E) Ictal EEG from 
Patient 10: showing right sided sharp 
waves and left sided slow waves. 
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7.3.4.4 Growth parameters (with reference to World Health Organisation [WHO] 
growth charts) 
The overall picture is one of short stature and progressive microcephaly. The short 
stature observed was in proportion to head circumference (Figure 7.3c). Birth 
occipital-frontal circumference (OFC) measurement was available for ten patients. 
All were below the mean, though only 2/10 had a birth OFC of ≤-2 z-scores. Mean 
birth OFC was -1.8 z-scores (standard deviation [SD] 0.87). Most recent OFC was 
available for 20 patients and for 17/20 this was ≤-2 z-scores. Mean most recent 
OFC was -2.9 z-scores (SD 1.8), which was significantly lower than birth OFC (2 
sample t-test, p = 0.018). Birth length was not available for any of the patients. 
Most recent height was available for 15 patients of whom 12 had a z-score ≤-2. 
Mean most recent height was -2.6 z scores (SD 1.5) and this was not significantly 
different from most recent OFC (2 sample t-test, p>0.05). 
7.3.4.5 Additional features 
Abnormalities of muscle tone were reported in 17/24 patients for whom 
information was available: Eight had a combination of axial hypotonia and 
peripheral hypertonia and nine had hypotonia only. 
Dysmorphic features were reported in 16/24 patients for whom information was 
available. The features reported were variable. In no case was the appearance 
considered to be characteristic of CdLS.  I reviewed the photographs of four 
patients with a consultant clinical geneticist (SJ) and we concluded that common 
features included a flattened mid-face, a short, upturned nose, and a shallow 
philtrum (Figure 7.3d). 
10 patients had congenital anomalies, including five with cardiac defects, three 
with cleft palate, two with bifid vertebrae, and one each with bilateral talipes, 
cystic kidneys, choanal atresia, semilobar holoprosencephaly, and diaphragmatic 
hernia.  
290 
 
MRI brain reports were available for 21 patients, with nine reportedly normal. 
Patient 9 had semilobar holoprocencephaly. The other 11 abnormal scans 
demonstrated non-specific findings, including thin or abnormally shaped corpus 
callosum (n = 3), white matter signal change (n = 3) and cerebral volume loss (n = 
7).
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Figure 7.3c: Growth parameters of patients with SMC1A truncations 
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Figure 7.3d: Facial appearances of patients with SMC1A truncations; from left to right, patients 6, 4, 8 and 10. Figure as 
published appears in Epilepsia publication (Symonds et al., 2017) - republished here with permission of Wiley and Sons 
publishers. Written consent obtained from parents of all participants.
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7.3.5 Therapy response 
In the phenotype form clinicians were asked to report all medications or other 
therapies (such as Ketogenic Diet, Vagal Nerve Stimulation or surgery) used, and to 
highlight any that had been associated with a notable decrease in seizure 
frequency. These sections of the form were completed for 15/17 of the new 
patients. All 15 had drug-resistant epilepsy. Between the 15 patients 96 therapy 
trials had taken place (mean 6.4 per patient), 24 of which were reported to be 
successful. 
Eight therapies were trialled in more than five patients (Figure 7.3e). Of these, the 
most successful were: Ketogenic Diet (4/6 responded), Sodium Valproate (5/13) 
and Levetiracetam (5/14). Topiramate was trialled in 12 patients and was 
successful in none of them. Trails of Carbamazepine, Clobazam and Lamotrigine 
were also undertaken in five or more patients without any reports of success. 
The only therapy that was significantly more successful than other therapies was 
the Ketogenic Diet (Fisher’s exact, p = 0.043, Odds ratio 6.3, 95% Confidence 
intervals 1.1-37.0).  
Isolated cases of dramatic therapy responses were reported in the case of patient 
2 (became seizure free after starting Gabapentin), patient 4 (became seizure-free 
after starting Phenobarbital), and Patient 6 (seizure-free for 12 months after 
starting Levetiracetam). 
Among the nine patients reported in the literature, medication response was 
reported in five. All were had drug-resistant seizures. In contrast to the new cases, 
three patients had been treated with the Ketogenic Diet without apparent benefit. 
Among the five case reports only one successful treatment is described. The 
second patient reported by Jansen et al. was commenced on hormonal therapy 
with oestrogen, in view of the fact that her seizures occurred in clusters every four 
weeks. The authors reported that this therapy “appeared to have a positive effect 
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on seizure frequency and that seizure clusters by the age of 14, when still on 
oestrogen therapy, were occurring every eight weeks (Jansen et al., 2016).” 
 
Figure 7.3e: Therapy trials applied to five or more patients with SMC1A 
truncation; Abbreviations: KD – Ketogenic Diet; VPA – Sodium Valproate; LEV – Levetiracetam; 
LMT – Lamotrigine; CLB – Clobazam; TPM – Topiramate; CBZ – Carbamazepine 
Table 7.3b: Ketogenic Diet response in the six patients with SMC1A truncation 
for whom it was trialled 
Patient Ketogenic Diet response 
2 Introduced aged 2 years, tried for 12 months then withdrawn, no reported benefit 
5 Introduced aged 4 years. Allowed 2 AEDs (Clobazam and Phenobarbital) to be 
weaned 
6 Introduced aged 3 years. Associated with decrease in seizure cluster frequency 
from once per 2 weeks to once per 6 months 
8 Introduced aged 16 years. Associated with decrease in seizure cluster frequency 
from once per 2 weeks to once per 6 weeks 
13 Introduced aged 3 years. Associated with improved seizure control and 
developmental progress 
15 Used but no reported benefit 
  
0
2
4
6
8
10
12
14
16
KD VPA LEV TPM CBZ CLB LMT
Beneficial Not beneficial
295 
 
7.4 Discussion 
7.4.1 A novel neurodevelopmental syndrome 
Analysis of these 25 patients has allowed delineation of a distinct X-linked 
neurodevelopmental disorder associated with truncating variants in the SMC1A 
gene. This condition is restricted to females. Males with truncations may be non-
viable. The evidence that these variants are causative of the phenotypes observed 
is strong: all the variants are predicted to result in truncation of the smc1 protein; 
truncating variants of SMC1A are not observed at all in the ExAC database (The 
Broad Institute Exome Aggregation Consortium, 2018); and there is a broad 
similarity between the phenotypes reported.  The most notable features are drug-
resistant epilepsy, progressive microcephaly, short stature, and tone abnormalities 
consisting of axial hypotonia with or without peripheral hypertonia. In several 
patients a notable pattern of seizure clustering is observed. Since eight of the 
patients were ascertained from the DDD study – which had broad inclusion criteria 
and in which only 24% of participants overall had seizures, and since no patients 
with SMC1A truncation variants who did not have drug-resistant epilepsy (DRE) 
were identified in the DDD study (Wright et al., 2015) – it can be concluded that 
the penetrance of SMC1A for a DRE phenotype is strong. 
7.4.2 Cohesinopathy 
SMC1A encodes the smc1 protein. Smc1 is a structural component of the cohesin 
complex (Musio et al., 2006). This is a multi-protein ring-shaped structure which is 
composed of four proteins: smc1, smc3, scc1, and sa. The cohesin complex binds 
to DNA and regulates its interaction with chromatin. The complex is believed to 
have diverse roles in cell division, transcriptional regulation and DNA repair 
(Horsfield, Print & Mӧnnich, 2012). Loading of cohesin onto DNA is dependent on a 
dimer composed of two proteins: nipbl and mau2. Off-loading of cohesin from DNA 
is carried out by walp and pds5, which open the interface between smc3 and rad21 
(Horsfield, Print & Mӧnnich, 2012) (see Figure 7.4a and table 7.4a).  
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Of the four genes encoding structural components of the cohesin complex (SMC1A, 
SMC3, RAD21 and STAG1) the first three are associated with Cornelia de Lange 
syndrome (CdLS), a multiorgan developmental syndrome first described in 1849 
(Vrolick, 1849). Variants in NIPBL and HDAC8, which both encode important 
regulators of the cohesin complex, are also associated with CdLS. The final 
structural component of the cohesin complex, sa, is encoded by the STAG1 gene. 
Variants in this gene have not been associated with CdLS, but with a separate 
neurodevelopmental disorder. Lehalle et al. reported 13 individuals with de novo 
heterozygous variants in, or deletions of, STAG1. All had intellectual disability, 
ranging from mild to severe. 11 patients had facial dysmorphism though this was 
not characteristic of CdLS. Five patients had epilepsy. Interestingly only two had 
microcephaly and only one had short stature. The epilepsy was not phenotyped in 
detail, but in at least two patients it was controlled with medication (Lehalle et 
al., 2017). 
 
Figure 7.4a: Schematic of the cohesin complex and its regulators 
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Table 7.4a: Genes and proteins involved in the cohesin complex, and their 
associations with disease 
Protein Full name Gene Locus Role Association with disease 
Smc1 Structural 
maintenance of 
chromosomes-1 
SMC1A Xp11.22 Structural 
component 
of cohesin 
ring 
Heterozygous missense 
variants associated with 
CdLS (Musio et al., 2006) 
Smc3 Structural 
maintenance of 
chromosomes-1 
SMC3 10q25.2 Structural 
component 
of cohesin 
ring 
Heterozygous missense 
variants associated with 
CdLS (Deardorff et al., 
2006) 
Scc1 Sister chromatid 
cohesion-1 
RAD21 8q24.11 Structural 
component 
of cohesin 
ring 
Heterozygous missense 
variants associated with 
CdLS (Deardorff et al., 
2012) 
Sa Cohesin subunit 1a STAG1 3q22.3 Structural 
component 
of cohesin 
ring 
Heterozygous missense 
variants, truncating 
variants, and deletions 
associated with 
intellectual disability 
and epilepsy (Lehalle et 
al., 2017) 
Wapl Wings apart-like 
protein 
WAPL 10.q23.2 Off-loads 
cohesin 
from 
chromatin 
None 
Pds5 Pds5 regulator of 
cohesion 
maintenance, 5a 
PDS5A 4p14 Off-loads 
cohesin 
from 
chromatin 
None 
Nipbl Nipped B-like NIPBL 5p13.2 Loads 
cohesin 
onto 
chromatin 
Heterozygous missense 
variants and truncating 
variants associated with 
CdLS (Krantz et al., 
2004) 
Mau2 Mau2 chromatic 
cohesion factor 
MAU2 19p13.11 Loads 
cohesin 
onto 
chromatin 
None 
Hdac8 Histone deacetylase 8 HDAC8 Xq13.1 Involved in 
the 
recycling 
of cohesin 
Heterozygous missense 
and truncating variants 
associated with CdLS 
(Deardorff et al., 2012) 
7.4.3 Similarities and differences with Cornelia de Lange syndrome 
Patients with CdLS have a characteristic facial appearance. Synophrys (single 
eyebrow) is considered an obligatory diagnostic criterion for the condition (Kline et 
al., 2007). Other typical facial features include short nose with anteverted nares, 
long philtrum, thin upper vermilion, high palate, and a small square chin (Boyle et 
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al., 2015). There is striking pre-and post-natal growth restriction, often associated 
with feeding difficulties and gastro-oesophageal reflux (Luzzani et al., 2003). 
Upper extremity malformations, ranging from small hands and/or digital anomalies 
to completely absent forearm(s) are observed in 27% of patients (Jackson et al., 
1993). Congenital organ anomalies are common in these patients. 20-35% have 
congenital cardiac disease – most commonly ventricular septal defect, atrial septal 
defect, tetralogy of Fallot, and hypoplastic left heart syndrome – and 40% have 
structural renal tract anomalies (Boyle et al., 2015). CdLS related to variants in 
SMC1A, SMC3 and RAD21 is considered to be a milder form that that associated 
with variants in NIPBL or HDAC8. There are milder cognitive impairments, milder 
skeletal anomalies, and major organ anomalies are considered rare (Boyle et al., 
2015; Mannini et al., 2013). 
Dysmorphic features were observed in the majority of the patients reported here 
(15/23) but in none were they considered to be characteristic of CdLS. Only one 
patient had synophrys (Lebrun et al., 2015). 10/23 had minor upper limb 
malformations, which is similar to the proportion observed in CdLS series (Jackson 
et al., 1993). The most obvious similarity between the patients reported here and 
CdLS is the shot stature and proportionate microcephaly. 
In case series of patients with CdLS between 4% and 80% have epilepsy. Epilepsy 
does not appear to be more common in SMC1A-associated CdLS compared with 
other cohesin complex genes, though the number of CdLS patients reported in 
which both genotype and epilepsy phenotype detail is described is small (Pavlidis 
et al., 2014; Musio et al., 2006; Deardorff et al., 2006; Pie et al., 2010; Borck et 
al., 2007). Focal seizures are the predominant seizure type in CdLS-associated 
epilepsy, and EEGs typically demonstrate focal or multifocal epileptiform 
abnormalities. In the majority of cases of CdLS-associated epilepsy seizure control 
is achieved (Pavlidis et al., 2014; Berney, Ireland & Burn, 1999; Verrotti et al., 
2013). 
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In summary, female patients with SMC1A truncation have some phenotypic 
similarities with those with CdLS associated with SMC1A missense variants, 
including short stature, microcephaly, minor limb anomalies, and intellectual 
disability. However, this disorder is distinct from CdLS in that drug-resistant 
epilepsy is seen in all cases, the degree of developmental impairment is usually 
more severe, and the typical dysmorphic features of CdLS are absent. 
7.4.4 Cohesin, transcriptional regulation and epilepsy 
Evidence that cohesin plays a role in gene transcription comes largely from RNA 
sequencing (transcriptomic) experiments in which cohesin function is disrupted and 
differences in relative gene expression are compared between cases and controls 
(Dorsett, 2011). For example, in Drosophila, cleavage of scc1 (RAD21) resulted in 
reduced transcription of a specific subset of genes, including a number that are 
regulated by the steroid hormone ecdysone (Pauli et al., 2010), the receptor for 
which plays a role in postmitotic axon pruning (Schuldiner et al., 2008). Significant 
alterations in the transcriptome are also observed in knockout models of NIPBL and 
SMC1A (Dorsett, 2011).  
Lui et al. generated lymphoblastoid cell lines (LCLs) from 16 patients with NIPBL-
associated CdLS. They identified a unique profile of dysregulated gene expression 
which they were able to correlate with the severity of phenotype (Liu et al., 
2009). Mannini et al. compared LCL transcriptome profiles between seven patients 
with CdLS-associated missense variants in SMC1A and four controls. They identified 
571 differentially upregulated genes and 616 differentially downregulated genes 
(Mannini et al., 2015). The authors used automated analysis to identify patterns of 
differentially expressed genes. Pathways implicated included those involved in 
glucose and lipid synthesis, the NOTCH pathway which is essential for neuronal and 
cardiac development (Bray, 2006), and the EGF-EGFR (Epidermal Growth Factor 
[Receptor]) pathway which promotes cell proliferation, differentiation and 
migration (Yarden & Sliwkowski, 2001). These findings must be interpreted with 
caution due to low numbers of cases and controls (Conesa et al., 2016). The 
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transcriptome profiles of patients with truncating variants in SMC1A have not yet 
been investigated so it is not known how these may relate to those of patients with 
SMC1A missense variants. 
7.4.5 Therapy response 
Analysis of therapy response was limited by data precision and small numbers. An 
ideal study would prospectively study objective measures of response to therapy 
such as proportionate decrease in seizure or seizure cluster frequency. It would 
also be more precise to ascertain exact doses and timings of drug therapies, as 
well as specific details of carbohydrate ratios for those treated with the Ketogenic 
Diet, in order to verify that therapeutic doses were used. Due to the retrospective 
and multicentre nature of this study it was practically not possible to acquire such 
precision of data and I have relied on clinicians’ general impressions. Despite these 
limitations, it is worth noting that the three most efficacious therapies in this 
group of patients were ones that are considered to have diverse or unclear 
mechanisms of action: Ketogenic Diet (Bough & Rho, 2007), Sodium Valproate and 
Levetiracetam (White, Smith & Wilcox, 2007). Conversely poor efficacy was 
reported for therapies with narrow mechanisms of action: Topiramate, 
Carbamazepine, Clobazam, and Lamotrigine (Bough & Rho, 2007). 
Among 14 patients with SMC1A truncation the Ketogenic Diet was significantly 
more efficacious for seizure treatment than other therapies combined. 4/6 
patients who were trialled on the Ketogenic Diet were considered to have 
benefited. Despite over a century of application to treating seizures, the 
anticonvulsant mechanism(s) of action of the Ketogenic Diet remain unknown. 
Postulated theories include a direct anticonvulsant effect of ketone bodies through 
agonist action at GABA-receptors; an impact of glucose restriction on neuronal 
proliferation, synaptogenesis and/or neuronal membrane stability; metabolic 
downregulation of the mTOR (Mammalian target of Rapamycin) pathway (McDaniel 
et al., 2011); membrane stabilising effects of polyunsaturated fatty acids; 
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improved energy delivery to neurones as a result of a high fat diet; and a 
modulating effect of the diet on noradrenergic neurotransmission.  
The potential therapeutic impact of the Ketogenic Diet through action on cellular 
growth and proliferation is of particular note. It is a therapy that appears to be 
particularly effective in patients with mTOR over activation due to Tuberous 
Sclerosis (Kossoff et al., 2005). Evidence from transcriptome studies suggests that 
SMC1A dysfunction may have an impact on pathways driving cellular proliferation, 
including NOTCH and EGF-EGFR. NOTCH signalling is implicated in diverse 
pathologies (neurological, cardiovascular, endocrine, malignant). In a mouse model 
of NOTCH inhibition, survival was reduced as a result of cardiovascular disease and 
mTOR was upregulated. Administration of the Ketogenic Diet was associated with 
improved survival (Jabs et al., 2018). 
7.4.6 Future directions 
Further advance of this field would benefit from the collection of phenotype and 
medication response data on a larger cohort of patients with SMC1A truncation-
related epilepsy. For medication response data to be reliable it should be 
collected prospectively and objectively, with seizure diaries and medication 
doses/dietary regimens documented precisely. If a sufficiently large cohort of 
patients were gathered, a randomised controlled trial of therapy could be 
considered, with the most promising candidate therapy being the Ketogenic Diet. 
Since there is mechanistic and phenotypic overlap between SMC1A-truncation 
related epilepsy, SMC1A-missense variant-associated CdLS with seizures, and other 
cohesinopathies in which epilepsy is a symptom, there would be value in more 
precisely delineating the epilepsy phenotype and therapy response. It is worth 
noting that patient P-962 in chapter 6 has a de novo missense variant in NIPBL. She 
had drug-resistant epilepsy, microcephaly and short stature. She was treated with 
the Ketogenic Diet but was not deemed to have a significant response. In her case 
the family felt that the most effective treatment was self-sourced Cannabinoid 
therapy. 
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It may be possible to gain a better understanding of the mechanisms of 
pathogenesis in SMC1A-trunaction related epilepsy by conducting transcriptome 
analysis in these patients, comparing patterns of gene expression with both 
SMC1A-CdLS patients and with healthy controls. Consideration should be given to 
the unusual clustering pattern of seizures observed in many of these patients, and 
to the reported benefit of hormonal therapy with oestrogen in one of the published 
cases. It is possible that the transcriptional regulation effect of SMC1A has a 
cyclical and hormone-dependent element. 
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7.5 Conclusion 
In this chapter I have discussed five broad mechanisms through which damaging 
genetic variants can lead to epilepsy. Though there is some degree of overlap 
between these groups they provide a useful conceptual framework, particularly 
when considering potential approaches to precision therapy. A significant 
proportion of monogenic epilepsies can be considered as disorders of 
transcriptional regulation. These conditions are particularly challenging to the 
concept of precision therapy since precise targetable biological pathways are 
difficult to delineate. An example of a genetic epilepsy related to transcriptional 
dysregulation is that caused by de novo truncating variants in the SMC1A gene. 
Careful phenotyping of 25 of these patients has revealed a distinct 
neurodevelopmental disorder in which non-epilepsy features such as growth 
parameters, tone, and developmental profile are perhaps more characterising than 
seizure-related features. All of these patients have drug-resistant epilepsy so there 
is arguably a pressing need to discover more specific treatments for this condition. 
The most promising treatment used to date appears to be the Ketogenic Diet. 
Transcriptome analysis may provide further insights into the biological mechanisms 
through which disorders of transcriptional regulation lead to as epileptic seizures 
and may help to guide efforts to develop precision approaches to therapy. 
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8. Analysis of the relationship between response to 
Cannabidiol and specific nature of the gene variant in a 
cohort of children with SCN1A-related Dravet Syndrome 
8.1 Introduction 
8.1.1 Cannabinoids and precision medicine 
The idea that Cannabinoids may have anti-convulsant properties is not new. The 
oldest documented application of the Cannabis-based therapy for epileptic 
seizures is considered to be inscribed on Sumerian tablets dated to 2000 years BC 
(Pereira, 1846). Various Arabic texts from between the ninth and 12th centuries 
provide evidence that Cannabis was administered for its anti-seizure properties 
(Russo, 2017). The first reference to the application of Cannabis to the treatment 
of epilepsy in Western medicine is an 1843 case report by Sir William 
O’Shaughnessy, an Irish physician in service to the British Crown in India. He 
reported in the Provinical Medical Journal the case of a 40-day old girl who 
presented with up to 30 seizures per day. He administered Cannabis tinctures until 
her seizures stopped. Subsequently she remained seizure-free and in good health 
(O'Shaughnessy, 1843). Despite the longevity of its use, until recently the only 
therapeutic trials of Cannabinoid-based preparations in the treatment of epilepsy 
involved extremely small numbers of patients. A 2014 Cochrane review concluded 
that due to low quality of evidence, no “reliable conclusions [could] be drawn 
regarding the efficacy of Cannabinoids as a treatment for epilepsy.” 
A recent resurgence of interest in Cannabinoids as epilepsy therapy has been 
driven by a high profile case reports in which patients with highly drug-resistant 
and severe epilepsies have apparently demonstrated a dramatic response to 
Cannabinoid-based therapy (Meacher & Clegg, 2016). The case of Charlotte Figi, a 
five-year old girl in Colorado was featured in a CNN documentary in 2013. 
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Charlotte had initially presented with status epilepticus at three months of age. 
She went on to develop multiple seizure types (tonic, tonic-clonic, and myoclonic) 
and to demonstrate developmental regression. Her seizures were resistant to at 
least eight anti-epileptic drugs as well as the Ketogenic Diet. She was diagnosed 
with Dravet syndrome, and had a de novo pathogenic variant in SCN1A (c.2791C>T, 
p.R931C). Before Charlotte was prescribed Cannabinoid therapy she was 
experiencing 50 generalised tonic-clonic seizures (GTCS) per day. After three 
months of treatment there had been a 90% reduction in GTCS frequency. At 20 
months she was having just 2-3 GTCS per month. The parents also reported 
improvements in sleep, alertness, behaviour and interaction (Maa & Figi, 2014). 
Following the profile raised by the CNN documentary, many other parents of 
children with Dravet syndrome acquired Cannabinoid treatment for their children, 
with the majority reporting positive results in terms of both seizure control and 
other factors such as alertness, mood and sleep (Porte & Jacobson, 2013). 
8.1.2 Cannabinoid pharmacology 
More than 500 different chemical compounds have been isolated from the Cannabis 
plant (Cannibis sativa). The most abundant are Cannabinoids, of which there are 
more than 100. Cannabinoids have a 21-carbon skeleton, and they act at G-protein 
coupled “Cannabinoid” receptors in the brain, of which there are many subtypes. 
Different Cannabinoids have different neuropharmacological properties owing to 
their specific affinity for the different Cannabinoid receptors (Friedman & 
Devinsky, 2015). The most abundant and well-studied of the Cannabinoids are Δ9-
Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD). Δ9-THC is a potent agonist 
at CBD1 and CBD2 receptors, which are predominantly found at presynaptic 
terminals. Δ9-THC is believed to be the principal psychoactive component of 
Cannabis. The subjective “high” associated with cannabis can be reversed by CBD1 
receptor blockade (Huestis et al., 2001). In animal models of epilepsy, Δ9-THC 
demonstrates both anti-convulsant and pro-convulsant effects (Rosenberg et al., 
2015). In contrast, CBD is a non-psychoactive Cannabinoid and has anti-convulsant 
effects in the majority of animal models (Rosenberg et al., 2015). CBD has low 
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affinity at CBD1 and CBD2 receptors (Thomas et al., 1998). It is an agonist at 
transient receptor potential (TRP) channels, serotonin receptors, and glycine 
receptors. It is an antagonist at GPR55 cannabinoid receptors (Rosenberg et al., 
2015). Of these various actions the effect on GPR55 receptors has generated 
specific interest. GPR55 agonism results in increased intracellular Ca2+ levels and 
vesicular release probability at excitatory hippocampal synapses, which is opposed 
by CBD (Sylantyev et al., 2013). 
The pharmacology of CBD is complex, multi-faceted, and incompletely understood. 
Nonetheless, owing to both theoretical and animal model evidence that is 
supportive of an anticonvulsant mechanism in absence of a psychoactive effect, 
the recent focus on generating evidence for Cannabinoids in the treatment of 
epilepsy has focused on high CBD, low Δ9-THC preparations. The majority of 
published successful case reports have been in relation to such preparations (Maa 
& Figi, 2014; Porter & Jacobson, 2013).  
Unfortunately, in regions where Cannabis production and supply is not regulated, it 
is easy for patients and families to access preparations whose Cannabinoid content 
is unquantified and potentially inconsistent from one batch to another. In regions 
where Cannabis is unregulated as a recreational drug there are usually no barriers 
to Cannabinoid production for therapeutic purposes. As a result pharmaceutical 
companies are now marketing Cannabinoid preparations without ever having 
generated a robust evidence base to support their efficacy and tolerability (Lough, 
2015). 
8.1.3 Towards an evidence base 
Recent efforts to generate an evidence base to support the use of Cannabinoids in 
the treatment of epilepsy have focussed on CBD.  
In 2016 Devinsky et al. published the first open label uncontrolled study of purified 
CBD for epilepsy. They recruited 214 children with drug-resistant epilepsies, of 
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whom 33 had Dravet syndrome. Patients were given CBD titrated to a maximum 
dose of 25mg/kg per day or 50mg/kg per day depending on study site. 79% of 
patients experienced adverse effects, the most common of which were somnolence 
(25%), decreased appetite (19%), and diarrhoea (19%). 3% discontinued treatment 
because of adverse effects. The primary efficacy endpoint was reduction in the 
number of motor seizures per month compared to baseline and there was no 
significant difference (Devinsky et al., 2016). 
In 2017 the first randomised-controlled trial (RCT) of CBD in epilepsy was 
published. Owing to the previous impressive anecdotes, the patient cohort 
selected was patients with Dravet Syndrome. 120 children were recruited, of 
whom 61 were randomised to CBD (20mg/kg per day) and 59 to placebo. Double 
blinding methodology was used. The primary outcome measure was percentage 
reduction in convulsive seizure frequency between four-week baseline and 14-
week treatment period (including two weeks of dose escalation to 20mg/kg per 
day and 12 weeks maintenance). There was a significant difference between the 
groups. The median frequency of convulsive seizures per month reduced from 12.4 
to 5.9 (38.9%) in the CBD group, compared with 14.9 to 14.1 (13.3%) in the placebo 
group. (p = 0.01). 5% of the CBD group became seizure-free compared with one of 
the placebo group (p=0.08). The adverse effect profile was similar to that 
observed in the open label study (Devinsky et al., 2017). 
CBD has subsequently undergone two double blind RCT trials in another form of 
childhood onset epilepsy, Lennox-Gastaut Syndrome (LGS). Here statistically 
significant effects were reported. Drop seizures are common in LGS so in these 
trials efficacy was measured in terms of reduction in drop seizure frequency 
between baseline and treatment period. In the first trial (GWPCARE3, n = 225) 
patients were randomised to high dose CBD (20mg/kg per day) low dose CBD 
(10mg/kg per day) or placebo. Median drop in drop seizure frequency was 17.2% in 
the placebo group, compared with 41.9% in the high dose CBD group (p=0.005) and 
37.2% in the low dose CBD group (p=0.002) (Devinsky et al., 2018). In the second 
trial (GWPCARE4, n = 171), patients were randomised to either 20mg/kg per day 
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CBD or placebo, and median reduction in drop seizure frequency was 43.9% versus 
21.8% (p = 0.0135) (Thiele et al., 2018).  
The success of CBD in LGS, which is an aetiologically heterogenous epilepsy, 
suggests that the drug, rather than having a specific effect on patients with Dravet 
Syndrome and SCN1A variants, may have broad anti-epileptic properties. 
Nonetheless, in view of the compelling anecdotal reports of extreme treatment 
success in some patients with Dravet Syndrome, a closer look at CBD response is 
warranted. It is possible that CBD response depends on the nature and location of 
the SCN1A variant. 
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8.2 Methods 
8.2.1 Participants 
The subjects in this study were all patients with Dravet Syndrome who were 
recruited to the multicentre double-blind RCT of CBD versus placebo (GWPCARE1) 
which involved 23 centres in the United States and Europe. For the trial, inclusion 
was dependent on a clinical diagnosis of Dravet Syndrome as determined by their 
clinician. To be included in the trial, patients had to be aged between two and 18 
years, they had to have ongoing seizures despite treatment with antiepileptic 
medication, and any current anti-epileptic medication doses had to been 
unchanged for four weeks prior to trial commencement. Seizure diaries were kept 
during a four-week baseline period. Patients were excluded if they had fewer than 
four convulsive seizures during the four-week baseline period. 
8.2.2 Procedures 
Informed consent was obtained from parents or legal guardians. Caregivers were 
trained to record daily seizure activity. Participants were then assigned on a 1:1 
ratio to receive either CBD, with the dose escalated to 20mg/kg/day over 14 days, 
or placebo. Daily total was administered in two divided doses. Treatment and 
seizure diary recoding continued for 14 weeks. 
8.2.3 Trial outcomes 
The primary outcome measure in the trial was median reduction in convulsive 
seizure frequency between the four-week baseline period and the 14-week 
treatment period. Safety data were also obtained. Overall trial outcomes were 
published in the New England Journal of Medicine in 2017 (Devinsky et al., 2017). 
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8.2.4 SCN1A variant information 
Though 120 participants completed the GWPCARE1 trial, only patients with 
confirmed pathogenic variants in the coding sequence of SCN1A were included in 
this analysis. Variant information was either provided by the recruiting clinician or 
was obtained through private testing organised by the trial’s funder’s, GW 
Pharma®. I reviewed the variant details in each case and only included those 
variants were either published cases in association with Dravet Syndrome, or had 
high pathogenicity scores on all in silico tools used: Align, Polyphen-2, SIFT, and 
Mutation Taster. For missense variants, variant location was classified according to 
the functional domain of the sodium channel affected by the variant. 
Table 8.2a: Definition of the functional regions of the Nav1.1 channel; Greyed 
rows indicate regions in which no pathogenic variants were identified. 
Code Region 
C Cytoplasmic loop between transmembrane segments, or at the C-terminus or N-
terminus of the protein 
S1 Transmembrane segment 1 
S1-S2 Extracellular loop between transmembrane segment 1 and transmembrane 
segment 2 
S2 Transmembrane segment 2 
S2-S3 Cytosplasmic loop between transmembrane segment 2 and transmembrane 
segment 3 
S3 Transmembrane segment 3 
S3-S4 Extracellular loop between transmembrane segment 3 and transmembrane 
segment 4 
S4 Transmembrane segment 4 (voltage-sensing unit) 
S4-S5 Cytosplasmic loop between transmembrane segment 4 and transmembrane 
segment 5 
S5 Transmembrane segment 5 
S5-pore Extracellular loop between transmembrane segment 5 and the pore of the channel 
pore Channel pore region 
Pore-S6 Extracellular loop between the pore of the channel and transmembrane segment 6 
S6 Transmembrane segment 6 
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8.2.5 Analysis 
Participants were divided into two groups: those with truncating variants, and 
those with missense variants. Within these groups, differences in response to CBD 
versus placebo in terms of the primary outcome measure were quantified. The 
Mann-Whitney-U test was applied to determine any significant difference in 
response between groups. For those patients with missense variants a waterfall 
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plot of CBD response and a separate waterfall plot of placebo response was 
produced to see if this highlighted any regions of interest in terms of CBD 
response.  Subsequently, missense variants were further divided into two groups 
for analysis, again using the Mann-Whitney-U test. These two group were: variants 
affecting regions between S5 and S6 inclusive (highlighted yellow in table 8.2a); 
and missense variants elsewhere. For intellectual property reasons GW pharma 
were unable to hand over the individual patient-response data form the study to 
me.  Statisticians working for GW pharma performed these analyses, though the 
subgroups were defined by me. 
  
313 
 
8.3 Results 
8.3.1 Exclusions  
Of the 120 participants recruited to the RCT, 111 were found to have a pathogenic 
or likely pathogenic variant in SCN1A and were included in these analyses. Of the 
nine participants excluded, two had benign or likely benign variants in SCN1A, two 
had undergone SCN1A testing and were negative, one had unclear information on 
SCN1A variant status, and four had unknown SCN1A status. 
8.3.2 Truncation versus missense 
61 participants had a truncating SCN1A variant and 50 had a missense variant. 
 
Figure 8.3a: Median reduction in convulsive seizure frequency in patients 
randomised to CBD and placebo; comparison between those with truncation 
variants and those with missense variants in SCN1A
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There was no significant difference in CBD treatment effect between patients with 
a truncation or missense variant for percent reduction in convulsive seizures 
(p=0.89); for any of the convulsive seizure responder thresholds of ≥25% (p=0.96), 
≥50% (p=0.60), or ≥75% (p=0.41); or for percent reduction in total seizures 
(p=0.59).  
8.3.3 Differences in response by missense domain location 
Step one of this process was to produce a “waterfall plot” of CBD and placebo 
response with each the missense domain location annotated for each participant. 
Observation of the plots could then be used to identify any trends.  
Looking at figures 8.3b and 8.3c it appeared that participants with SCN1A variants 
in the S5-S6 region who were randomised to CBD were concentrated at the positive 
response end of the plot, and none of these patients had any significant increase in 
convulsive seizure frequency. In contrast, those who with missense variants in this 
region who were randomised to placebo were more evenly spread throughout the 
plot, with seven of these patients reporting an increase in convulsive seizure 
frequency.  In order to test for significance of this potential interaction I 
performed a Mann-Whitney-U test on the data, with missense variants divided into 
“S5-S6” and “non S5-S6” categories (figure 8.3d). Though there appears to be a 
striking differential in CBD response between these groups, the numbers were 
small, and this did not reach statistical significance (p = 0.242).
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Figure 8.3b: Waterfall plot of CBD response, with missense domain location annotated; each column represents an 
individual participant; a negative y axis value indicates that a seizure frequency increase occurred; yellow columns 
indicate participants with variants in the S5-S6 region 
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Figure 8.3c: Waterfall plot of placebo response, with missense domain location annotated; each column represents an 
individual participant; a negative y axis value indicates that seizure frequency increase occurred; yellow columns indicate 
participants with variants in the S5-S6 region
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Figure 8.3d: Median reduction in convulsive seizure frequency in patients randomised to CBD and placebo and missense 
variants in SCN1A; comparison of those with S5-S6 variants and those with missense variants elsewhere; truncation and 
missense data also plotted on this chart 
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8.4 Discussion 
In this chapter, taking data from a randomised-controlled trial, I have attempted 
the investigate whether variant type (truncation or missense), or variant missense 
location, are associated with response to Cannabidiol therapy in SCN1A-related 
Dravet syndrome.  
One of the potential limitations of taking an approach to epilepsy precision 
therapy that focuses solely on primary genetic cause, as in chapter 4 of this thesis, 
is that within each genetic causal group there may be significant heterogeneity of 
treatment response. Therapy response, like other aspects of phenotype, will 
depend not only on the causal gene, but on the nature and effect of the causal 
variant, and on other factors such as genetic modifiers, epigenetic changes, and 
environmental influences.  
It is broadly accepted that in Dravet syndrome, sodium channel blocking 
medications are best avoided. The potential for these medications to exacerbate 
seizures in patients with Dravet syndrome was described before the genetic basis 
for Dravet syndrome was understood (Dravet, 1978). The most commonly 
prescribed sodium channel blocking medications are Carbamazepine and 
Lamotrigine. A retrospective review of a large cohort of patients with Dravet 
syndrome (n = 241) showed that 60% (36/60) of patients treated with 
Carbamazepine, and 43% (26/60) of patients treated with Lamotrigine, 
experienced seizure exacerbation whilst taking these mediations (Brunklaus et al., 
2012). As well as exacerbating seizures, taking these medications may have an 
impact on cognitive outcome. de Lange et al. studied 164 Dutch patients with 
Dravet syndrome and found a significant association between duration of sodium 
channel blocking therapy use and long-term cognitive outcome (de Lange et al., 
2018). Since SCN1A is preferentially expressed in inhibitory interneurons (Ogiwara 
et al., 2007), and since the majority of Dravet syndrome associated SCN1A variants 
appear to result in loss of function, it has been hypothesised that an epileptogenic 
predisposition in this disease is as a result of reduced inhibitory GABA-ergic 
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transmission, and that further sodium channel blockade is likely to exacerbate this 
tendency (Catterall, Kalume & Oakley, 2010). 
Contrary to this theory, there appear to be a minority of patients with SCN1A-
related Dravet syndrome who benefit from sodium channel blocking medication. In 
their report of three patients with SCN1A-related Dravet syndrome who benefited 
from Lamotrigine, and who experienced deterioration when this mediation was 
temporarily withdrawn, all three had a missense variant rather than a truncation 
variant in the gene, prompting the hypothesis that there may be a variant specific 
effect to this response (Dalic et al., 2015). It is difficult to draw firm conclusions 
from a small case series like this, since so many uncontrolled factors have the 
potential to influence medication response, and because in a retrospective and 
unblinded model subjective factors may come into play when reporting treatment 
benefit. In contrast, the randomised controlled trial offers an excellent model to 
investigate the potential role of genetic variant type on treatment response.  
In this trial of CBD in Dravet syndrome, 93% of participants had a causative SCN1A 
variant; all had a baseline seizure frequency above a specific threshold; all kept 
prospective seizure diaries in order to objectively report treatment responses; and 
all those treated with CBD or placebo received the same dosing schedule whilst all 
other medications remained unchanged. 
Overall median convulsive seizure reduction in the CBD group was 39%, compared 
with 13% in the placebo group. In the group with truncation variants who were 
randomised to CBD, median convulsive seizure reduction was 36%, and in those 
with missense variants it was 29%. Hence there is no evidence to suggest that CBD 
response depends on variant type. Analysis within the missense variant group 
showed that median convulsive seizure reduction was 52% in the group with 
variants in the S5-S6 region, whilst the group with missense variants outwith this 
region experienced a 4% increase in convulsive seizure frequency on CBD 
treatment. Though this difference appears striking it must be considered with 
caution for the following reasons: it is based on small numbers; it is not 
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statistically significant; and these groupings of missense variants were not based 
on an a priori hypothesis but on empirical review of the response data. To 
determine whether there is any basis to this finding would require testing this 
hypothesis on another RCT group, ideally with larger numbers of participants. The 
GWPCARE2 study, enrolled 200 participants with Dravet syndrome to an RCT of 
CBD versus placebo, and would have provided an opportunity to test the hypothesis 
generated from the present study. Our research group were initially given 
permission by GW Pharma® to analyse the data from GWPCARE2. Following 
presentation of my preliminary analysis to GW Pharma the decision was made to 
not to proceed analysis of the second cohort. 
8.4.1 Limitations of this study: 
CBD is arguably not the best medication to investigate for variant specific response 
in SCN1A-related epilepsy, since it is not known to have any direct action on the 
Nav1.1 sodium channel. It would be interesting to perform similar analysis on 
patients receiving sodium channel modulating therapy, but since no such RCT has 
been performed, this is not a possibility. CBD appears to have multiple 
neuropharmacological actions. There is some in vitro evidence, from a single cell 
model using human embryonic kidney cells, of a modulating effect on Nav1.6 
sodium channels, though the clinical significance of this remains to be explored 
(Patel et al., 2016). In the absence scientific grounds upon which to base a 
hypothesis, SCN1A variants were divided into crude groupings of truncation versus 
missense variants. Since most Dravet syndrome associated missense variants are 
believed to act via a loss-of-function mechanism, it is perhaps not surprising that 
no significant differences in response were observed between these groups. 
Division of missense variants was also based crudely – on location in relation to the 
pore forming region of the channel. A more comprehensive evaluation could have 
considered more precise details of variant location, or even the functional effects 
of each missense variant. A major barrier to the latter approach is that the 
majority of disease-associated SCN1A missense variants have not been functionally 
characterised, and of those that have, methodologies have varied between studies. 
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Of course, the more precision with which one desires to investigate relationships 
between variant characteristics and treatment response, the larger numbers one 
will need in any study to achieve sufficient power. It must also be borne in mind 
that non-pathogenic variants in SCN1A may prove equally as important as 
pathogenic ones when it comes to medication response, as too may variants in 
other genes, such as those involved in the transport and metabolism of the study 
drug. From a pharmacogenetic perspective particular focus has been on the 
rs3812718*AA (IVS5 G>A/c.603-91 G>A) polymorphism of SCN1A, which is found in 
approximately 10% of the population, and is associated with resistance to sodium 
channel blocking medications across a spectrum of epilepsies (Yip et al., 2013). 
8.4.2 Conclusions: 
In this chapter I have demonstrated how RCT data can be harnessed to investigate 
for relationships between causal variants and therapy response in monogenic 
epilepsies. Due to its relatively high incidence, and its strong association with a 
single genetic cause, Dravet syndrome provides a particularly good model for this 
approach. Though no statistically significant relationships were identified, there 
was a suggestion that patients with missense variants around the pore forming 
region of the channel may derive particular benefit from CBD. Without access to 
GWPCARE2 data I was unable to undertake further scientific evaluation of this 
observation. Pharmacogenetic research is rapidly developing and it is likely that 
the discipline would benefit from open access to data from pharmaceutical trials 
in genetic epilepsies. 
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9. General Discussion 
9.1 The research question 
The question this thesis asks is: “what is the potential impact of genotype-driven 
precision therapy for children with epilepsy.” This question was something I 
wanted to explore because during my clinical training I had become aware that 
clinicians treating children with epilepsy were being presented with rapidly 
increasing access to genetic testing technologies, enabling them more easily to 
identify specific genetic aetiologies for these patients and their families. 
Inevitably, when a family is informed that a genetic cause for their epilepsy has 
been identified, further questions will be asked: What does this mean? What can 
we now expect in the future? What are the implications for other family members 
and/or future children? Families may also ask this: Does this mean there is a 
specific treatment that should be given? In the case of the condition caused by 
pathogenic variants in the SLC2A1 gene, Glut-1 deficiency syndrome (Glut1-D), 
most paediatric neurologists would agree that the answer here is “yes” (Kossoff et 
al., 2018). SLC21A encodes the principal active transporter of glucose into the 
human brain. Variants that impair the function of this transporter result in relative 
deficiency of cerebral glucose and are associated with a constellation of symptoms 
as a result, including seizures, dystonia, cognitive impairment, and microcephaly 
(Pearson et al., 2013). Use of the Ketogenic Diet provides the brain with an 
alternative energy source, bypassing the need for cerebral glucose and overcoming 
many of the symptoms (Kass et al., 2016). One of the most clinically significant 
findings arising from this thesis is that the incidence of Glut1-D is more than twice 
that which has previously been reported (Coman et al., 2006, Larsen et al., 2015b) 
and that initial symptoms of the condition can be mild and variable (chapter 5). 
Early introduction of the Ketogenic Diet in the seven patients identified in the 
Scottish cohort appeared to result in better short-term epilepsy and developmental 
outcomes than observed in historical controls (Akman et al., 2016). This 
combination of poor predictability of Glut1-D from early clinical features, 
alongside good outcomes associated with early therapeutic intervention, makes a 
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good case for screening for this genetic cause in children presenting with seizures 
in early childhood. That said, in the absence of a randomised trial, the evidence 
supporting the use of Ketogenic Diet leaves this a grade C recommendation. A 
similar scenario plays out across many of the genetic epilepsies. Very few 
randomised trials of therapy have been performed in defined genetic epilepsies 
and therefore clinicians resort to low level evidence, or making logical decisions 
based on what is known about the mechanism of the genetic cause, when deciding 
on a therapy. 
9.1.1 Sub-questions of the research question 
In order to understand the potential impact of precision medicine in childhood 
onset epilepsy, a number of questions need to be answered along the way. First 
and foremost of these questions is: 
9.1.1.1 “How common is childhood-onset epilepsy?”  
Through establishing a population-based cohort of children presenting with 
epilepsy before their third birthday I have shown that epilepsy of onset in these 
early childhood years is significantly more common than previously estimated 
(Wirrell et al., 2012) at 1 per 383 live births (chapter 5).  
The next logical question is: 
9.1.1.2 “How often can we find a monogenic cause of childhood-onset epilepsy?” 
Performing a meta-analysis of the published literature on gene panel testing in 
epilepsy (chapter 3), the answer to this is that diagnostic yield varies markedly 
between 4% and 50%, but the overall diagnostic rate is 17%. The reason for such 
variability largely relates to heterogeneity of study populations and of testing 
protocols. Due to this heterogeneity it is very difficult to draw any conclusions 
about the epidemiology of individual monogenic epilepsies. Nonetheless is 
becomes clear that the majority of currently achievable genetic diagnoses are 
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concentrated in a relatively small number of genes, with SCN1A, KCNQ2, CDKL5, 
SCN2A, STXBP1, and PCDH19 between them accounting for more than 50% of 
diagnostic results. In order to overcome the limitations of the meta-analysis in 
relation to population heterogeneity I analysed the results of gene panel testing in 
a population-based cohort of children presenting with seizures who were only 
selected on the basis of age, being under three years at the time of presentation 
(chapter 5). Using a 104 gene panel, overall diagnostic yield of monogenic seizure 
disorders was 23.5%. Representing monogenic causes relative to other aetiologies 
it becomes clear that this is the single largest aetiological category, at least in 
those presenting before the age of 3 years. In line with the results of the meta-
analysis the majority of single gene diagnoses were concentrated in a small 
number of genes, with 74% of diagnoses involving just eight genes, PRRT2, SCN1A, 
KCNQ2, SLC2A1, CDKL5, DEPDC5, PCDH19, and SLC6A1. The clear limitation of this 
epidemiological data is that it tells us nothing about the incidence of genetic 
epilepsies in those presenting beyond the age of three years. It is likely, though 
difficult to quantify, that the majority of single gene epilepsies have been 
captured despite this restriction. This is because there is a marked drop off in 
yield from genetic testing when age of presentation extends beyond six months, as 
well as a marked drop in incidence of epilepsy itself, until incidence rises again as 
age reaches >60 years. 
The final key question of the sequence is this: 
9.1.1.3 “How often could making single gene diagnosis influence therapeutic 
approach?” 
In chapter 4 I performed a systematic review of the evidence to support precision 
approaches in the monogenic epilepsies. Only four trials could be considered as 
grade I evidence, with the majority of evidence being grade III. Nonetheless, 
assuming all levels of evidence could have the potential to influence a clinician’s 
therapy choice, I was able to estimate that this was the case 85% of genetic 
diagnoses made in the Scottish cohort, and 71% of the diagnoses made in the meta-
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analysis (chapter 3). Combining these findings with the epidemiology from chapter 
5 I have shown that for every 2,000 children born, one is likely to develop a 
monogenic epilepsy for which there is some supportive evidence for a specific 
therapeutic approach. To put this figure in context, 1 in 130 people born is 
expected to develop epilepsy at some point in their life (Fiest et al., 2017). 
9.2 Common monogenetic epilepsies, and beyond 
The meta-analysis of next generation sequencing studies (chapter 3) and 
population based cohort study (chapter 5) both demonstrated that the majority of 
currently diagnosable genetic epilepsies are accounted for by a small number of 
genes. Using the population-based approach I have been able to define the 
incidence of several of these for the first time, with PRRT2-associated epilepsy 
being the most common, followed by SCN1A, KCNQ2 and SLC2A1. Having these 
incidence figures in the public domain will be valuable for research teams 
designing observational and interventional studies in the future. Beyond the 
common monogenic causes there is a long tail of exceedingly rare genetic 
epilepsies, with 104/210 genes being implicated on just one occasion among 
13,063 patients included in the meta-analysis, giving a diagnostic yield of 0.007% 
per gene. My experience from application of Whole Genome Sequencing technology 
in this thesis (chapter 6) echoes this. Just one of the diagnoses made among those 
patients who had been pre-screened on the Glasgow panel of 104 genes implicated 
a gene that had also been implicated among the 13,063 patients in the meta-
analysis (NEXMIF, 3 diagnoses). An interesting aspect of these infrequently 
implicated genes is that many are also implicated in other neurodevelopmental 
disorders, such as autism and intellectual disability. Some of these monogenic 
disorders may in fact be more commonly observed in patients without epilepsy 
than those who have seizures. This observation lends support to the arguments of 
those who think it best to consider epilepsy as a symptom of an underlying brain 
disease, rather than a disease entity in itself (Reynolds & Rodin, 2009). Genetic 
brain disorders that are extremely rare pose a challenge to those trying to progress 
precision therapy initiatives for the obvious reason that it is difficult to gather a 
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cohort of patients if those patients are very infrequently encountered. In chapter 7 
I have demonstrated how this can be done. Rare genetic brain disorders in which 
epilepsy is a symptom that may or may not be present, alongside other 
developmental problems, pose and an additional challenge: they demonstrate that 
an epileptic predisposition is not a necessary component of that genetic brain 
disorder and therefore imply that any anti-epileptic treatment approach is unlikely 
to be aetiology-specific. If it is possible to have the same brain disorder and not 
have seizures, it has to be questioned whether treating the seizures can be 
expected to improve the brain disorder. 
9.3 Challenges encountered in this thesis 
9.3.1 When is an aetiology causative? 
An unexpected challenge encountered in developing this research was that of 
determining when exactly an identified aetiology could be considered sufficient to 
explain a patient’s epilepsy and be deemed causative. This was of critical 
importance considering many of the analyses undertaken were done on the basis of 
a binomial system of cause identified/cause not identified. This challenge of 
thresholds of causation manifested in several of the studies undertaken, and partly 
reflects the binary nature in which clinical medicine tends to operate when it 
comes to determining aetiology. 
9.3.2 Variant interpretation 
In the population-based cohorts reported in chapter 5, genetic variants were 
interpreted and an objective manner. Variants identified from gene panel testing 
were discussed within an experienced multi-disciplinary team of clinicians and 
scientists, and this team was assisted by being able to reference the UK 
Association of Clinical Genetic Science (ACGS) guidelines for variant interpretation 
(Association for Clinical Genetic Science, 2017). This task was made significantly 
easier than, for example, interpretation of Whole Genome Sequencing results, 
327 
 
because the gene panel of 104 epilepsy-associated genes only included genes that 
had been well studied, whose mechanisms were reasonably well-understood, and 
whose associated phenotypes were well-described. Nonetheless subjective 
judgement was still an essential component of variant interpretation, particularly 
since the ACGS guidelines emphasise that variants must always be considered in 
the context of phenotype. In neurodevelopmental disorders phenotype is often a 
multifaceted complex of symptoms that may be difficult to objectify. When it 
came to interpretation of many of the variants identified though Whole Genome 
Sequencing, taking an objective approach was significantly more difficult since 
many of the genes implicated had very little clinical literature published on them.  
9.3.3 Multiple aetiology 
12% of patients in cohort 2 of chapter 5 were deemed to have an aetiology that fell 
into more than one of the broad categories of genetic, structural, metabolic, 
infectious, immune. Some such patients had a single aetiology, but one that could 
be considered to belong to more than one group. For example, tuberous sclerosis is 
a genetic disorder invariably associated with structural brain malformations. For 
others there was a genetic disorder or infectious component present which had 
predisposed them to a secondary event. For example one patient in this study had 
both trisomy 21 and a hypoxic ischaemic injury, and another had Herpes Simplex 
Virus encephalitis followed by anti-NMDA receptor autoimmune encephalitis. For 
others the combination of two aetiologies could be considered as coincidental, for 
example a patient had both a pathogenic KCNQ2 variant and accidental head 
trauma. 
In reality, all patients with epilepsy will have multiple aetiological factors 
contributing to their condition. When one single factor appears to dominate the 
picture we ascribe causation, though this is process inevitably involves some 
degree of subjective judgement. Figure 9a illustrates this concept of multiple 
aetiological factors contributing to an overall phenotype. In this figure I have 
divided aetiological contributors to phenotype into four groups: environmental 
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factors, for example head trauma or exposure to infection; common genetic 
variants; rare genetic variants; and extremely rare genetic variants. Within each of 
these groups there will be factors that we are currently able to identify and 
understand and there will be others that remain concealed, so each aetiology 
group has been divided into explained and unexplained groups. We know from 
large twin studies that epilepsy is approximately 60% heritable, but that most of 
this heritability is currently unexplained (Manolio et al., 2009; Kjeldsen et al., 
2005; Speed et al., 2012), thus the largest proportion of this figure is occupied by 
unexplained common and rare genetic variants. Here common genetic variants 
could be considered those that have a population frequency of >1% and rare 
genetic variants could be considered those that have a population frequency of 
between 0.01% and 1%, though these distinctions are somewhat arbitrary. Evidence 
that common genetic variants contribute to epilepsy heritability comes from 
genome wide association studies (Hibbar et al., 2014; Stefffens et al., 2012; Speed 
et al., 2014; Tan & Berkovic, 2010) whilst evidence that rare genetic variants 
contribute comes from burden analysis studies (Allen et al., 2017). Importantly, 
neither a common genetic variant nor a rare genetic variant is likely to explain the 
presence of an epilepsy phenotype on its own, but must act in combination with 
other genetic and environmental risk factors. 
The concept of the monogenic epilepsy arises when a single genetic variant, or a 
pair of recessively inherited variants, is thought sufficient to explain an epilepsy 
phenotype alone. Invariably, such highly penetrant variants are extremely rare, 
present <0.01% of the population. This explains why the monogenic epilepsies are 
individually extremely rare. Such variants will never explain all aspects of a 
phenotype since there will be genetic and environmental modifiers which explain 
why two patients with an identical genetic cause can sometimes present quite 
different phenotypes. Nonetheless, conceptually, there is a threshold where a 
sufficient proportion of the phenotype is felt to be explained by the variant(s), 
that it is ascribed as causative. This conceptual threshold is marked A. in figure 9a. 
We know that monogenic causes are identified more often in severe epilepsies 
than they are in mild epilepsies, and this is illustrated in the lower portion of 
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figure 9a. Here mild epilepsies might be those in which seizure control is achieved 
and cognitive comorbidities are absent and severe epilepsies might be considered 
those in which there is therapy resistance and/or cognitive comorbidity. In much 
the same way there is a threshold point at which an environmental factor will be 
deemed to be sufficient on its own to have caused a person’s epilepsy (point B. in 
figure 9a.). Here again there will genetic modifiers of the phenotype. Occasionally 
a patient will have both a monogenic and an environmental factor, each of which 
would be considered sufficient on its own to have caused their epilepsy. This 
scenario is illustrated as point C. in figure 9a. 
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Figure 9a: Illustration of the concepts of multiple aetiologies and causation thresholds in epilepsy
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9.4 Capturing complexity and moving forward 
As figure 9a. illustrates, epilepsy aetiology is complex and multi-faceted in all 
cases. It is therefore perhaps not surprising that it has been difficult to find strong 
evidence to support the notion that knowledge of specific genetic cause 
meaningfully informs therapeutic decisions. Even the gold standard of evidence-
base medicine, the double blind randomised controlled trial (RCT) has significant 
limitations when it comes to answering the question posed by this thesis. Though 
the RCT of Cannabidiol in Dravet syndrome demonstrated efficacy and tolerability 
of this therapeutic compound when used as add-on therapy for patients with drug-
resistant seizures, this key question remains. Was the response to CBD in any way 
related to the genetic cause? Response to CBD varied markedly between patients 
with causative SCN1A variants in this RCT, yet an investigation into whether this in 
any way related to the nature of the SCN1A variant was unrevealing (chapter 8 of 
this thesis). 
In vitro models of human epilepsies in which disease-associated genetic variants 
are introduced, physiological parameters measured, and response to medications 
investigated are an attractive model for precision therapy, and are often promoted 
as such in the titles of scientific publications. Unfortunately these models miss 
much of the complexity of the human brain, both in terms of genetic background 
and neuronal circuits which are made up of trillions interconnected pathways of 
excitatory and inhibitory circuits. Successful in vitro models have almost 
exclusively been restricted to ion channel disorders (Symonds, Zuberi & Johnson, 
2017), and these are likely to comprise just half of the patients with monogenic 
epilepsy (chapter 3). In order to progress this field models that incorporate both 
genetic background and complex neuronal circuitry will be required. Thanks to the 
rapidly progressing technologies of induced pluripotent stem cells (iPSCs) (Okita et 
al., 2011) and CRISPR/CAS gene editing (Sánchez-Rivera &Jacks, 2015) progress is 
being made on this front though there have been no translational results so far 
(Tidball et al., 2017).  
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9.5 Final reflections on this PhD project 
Through designing and conducting the six studies which make up this thesis I have 
developed a number of transferrable research skills, including those involved in 
systematic review and meta-analysis; in primary epidemiological research; and in 
the acquisition and analysis of large genomic datasets. Given the rapid advance of 
the genetic-epilepsy field, the specific skills I have gained in genetic analysis and 
interpretation are likely to prove valuable to me in the future in both clinical and 
research settings. The professional links which I have been able to build between 
Oxford and Glasgow on this front will hopefully endure and continue to be fruitful.  
The highest impact aspect of this research is likely to be that described in chapter 
5. Here, using a prospective population-based epidemiological cohort study design, 
I have been able to describe the incidence and phenotypic spectrum of a number 
of early childhood-onset single gene epilepsies for the first time. This aspect of the 
project would not have been successful without the good will and cooperation of 
many clinicians throughout Scotland, most of whom contributed to this research in 
their own personal time. Coordination of the research effort, and maintenance of 
motivation was strongly facilitated by the Scottish Paediatric Epilepsy Network. 
Acquisition of clinical data was made relatively easy by development of functional 
fully-computerised health records, many of which only came online within the past 
five years. Through my experience over the last five years, I have come to fully 
appreciate that Scotland offers real opportunities when it comes to this type of 
epidemiological research, and it is on this front that I would like to focus further 
research efforts in future.  
Given the number of variables, it seems unlikely that many questions in relation to 
precision medicine in epilepsy will be answered by traditional randomised 
controlled trials (RCTs). Conversely some important answers may well come from 
good quality prospectively gathered data, if this approach can be refined and 
scaled up sufficiently. Where RCT data may come in useful is in relation to some of 
the more common genetic epilepsies, such as SCN1A. As demonstrated in chapter 
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8, progress in this area may be hindered unless a framework for transparency of 
genomic data is developed. To some extent the whole concept of precision 
medicine is contrary to the objectives of the pharmaceutical industry.  
Gaining a greater understanding of some of the rarer genetic epilepsies requires 
the casting of a much wider net than would be possible for either an RCT, or a 
single nation epidemiological study. The syndrome of SMC1A-truncation, described 
in chapter 7, is estimated to affect between 1 per 50,000 and 1 per 100,000 births. 
In circumstances such as these, multi-centre collaboration, facilitated by gene-
matching software systems can prove valuable. Since publication of the manuscript 
“Heterozygous truncation mutations of the SMC1A gene cause a severe early onset 
epilepsy with cluster seizures in females: Detailed phenotyping of 10 new cases” 
(Symonds et al., 2017) I have been contacted by a number of clinicians and 
researchers, and through this have been able to further develop my understanding 
of this extremely rare condition.  
Through attendance and presentation of my data at a number of international 
conferences I have been able to disseminate the findings from this thesis. Such 
meetings have also provided opportunities for me to network and collaborate with 
clinicians and researchers in other centres. Without such collaboration knowledge 
of the very rare genetic epilepsies cannot be progressed. 
Finally, a core component of my time during this project was spent directly 
interacting with the families of children with early-onset epilepsy, in order to 
acquire the comprehensive history necessary to understand phenotype in detail. 
The narratives of many of these families are presented in the results section of 
chapter 6.  At the time of their involvement in this project, many of these families 
were undertaking a frightening journey, with unpredictable turns at every corner, 
and multiple challenges facing them far beyond just “seizure control.” 
Participating in a research study on top of these challenges often added more 
uncertainty to this journey, yet all of these families welcomed me into their lives 
and passed on their stories to me freely and gracefully. History taking remains the 
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bedrock of clinical medicine, and these experiences have no doubt helped develop 
me as a clinician. Despite all the technical genetic detail, this thesis remains 
grounded in the narratives of these families.  
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